WO2009099982A1 - 2-aminopyridine kinase inhibitors - Google Patents

Abstract

2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, F1t3, FGFR3, Ab1, Aurora A, c-Src, IGF- IR, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

Description

2-AMINOPYRIDINE KINASE INHIBITORS

BACKGROUND OF THE INVENTION

The present invention is directed to novel 2-aminopyridine compounds, their salts, and compositions comprising them. In particular, the present invention is directed to novel 2-aminopyridine compounds that inhibit the activity of tyrosine kinase enzymes in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.

Protein tyrosine kinases (PTKs) are enzymes that catalyze the phosphorylation of specific tyrosine residues in various cellular proteins involved in regulation of cell proliferation, activation, or differentiation (Schlessinger and Ullrich, 1992, Neuron 9:383-391). Aberrant, excessive, or uncontrolled PTK activity has been shown to result in uncontrolled cell growth and has been observed in diseases such as benign and malignant proliferative disorders, as well as having been observed in diseases resulting from an inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease. In addition, endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas). Other kinases that are believed to be important mediators of tumor angiogenesis include FGFR3, Tie-2, and Flt3. For example, FGFR3 mutations are often seen in bladder cancer cells. Tie-2 is a protein receptor found on cells lining blood vessels. When activated by growth factors secreted by tumor cells, Tie2 triggers vessel cell walls to part and grow new capillaries. . Flt3, also known as "vascular endothelial cell growth factor receptor 3" or VEGFR-3, is believed to assist in vascular development important to angiogenesis. Thus, it is desirable to identify inhibitors of FGFR3, Tie-2, and/or Flt3. Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). The Receptor Tyrosine Kinases (RTKs) comprise a large family of transmembrane receptors with at least nineteen distinct RTK subfamilies having diverse biological activities. The RTK family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, Ann. Rev. Biochem. 57:433-478, 1988; Ullrich and Schlessinger, Cell 61 :243-254, 1990). The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently results in a variety of cellular responses (Ullrich & Schlessinger, Cell 61 :203-212, 1990). Thus, RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor trans-phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate a corresponding cellular response such as cell division, differentiation, metabolic effects, and changes in the extracellular microenvironment (Schlessinger and Ullrich, Neuron 9:1-20, 1992).

Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly by a failure of the proper control mechanisms for the kinase, related to mutation, over-expression or inappropriate activation of the enzyme; or by an over- or underproduction of cytokines or growth factors participating in the transduction of signals upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.

Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways involved in numerous disorders, including cancer, psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and other hyperproliferative disorders or hyperimmune responses. It is desirable to provide novel inhibitors of kinases involved in mediating or maintaining disease states to treat such diseases. Cells may migrate and divide inappropriately if the signals for division or motility cannot be stopped. This might occur if the complex system of control proteins and messengers, which signal changes in the actin system, goes awry. One such control factor is the proto-oncogene protein AbI, a tyrosine kinase. It is implicated in cancer, including leukemia. Accordingly, it is desirable to identify inhibitors of AbI. The Aurora kinase family is one regulator of chromosome segregation - regulating the structure and function of centrosomes and mitotic spindle. One member, the Aurora-A kinase, has been shown to play a role in tumorigenesis - being located at a chromosomal hot-spot, 20ql 3, frequently amplified in a variety of human cancers such as those of colon, ovary, breast and pancreas. It appears that overexpression of Aurora-A kinase alone is sufficient to cause aneupoidy in normal diploid epithelial cells. Over-expression of Aurora-A kinase in NIH3T3 cells results in centrosome aneupoidy. Thus, it is desirable to identify inhibitors of Aurora-A.

The cytoplasmic tyrosine kinase c-Src is involved in the signal transduction pathway and is elevated in breast cancer cell lines. Similarly, Src is involved in the regulation of cell growth and transformation. Thus over-expression of c-Src can lead to excess proliferation. Thus, it is desirable to identify inhibitors of c-Src.

IGF-IR (type 1 insulin- like growth factor receptor) performs important roles in cell division, development, and metabolism, and in its activated state, plays a role in oncogenesis and suppression of apoptosis. IGF-IR is known to be overexpressed in a number of cancer cell lines (IGF-IR overexpression is linked to acromegaly and to cancer of the prostate). By contrast, down-regulation of IGF-IR expression has been shown to result in the inhibition of tumorigenesis and an increased apoptosis of tumor cells. Thus, it is desirable to identify compounds that inhibit IGF-IR.

ALK (Anaplastic Lymphoma Kinase) is a receptor tyrosine kinase that belongs to the insulin receptor subfamily. It is implicated in the progression of certain tumors such as anaplastic large cell lymphomas (ALCL; Kutok JX. & Aster J.C., J. Clin Oncol, 20:3691-3702, 2002; Duyster J. et al, Oncogene, 20:5623-5637, 2001), inflammatory myofibroblastic tumors (IMT; Duyster J. et al), and glioblastomas (Powers C. et al., J. Biol Chem., 276: 16772-16779, 2001). It has been demonstrated that inhibition of ALK can impair the growth and induce apoptosis of lymphoma cells containing ALK (Turturro F. et al, Clin. Cancer Res., 8:240-245, 2002). Thus, it is desirable to identify compounds that inhibit ALK. RON (recepteur d'origine nantais) is a receptor tyrosine kinase that is part of the MET proto- oncogene family. It is activated by binding to its natural ligand MSP and signals via the PI3K and MAPK pathways. RON can be deregulated in cancer by mechanisms such as over-expression of the receptor and/or the presence of constitutively active splice variants. Inhibition of RON has been shown to lead to a decrease in proliferation, induction of apoptosis and affects cell metastasis. RON overexpression is observed in a variety of human cancers and exhibit increased expression with progression of the disease.

MET is a receptor tyrosine kinase that is a heterodimeric protein comprising of a 50 kDa α-subunit and a 145kDa β-subunit (Maggiora et al, J. Cell Physiol, 173: 183-186, 1997). It is activated by binding to its natural ligand HGF (hepatocyte growth factor, also known as scatter factor) and signals via the PI3K and MAPK pathways. MET can be deregulated in cancer by mechanisms such as autocrine / paracrine HGF activation, over-expression of the receptor, and/or the presence of activating mutations. Significant expression of MET has been observed in a variety of human tumors, such as colon, lung, prostate (including bone metastases), gastric, renal, HCC, ovarian, breast, ESCC, and melanoma (Maulik et al, Cytokine & Growth Factor Reviews 13:41-59, 2002). MET is also implicated in atherosclerosis and lung fibrosis. Inhibition of MET can cause a decrease in cell motility, proliferation and metastasis, as reviewed in, e.g., Chemical & Engineering News 2007, 85 (34), 15-23.

As human cancers progress to a more invasive, metastatic state, multiple signaling programs regulating cell survival and migration programs are observed depending on cell and tissue contexts (Gupta and Massague, 2006). Recent data highlight the transdifferentiation of epithelial cancer cells to a more mesenchymal-like state, a process resembling epithelial-mesenchymal transition (EMT; (Oft et al., 1996; Perl et al., 1998), to facilitate cell invasion and metastasis (Brabletz et al., 2005; Christofori, 2006). Through EMT-like transitions mesenchymal-like tumor cells are thought to gain migratory capacity at the expense of proliferative potential. A mesenchymal-epithelial transition (MET) has been postulated to regenerate a more proliferative state and allow macrometastases resembling the primary tumor to form at distant sites (Thiery, 2002). MET and RON kinases have been shown to play a role in the EMT process (Camp et al., 2007; Grotegut et al., 2006; Wang et al., 2004).

Thus, it is desirable to identify inhibitors of RON and/or it related family MET for use in proliferative diseases, such as, but not limited to, cancer.

It has been documented in vitro that RON and MET can form heterodimers and signal via such RON-MET dimers. Since co-expression of RON and MET in cancer has been observed, such "crosstalk" may contribute to tumor growth. It is therefore especially desirable to identify compounds that inhibit both RON and MET.

In view of the importance of PTKs to the control, regulation, and modulation of cell proliferation and the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify small molecule tyrosine kinase inhibitors. International Patent Publications Nos. WO 2006/021881 and WO 2004/076412 describe 3-alkoxysubstituted 2-aminopyridines and 2- aminopyrazines as kinases inhibitors. International Patent Publication No. WO 2004/069160 describes benzimidazolyl-pyridines as SGK-I inhibitors. International Patent Publication No. WO 2007/111904 describes tetrazolyl substituted pyridinamines or pyrazinamines as c-Met protein kinase inhibitors. Although the anticancer compounds described above have made contribution to the art, there is a continuing need to improve anticancer pharmaceuticals with better selectivity or potency, reduced toxicity, or fewer side effects.

It has been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of kinases. In particular, the compounds are effective as inhibitors of at least one of the KDR, Tie-2, Flt3, FGFR3, AbI, Aurora A, c-Src, IGF-IR, ALK, c-MET, RON, PAKl, PAK2, and TAKl kinases.

SUMMARY OF THE INVENTION

The present invention is directed to a novel class of 2-aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. The compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and they are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, AbI, Aurora A, c-Src, IGF-IR, ALK, c-MET, RON, PAKl, PAK2, and TAKl, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. Compounds disclosed herein are also useful in the treatment and/or prevention of various diseases and conditions in which EMT is involved, for example, the treatment of conditions characterized by a disregulation of EMT. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

I

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a compound of Formula I:

I or a pharmaceutically acceptable salt thereof, wherein:

Rl is isoquinolin-3-yl, benzothiazol-2-yl, l,2,3,4-tetrahydroisoquinolin-3-yl, 4,5,6,7- tetrahydrobenzothiazol-2-yl, benzofuran-2-yl, benzoxazol-2-yl, benzothiophen-2-yl, 5,6,7,8-tetrahydro- 4H-cycloheptathiazol-2-yl, 3,3-disubstituted 3H-indol-2-yl, imidazo[l,2-α]pyridine-2-yl, thiazolo[4,5- c]pyridin-2-yl, oxazolo[4,5-c]pyridin-2-yl, imidazo[l,2-α]pyrazin-2-yl, furo[2,3-c]pyridin-2-yl, thieno[2,3-c]pyridin-2-yl, or 2-naphthyl, any of which is optionally further substituted with one to four independent R3 groups;

X is pyrazol, phenyl, pyridyl, thiazolyl, imidazolyl, furyl, thienyl, pyrrolyl, indolyl, indazolyl, or tetrahydropyridyl;

R2 is Η, halogen, CN, alkyl, cycloalkyl, bicycloalkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, amino, aminoalkyl, alkylamino, alkylsulfonyl, C(=O)R4, C(=O)OR4, C(=O)NR5R6, NR7C(=O)R4, NR7C(=O)OR4, NR7C(=O)NR5R6, NR7S(=O)₂R4, NR7S(=O)R4, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, heteroaryl, -alkyl-C(=O)R4, -alkyl-C(=O)OR4, -alkyl- C(=O)NR5R6, -alkyl-NR7C(=O)R4, -alkyl-NR7C(=O)OR4, -alkyl-NR7C(=O)NR5R6, -alkyl-

NR7SO₂R4, -alkyl-NR7SOR4, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally substituted by one or more independent R3 groups;

R3 is Η, halogen, CN, alkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, amino, aminoalkyl, alkylamino, alkylsulfonyl, C(=O), C(=S), C(=O)R4, C(=O)OR4, C(=O)NR5R6, NR7C(=O)R4, NR7C(=O)OR4, NR7C(=O)NR5R6, NR7SO₂R4, NR7SOR4, aryl, heterocyclyl, heteroaryl, -alkyl-C(=O)R4, -alkyl-C(=O)OR4, -alkyl-C(=O)NR5R6, -alkyl-NR7C(=O)R4, -alkyl- NR7C(=O)OR4, -alkyl-NR7C(=O)NR5R6, -alkyl-NR7SO₂R4, -alkyl-NR7SOR4, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally further substituted by one or more independent R7 groups; R4 is alkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, amino, aminoalkyl, alkylamino, dialkylamino, alkylsulfonyl, aryl, heterocyclyl, heteroaryl, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally further substituted by one or more independent R7 groups;

R5 and R6 are each independently H, alkyl, cycloalkyl, or alkoxyalkyl, any of which is optionally substituted by one or more independent R7 groups; or R5 and R6 taken together with the atom that they are attached to form a 4-7 membered saturated or unsaturated heterocycle; wherein said heterocycle is optionally further substituted by one or more independent R7 groups;

R7 is H, halogen, alkyl, trifluoroalkyl, alkoxy, CN, cycloalkyl, alkoxyalkyl, aryl, hetaryl, or heterocyclyl; n is 0, 1 or 2.

In one embodiment of the invention, Rl is isoquinolin-3-yl, benzothiazol-2-yl, 1,2,3,4- tetrahydroisoquinolin-3-yl, 4,5,6,7-tetrahydrobenzothiazol-2-yl, benzofuran-2-yl, benzoxazol-2-yl, benzothiophen-2-yl, 3,3-disubstituted 3H-indol-2-yl, imidazo[l,2-α]pyridine-2-yl, thiazolo[4,5- c]pyridin-2-yl, oxazolo[4,5-c]pyridin-2-yl, imidazo[l,2-α]pyrazin-2-yl, furo[2,3-c]pyridin-2-yl, or thieno[2,3-c]pyridin-2-yl, any of which is optionally further substituted by one to four independent R3 groups as defined in Formula I.

In another embodiment of the invention, Rl is isoquinolin-3-yl, benzothiazol-2-yl, 1,2,3,4- tetrahydroisoquinolin-3-yl, 4,5,6,7-tetrahydrobenzothiazol-2-yl, benzoxazol-2-yl, 3,3-disubstituted 3H- indol-2-yl, or imidazo[l,2-α]pyridine-2-yl, any of which is optionally further substituted by one to four independent R3 groups as defined in Formula I.

In another embodiment of the invention, Rl is isoquinolin-3-yl, benzothiazol-2-yl, benzoxazol-2-yl, or imidazo[l,2-α]pyridine-2-yl, any of which is optionally further substituted by one to four independent R3 groups as defined in Formula I.

In another embodiment of the invention, Rl is isoquinolin-3-yl or benzothiazol-2-yl, any of which is optionally further substituted by one to four independent R3 groups as defined in Formula I.

In another embodiment of the invention, Rl is thiazolo[4,5-c]pyridin-2-yl, oxazolo[4,5-c]pyridin-2- yl, imidazo[l,2-α]pyrazin-2-yl, furo[2,3-c]pyridin-2-yl, or thieno[2,3-c]pyridin-2-yl, any of which is optionally further substituted by one to four independent R3 groups as defined in Formula I.

In another embodiment of the invention, the compound of Formula I has the Formula Ia wherein X is pyrazolyl and n is 1, and all other variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula Iaa wherein Raa is H, alkoxy, or alkyl wherein alkoxy or alkyl is optionally further substituted with halogen; Rab is H or F; and all other variables are as defined in Formula I.

Iaa

In another embodiment of the invention, the compound of Formula Ia has the formula lab wherein all variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula lac wherein Rc is H or alkyl wherein alkyl is optionally further substituted with halogen; and all other variables are as defined in Formula I.

lac

In another embodiment of the invention, the compound of Formula Ia has the Formula lad wherein all variables are as defined in Formula I.

lad In another embodiment of the invention, the compound of Formula Ia has the Formula Iae wherein Y is O or S; and all other variables are as defined in Formula I.

Iae

In another embodiment of the invention, the compound of Formula Ia has the Formula Iaf wherein all variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula lag wherein Rga and Rgb are independently alkyl, alkoxy or alkylthio wherein said alkyl group is optionally further substituted with halogen; or Rga and Rgb, together with the carbon atom that both are attached to, form a 3-7-membered saturated or unsaturated ring containing zero to two O, N, or S atoms; and all other variables are as defined in Formula I.

lag

In another embodiment of the invention, the compound of Formula Ia has the Formula Iah wherein all variables are as defined in Formula I.

Iah In another embodiment of the invention, the compound of Formula Ia has the Formula Iai wherein W is CR3 or N; and all other variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula Iaj wherein W is CR3 or N; and all other variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula Iak wherein W is CR3 or N; and all other variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula IaI wherein Y is O or S, W is CR3 or N; and all other variables are as defined in Formula I.

In another embodiment of the invention, the compound of Formula Ia has the Formula lam wherein all variables are as defined in Formula I.

In another embodiment of compounds of formula Ia, R2 is H, alkyl, cycloalkyl, bicycloalkyl, alkylsulfonyl, C(=O)NR5R6, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, heteroaryl, -alkyl- C(=O)R4, -alkyl-C(=O)OR4, -alkyl-C(=O)NR5R6, -alkyl-NR7C(=O)R4, -alkyl-NR7C(=O)OR4, - alkyl-NR7C(=O)NR5R6, -alkyl-NR7SO₂R4, -alkyl-NR7SOR4, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Ia, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Ia, R2 is heterocyclyl or heterobicycloalkyl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iaa, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula lab, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula lac, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups. In another embodiment of compounds of formula lad, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iae, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iaf, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups. In another embodiment of compounds of formula lag, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iah, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iai, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iaj, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula Iak, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups. In another embodiment of compounds of formula IaI, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

In another embodiment of compounds of formula lam, R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

The compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and they are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, AbI, Aurora A, c-Src, IGF-IR, ALK, c-MET, RON, PAKl, PAK2, and TAKl, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. Since MET and RON kinases have been shown to play a role in the EMT process, the compounds of Formula I are useful in the treatment and/or prevention of various diseases and conditions in which EMT is involved, for example, the treatment of conditions characterized by a disregulation of EMT.

Specifically, the compounds of Formula I of the present invention are useful in the treatment of a variety of cancers, including, but not limited to, solid tumor, sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, hematopoietic malignancy, and malignant ascites. More specifically, the cancers include, but not limited to, lung cancer, bladder cancer, pancreatic cancer, kidney cancer, gastric cancer, breast cancer, colon cancer, prostate cancer (including bone metastases), hepatocellular carcinoma, ovarian cancer, esophageal squamous cell carcinoma, melanoma, an anaplastic large cell lymphoma, an inflammatory myofibroblastic tumor, and a glioblastoma.

In another embodiment, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

Unless otherwise stated, the connections of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety. For example, hetarylthioCi_₄alkyl has a heteroaryl group connected through a thio sulfur to a

alkyl that connects to the chemical species bearing the substituent.

As used herein, for example, "Co-₄alkyl" is used to mean an alkyl having 0-4 carbons - that is, 0, 1 , 2, 3, or 4 carbons in a straight or branched configuration. An alkyl having no carbon is hydrogen when the alkyl is a terminal group. An alkyl having no carbon is a direct bond when the alkyl is a bridging

(connecting) group. Further, Coalkyl includes being a substituted bond - that is, for example, -X-Y-Z is -C(O)-C₂-₄alkyl when X is C_oalkyl, Y is C_oalkyl, and Z is -C(O)-C₂-₄alkyl.

In all embodiments of this invention, the term "alkyl" includes both branched and straight chain alkyl groups. Typical alkyl groups are methyl, ethyl, w-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, «-hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, eicosyl, and the like.

The term "halo" refers to fluoro, chloro, bromo, or iodo.

The term "haloalkyl" refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl, and the like.

The term "acyl" refers to the structure -C(=O)-R, in which R is a general substituent variable such as, for example R¹ described above. Examples include, but are not limited to, (bi)(cyclo)alkylketo, (cyclo)alkenylketo, alkynylketo, arylketo, hetarylketo, heterocyclylketo, heterobicycloalkylketo, spiroalkylketo. Unless otherwise specified, the term "cycloalkyl" refers to a 3-8 carbon cyclic aliphatic ring structure, optionally substituted with for example, alkyl, hydroxy, oxo, and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxycyclopentyl, cyclohexyl, 4-chlorocyclohexyl, cycloheptyl, cyclooctyl, and the like.

The term "bicycloalkyl" refers to a structure consisting of two cycloalkyl moieties that have two or more atoms in common. If the cycloalkyl moieties have exactly two atoms in common they are said to be "fused". Examples include, but are not limited to, bicyclo[3.1.0]hexyl, perhydronaphthyl, and the like. If the cycloalkyl moieties have more than two atoms in common they are said to be "bridged". Examples include, but are not limited to, bicyclo[2.2.1]heptyl ("norbornyl"), bicyclo[2.2.2]octyl, and the like.

The term "spiroalkyl" refers to a structure consisting of two cycloalkyl moieties that have exactly one atom in common. Examples include, but are not limited to, spiro[4.5]decyl, spiro[2.3]hexyl, and the like.

The term "heterobicycloalkyl" refers to a bicycloalkyl structure in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.

The term "heterospiroalkyl" refers to a spiroalkyl structure in which at least one carbon atom is replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur.

The term "alkylcarbonyloxyalkyl" refers to an ester moiety, for example acetoxymethyl, n- butyryloxyethyl, and the like.

The term "alkynylcarbonyl" refers to an alkynylketo functionality, for example propynoyl and the like. The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, for example hydroxymethyl, 2,3-dihydroxybutyl, and the like.

The term "alkylsulfonylalkyl" refers to an alkyl group substituted with an alkylsulfonyl moiety, for example mesylmethyl, isopropylsulfonylethyl, and the like.

The term "alkylsulfonyl" refers to a sulfonyl moiety substituted with an alkyl group, for example mesyl, n-propylsulfonyl, and the like.

The term "acetylaminoalkyl" refers to an alkyl group substituted with an amide moiety, for example acetylaminomethyl and the like.

The term "acetylaminoalkenyl" refers to an alkenyl group substituted with an amide moiety, for example 2-(acetylamino)vinyl and the like. The term "alkenyl" refers to an ethylenically unsaturated hydrocarbon group, straight or branched chain, having 1 or 2 ethylenic bonds, for example vinyl, allyl, 1 -butenyl, 2-butenyl, isopropenyl, 2- pentenyl, and the like.

The term "haloalkenyl" refers to an alkenyl group substituted with one or more halo groups.

Unless otherwise specified, the term "cycloalkenyl" refers to a cyclic aliphatic 3 to 8 ring structure, optionally substituted with alkyl, hydroxy and halo, having 1 or 2 ethylenic bonds such as methylcyclopropenyl, trifluoromethylcyclopropenyl, cyclopentenyl, cyclohexenyl, 1 ,4-cyclohexadienyl, and the like.

The term "alkynyl" refers to an unsaturated hydrocarbon group, straight or branched, having at least one acetylenic bond, for example ethynyl, propargyl, and the like. The term, "haloalkynyl" refers to an alkynyl group substituted with one or more independent halo groups.

The term "alkylcarbonyl" refers to an alkylketo functionality, for example acetyl, «-butyryl, and the like.

The term "alkenylcarbonyl" refers to an alkenylketo functionality, for example, propenoyl and the like.

The term "aryl" refers to phenyl or naphthyl which may be optionally substituted. Examples of aryl include, but are not limited to, phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3- methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4- methoxyphenyl, naphthyl, 2-chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl, and 2- iodo-4-methylphenyl.

The terms "heteroaryl" or "hetaryl" or "heteroar-" or "hetar-" refer to substituted or unsubstituted 5- or 6-membered heteroaryl rings containing 1-4 heteroatoms chosen from oxygen, sulfur, and nitrogen in which oxygen and sulfur are not next to each other. Examples of such heteroaryl rings are furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl. The terms "heteroaryl" or "hetaryl" or "heteroar-" or "hetar-" also include hetaryl rings with fused carbocyclic ring systems that are partially or fully unsaturated, such as a benzene ring, to form a benzofused hetaryl. For example, benzimidazole, benzoxazole, benzothiazole, benzofuran, quinoline, isoquinoline, quinoxaline, and the like. Furthermore, the terms "heteroaryl" or "hetaryl" or "heteroar-" or "hetar-" include fused 5-6, 5-5, 6-6 ring systems, optionally possessing one nitrogen atom at a ring junction. Examples of such hetaryl rings include, but are not limited to, pyrrolopyrimidinyl, imidazo [ 1 ,2-α]pyridinyl, imidazo[2, 1 -Z?]thiazolyl, imidazo[4,5-Z?]pyridine, pyrrolo[2, 1 -J] [ 1 ,2,4]triazinyl, and the like. Hetaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For example, pyrrole may be connected at the nitrogen atom or at any of the carbon atoms.

The terms "aryl-alkyl" or "arylalkyl" or "aralkyl" are used to describe a group wherein the alkyl chain can be branched or straight chain forming a bridging portion with the terminal aryl, as defined above, of the aryl-alkyl moiety. Examples of aryl-alkyl groups include, but are not limited to, optionally substituted benzyl, phenethyl, phenpropyl and phenbutyl such as 4-chlorobenzyl, 2,4- dibromobenzyl, 2-methylbenzyl, 2-(3-fluorophenyl)ethyl, 2-(4-methylphenyl)ethyl, 2-(4- (trifluoromethyl)phenyl) ethyl, 2-(2-methoxyphenyl)ethyl, 2-(3-nitrophenyl)ethyl, 2-(2,4- dichlorophenyl)ethyl, 2-(3,5-dimethoxyphenyl)ethyl, 3-phenylpropyl, 3-(3-chlorophenyl)propyl, 3-(2- methylphenyl)propyl, 3-(4-methoxyphenyl)propyl, 3-(4-(trifluoromethyl)phenyl)propyl, 3-(2,4- dichlorophenyl)propyl, 4-phenylbutyl, 4-(4-chlorophenyl)butyl, 4-(2-methylphenyl)butyl, 4-(2,4- dichlorophenyl)butyl, 4-(2-methoxphenyl)butyl, and 10-phenyldecyl.

The terms "aryl-cycloalkyl" or "arylcycloalkyl" are used to describe a group wherein the terminal aryl group is attached to a cycloalkyl group, for example phenylcyclopentyl and the like.

The terms "aryl-alkenyl" or "arylalkenyl" or "aralkenyl" are used to describe a group wherein the alkenyl chain can be branched or straight chain forming a bridging portion of the aralkenyl moiety with the terminal aryl portion, as defined above, for example styryl (2-phenylvinyl), phenpropenyl, and the like.

The terms "aryl-alkynyl" or "arylalkynyl" or "aralkynyl" are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a bridging portion of the aryl-alkynyl moiety with the terminal aryl portion, as defined above, for example 3 -phenyl- 1-propynyl, and the like.

The terms "aryl-oxy" or "aryloxy" or "aroxy" are used to describe a terminal aryl group attached to a bridging oxygen atom. Typical aryl-oxy groups include phenoxy, 3,4-dichlorophenoxy, and the like.

The terms "aryl-oxyalkyl" or "aryloxyalkyl" or "aroxyalkyl" are used to describe a group wherein an alkyl group is substituted with a terminal aryl-oxy group, for example pentafluorophenoxymethyl and the like.

The term "heterocycloalkenyl" refers to a cycloalkenyl structure in which at least one carbon atom is replaced with a heteroatom selected from oxygen, nitrogen, and sulfur.

The terms "hetaryl-oxy" or "heteroaryl-oxy" or "hetaryloxy" or "heteroaryloxy" or "hetaroxy" or "heteroaroxy" are used to describe a terminal hetaryl group attached to a bridging oxygen atom. Typical hetaryl-oxy groups include 4,6-dimethoxypyrimidin-2-yloxy and the like.

The terms "hetarylalkyl" or "heteroarylalkyl" or "hetaryl-alkyl" or "heteroaryl-alkyl" or "hetaralkyl" or "heteroaralkyl" are used to describe a group wherein the alkyl chain can be branched or straight chain forming a bridging portion of the heteroaralkyl moiety with the terminal heteroaryl portion, as defined above, for example 3-furylmethyl, thenyl, furfuryl, and the like. The terms "hetarylalkenyl" or "heteroarylalkenyl" or "hetaryl-alkenyl" or "heteroaryl-alkenyl" or

"hetaralkenyl" or heteroaralkenyl" are used to describe a group wherein the alkenyl chain can be branched or straight chain forming a bridging portion of the heteroaralkenyl moiety with the terminal heteroaryl portion, as defined above, for example 3-(4-pyridyl)-l-propenyl.

The terms "hetarylalkynyl" or "heteroarylalkynyl" or "hetaryl-alkynyl" or "heteroaryl-alkynyl" or "hetaralkynyl" or "heteroaralkynyl" are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a bridging portion of the heteroaralkynyl moiety with the heteroaryl portion, as defined above, for example 4-(2-thienyl)- 1 -butynyl.

Unless otherwise stated, the terms "heterocyclic ring", "heterocyclyl" and "heterocycle" are equivalent, and include 4-10-membered, e.g. 5-membered, saturated or partially saturated rings containing 1 -4 heteroatoms chosen from oxygen, sulfur, and nitrogen. The sulfur and oxygen heteroatoms are not directly attached to one another. Any nitrogen heteroatoms in the ring may optionally be substituted with Ci_₄alkyl. Examples of heterocyclic rings include azetidine, oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, thiazolidine, oxazolidine, oxazetidine, pyrazolidine, isoxazolidine, isothiazolidine, tetrahydrothiophene, tetrahydrothiopyran, thiepane, thiocane, azetidine, pyrrolidine, piperidine, N-methylpiperidine, azepane, 1 ,4-diazapane, azocane, [l,3]dioxane, oxazolidine, piperazine, homopiperazine, morpholine, thiomorpholine, 1,2,3,6- tetrahydropyridine and the like. Other examples of heterocyclic rings include the oxidized forms of the sulfur-containing rings. Thus, tetrahydrothiophene- 1 -oxide, tetrahydrothiophene- 1 , 1 -dioxide, thiomorpholine- 1 -oxide, thiomorpholine- 1 , 1 -dioxide, tetrahydrothiopyran- 1 -oxide, tetrahydrothiopyran- 1 , 1 -dioxide, thiazolidine- 1 -oxide, and thiazolidine- 1 , 1 -dioxide are also considered to be heterocyclic rings. The term "heterocyclic" also includes fused ring systems and can include a carbocyclic ring that is partially or fully unsaturated, such as a benzene ring, to form benzofused heterocycles. For example, 3,4-dihydro-l,4-benzodioxine, tetrahydroquinoline, tetrahydroisoquinoline and the like. The terms "heterocyclylalkyl" or "heterocyclyl-alkyl" or "hetcyclylalkyl" or "hetcyclyl-alkyl" are used to describe a group wherein the alkyl chain can be branched or straight chain forming a bridging portion of the heterocyclylalkyl moiety with the terminal heterocyclyl portion, as defined above, for example 3-piperidinylmethyl and the like.

The terms "heterocyclylalkenyl" or "heterocyclyl-alkenyl" or "hetcyclylalkenyl" or "hetcyclyl- alkenyl" are used to describe a group wherein the alkenyl chain can be branched or straight chain forming a bridging portion of the heterocyclylalkenyl moiety with the terminal heterocyclyl portion, as defined above, for example 2-morpholinyl- 1 -propenyl and the like.

The terms "heterocyclylalkynyl" or "heterocyclyl-alkynyl" or "hetcyclylalkynyl" or "hetcyclyl-alkynyl" are used to describe a group wherein the alkynyl chain can be branched or straight chain forming a bridging portion of the heterocyclylalkynyl moiety with the terminal heterocyclyl portion, as defined above, for example 2-pyrrolidinyl- 1 -butynyl and the like.

The term "carboxylalkyl" refers to a terminal carboxyl (-COOH) group attached to branched or straight chain alkyl groups as defined above.

The term "carboxylalkenyl" refers to a terminal carboxyl (-COOH) group attached to branched or straight chain alkenyl groups as defined above.

The term "carboxylalkynyl" refers to a terminal carboxyl (-COOH) group attached to branched or straight chain alkynyl groups as defined above.

The term "carboxylcycloalkyl" refers to a terminal carboxyl (-COOH) group attached to a cyclic aliphatic ring structure as defined above. The term "carboxylcycloalkenyl" refers to a terminal carboxyl (-COOH) group attached to a cyclic aliphatic ring structure having ethylenic bonds as defined above.

The terms "cycloalkylalkyl" or "cycloalkyl-alkyl" refer to a terminal cycloalkyl group as defined above attached to an alkyl group, for example cyclopropylmethyl, cyclohexylethyl, and the like.

The terms "cycloalkylalkenyl" or "cycloalkyl-alkenyl" refer to a terminal cycloalkyl group as defined above attached to an alkenyl group, for example cyclohexylvinyl, cycloheptylallyl, and the like.

The terms "cycloalkylalkynyl" or "cycloalkyl-alkynyl" refer to a terminal cycloalkyl group as defined above attached to an alkynyl group, for example cyclopropylpropargyl, 4-cyclopentyl-2- butynyl, and the like.

The terms "cycloalkenylalkyl" or "cycloalkenyl-alkyl" refer to a terminal cycloalkenyl group as defined above attached to an alkyl group, for example 2-(cyclopenten-l-yl)ethyl and the like.

The terms "cycloalkenylalkenyl" or "cycloalkenyl-alkenyl" refer to terminal a cycloalkenyl group as defined above attached to an alkenyl group, for example l-(cyclohexen-3-yl)allyl and the like.

The terms "cycloalkenylalkynyl" or "cycloalkenyl-alkynyl" refer to terminal a cycloalkenyl group as defined above attached to an alkynyl group, for example l-(cyclohexen-3-yl)propargyl and the like. The term "carboxylcycloalkylalkyl" refers to a terminal carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkyl group as defined above.

The term "carboxylcycloalkylalkenyl" refers to a terminal carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkenyl group as defined above.

The term "carboxylcycloalkylalkynyl" refers to a terminal carboxyl (-COOH) group attached to the cycloalkyl ring portion of a cycloalkylalkynyl group as defined above.

The term "carboxylcycloalkenylalkyl" refers to a terminal carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkyl group as defined above.

The term "carboxylcycloalkenylalkenyl" refers to a terminal carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkenyl group as defined above. The term "carboxylcycloalkenylalkynyl" refers to a terminal carboxyl (-COOH) group attached to the cycloalkenyl ring portion of a cycloalkenylalkynyl group as defined above.

The term "alkoxy" includes both branched and straight chain terminal alkyl groups attached to a bridging oxygen atom. Typical alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, tert- butoxy and the like. The term "haloalkoxy" refers to an alkoxy group substituted with one or more halo groups, for example chloromethoxy, trifluoromethoxy, difluoromethoxy, perfluoroisobutoxy, and the like.

The term "alkoxyalkoxyalkyl" refers to an alkyl group substituted with an alkoxy moiety which is in turn is substituted with a second alkoxy moiety, for example methoxymethoxymethyl, isopropoxymethoxyethyl, and the like. The term "alkylthio" includes both branched and straight chain alkyl groups attached to a bridging sulfur atom, for example methylthio and the like.

The term "haloalkylthio" refers to an alkylthio group substituted with one or more halo groups, for example trifluoromethylthio and the like.

The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group, for example isopropoxymethyl and the like.

The term "alkoxyalkenyl" refers to an alkenyl group substituted with an alkoxy group, for example 3-methoxyallyl and the like.

The term "alkoxyalkynyl" refers to an alkynyl group substituted with an alkoxy group, for example 3 -methoxypropargyl. The term "alkoxycarbonylalkyl" refers to a straight chain or branched alkyl substituted with an alkoxycarbonyl, for example ethoxycarbonylmethyl, 2-(methoxycarbonyl)propyl and the like.

The term "alkoxycarbonylalkenyl" refers to a straight chain or branched alkenyl as defined above substituted with an alkoxycarbonyl, for example 4-(ethoxycarbonyl)-2-butenyl and the like.

The term "alkoxycarbonylalkynyl" refers to a straight chain or branched alkynyl as defined above substituted with an alkoxycarbonyl, for example 4-(ethoxycarbonyl)-2-butynyl and the like.

The term "haloalkoxyalkyl" refers to a straight chain or branched alkyl as defined above substituted with a haloalkoxy, for example 2-chloroethoxymethyl, trifluoromethoxymethyl and the like.

The term "haloalkoxyalkenyl" refers to a straight chain or branched alkenyl as defined above substituted with a haloalkoxy, for example 4-(chloromethoxy)-2-butenyl and the like. The term "haloalkoxyalkynyl" refers to a straight chain or branched alkynyl as defined above substituted with a haloalkoxy, for example 4-(2-fluoroethoxy)-2-butynyl and the like.

The term "alkylthioalkyl" refers to a straight chain or branched alkyl as defined above substituted with an alkylthio group, for example methylthiomethyl, 3-(isobutylthio)heptyl, and the like.

The term "alkylthioalkenyl" refers to a straight chain or branched alkenyl as defined above substituted with an alkylthio group, for example 4-(methylthio)-2-butenyl and the like.

The term "alkylthioalkynyl" refers to a straight chain or branched alkynyl as defined above substituted with an alkylthio group, for example 4-(ethylthio)-2-butynyl and the like.

The term "haloalkylthioalkyl" refers to a straight chain or branched alkyl as defined above substituted with an haloalkylthio group, for example 2-chloroethylthiomethyl, trifluoromethylthiomethyl and the like.

The term "haloalkylthioalkenyl" refers to a straight chain or branched alkenyl as defined above substituted with an haloalkylthio group, for example 4-(chloromethylthio)-2-butenyl and the like.

The term "haloalkylthioalkynyl" refers to a straight chain or branched alkynyl as defined above substituted with a haloalkylthio group, for example 4-(2-fluoroethylthio)-2-butynyl and the like. One in the art understands that an "oxo" requires a second bond from the atom to which the oxo is attached. Accordingly, it is understood that oxo cannot be subststituted onto an aryl or heteroaryl ring. The term "oligomer" refers to a low-molecular weight polymer, whose number average molecular weight is typically less than about 5000 g/mol, and whose degree of polymerization (average number of monomer units per chain) is greater than one and typically equal to or less than about 50. Compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

When a tautomer of the compound of Formula (I) exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.

When the compound of Formula (I) and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. A type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non- toxic bases from which salts can be formed include ion exchange resins such as, for example, arginine, betaine, caffeine, choline, N',N'- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Preferred are citric, hydrobromic, formic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids. Particularly preferred are formic and hydrochloric acid. Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure especially at least 98% pure (% are on a weight for weight basis).

The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

In practice, the compounds represented by Formula I, or a prodrug, or a metabolite, or a pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in- oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.

For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, lOOmg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or lOOOmg.

Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms. Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.

In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

Generally, dosage levels on the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day. For example, inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.

It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

Biological Assays

The efficacy of the Examples of the invention, compounds of Formula I, as inhibitors of protein tyrosine kinases were demonstrated and confirmed by a number of pharmacological in vitro assays.

The following assays and their respective methods can be carried out with the compounds according to the present invention. Activity possessed by compounds of Formula I may be demonstrated in vivo.

Person skilled in the art will appreciate that a variety of assay formats may be used to determine the activity of the compounds of this invention. For example, AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay) technology was used with the kinases described below. Assay ATP concentrations for individual kinases are included in the text.

KDR (human) - lOOμM ATP: 9μL of the reaction mix containing ATP at the desired concentration, biotinylated poly(Glu,Tyr) (84ng/mL) and 0.334mM vanadate in assay buffer (5OmM HEPES (pH = 7.4), 12.5mM MgCl₂ and 1% glycerol) are added to a well of a 384 well plate along with 1 μl of compound (or vehicle control, usually DMSO). DMSO concentration is controlled at a concentration of 1%. KDR is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer (5OmM HEPES pH = 7.4, 12.5mM MgCl₂ and 1% glycerol, 0.03% Brij35 and 0.3mM EGTA). 5μL of this solution are then added to the well, and the complete reaction mixture is incubated for 60min at RT. In subdued light, 5μL of PT66 donor and acceptor beads (diluted 1:200 from manufacturers provision in a 25mM Tris HCl (pH = 7.5), 20OmM NaCl, 10OmM EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

IGF-IR (human) - lOOμM ATP: To a well of a 384 well plate are added 9μL of the reaction mix containing ATP at the desired concentration, biotinylated poly(Glu,Tyr) (84ng/mL) and 0.334mM vanadate in assay buffer (5OmM HEPES (pH = 7.4), 12.5mM MgCl₂ and 1% glycerol) along with 1 μL of compound (or vehicle control, usually DMSO). DMSO concentration is controlled at a concentration of 1%. IGF-IR is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer (5OmM HEPES pH = 7.4, 12.5mM MgCl₂ and 1% glycerol, 0.03% Brij35, 0.3mM EGTA, 6mM DTT, and 0.003% BSA). 5μL of this solution are then added to the well, and the complete reaction mixture is incubated for 60min at RT. In subdued light, 5μL of PT66 donor and acceptor beads (diluted 1 :200 from manufacturer's provision in a 25mM Tris HCl (pH = 7.5), 20OmM NaCl, 10OmM EDTA, 0.3% BSA buffer) are added to the wells. The plates are then incubated for 4h and read on an AlphaQuest plate reader.

RON (human) - K_m of ATP: RON assay is performed in a 384 well assay containing 200ng/μL biotinylated poly(Glu,Tyr), 0.334mM vanadate, desired concentration of ATP optimized for the enzyme in assay buffer (5OmM HEPES (pH = 7.4), 12.5mM MgCl₂ and 1% glycerol). Desired compound is added in a final concentration of 1%DMSO with control being vehicle of DMSO alone. RON is diluted to the optimized (on a lot-by-lot basis) concentration in an enzyme diluent buffer (5OmM HEPES pH = 7.4, 12.5mM MgCl₂ and 1% glycerol, 0.03% Brij35, 0.3mM EGTA, ImM DTT, and 0.003% BSA). Enzyme is added to initiate the reaction and incubated for 30min at RT. In subdued light, appropriate amount of PT66 donor and acceptor beads (diluted 1 :260 from manufacturer's provision in a 25mM Tris HCl (pH = 7.5), 20OmM NaCl, 10OmM EDTA, 0.3% BSA buffer) are added to the wells. The plates, incubated for Ih, are read on an AlphaQuest plate reader.

MET (human) - Km of ATP: MET assay is performed in a 384 well assay containing 200ng/μL biotinylated poly(Glu,Tyr), 0.334mM vanadate, desired concentration of ATP optimized for the enzyme in assay buffer (5OmM HEPES (pH = 7.4), 5mM MgCl₂, 5mM MnCl₂, and 1% glycerol). Desired compound is added in a final concentration of 1%DMSO with control being vehicle of DMSO alone. MET is diluted to the optimized concentration (optimized on a lot-by-lot basis) in an enzyme diluent buffer (5OmM Tris pH = 7.4, 1% glycerol, 0.03% Brij35, 0.24mM EGTA, ImM DTT, and 0.003% BSA). Enzyme is added to initiate the reaction and incubated for 60min at RT. In subdued light, appropriate amount of PT66 donor and acceptor beads (diluted 1 :260 from manufacturer's provision in a 25mM Tris HCl (pH = 7.5), 40OmM NaCl, 100 mM EDTA, 0.3% BSA buffer) are added to the wells. The plates, incubated for Ih, are read on an AlphaQuest plate reader

The activities of compounds of the present invention against the kinases for which assays are not described above were determined at Invitrogen using the SelectScreen™ Kinase Profiling Service. The examples of this invention were tested for inhibition of various kinases according to the procedures described herein. Activities of exemplary compounds of the present invention are shown in Table I. The IC₅₀ values determined against RON and MET in at least duplicate experiments are abbreviated as follows and are shown in Table 1 : A, IC₅₀ < 0.1 μM; B, 0.1 μM < IC₅₀ < 1 μM; C, 1 μM < IC₅₀ ≤ 20 μM; D, IC₅₀ > 20 μM; ND, not determined. The Example # of Table I corresponds to the compound example number as illustrated under the following working examples section.

Table 1. IC₅₀ values of examples against RON and MET

Example RON IC₅₀ MET IC₅₀ Example RON IC₅₀ MET IC₅₀

1 C C 2 D C

3 A A 4 C B

5 B B 6 B B

7 B A 8 C C

9 B A 10 C B

11 B A 12 C B

13 C B 14 C C

15 B A 16 B B

17 B B 18 B B

19 B B 20 B B

21 C B 22 C B

23 B B 24 B B B B 26 B B

B B 28 C B

B B 30 C B

C C 32 B B

B B 34 C B

C C 36 B B

B B 38 B A

B A 40 B B

C B 42 B B

B B 44 C C

C B 46 C B

B B 48 B B

B A 50 B B

A A 52 A A

B B 54 C B

C B 56 B B

C B 58 B B

B B 60 C C

D D 62 B B

B B 64 B B

C C 66 C C

B B 68 B B

C C 70 C B

B A 72 B A

B B 74 C C

ND ND 76 D D

D D 78 C C

C C 80 C C

C C 82 D C

C C 84 C C

D C 86 D C

C C 88 C C

C C 90 B B

D D 92 C B

B B 94 C B

C C 96 C C

C B 98 C B

B B 100 B B

C C 102 C B

C B 104 B A

C C 106 B A

A A 108 A A

A A 110 B B

B B 112 C C

C B 114 B B

C C 116 B B

B B 118 B B

C C 120 C C

B B 122 B B

B B 124 C D

D C 126 D C

C C 128 C C

C C 130 C B

C C 132 C C 133 C C 134 C C

135 C C 136 C C

137 D D 138 C C

139 C C 140 C C

141 C C 142 C C

143 C C 144 C C

145 C B 146 C C

147 C C 148 C C

149 C C 150 B B

151 B B 152 C C

153 D B 154 B A

155 B A 156 A A

157 A A 158 A A

159 A A 160 B A

161 B A 162 B A

163 B B 164 B B

165 B B 166 B A

167 B A 168 B B

169 B A 170 B A

171 B A 172 B B

173 B B 174 C A

175 B B 176 B B

177 B A 178 B B

179 B A 180 B A

181 B A 182 C B

183 C C 184 C C

185 C B 186 D C

187 C C 188 C C

189 C C 190 D C

191 D D 192 C C

193 C C 194 D D

195 D D 196 C C

197 C C 198 D C

199 C C 200 ND ND

201 C C 202 C B

203 C B 204 D C

205 C C 206 D C

207 C C 208 C B

209 C C 210 C B

211 C C 212 D C

213 C C 214 D C

215 C C 216 D D

217 C B 218 C B

219 D B 220 C B

221 C C 222 C C

223 C C 224 C B

225 C C 226 C B

227 C C 228 C B

229 C C 230 C C

231 C C 232 C B

233 D C 234 D C

235 C C 236 C C

237 C B 238 C C

239 C C 240 C C 241 D C 242 C C

243 D C 244 D C

245 D C 246 C B

247 B A 248 B B

249 B A 250 B A

251 B B 252 B B

253 B B 254 B B

255 B B 256 B A

257 B B 258 B A

259 A A 260 B B

261 B B 262 B B

263 A A 264 B A

265 B A 266 C C

267 A A 268 B B

269 B B 270 B B

271 B B 272 B B

273 A A 274 B A

275 B B 276 B B

277 B B 278 B A

279 B B 280 B B

281 B B 282 B B

283 A A 284 B B

285 C B 286 B B

287 B C 288 D B

289 C B 290 C B

291 D C 292 D C

293 C B 294 C C

295 C B 296 C C

297 C B 298 A A

299 B B 300 C B

301 C C 302 B B

303 B B 304 C B

General Synthetic Schemes

The compounds of the formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art (such as those methods disclosed in standard reference books such as the COMPENDIUM OF ORGANIC SYNTHETIC METHODS, Vol. I- VI (published by Wiley- Interscience)). Preferred methods include, but are not limited to, those described below.

During any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference. Compounds of Formula I, or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed hereinbelow. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.

Scheme I illustrates a method for the preparation of compounds of Formula I. Scheme 1

Vl IV

Compounds of formula II wherein RlO = boronic acid/ester or trialkyltin can be reacted under catalysis by metals such as palladium or nickel with compounds of formula III wherein RI l = Cl, Br, I, triflate to give compounds of formula I. Alternatively, compounds IV and V in which RlO and Rl 1 are switched can also be coupled under substantially similar conditions to give compounds of formula I. Such coupling reactions are known to someone skilled in the art. Compounds of formula IV wherein RI l = Cl, Br, or I can be prepared from compounds of formula VI by reaction with a halogenating agent. Typical halogenating agents include, but are not limited to, Cl₂, Br₂, 1₂, NCS, NBS, NIS, ICl. Compounds of formula VI may be prepared under similar coupling conditions from compounds of formulas VII and VIII, or from compounds of formulas IX and X. Many compounds of formulas VII- X are commercially available, have been described in the literature, or can be prepared according to the literature.

In the alternate route shown in Scheme 2, the X-(R2)_n moiety of compounds of formula I can be introduced on the last step. Scheme 2

XIII XII ^Vl"

Compounds of formula XI wherein RlO = boronic acid/ester or trialkyltin can be reacted under catalysis by metals such as palladium or nickel with compounds of formula X wherein RI l = Cl, Br, I, triflate to give compounds of formula I. Alternatively, compounds XII and VIII in which RlO and Rl 1 are switched can also be coupled under substantially similar conditions to give compounds of formula I. Such coupling reactions are known to someone skilled in the art. Compounds of formula XII wherein RI l = Cl, Br, or I can be prepared from compounds of formula XIII by reaction with a halogenating agent. Typical halogenating agents include, but are not limited to, Cl₂, Br₂, 1₂, NCS, NBS, NIS, ICl. Compounds of formula XIII may be prepared under similar coupling conditions from compounds of formulas XIV and V, or from compounds of formulas XV and III. Many compounds of formulas XIV-XV are commercially available, have been described in the literature, or can be prepared according to the literature.

While the above descriptions for Schemes 1 and 2 mention coupling reactions of boronic esters / acids or organotin compounds with halides or triflates, commonly referred to as Suzuki and Stille couplings, respectively, someone skilled in the art will recognize that further types of coupling can be applied here if deemed advantageous, such as, but not limited to, Negishi couplings (with organozinc reagents), Hiyama couplings (with organosilicon reagents), or couplings that involve C-H activation.

Scheme 3 shows two routes used for the preparation of building blocks III. Building blocks III are compounds Rl-Rl 1 shown in the above Schemes 1 and 2 wherein Rl is isoquinolin-3-yl optionally substituted with 1-4 R3 group and Rl 1 is triflate. In the first route, benzylamines are first converted into their dimethoxyacetamides. This can be accomplished conveniently by reacting the amine neat with methyl dimethoxyacetate, or the amine hydrochloride with methyl dimethoxyacetate in the presence of a base in a solvent such as methanol. Those amides can be cyclized to yield 3- hydroxyisoquinolines by treatment with strong acids, such as, but not limited to, concentrated sulfuric acid. In the second route, a phenylacetyl chloride is reacted with formamide in the presence of a base, such as pyridine, to give an N-formylphenylacetamide that can be cyclized to yield 3- hydroxyisoquinolines by treatment with strong acids, such as, but not limited to, concentrated sulfuric acid. Many of the needed starting materials are commercially available, have been described in the literature, or can be prepared according to the literature. The conversion of the resulting 3- hydroxyisoquinolines to the corresponding trifluoromethanesulfonate esters (triflates) III can be accomplished by reacting the hydroxy compounds with triflating agents such as, but not limited to, trifluoromethanesulfonic anhydride or N-phenylbis(trifluoromethanesulfonimide).

Scheme 3

Scheme 4 illustrates three routes used for the preparation of building blocks III. Building blocks III are compounds Rl-Rl 1 shown in the above Schemes 1 and 2 wherein Rl is benzothiazol-2-yl optionally substituted with 1-4 R3 group and Rl 1 is Cl, Br or I. In Route 1, anilines wherein LG is F, Cl, or Br are reacted with potassium ethyl xanthogenate to give 2-mercaptobenzothiazoles. These compounds may be converted by reaction with sulfuryl chloride to 2-chlorobenzothiazoles. Alternatively, in Route 2, the 2-mercaptobenzothiazoles are reacted with a methyl halide or sulfate, such as methyl iodide, and a base to give 2-methylsulfanylbenzothiazoles. Longer-chain alkyl halides or sulfates may alternatively be used. Such compounds can be converted by various oxidizing agents to the corresponding 2-methylsulfonylbenzothiazoles. Nucleophilic displacement of the methylsulfonyl group with ammonia yields 2-aminobenzothiazoles. Someone skilled in the art will recognize that the 2-amino group in these compounds can be converted to halogen such as Cl, Br, or I by the Sandmeyer reaction resulting in compounds III. In Route 3, anilines are first converted into thioureas, a conversion well known in the literature, and then reacted with an oxidizing agent such as bromine to give 2- aminobenzothiazoles. This conversion may also be accomplished directly by reacting the aniline, ammonium or sodium or potassium thiocyanate, and bromine in a one-pot procedure. The resulting 2- aminobenzothiazoles are converted to compounds III as described for Route 2. Many of the needed starting materials are commercially available, have been described in the literature, or can be prepared according to the literature.

Scheme 4

Person skilled in the art will realize that further functionalization of the above-described Rl moieties in Schemes 3 and 4 may be possible at various stages during their synthesis, or at the stage of the compounds of Formula I. Compounds or intermediates wherein substituents R3 (shown in Schemes 3 and 4) is Cl, Br, I, or triflate may be reacted under transition metal catalysis with (het)arylboronic acids or -trialkyltin reagents or alkylzinc reagents to introduce R3 as (het)aryl or alkyl, respectively, or with a cyanide source to introduce R3 as CN (which itself may be reacted further), or with KOH to introduce R3 as OH. In compounds or intermediates wherein R3 is F, the fluorine may be displaced with alkoxides to introduce R3 as alkoxy. In compounds or intermediates wherein R3 is alkoxy, these ethers may be cleaved to introduce R3 as OH. The intermediate 3-hydroxyisoquinolines wherein C4 is unsubstituted may be reacted with electrophiles to introduce substitution at C4. These examples are not meant in any way to be limiting.

Working Examples

The following illustrate the synthesis of various compounds of the present invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.

The following abbreviations are used:

NMR Nuclear magnetic resonance

MDPS Mass-directed HPLC purification system MDP Mass-directed HPLC purification LC/MS Liquid chromatography mass spectrometry

LDA Lithium diisopropylamide

DCM Dichloromethane

THF Tetrahydrofuran

EtOAc Ethyl acetate

MeCN Acetonitrile

DMSO Dimethylsulfoxide

Boc t-Butyloxycarbonyl

DMF N, JV-Dimethylformamide

PS-DIEA Polymer-supported diisopropylethylamine

PS-PPh₃-Pd Polymer-supported Pd(PPh₃ )₄

EDCI or EDC 1 -(3 -Dimethylaminopropyl)-3 -ethylcarbodiimide

HOBt 1 -Hydroxybenzotriazole

DMAP 4-Dimethylaminopyridine

TFA Trifluoroacetic acid

TLC Thin layer chromatography

Min Minute(s) h Hour(s) d Day(s)

RT or rt Room temperature

Retention time

Unless otherwise noted, all materials/reagents were obtained from commercial suppliers and used without further purification. ¹H NMR (400 MHz or 300 MHz) and ¹³C NMR (100.6 MHz) spectra were recorded on Bruker or Varian instruments at ambient temperature with TMS or the residual solvent peak as the internal standard. The line positions or multiples are given in ppm (δ) and the coupling constants (J) are given as absolute values in Hertz (Hz). The multiplicities in ¹H NMR spectra are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), m_c (centered multiplet), br or broad (broadened), AA'BB'. The signal multiplicities in ¹³C NMR spectra were determined using the DEPT135 pulse sequence and are abbreviated as follows: + (CH or CH₃), - (CH₂), C_qua_rt (C). Reactions were monitored by thin layer chromatography (TLC) on silica gel 60 F₂5₄ (0.2 mm) precoated aluminum foil and visualized using UV light. Flash chromatography was performed with silica gel (400-230 mesh). Preparatory TLC was performed on Whatman LK6F Silica Gel 60 A size 20 x 20 cm plates with a thickness of 1000 μm. Hydromatrix (= diatomaceous earth) was purchased from Varian. Mass-directed HPLC purification of compounds was performed on a Waters system composed of the following: 2767 Sample Manager, 2525 Binary Gradient Module, 600

Controller, 2487 Dual λ Absorbance Detector, Micromass ZQ2000 for ionization, Phenomenex Luna 5μ C 18(2) 100 A 150 x 21.2mm 5μ column with mobile phases of 0.01% Formic Acid Acetonitrile (A) and 0.01% Formic Acid in HPLC water (B), a flow rate of 20 mL/min, and a run time of 13 min. LC- MS data was collected on ZQ2, ZQ3, or UPLC-ACQUITY. ZQ2 is an Agilent 1100 HPLC equipped with a Gilson 215 Liquid Handler, Gilson 819 Injection Module, and Waters Micromass ZQ2000 for ionization. ZQ3 is an Agilent 1100 HPLC equipped with an HP Series 1100 auto injector and Waters Micromass ZQ2000 for ionization. Both systems use the Xterra MS C18, 5μ particle size, 4.6 x 50 mm with a mobile phase of Acetonitrile (A) and 0.01% Formic Acid in HPLC water (B). The flow rate is 1.3 mL/min, the run time is 5 min, and the gradient profiles are 0.00 min 5%A, 3.00 min 90%A, 3.50 min 90%A, 4.00 min 5%A, 5.00 min 5%A for polar_5min and 0.00 min 25%A, 3.00 min 99%A, 3.50 min 99%A, 4.00 min 25%A, 5.00 min 25%A for nonpolar_5min. All Waters Micromass ZQ2000 instruments utilized electrospray ionization in positive (ES+) or negative (ES-) mode. The Waters Micromass ZQ2000 instruments from ZQ2 and ZQ3 can also utilize atmospheric pressure chemical ionization in positive (AP+) or negative (AP-) mode. The Waters UPLC- ACQUITY system consists of an ACQUITY sample manager attached to ACQUITY SQ MS and ACQUITY PDA detectors. It uses an ACQUITY UPLC BEH^® C 18 2.1 x50mm 1.7μm column with a mobile phase of 0.1 % formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The flow rate is 1.0 mL/min, run time is 2 min, and the gradient profile is 0.00 min 95%A, 1.50 min 1%A, 1.85 min 1%A, 2.0 min 95% A for analytical. UV detection is at 254 nm, and the MS utilizes electrospray ionization in positive mode (ES+). HPLC purification of compounds was performed on a Gilson system consisting of a 215 Liquid Handler, 819 Injection Module, a 322 Pump, and a 155 UV/VIS dual wavelength detector set to 254 and 210 nm. This system uses Phenomenex Luna Cl 8(2), 5μ particle size, 50 x 21.2 mm or 60 x 21.2 mm columns with a mobile phase of Acetonitrile and 0.1% Formic Acid in HPLC water. The flow rate is 15 mL/min and the run time is 25 min. All melting points were determined with a Mel-Temp II apparatus and are uncorrected. Elemental analyses were obtained by Atlantic Microlab, Inc., Norcross, GA.

Scheme 5: Synthesis of key building blocks BBl, BB2, and BB3

BB3: 4-{4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-pyrazol-l- yl}-piperidine-l-carboxylic acid tert-buty\ ester Into a solution of Pd₂(dba)₃ (627 mg, 0.686 mmol) and tricyclohexylphosphine (768 mg, 2.74 mmol) in dioxane (200 mL), nitrogen was bubbled for 15 min at ambient temperature. Bispinacolatodiborane (11.32 g, 44.6 mmol), potassium acetate (5.37 g, 54.8 mmol), and 4-[4-(6- amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (14.5 g, 34.3 mmol) were added to the stirred solution and N₂ gas bubbling was continued for another 10 min. The reaction mixture was then heated at 100 ⁰C for 8 h. The reaction mixture was cooled to ambient temperature and filtered. The filtrate was evaporated under reduced pressure. The residue was stirred with diisopropyl ether (100 mL) for 10 min at ambient temperature. The white precipitate that formed was filtered off and dried in vacuo. The filtrate was evaporated under reduced pressure, and the residue was stirred with diethyl ether (50 mL) for 10 min. The off- white precipitate that formed was filtered off, combined with the first precipitate, and dried in vacuo to give the title compound as white solid. ¹H NMR (300 MHz, CDCl₃): δ = 1.27 (s, 12H), 1.48 (s, 9H), 1.92-1.96 (m, 2H), 2.13-2.17 (m,2H), 2.89 (m, 2H), 4.23-4.28 (m, 3H), 5.48 (s, broad, 2H), 7.59 (s, IH), 7.70 (s, IH), 7.90 (d, IH, J = 2.1 Hz), 8.25 (d, IH, J= 2.1 Hz).

BB2: 4-[4-(6-Amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert- butyl ester

To a well stirred solution of 4-[4-(6-aminopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (24.4 g, 71.1 mmol) in DCM (800 mL) was added solid Na₂CO₃ (11.2 g, 107 mmol), and the mixture was cooled to 0 ⁰C. A solution of bromine (3.6 mL, 71 mmol) in DCM (200 mL) was added dropwise during 30 min, and the reaction mixture was stirred for further 5 h at ambient temperature. The reaction mixture was then cooled to 10 ⁰C, and a cold solution of 10% sodium thiosulfate in water (100 mL) followed by saturated sodium bicarbonate solution (100 mL) was added. After stirring for 10 min, the organic layer was separated, washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to yield a brown solid. It was triturated twice with tert-butyl methyl ether (100 mL) at 40-45 ⁰C, filtered, and dried in vacuo to yield the title compound as white solid. ¹HNMR (300 MHz, CDCl₃): δ = 1.48 (s, 9H), 1.92-1.96 (m, 2H), 2.13-2.17 (m,2H), 2.89 (m, 2H), 4.23-4.28 (m, 3H), 4.86 (s, broad, 2H), 7.56 (s, IH), 7.66 (s, IH), 7.75 (d, IH, J= 2.1 Hz), 8.15 (d, IH, J= 2.1 Hz).

4-[4-(6-Aminopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-buty\ ester Into a well stirred suspension of 2-amino-5-bromopyridine (14.6 g, 84.8 mmol), 4-[4-(4,4,5,5- tetramethyl[l ,3,2]dioxaborolan-2-yl)- lH-pyrazol- 1 -yl]-piperidine- 1 -carboxylic acid tert-butylester

(40.0 g, 106 mmol) and Cs₂CO₃ (55.1 g, 170 mmol) in dioxane (700 mL) / water (140 mL) was bubbled N₂ gas for 15 min at ambient temperature. Pd(PPh₃ )₄ (4.8 g, 4.2 mmol) was then added to the solution followed by N₂ gas bubbling for another 10 min. The reaction mixture was then heated at 100 ⁰C for 3 h. The cooled reaction mixture was concentrated under reduced pressure to yield an off-white residue. It was stirred with water / DCM (100 mL each) for 5 min, and the organic layer was separated. The aqueous layer was extracted with DCM (3x 100 mL). The combined organic layers were washed with water (50 mL) followed by brine (50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield a light yellowish residue. It was triturated with 1 : 1 EtOAc:Hexane (100 mL) with ice cooling for 10 min. Off- white crystals separated out which were filtered and dried in vacuo to give the title compound as white solid. ¹H NMR (300 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.89-2.03 (m, 2H), 2.12-2.22 (m, 2H), 2.91 (m, 2H), 4.23^.28 (m, 3H), 4.48 (s, broad, 2H), 6.53 (d, J = 8.4 Hz, IH), 7.24-7.33 (d, J = 8.4 Hz, IH), 7.67 (s, IH), 7.90 (d, IH, J= 2.1 Hz), 8.25 (d, IH, J= 2.1 Hz).

BBl: 4-[4-(4,4,5,5-Tetramethyl[l,3,2]dioxaborolan-2-yl)-lH-pyrazol-l-yl]-piperidine-l- carboxylic acid tert-buty\ester

A mixture of 4-(4,4,5,5-tetramethyl[l,3,2]dioxaborolan-2-yl)-lH-pyrazole (30.0 g, 154 mmol), 4- methanesulfonyloxypiperidine- 1 -carboxylic acid tert-butylester (52.5 g, 200 mmol) and cesium carbonate (80.1 g, 246 mmol) in anhydrous DMF (400 mL) was heated to 100 ⁰C for 24 h. DMF was removed under high vacuum. The residue was then diluted with water (200 mL) and extracted with EtOAc (3x200 mL). The combined organic phases were washed with water (3x50 mL) and brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. To the orange-brown oily residue was added diisopropyl ether (300 mL), and the mixture was stirred at 0 ⁰C for 2 h. Colorless crystals separated out that were filtered off and dried in vacuo to give a 1^st crop of the title compound. The filtrate was then concentrated in vacuo, the residue was mixed with diisopropyl ether (100 mL), a small amount of the 1^st crop was added as a seed, and the mixture was stirred overnight. The resulting white precipitate was filtered and dried in vacuo as 2^nd crop of the title compound. ¹H NMR (300 MHz, CDCl₃): δ = 1.33 (s, 12H), 1.48 (s, 9H), 1.85-1.93 (m, 2H), 2.15-2.18 (m, 2H), 2.83-2.92 (m, 2H), 4.23-4.39 (m, 3H), 7.76 (s, IH), 7.84 (s, IH). 4-Methanesulfonyloxypiperidine-l-carboxylic acid tert-buty\ ester

To a solution of l-Boc-4-hydroxypiperidine (32.2 g, 0.160 mol) in DCM (400 mL) were added triethylamine (26.8 mL, 0.192 mol), methanesulfonyl chloride (13.6 mL, 0.176 mol) and 4- dimethylaminopyridine (0.20 g, 0.0016 mol) at 0 ⁰C under nitrogen atmosphere. The resulting mixture was slowly warmed to rt and stirred at rt overnight. The mixture was washed with sat. aq. NaHCO₃ (3x80 mL), brine (2x80 mL), and dried over anhydrous sodium sulfate. The filtrate was concentrated to give the title compound as a white solid. It was used in the next step without further purification. ¹H NMR (CDCl₃): δ = 1.47 (s, 9H), 1.80-1.85 (m, 2H), 1.95-1.99 (m, 2H), 3.05 (s, 3H), 3.28-3.34 (m, 2H), 3.68-3.74 (m, 2H), 4.89 (m_c, IH).

Example 1 : 3-(l-Methylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

To a solution of 4-{4-[6-Amino-5-(l-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-buiyl ester (36.8 mg, 0.0759 mmol) in 1,4-dioxane (1.0 mL, 13 mmol) was added 4.0 M of HCl in 1,4-dioxane (1.0 mL, 4.0 mmol), and the mixture was stirred at ambient temperature for 1.5 h. Almost immediately a pale yellow solid precipitated. The solid was filtered off, washed with MTBE, and dried in vacuo, giving the title compound as pale yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 14.7 (very brs, IH), 9.33-9.23 (brm, IH), 9.21-9.08 (brm, IH), 8.82 (d, J= 1.8 Hz, IH), 8.8 (very brs, 2H), 8.59 (s, IH), 8.50 (s, IH), 8.48 (d, J= 1.8 Hz, IH), 8.38 (d, J= 8.4 Hz, IH), 8.14 (s, IH), 8.13 (d, J= 8.0 Hz, IH), 7.95 (dd, J= 7.2, 7.2 Hz, IH), 7.84 (dd, J= 7.8, 7.8 Hz, IH), 4.58-4.49 (m_c, IH), 3.39 (brd, J= 12.6 Hz, 2H), 3.11 (brq, J= 11.4 Hz, 2H), 3.07 (s, 3H), 2.30- 2.13 (m, 4H). MS(ES+): m/z = 385.15 (53) [MH⁺], 302.12 (100) [MH⁺ - piperidine]. HPLC: t_R = 1.88 min (polar_5min, ZQ3).

4-{4-[6-Amino-5-(l-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester To a solution of 4-{4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-1-yl} -piperidine- 1-carboxylic acid tert-butyl ester (BB3) (97.5 mg, 0.208 mmol), trifluoromethanesulfonic acid l-methylisoquinolin-3-yl ester (62.3 mg, 0.214 mmol), and Pd(PPh₃)₄ (15 mg, 0.013 mmol) in 1,4-dioxane (3.2 mL, 41 mmol) in a sealable microwave tube was added a solution of CS₂CO3 (135 mg, 0.413 mmol) in H₂O (0.95 mL, 53 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 100 ⁰C for 30 minutes. The reaction mixture was diluted with EtOAc, washed with water and brine, and dried over MgSO₄. The EtOAc extract was diluted with DCM (to give DCM:EtOAc « 1 :1) and filtered through a plug of silica gel. The silica gel was then washed with DCM:EtOAc 1 :2, DCM:EtOAc 1 :5, and EtOAc until no more product eluted. Filtrate/washings that contained product were concentrated in vacuo. The crude material was chromatographed on silica gel [10 g / 70 mL prepacked cartridge, eluting with DCM → DCM:EtOAc 2: 1 → DCM:EtOAc 1 : 1 → DCM:EtOAc 1 :2 → EtOAc]. Mixed fractions were combined, concentrated in vacuo, and purified by prep. TLC [20x20 cm plates, 500 μm, eluting with 2% MeOH/DCM (1 x) and 4% MeOH/DCM (3x)]. Clean material from prep. TLC was combined with pure fractions from the column chromatography and dried in vacuo, yielding the title compound as viscous, yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 8.26 (d, J = 2.0 Hz, IH), 8.15 (dd, J = 0.8, 8.4 Hz, IH), 7.94 (d, J= 2.0 Hz, IH), 7.89 (d, J= 8.0 Hz, IH), 7.88 (s, IH), 7.77 (d, J= 0.4 Hz, IH), 7.72 (ddd, J= 1.2, 7.2, 8.2 Hz, IH), 7.66 (d, J= 0.4 Hz, IH), 7.62 (ddd, J= 1.2, 6.8, 8.2 Hz, IH), 6.49 (brs, 2H), 4.38^.20 (m, 3H), 3.03 (s, 3H), 2.92 (brt, J= 12.0 Hz, 2H), 2.19 (brd, J= 12.0 Hz, 2H), 1.98 (dq, J= 4.4, 12.2 Hz, 2H), 1.49 (s, 9H). MS(ES+): m/z = 485.18 (100) [MH⁺], 429.06 (39) [MH⁺ - isobutene]. HPLC: fe = 2.76 min (polar_5min, ZQ3).

Trifluoromethanesulfonic acid l-methylisoquinolin-3-yl ester

To a suspension of l-methylisoquinolin-3-ol (0.242 g, 1.52 mmol) and triethylamine (0.40 mL, 2.9 mmol) in DCM (10 mL, 160 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.31 mL, 1.8 mmol). The solid dissolved, and the solution was stirred at 0 ⁰C for 75 min. More trifluoromethanesulfonic anhydride (0.15 mL, 0.89 mmol) and triethylamine (0.15 mL, 1.1 mmol) were added, and stirring at O ⁰C was continued for 1 h. The reaction solution was then diluted with more DCM to a total volume of « 40 mL, washed with water, NaHCO₃ solution, and brine, and dried over MgSO4. The extract was filtered through a plug of silica gel (~ 1" high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The combined fractions containing product were concentrated and dried in vacuo to give the title compound as a brown oil. It was used in the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 8.17 (dd, J = 1.2, 8.4 Hz, IH), 7.88 (d, J= 8.4 Hz, IH), 7.76 (ddd, J= 1.2, 6.8, 8.4 Hz, IH), 7.67 (ddd, J= 1.2, 6.8, 8.4 Hz, IH), 7.42 (s, IH), 2.97 (s, 3H). MS(ES+): m/z = 291.98 (100) [MH⁺], 159.08 (90) [MH⁺ - SO₂CF₃]. HPLC: t_R = 3.95 min (polar_5min, ZQ3). l-Methylisoquinolin-3-ol Concentrated sulfuric acid (18 M; 6.0 mL) was added to 2,2-dimethoxy-N-(l-phenylethyl)- acetamide (2.49 g, 11.2 mmol), and the resulting solution was stirred at 60 ⁰C for 105 min. The reaction mixture was added to « 100 mL of ice, and the yellow precipitate was filtered off. The pH of the filtrate was adjusted to 7-8 with NaHCO₃ solution, the initial yellow solid was added, and the yellow precipitate was filtered off, washed with water, and dried in vacuo, giving the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 10.68 (brs, IH), 8.00 (dd, J= 1.0, 8.6 Hz, IH), 7.64 (d, J= 8.4 Hz, IH), 7.53 (dt, J= 1.0, 8.0 Hz, IH), 7.28 (dt, J= 0.8, 8.0 Hz, IH), 6.69 (s, IH), 2.78 (s, 3H). MS(ES+): m/z = 160.10 (100) [MH⁺]. HPLC: t_R = 2.13 min (polar_5min, ZQ3). 2,2-Dimethoxy-Λ'-(l-phenylethyl)-acetamide A mixture of methyl dimethoxyacetate (2.10 g, 15.6 mmol) and α-methylbenzylamine (1.90 g, 15.7 mmol) was stirred at ambient temperature for 5 d and at 40 ⁰C for 4 d. To the reaction mixture was added hexane (5 mL), and the mixture was sonicated. Two layers formed, but no solid precipitated, even upon cooling, and the hexane layer was withdrawn with a pipette. This was repeated twice. The residue was dissolved in EtOAc (~ 100 mL), and the solution was washed with aqueous solutions of NH₄Cl, NaHCO₃, and brine, and dried over MgSO₄. The solution was filtered and dried in vacuo overnight to give the title compound as pale yellow oil. ¹H NMR (CDCl₃, 400 MHz): δ = 7.38-7.30 (m, 4H), 7.29-7.24 (m, IH), 6.80 (brs, IH), 5.16 (dq, J= 8.0, 6.8 Hz, IH), 4.70 (s, IH), 3.42 (s, 3H), 3.36 (s, 3H), 1.52 (d, J= 6.8 Hz, 3H). MS(ES+): m/z = 246.07 (64) [MNa⁺], 224.11 (78) [MH⁺], 192.11 (52) [MH⁺ - MeOH], 160.10 (60) [MH⁺ - 2 MeOH]. HPLC: t_R = 2.76 min (polar_5min, ZQ3). Example 2: 3-(4-Methylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

To a solution of 4-{4-[6-amino-5-(4-methylisoquinolm-3-yl)-pyridm-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-buiyl ester (79.1 mg, 0.163 mmol) in 1,4-dioxane (2.0 mL, 26 mmol) was added 4.0 M of HCl in 1,4-dioxane (2.0 mL), and the mixture was stirred at ambient temperature for 3 h. Almost immediately an off-white solid precipitated. The solid was filtered off, washed with MTBE, and dried in vacuo overnight to give the title compound as an off- white solid. It appeared to be slightly hygroscopic during the filtration; however, after the washing and initial drying it appeared to be non-hygroscopic. ¹H NMR (400 MHz, DMSO-^₆): δ = 14.6 (very brs, IH), 9.68 (s, IH), 9.37-9.24 (brm, IH), 9.24-9.10 (brm, IH), 8.55 (d, J = 2.0 Hz, IH), 8.47 (d, J = 7.6 Hz, IH), 8.46 (d, J= 2.0 Hz, IH), 8.39 (s, IH), 8.38 (d, J= 7.6 Hz, IH), 8.14 (t, J= 7.2 Hz, IH), 8.05 (s, IH), 7.98 (t, J= 7.6 Hz, IH), 7.81 (brs, 2H), 4.54^.45 (m_c, IH), 3.35 (brd, J= 12.6 Hz, 2H), 3.07 (brq, J= 11.2 Hz, 2H), 2.59 (s, 3H), 2.26-2.09 (m, 4H). MS(ES+): m/z = 385.17 (96) [MH⁺], 302.1 (100) [MH⁺ - piperidine]. HPLC: t_R = 0.65 & 1.72 min (peak splitting; polar_5min, ZQ3).

4-{4-[6-Amino-5-(4-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester (BB3) (86.3 mg, 0.184 mmol), trifluoromethanesulfonic acid 4-methylisoquinolin-3-yl ester (54.8 mg, 0.188 mmol), and Pd(PPh₃ )₄ (14 mg, 0.012 mmol) in 1,4-dioxane (2.8 mL, 36 mmol) in a sealable microwave tube was added a solution of CS₂CO3 (118 mg, 0.361 mmol) in H₂O (0.80 mL, 44 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 100 ⁰C for 30 min. The reaction mixture was diluted with DCM, washed with water and brine, and dried over MgSO₄. The crude material was chromatographed on silica gel [20 g / 70 mL prepacked cartridge, eluting with DCM → 1% MeOH in DCM → 2% MeOH in DCM → 2.5% MeOH in DCM → 3% MeOH in DCM → 3.5% MeOH in DCM → 4% MeOH in DCM]. Fractions containing the title compound were combined and dried in vacuo, giving the title compound as a glassy solid. ¹H NMR (400 MHz, CDCI3): δ = 9.22 (s, IH), 8.30 (d, J= 2.4 Hz, IH), 8.08 (dd, J= 0.8, 8.6 Hz, IH), 8.03 (d, J= 8.0 Hz, IH), 7.81 (ddd, J = 1.2, 6.8, 8.3 Hz, IH), 7.71 (d, J= 0.8 Hz, IH), 7.68 (ddd, J= 0.8, 7.0, 8.0 Hz, IH), 7.62 (s, IH), 7.57 (d, J= 2.4 Hz, IH), 4.85 (brs, 2H), 4.42-4.13 (m, 3H), 2.90 (brt, J= 11.2 Hz, 2H), 2.62 (s, 3H), 2.15 (brdd, J= 2.0, 12.4 Hz, 2H), 1.95 (dq, J= 4.0, 12.0 Hz, 2H), 1.48 (s, 9H). MS(ES+): m/z = 485.14 (100) [MH⁺], 429.12 (66) [MH⁺ - isobutene]. HPLC: t_R = 2.62 min (polar_5min, ZQ3). Trifluoromethanesulfonic acid 4-methylisoquinolin-3-yl ester

To a suspension of 4-methylisoquinolin-3-ol (0.243 g, 1.53 mmol) and triethylamine (0.40 mL, 2.9 mmol) in DCM (10 mL, 160 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.31 mL, 1.8 mmol) at 15:20. The solid dissolved, and the solution was stirred at 0 ⁰C for 1 h. More trifluoromethanesulfonic anhydride (0.10 mL, 0.59 mmol) was added (the yellow color of the reaction solution faded to a very pale yellow), and stirring at 0 ⁰C was continued for 30 min. The reaction solution was diluted with more DCM to a total volume of _* 40 mL, washed with water, NaHCO₃ solution, and brine, and dried over MgSO₄. The extract was filtered through a plug of silica gel (~ 1 " high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The combined fractions containing product were concentrated and dried in vacuo, giving the title compound as a pale yellow solid. It was used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 8.93 (s, IH), 8.08-8.03 (m, 2H), 7.83 (ddd, J = 1.4, 6.8, 8.4 Hz, IH), 7.69 (ddd, J= 1.2, 7.0, 8.0 Hz, IH), 2.68 (d, J= 0.4 Hz, 3H). MS(ES+): m/z = 292.00 (95) [MH⁺], 159.08 (100) [MH⁺ - SO₂CF₃]. HPLC: t_R = 3.96 min (polar_5min, ZQ3). 4-Methylisoquinolin-3-ol Concentrated sulfuric acid (18 M; 6.0 mL) was added to N-benzyl-2,2-dimethoxypropionamide (1.38 g, 6.18 mmol) at ambient temperature, and the solution was stirred at ambient temperature for 30 min and at 55 ⁰C overnight. The reaction mixture was added to « 100 mL of ice, and the pH of the yellow solution was adjusted to 7-8 with NaHCO₃ solution. Small amounts of a brown solid that precipitated very soon during the addition (pH was still < 2) were filtered off, and neutralization was continued. The yellow precipitate was filtered off, washed with water, and dried in vacuo, giving the title compound as yellow solid. It was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 10.6 (very brs, IH), 8.74 (s, IH), 7.91 (d, J= 8.4 Hz, IH), 7.83 (dd, J= 0.8, 8.6 Hz, IH), 7.61 (ddd, J= 1.6, 6.4, 8.4 Hz, IH), 7.31 (ddd, J= 0.8, 6.4, 8.0 Hz, IH), 2.37 (d, J= 0.4 Hz, 3H). MS(ES+): m/z = 160.10 (100) [MH⁺]. HPLC: t_R = 2.3 min (polar_5min, ZQ3). jY-Benzyl-l^-dimethoxypropionamide A mixture of methyl 2,2-dimethoxypropionate (2.33 g, 15.7 mmol) and benzylamine (1.68 g, 15.7 mmol) in a 20 mL screw-capped vial was stirred at 55 ⁰C for 12 d. To the reaction mixture, which mostly solidified upon cooling to ambient temperature was added hexane (5 mL), and the mixture was sonicated and stirred vigorously. The solid was filtered off, washed with hexanes, and dried in vacuo to give the title compound as off-white solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.38-7.25 (m, 5H), 7.08 (brs, IH), 4.49 (d, J= 5.6 Hz, 2H), 3.25 (s, 6H), 1.52 (s, 3H). MS(ES+): m/z = 246.07 (58) [MNa⁺],

224.11 (58) [MH⁺], 192.12 (100) [MH⁺ - MeOH], 160.11 (33) [MH⁺ - 2 MeOH]. HPLC: t_R = 2.78 min (polar_5min, ZQ3).

Example 3 : 3-(8-Chloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride To a solution of 4-{4-[6-amino-5-(8-chloroisoquinolin-3-yl)-pyridm-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-buiyl ester (64.2 mg, 0.127 mmol) in 1,4-dioxane (1.5 mL, 19 mmol) was added HCl (4.0 M in 1,4-dioxane; 1.2 mL, 4.8 mmol), and the mixture was stirred at ambient temperature for 70 min. Almost immediately an off-white solid precipitated. The solid was filtered off, washed with MTBE, and dried in vacuo overnight to give the title compound as yellow solid. It appeared to be slightly hygroscopic during the filtration; however, after the washing and initial drying it appeared to be non-hygroscopic. ¹H NMR (400 MHz, OMSO-d₆): δ = 14.7 (very brs, IH), 9.68 (s, IH), 9.23-9.14 (brm, IH), 9.12-8.99 (brm, IH), 8.89 (d, J= 2.0 Hz, IH), 8.82 (s, IH), 8.76 (brs, 2H), 8.52 (s, IH), 8.49 (d, J= 2.0 Hz, IH), 8.16 (s, IH), 8.12 (d, J= 8.0 Hz, IH), 7.95 (dd, J= 1.2, 7.6 Hz, IH), 7.90 (t, J= 7.8 Hz, IH), 4.58-4.49 (me, IH), 3.40 (brd, J= 12.0 Hz, 2H), 3.07 (brq, J= 11.2 Hz, 2H), 2.30-2.12 (m, 4H). MS(ES+): m/z = 405.13/407.13 (88/60) [MH⁺], 322.07/324.05 (90/64) [MH⁺ - piperidine]. HPLC: t_R = 1.98 min (polar_5min, ZQ3). UV: X_n^ = 210, 244, 352 nm.

4-{4-[6-Amino-5-(8-chloroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester (BB3) (70.1 mg, 0.149 mmol), trifluoromethanesulfonic acid 8-chloroisoquinolin-3-yl ester (47.9 mg, 0.154 mmol), and Pd(PPh₃ )₄ (11.5 mg, 0.00995 mmol) in 1,4-dioxane (2.3 mL, 29 mmol in a sealable microwave tube was added a solution Of Cs₂CO₃ (95.5 mg, 0.293 mmol) in H₂O (0.65 mL, 36 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 30 minutes. The reaction mixture was diluted with DCM, washed with water, sat. NaHCO₃ solution, and brine, dried over MgSO₄, filtered, and concentrated in vacuo. The crude material was chromatographed on silica gel [20 g / 70 mL prepacked cartridge, eluting with DCM → 1% MeOH in DCM → 2% MeOH in DCM → 3% MeOH in DCM]. Fractions containing the title compound were combined and dried in vacuo, yielding the title compound as a glassy, yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 9.70 (t, J= 0.8 Hz, IH), 8.29 (d, J = 2.0 Hz, IH), 8.04 (d, J= 0.4 Hz, IH), 7.96 (d, J= 2.4 Hz, IH), 7.82 (dt, J= 5.8, 3.0 Hz, IH), 7.78 (d, J= 1.2 Hz, IH), 7.67 (d, J= 0.8 Hz, IH), 7.66-7.62 (m, 2H), 6.47 (brs, 2H), 4.40-4.19 (m, 3H), 2.92 (brt, J= 11.6 Hz, 2H), 2.19 (brdd, J= 1.8, 12.2 Hz, 2H), 1.95 (dq, J= 4.0, 12.0 Hz, 2H), 1.49 (s, 9H). MS(ES+): m/z = 505.16/507.13 (100/42) [MH⁺], 449.05/451.07 (3/1) [MH⁺ - isobutene]. HPLC: t_R = 3.15 min (polar_5min, ZQ3). Trifluoromethanesulfonic acid 8-chloroisoquinolin-3-yl ester

To a suspension of 8-chloroisoquinolin-3-ol (0.260 g, 1.45 mmol) and triethylamine (0.40 mL, 2.9 mmol) in DCM (10 mL, 160 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.31 mL, 1.8 mmol). The solid dissolved, the color changed from yellow to brown, and the solution was stirred at 0 ⁰C for 1 h. The reaction solution was diluted with more DCM to a total volume of _* 40 mL, washed with water, NaHCO₃ solution, and brine, and dried over MgSO₄. The extract was filtered through a plug of silica gel (~ 1 " high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The fractions containing product were concentrated and dried in vacuo to give the title compound as beige solid. It was used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 9.50 (s, IH), 7.84 (dd, J= 2.8, 6.4 Hz, IH), 7.74-7.68 (m, 2H), 7.60 (s, IH). MS(ES+): m/z = 311.66/313.63 (66/24) [MH⁺], 178.88/180.87 (100/38) [MH⁺ - SO₂CF₃]. 8-Chloroisoquinolin-3-ol

Concentrated sulfuric acid (18 M; 7.0 mL) was added to N-(2-chlorobenzyl)-2,2- dimethoxyacetamide (2.21 g, 9.07 mmol) at ambient temperature, and the solution was stirred overnight at ambient temperature and at 60 ⁰C for 5 h. The cooled reaction mixture was added to « 50 mL of ice, and the pH of the yellow mixture was adjusted to 7 with NaHCθ3 solution. The yellow precipitate was filtered off, washed with water, and dried in vacuo, giving the title compound as yellow solid. The material was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-dβ): δ = 11.13 (brs, IH), 9.11 (s, IH), 7.72 (d, J= 8.4 Hz, IH), 7.54 (dd, J = 8.2, 7.2 Hz, IH), 7.45 (dd, J= 0.8, 7.2 Hz, IH), 7.00 (s, IH). MS(ES+): m/z = 180.07/182.02 (100/38) [MH⁺]. HPLC: t_R = 2.45 min (polar_5min, ZQ3).

A^l-chlorobenzyl^l-dimethoxyacetamide

A mixture of methyl dimethoxyacetate (1.41 g, 10.4 mmol) and 2-chlorobenzylamine (1.45 g, 9.73 mmol) in a microwave vial was sealed and heated in the microwave reactor to 130 ⁰C for 30 min and then to 140 ⁰C for 40 min. The reaction solution was dissolved in EtOAc (~ 60 mL) and washed with dil. HCl, water, sat. Na₂Cθ3 solution, and brine, and dried over MgSOφ The EtOAc extract was filtered, concentrated, and dried in vacuo overnight, giving the title compound as pale yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 7.41-7.35 & 7.27-7.22 (AA¹BB', 4H), 6.98 (brs, IH), 4.74 (s, IH), 4.58 (d, J= 6.0 Hz, 2H), 3.40 (s, 6H). MS(ES+): m/z = 266.05/268.01 (41/13) [MNa⁺], 244.07/246.02 (86/58) [MH⁺], 212.03/214.02 (56/21) [MH⁺ - MeOH], 180.07/182.05 (63/26) [MH⁺ - 2 MeOH]. HPLC: t_R = 2.87 min (polar_5min, ZQ3).

Example 4: 3-(6-Methylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

To a solution of 4-{4-[6-amino-5-(6-methylisoquinolm-3-yl)-pyridm-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-buiyl ester (29.5 mg, 0.0609 mmol) in DCM (1.0 mL, 16 mmol) was added 1.0 M of HCl in Et20 (1.7 mL, 1.7 mmol), and the mixture was stirred at ambient temperature for 6 h. Almost immediately a yellow solid precipitated. The solvents were evaporated, and the residue was transferred into a vial and dried in vacuo overnight to give the title compound as yellow solid. It appeared to be slightly hygroscopic. ¹H NMR (400 MHz, DMSO-d6): δ = 14.7 (very brs, IH), 9.41 (s, IH), 9.26-9.17 (brm, IH), 9.14-9.02 (brm, IH), 8.83 (d, J= 2.0 Hz, IH), 8.79 (brs, IH), 8.62 (s, IH), 8.51 (s, IH), 8.46 (d, J= 2.0 Hz, IH), 8.18 (d, J= 8.4 Hz, IH), 8.15 (d, J= 0.4 Hz, IH), 7.87 (s, IH),

7.66 (dd, J= 1.2, 8.4 Hz, IH), 7.36 (s, IH), 7.23 (s, IH), 7.10 (s, IH), 4.58-4.49 (m_c, IH), 3.40 (brd, J = 12.4 Hz, 2H), 3.11 (brq, J= 11.8 Hz, 2H), 2.58 (s, 3H), 2.31-2.13 (m, 4H). MS(ES+): m/z = 385.20 (38) [MH⁺], 302.14 (100) [MH⁺ - piperidine]. HPLC: t_R = 1.78 min (polar_5min, ZQ2). 4-{4-[6-Amino-5-(6-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l -carboxylic acid tert-butyl ester (BB3) (53.7 mg, 0.114 mmol), trifluoromethanesulfonic acid 6-methylisoquinolin-3-yl ester (35.0 mg, 0.120 mmol), and PS-PPh₃-Pd (0.10 mmol/g loading; 76 mg, 0.0076 mmol; Argonaut) in 1,4-dioxane (2.0 mL, 25 mmol) in a sealable microwave tube was added a solution Of Cs₂CO₃ (75.6 mg, 0.232 mmol) in H₂O (0.60 mL, 33 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 30 minutes. The resin was filtered off and washed with DCM. The combined filtrate and washings were washed with IM NaOH, water and brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by preparative TLC [20x20 cm plate, 500 μm layer of silica gel, eluting with 3.5% MeOH in DCM (3x)]. Material from the main band was collected and dried in vacuo overnight to give the title compound as a yellow glassy solid. ¹H NMR (400 MHz, CDCl₃): δ = 9.22 (s, IH), 8.26 (d, J = 2.0 Hz, IH), 7.94 (s, IH), 7.93 (d, J = 2.0 Hz, IH), 7.91 (d, J= 8.4 Hz, IH), 7.77 (d, J = 0.4 Hz, IH), 7.67 (brs, IH), 7.66 (s, IH), 7.46 (dd, J= 8.4, 1.6 Hz, IH), 6.43 (brs, 2H), 4.38-4.19 (m, 3H), 2.92 (brt, J= 11.0 Hz, 2H), 2.58 (s, 3H), 2.19 (brdd, J= 2.0, 12.4 Hz, 2H), 1.98 (dq, J= 4.4, 12.0 Hz, 2H), 1.49 (s, 9H). MS(ES+): m/z = 485.19 (100) [MH⁺], 429.13 (7) [MH⁺ - isobutene]. HPLC: fe = 2.71 min (polar_5min, ZQ2).

Trifluoromethanesulfonic acid 6-methylisoquinolin-3-yl ester

To a suspension of 6-methylisoquinolin-3-ol (97.2 mg, 0.611 mmol) and triethylamine (0.17 mL, 1.2 mmol) in DCM (4.8 mL, 74 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.13 mL, 0.77 mmol). Upon addition, all solid material dissolved, and the solution was stirred at 0 ⁰C for 30 min. The reaction solution was diluted with more DCM to a total volume of _* 40 mL, washed with water, NaHCO₃ solution, and brine, and dried over MgSO₄. The extract was filtered through a plug of silica gel (~ 1 " high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The fraction containing product was concentrated and dried in vacuo overnight to give the title compound as orange oil. The material was used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 9.00 (s, IH), 7.95 (d, J= 8.4 Hz, IH), 7.67 (s, IH), 7.52 (dd, J= 1.6, 8.4 Hz, IH), 7.48 (s, IH), 2.59 (s, 3H). MS(ES+): m/z = 292.08 (37) [MH⁺], 159.17 (100) [MH⁺ - SO₂CF₃]. HPLC: t_R = 3.81 min (polar_5min, ZQ2). 6-Methylisoquinolin-3-ol Concentrated sulfuric acid (18 M; 11.0 mL) was added to 2,2-dimethoxy-N-(4-methylbenzyl)- acetamide (1.95 g, 8.73 mmol) at ambient temperature, and the solution was stirred overnight at ambient temperature. The reaction mixture was added to « 100 mL of ice, and the pH of the mixture was adjusted to « 5 with concentrated aq. NH₃ solution. The yellow precipitate was filtered off, washed with water, and dried in vacuo overnight to give the title compound as yellow solid. It was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-^₆): δ = 8.79 (s, IH), 7.81 (d, J = 8.4 Hz, IH), 7.44 (s, IH), 7.14 (dd, J= 1.6, 8.4 Hz, IH), 6.76 (s, IH), 2.42 (s, 3H); -OH not apparent. MS(ES+): m/z = 160.25 (100) [MH⁺], 142.13 (12) [MH⁺ - H₂O]. HPLC: t_R = 2.15 min (polar_5min, ZQ2), 2.25 min (polar_5min, ZQ3).

2,2-Dimethoxy-Λ'-(4-methylbenzyl)-acetamide

A mixture of methyl dimethoxyacetate (1.35 g, 9.96 mmol) and 4-methylbenzylamine (1.21 g, 9.98 mmol) in a sealable tube was heated in a microwave reactor to 140 ⁰C for 50 min. The reaction mixture was diluted with EtOAc (« 60 mL), washed with diluted aq. HCl, water, sat. NaHCO₃ solution, and brine, and dried over MgSO₄. The EtOAc extract was filtered, concentrated, and dried in vacuo overnight to give the title compound as pale yellow oil. It was used for the next step without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 7.20-7.13 (AA¹BB', 4H), 6.82 (brs, IH), 4.75 (s, IH), 4.44 (d, J= 5.6 Hz, 2H), 3.40 (s, 6H), 2.34 (s, 3H). MS(ES+): m/z = 246.10 (43) [MNa⁺], 224.11 (91) [MH⁺], 192.14 (8) [MH⁺ - MeOH], 160.06 (80) [MH⁺ - 2 MeOH]. HPLC: t_R = 2.84 min (polar_5min, ZQ3).

Example 5: 3-(8-Methylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

To a solution of 4-{4-[6-amino-5-(8-methylisoquinolm-3-yl)-pyridm-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-butyl ester (11.0 mg, 0.0227 mmol) in DCM (0.40 mL, 6.2 mmol) was added 1.0 M of HCl in Et₂O (0.60 mL, 0.60 mmol), and the mixture was stirred at ambient temperature for 2 h. Almost immediately an off-white solid precipitated. The solvents were evaporated, and the residue was suspended in Et₂O, filtered off, and dried in vacuo overnight, yielding the title compound as yellow solid. It appeared to be hygroscopic during the filtration; however, after the washing and initial drying it appeared to be non-hygroscopic. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 14.6 (very brs, IH), 9.60 (s, IH), 9.18-9.07 (brm, IH), 9.05-8.92 (brm, IH), 8.88 (d, J = 2.0 Hz, IH), 8.86 (brs, IH), 8.73 (s, IH), 8.51 (s, IH), 8.45 (d, J= 2.0 Hz, IH), 8.16 (d, J= 0.4 Hz, IH), 7.95 (d, J= 8.4 Hz, IH), 7.81 (dd, J= 8.4, 6.8 Hz, IH), 7.61 (d, J= 6.8 Hz, IH), 4.58-4.49 (m_c, IH), 3.40 (brd, J= 12.4 Hz, 2H), 3.12 (brq, J= 12.2 Hz, 2H), 2.83 (s, 3H), 2.30-2.12 (m, 4H). MS(ES+): m/z = 385.21 (43) [MH⁺], 302.15 (100) [MH⁺ - piperidine]. HPLC: t_R = 1.80 min (polar_5min, ZQ2).

4-{4-[6-Amino-5-(8-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-1-yl} -piperidine- 1 -carboxylic acid tert-butyl ester (BB3) (18.9 mg, 0.0403 mmol), trifluoromethanesulfonic acid 8-methylisoquinolin-3-yl ester (12.0 mg, 0.0412 mmol), and PS-PPh₃-Pd (0.10 mmol/g loading; 26 mg, 0.0026 mmol; Argonaut) in 1,4-dioxane (0.70 mL, 9.0 mmol) in a sealable microwave tube was added a solution Of Cs₂CO₃ (26.7 mg, 0.0819 mmol) in H₂O (0.20 mL, 11 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 30 minutes. The resin was filtered off and washed with DCM. The combined filtrate and washings were washed with water and brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by preparative TLC [20x20 cm plate, 500 μm layer of silica gel, eluting with 3% MeOH in DCM (2x) and 4% MeOH in DCM (2x)]. Material from the main band was collected and dried in vacuo overnight giving the title compound as a yellow glassy solid. ¹H NMR (400 MHz, CDCl₃): δ = 9.50 (s, IH), 8.26 (d, J= 2.0 Hz, IH), 8.02 (d, J= 0.4 Hz, IH), 7.97 (d, J= 2.4 Hz, IH), 7.78 (d, J= 0.8 Hz, IH), 7.75 (d, J= 8.4 Hz, IH), 7.67 (d, J= 0.4 Hz, IH), 7.62 (dd, J= 7.2, 8.4 Hz, IH), 7.42 (dt, J = 7.2, 0.8 Hz, IH), 6.56 (brs, 2H), 4.38-4.19 (m, 3H), 2.92 (brt, J = 11.0 Hz, 2H), 2.83 (s, 3H), 2.19 (brdd, J= 2.2, 11.4 Hz, 2H), 1.95 (dq, J= 4.0, 12.0 Hz, 2H), 1.49 (s, 9H). MS(ES+): m/z = 485.23 (100) [MH⁺], 429.16 (7) [MH⁺ - isobutene]. HPLC: t_R = 2.88 min (polar_5min, ZQ3).

Trifluoromethanesulfonic acid 8-methylisoquinolin-3-yl ester To a solution of 8-methylisoquinolin-3-ol (40.7 mg, 0.256 mmol) and triethylamine (0.071 mL,

0.51 mmol) in DCM (2.0 mL, 31 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.054 mL, 0.32 mmol). The color of the reaction mixture changed from yellow to brown, and the solution was stirred at 0 ⁰C for 1 h. The reaction solution was diluted with more DCM to a total volume of « 40 mL, washed with water, NaHCθ3 solution, and brine, and dried over MgSO/t. The extract was filtered through a plug of silica gel (~ 1" high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The fraction containing product was concentrated and dried in vacuo overnight, giving the title compound as brown oil. The material was used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 9.27 (s, IH), 7.75 (d, J= 8.4 Hz, IH), 7.67 (dd, J= 6.8, 8.2 Hz, IH), 7.57 (s, IH), 7.47 (dt, J= 6.8, 1.2 Hz, IH), 2.82 (s, 3H). MS(ES+): m/z = 292.00 (100) [MH⁺], 159.04 (70) [MH⁺ - SO₂CF₃]. HPLC: t_R = 3.92 min (polar_5min, ZQ3).

8-Methylisoquinolin-3-ol

Concentrated sulfuric acid (18 M; 7.0 mL) was added to 2,2-dimethoxy-N-(2-methylbenzyl)- acetamide (3.04 g, 13.6 mmol) at ambient temperature, and the solution was stirred overnight at ambient temperature and 6 h at 60 ⁰C. The cooled reaction mixture was added to « 50 mL of ice, and the pH of the yellow mixture was adjusted to 7 with NaHCO₃ solution. The yellow precipitate was filtered off, washed with water, and dried in vacuo overnight. The yellow solid thus obtained was triturated from EtOH, the mother liquor was concentrated to give a solid, which was triturated against from EtOH. After four such triturations, the mother liquor was adsorbed onto Hydromatrix and chromatographed on silica gel [20 g / 70 mL prepacked cartridge, eluting with DCM → 2% MeOH in DCM → 3% MeOH in DCM → 4% MeOH in DCM]. Fractions containing the title compound were combined and dried in vacuo, giving a yellow oil. It was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-^₆): δ = 10.9 (brs, IH), 8.96 (s, IH), 7.51 (d, J= 8.0 Hz, IH), 7.42 (dd, J= 6.8, 8.0 Hz, IH), 7.12-6.97 (m, 2H), 6.85 (s, IH), 2.64 (s, 3H). MS(ES+): m/z = 160.06 (100) [MH⁺]. HPLC: t_R = 2.27 min (polar_5min, ZQ3). 2,2-Dimethoxy-Λ'-(2-methylbenzyl)-acetamide

A mixture of methyl dimethoxyacetate (2.11 g, 15.6 mmol) and o-xylylamine (1.90 g, 15.4 mmol) in a 15 mL sealed tube was stirred at 55 ⁰C for H d. The reaction solution was dissolved in EtOAc (~ 60 mL) and washed with dil. HCl, water, sat. NaHCO₃ solution, and brine, and dried over MgSO/j. The EtOAc extract was filtered, concentrated, and dried in vacuo overnight to give the title compound as pale yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 7.25-7.16 (m, 4H), 6.69 (brs, IH), 4.75 (s, IH), 4.48 (d, J = 5.6 Hz, 2H), 3.40 (s, 6H), 2.33 (s, 3H). MS(ES+): m/z = 246.07 (83) [MNa⁺], 224.11 (100) [MH⁺], 192.14 (60) [MH⁺ - MeOH], 160.10 (95) [MH⁺ - 2 MeOH]. HPLC: t_R = 2.82 min (polar_5min, ZQ3).

Example 6: 3-(8-Fluoro-5-methylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride

To a solution of 4-{4-[6-amino-5-(8-fluoro-5-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-butyl ester (11.5 mg, 0.0229 mmol) in DCM (0.60 mL, 9.4 mmol) was added 1.0 M of HCl in Et₂O (0.80 mL, 0.80 mmol), and the mixture was stirred at ambient temperature for 2 h. Almost immediately a pale yellow solid precipitated. The solvents were evaporated, and the residue was transferred into a vial and dried in vacuo overnight, yielding the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-</₆): δ = 14.6 (very brs, IH), 9.59 (d, J = 0.8 Hz, IH), 9.19-9.09 (brm, IH), 9.02-8.91 (brm, IH), 8.88 (d, J= 2.4 Hz, IH), 8.56 (brs, IH), 8.54 (s, IH), 8.48 (s, IH), 8.47 (d, J= 2.4 Hz, IH), 8.15 (s, IH), 7.73 (ddd, J= 0.8, 6.4, 8.0 Hz, IH), 7.51 (dd, J= 8.0, 10.2 Hz, IH), 4.59-4.50 (m_c, IH), 3.40 (brd, J= 12.2 Hz, 2H), 3.11 (brq, J= 11.4 Hz, 2H), 2.76 (s, 3H), 2.30- 2.12 (m, 4H). MS(ES+): m/z = 403.16 (23) [MH⁺], 320.12 (100) [MH⁺ - piperidine]. HPLC: t_R = 1.89 min (polar_5min, ZQ2).

4-{4-[6-Amino-5-(8-fluoro-5-methylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-1-yl} -piperidine- 1 -carboxylic acid tert-butyl ester (BB3) (56.1 mg, 0.120 mmol), trifluoromethanesulfonic acid 8-fluoro-5-methylisoquinolin-3-yl ester (40.2 mg, 0.130 mmol), and PS- PPh₃-Pd (0.10 mmol/g loading; 83 mg, 0.0083 mmol; Argonaut) in 1,4-dioxane (2.0 mL, 26 mmol) in a sealable microwave tube was added a solution Of Cs₂CO₃ (80.5 mg, 0.247 mmol) in H₂O (0.60 mL, 33 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 30 minutes. The resin was filtered off and washed with DCM. The combined filtrate and washings were washed with water and brine, dried over MgSOzt, filtered, and concentrated in vacuo. The residue was purified by preparative TLC [20x20 cm plate, 500 μm layer of silica gel, eluting with 3% MeOH in DCM (2x)]. Material from the main band was collected and dried in vacuo overnight giving the title compound as a yellow glassy solid. ¹H NMR (400 MHz, CDCl₃): δ = 9.57 (s, IH), 8.21 (d, J= 2.4 Hz, IH), 8.05 (s, IH), 7.96 (d, J= 2.4 Hz, IH), 7.77 (s, IH), 7.66 (d, J= 0.4 Hz,

IH), 7.49 (ddd, J= 1.0, 5.2, 7.8 Hz, IH), 7.15 (dd, J= 7.8, 9.8 Hz, IH), 6.89 (brs, 2H), 4.39-4.19 (brm, 3H), 2.92 (brt, J= 11.6 Hz, 2H), 2.70 (s, 3H), 2.19 (brdd, J= 2.0, 12.4 Hz, 2H), 1.97 (brdq, J= 4.2, 12.4 Hz, 2H), 1.49 (s, 9H). MS(ES+): m/z = 503.19 (100) [MH⁺], 447.13 (2) [MH⁺ - isobutene]. HPLC: t_R = 3.08 min (polar_5min, ZQ2). Trifluoromethanesulfonic acid 8-fluoro-5-methylisoquinolin-3-yl ester To a suspension of 8-fluoro-5-methylisoquinolin-3-ol (114 mg, 0.643 mmol) and triethylamine

(0.18 mL, 1.3 mmol) in DCM (4.5 mL, 70 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.14 mL, 0.81 mmol). The solid dissolved, the color of the reaction mixture changed from yellow to brown, and the solution was stirred at 0 ⁰C for 35 min. The reaction solution was diluted with more DCM to a total volume of « 40 mL, washed with water, NaHCθ3 solution, and brine, and dried over MgSO₄. The extract was filtered through a plug of silica gel (~ 1 " high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The fraction containing product was concentrated and dried in vacuo overnight, giving the title compound as brown oil. The material was used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 9.34 (d, J = 0.8 Hz, IH), 7.63 (dd, J = 0.8, 1.8 Hz, IH), 7.55 (ddd, J = 0.8, 5.2, 8.0 Hz, IH), 7.21 (dd, J= 8.0, 9.8 Hz, IH), 2.65 (t, J= 1.0 Hz, 3H). MS(ES+): m/z = 310.00 (100) [MH⁺], 177.11 (27) [MH⁺ - SO₂CF₃]. HPLC: t_R = 4.01 min (polar_5min, ZQ3). 8-Fluoro-5-methylisoquinolin-3-ol

A solution of 5-Bromo-8-fluoroisoquinolin-3-ol (76.5 mg, 0.316 mmol), 2.0 M of dimethylzinc in toluene (0.40 mL, 0.80 mmol), and Pd(PPh₃ )₄ (22 mg, 0.019 mmol) in THF in a microwave reactor tube was heated in the microwave reactor to 80 ⁰C for 60 min. The reaction solution was poured into sat. aq. NH₄Cl, and the resulting mixture was extracted with DCM (3x25 mL). The combined DCM extracts were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was triturated with Et₂O. The resulting light greenish-yellow solid was washed with Et₂O and dried in vacuo to give the title compound as light greenish-yellow solid. It was used in the next step without further purification. MS(ES+): m/z = 178.17 (100) [MH⁺]. HPLC: t_R = 2.36 min (polar_5min, ZQ2). 5-Bromo-8-fluoroisoquinolin-3-ol

To N-(5-bromo-2-fluorobenzyl)-2,2-dimethoxyacetamide (12.0 g, 39 mmol) were added concentrated H₂SO₄ (21 mL) and oleum (30%, 25.0 mL, 394 mmol). The mixture was heated at 85 ⁰C for 2 h. The reaction mixture was cooled to ambient temperature and poured slowly into a cold aqueous satd. solution OfNaHCO₃ in a beaker with efficient stirring (Note: frothing occurs). The solid that formed was filtered off, washed with water (50 mL), and dried in vacuo to give the title compound as yellow solid. ¹H NMR (DMSO-^₆, 300 MHz) δ = 7.03 (s, IH), 7.11 (dd, J= 7.2, 2.1 Hz, IH), 7.98 (dd, J= 7.2, 2.4 Hz, IH), 9.15 (s, IH). MS (ES+): m/z 242.11/244.13 [MH⁺]. HPLC: t_R = 2.63 min (ZQ2, polar_5min). Λ^S-Bromo-l-fluorobenzylJ-ljl-dimethoxyacetamide

A mixture of 5-bromo-2-fluorobenzylamine hydrochloride (15.0 g, 62 mmol), methyl dimethoxyacetate (10.0 g, 75 mmol), and DIPEA (10.3 mL, 62 mmol) in methanol (15 mL) was heated at 60 ⁰C for 16 h in a bomb apparatus. After cooling to RT, the solvent was evaporated and DCM (150 mL) was added. The solution was washed with water (2x30 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product. It was purified by column chromatography on silica gel using EtOAc/Hexanes (1 : 1) to give the title compound. ¹H NMR (CDCI3, 300 MHz) δ = 3.42 (s, 6H), 4.53 (d, J= 4.8 Hz, 2H), 4.81 (s, IH), 6.96 (t, J = 6.8 Hz, IH), 7.40-7.42 (m, IH), 7.51-7.54 (m, IH). MS(ES+): m/z = 305.73/307.69 [MH⁺]. HPLC: f_R = 2.89 min (polar_5min, ZQ2).

Example 7: 3-(5-Bromo-8-fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride

To a solution of 4-{4-[6-amino-5-(5-bromo-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-butyl ester (82 mg, 0.14 mmol) in DCM (3.0 mL) was added 1.0 M of HCl in Et₂O (3.0 mL, 3.0 mmol), and the mixture was stirred at ambient temperature for 1 h. Almost immediately a pale yellow solid precipitated. The solvents were evaporated, and the residue was transferred into a vial and dried in vacuo overnight, yielding the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.09-2.28 (m, 4H), 3.03-3.16 (m, 2H), 3.39 (dd, J = 13.8, 1.9 Hz, 2H), 4.47-4.58 (m, IH), 7.61 (dd, J = 9.8, 8.4 Hz, IH), 8.12 (s, IH), 8.23-8.32 (m, 2H), 8.42 (s, IH), 8.46 (s, IH), 8.48 (d, J = 2.0 Hz, IH), 8.71 (d, J = 2.0 Hz, IH), 9.01 (br. s., IH), 9.16 (br. s., IH), 9.65 (s, IH). MS (ES+): m/z = 466.73/468.63 [MH⁺]. HPLC: t_R = 1.88 min (ZQ2, polar_5min). 4-{4-[6-Amino-5-(5-bromo-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l -carboxylic acid tert-butyl ester (BB3) (370 mg, 0.67 mmol), trifluoromethanesulfonic acid 5-bromo-8-fluoroisoquinolin-3-yl ester (250 mg, 0.67 mmol), and Pd(PPh₃)₄ (40 mg, 0.03 mmol) in 1,4-dioxane (8.0 mL) in a sealable microwave tube was added a solution Of Cs₂CO₃ (440 mg, 1.3 mmol) in H₂O (2 mL). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 100 ⁰C for 30 minutes. The reaction mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by chromatography on silica gel, eluting with 5% 7M NH₃ in MeOH and DCM. One obtained the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.24- 1.35 (m, 4H), 1.49 (s, 9H), 1.93-2.06 (m, 2H), 2.19 (d, J = 2.3 Hz, IH), 2.86-2.96 (m, IH), 6.44 (br. s., 2H), 7.17 (dd, J = 9.4, 8.3 Hz, IH), 7.68 (s, IH), 7.80 (s, IH), 7.95 (dd, J = 8.3, 4.8 Hz, IH), 8.00 (d, J = 2.3 Hz, IH), 8.31 (s, IH), 8.32 (d, J = 2.3 Hz, IH), 9.57 (s, IH). MS (ES+): m/z = 566.87/567.69 [MH⁺]. HPLC: t_R = 3.08 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 5-bromo-8-fluoroisoquinolin-3-yl ester

A DCM (3 mL) solution of 5-bromo-8-fluoroisoquinolin-3-ol (0.200 g, 0.826 mmol) and triethylamine (0.3 mL, 2.1 mmol) was cooled in an ice bath and charged with trifluoromethanesulfonic anhydride (0.3 mL, 2 mmol); this mixture was allowed to stir for 1 h while slowly warming to rt. The reaction was quenched with some water and then diluted with more DCM, washed with NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude product was passed through a small Siθ₂ plug eluting with 10% EtO Ac/Hex to yield the title compound as yellow solid. MS (ES+): m/z = 373.58/375.55 [MH⁺]. HPLC: t_R = 4.03 min (ZQ2, polar_5min)

Example 8: 3-(4-Fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

To a solution of 4-{4-[6-amino-5-(4-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidme- 1-carboxylic acid tert-butyl ester (16.0 mg, 0.0327 mmol) in DCM (0.60 mL, 9.4 mmol) was added 1.0 M of HCl in Et₂O (0.90 mL, 0.90 mmol), and the mixture was stirred at ambient temperature for 2 h. Almost immediately a pale yellow solid precipitated. The solvents were evaporated, and the residue was transferred into a vial and dried in vacuo overnight, yielding the title compound as pale yellow solid. ¹H NMR (400 MHz, DMSO-</₆): δ = 14.6 (very brs, IH), 9.38 (s, IH), 9.08-8.99 (brm, IH), 8.91-8.80 (brm, IH), 8.53 (brs, IH), 8.46 (d, J = 2.0 Hz, IH), 8.40 (s, IH), 8.37 (d, J = 8.4 Hz, IH), 8.24 (AA, J= 8.2, 0.8 Hz, IH), 8.06 (A, J= 0.4 Hz, IH), 8.03 (AAA, J= 0.8, 7.0, 8.2 Hz, IH), 7.92 (ddd, J= 1.0, 7.0, 8.2 Hz, IH), 7.88 (brs, IH), 4.54-4.45 (m_c, IH), 3.38 (brd, J= 13.2 Hz, 2H), 3.09 (brq, J = 11.6 Hz, 2H), 2.27-2.08 (m, 4H). MS(ES+): m/z = 389.18 (18) [MH⁺], 306.13 (100) [MH⁺ - piperidine]. HPLC: t_R = 1.69 min (polar_5min, ZQ2). 4-{4-[6-Amino-5-(4-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine- 1-carboxylic acid tert-butyl ester (BB3) (39.0 mg, 0.0831 mmol), trifluoromethanesulfonic acid 4-fluoroisoquinolin-3-yl ester (25.1 mg, 0.0850 mmol), and PS-PPh₃-Pd (0.10 mmol/g loading; 55 mg, 0.0055 mmol; Argonaut) in 1,4-dioxane (1.3 mL, 16 mmol) in a sealable microwave tube was added a solution Of Cs₂CO₃ (53.1 mg, 0.163 mmol) in H₂O (0.36 mL, 20 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 30 minutes. The resin was filtered off and washed with DCM. The combined filtrate and washings were washed with water and brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by preparative TLC [20x20 cm plate, 500 μm layer of silica gel, eluting with 3.5% MeOH in DCM (3x)]. Material from the main band was collected and dried in vacuo overnight giving the title compound as a yellow glassy solid. ¹H NMR (400 MHz, CDCl₃): δ = 9.14 (s, IH), 8.29 (d, J= 2.2 Hz, IH), 8.18 (dd, J= 0.8, 8.2 Hz, IH), 8.06 (dt, J= 8.0, 0.8 Hz, IH), 8.01 (dd, J= 2.6, 2.6 Hz, IH), 7.84 (ddd, J= 1.2, 7.2, 8.2 Hz, IH), 7.75 (A, J= 0.6 Hz, IH), 7.72 (ddd, J= 1.0, 7.0, 8.2 Hz, IH), 7.64 (d, J= 0.6 Hz, IH), 5.90 (brs, 2H), 4.40-4.15 (m, 3H), 2.91 (brt, J= 10.6 Hz, 2H), 2.18 (brdd, J= 2.2, 12.4 Hz, 2H), 1.97 (dq, J= 4.4, 12.2 Hz, 2H), 1.48 (s, 9H). MS(ES+): m/z = 489.16 (100) [MH⁺], 433.16 (4) [MH⁺ - isobutene]. HPLC: t_R = 3.05 min (polar_5min, ZQ3), 2.71 min (polar_5min, ZQ2).

Trifluoromethanesulfonic acid 4-fluoroisoquinolin-3-yl ester To a suspension of 4-fluoroisoquinolin-3-ol (95.4 mg, 0.585 mmol) and triethylamine (0.16 mL, 1.2 mmol) in DCM (4.0 mL, 63 mmol), cooled in an ice bath, was added dropwise trifluoromethanesulfonic anhydride (0.12 mL, 0.74 mmol). The solid dissolved, the color of the reaction mixture changed from yellow to brown, and the solution was stirred at 0 ⁰C for 7 h. The reaction solution was diluted with more DCM to a total volume of « 40 mL, washed with water, NaHCθ3 solution, and brine, and dried over MgSO/t. The extract was filtered through a plug of silica gel (~ 1 " high in a 60 mL fritted funnel), which was rinsed with DCM until no further product eluted. The fraction containing product was concentrated and dried in vacuo overnight, giving the title compound as yellow oil. The yellow oil was chromatographed on silica gel [10 g / 70 mL prepacked cartridge, eluting with hexanes → 9: 1 hexanes:EtOAc → 5: 1 hexanes: EtOAc]. Fractions containing the title compound were combined and dried in vacuo overnight. One obtained the title compound as yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 8.87 (d, J = 0.8 Hz, IH), 8.20 (dd, J= 0.8, 8.4 Hz, IH), 8.10 (dt, J= 8.4, 1.0 Hz, IH), 7.89 (ddd, J = 0.8, 6.8, 8.2 Hz, IH), 7.77 (ddd, J= 1.0, 6.8, 8.2 Hz, IH). MS(ES+): m/z = 296.02 (72) [MH⁺], 163.06 (100) [MH⁺ - SO₂CF₃]. HPLC: t_R = 3.92 min (polar_5min, ZQ3). 4-Fluoroisoquinolin-3-ol A mixture of 3-hydroxyisoquinoline (84.3 mg, 0.581 mmol) and 1 -chloromethyl-4-fluoro- 1 ,4- diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (236 mg, 0.666 mmol) in THF (6.0 mL, 74 mmol) was stirred at ambient temperature for 17 d. More 1 -chloromethyl-4-fluoro- 1 ,4- diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (25 mg, 0.070 mmol) was added, and the reaction mixture was heated to 50 ⁰C for Id. Solid material was filtered off and rinsed with THF. The filtrate was diluted with DCM (« 75 mL), washed with water (2x) and brine, dried over MgSO₄, filtered, and dried in vacuo overnight. One obtained the title compound as yellow solid. It was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-^₆): δ = 11.54 (brs, IH), 8.75 (s, IH), 8.01 (d, J= 8.4 Hz, IH), 7.84 (d, J= 8.0 Hz, IH), 7.69 (t, J= 8.0 Hz, IH), 7.40 (t, J= 7.6 Hz, IH). MS(ES+): m/z = 164.03 (100) [MH⁺]. HPLC: t_R = 2.2 min (polar_5min, ZQ3). Example 9: 3-(5,8-Dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

4-{4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-pyrazol-l- yl}piperidine-l-carboxylic acid tert-butyl ester (BB3) (75 mg, 0.16 mmol), trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3-yl ester (66 mg, 0.19 mmol), Cs₂CO₃ (87 mg, 0.27 mmol) and Pd(PPh₃ )₄ (8 mg, 0.007 mmol) were placed in a sealable microwave tube and taken up in 1,4-dioxane (2 mL) and H₂O (0.619 mL), flushed with nitrogen, sealed and heated in the microwave reactor to 100 ⁰C for 30 minutes. The reaction mixture was diluted with EtOAc, washed with water, brine, dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography on silica gel [eluting with 3% 7N NH₃/MeOH in DCM] giving the Boc-protected compound. It was dissolved in ImL DCM and charged with 2 mL IM HCl in ether and stirred at 40 ⁰C overnight. The product precipitated out of solution and was filtered off to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.09-2.29 (m, 4H), 3.05-3.17 (m, 2H), 3.41 (d, J = 11.3 Hz, 2H), 4.47-4.59 (m, IH), 7.96 (d, J= 8.0 Hz, IH), 8.07-8.14 (m, IH), 8.45 (s, 2H), 8.59 (s, IH), 8.73 (br. s., IH), 8.93 (br. s., IH), 9.75 (s, IH). MS (ES+): m/z: 439.07/441.09 (3:2) [MH⁺]. HPLC: t_R = 1.94 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3-yl ester

A solution of 5,8-dichloroisoquinolin-3-ol (0.400 g, 1.87 mmol) and N- phenylbis(trifluoromethanesulphonimide) (0.80 g, 2.2 mmol) in DCM (10 mL) was charged with triethylamine (0.326 mL, 2.34 mmol) and stirred overnight at rt. The reaction mixture was partitioned between DCM and water and separated. The aqueous layer was extracted with DCM (3x) and the combined organic fractions were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography on silica gel [eluting with 10% EtOAc in hexanes] to afford the title compound as a white solid. ¹H ΝMR (400 MHz, CDCl₃): δ = 7.42 (d, J = 7.7 Hz, IH), 7.50-7.56 (m, 2H), 7.58-7.63 (m, IH). 5,8-Dichloroisoquinolin-3-ol A solution ofN-(2,5-dichlorobenzyl)-2,2-dimethoxyacetamide (1.0 g, 3.6 mmol) in sulfuric acid

(18M; 4 mL) was stirred at 50 ⁰C for 1 h. The reaction mixture was charged with ice and neutralized with NaHCO₃. The aqueous mixture was extracted with 5% MeOH in DCM (3x), washed with NaHCO₃, dried over sodium sulfate, filtered and concentrated to afford the title compound as yellow solid. MS (ES+): m/z = 215.75/217.75 (3: 1) [MH⁺]. HPLC: t_R = 2.76 min (ZQ2, polar_5 min). N-^S-Dichlorobenzyl^l-dimethoxyacetamide

A solution of methyl dimethoxyacetate (0.823 g, 6.08 mmol) and 2,5-dichlorobenzylamine (1.0 g, 5.7 mmol) was heated to 90 ⁰C in a sealed tube for 48 h. The crude material was purified by column chromatography on silica gel [eluting with 40% EtOAc in hexanes] to afford the title compound as a clear oil. ¹H NMR (400 MHz, CDCl₃) δ = 3.41 (s, 6H), 4.53 (d, J= 6.6 Hz, 2H), 4.75 (s, IH), 7.19- 7.23 (m, IH), 7.30 (d, J= 8.4 Hz, IH), 7.35 (d, J= 2.5 Hz, IH). MS (ES+): m/z = 278/280/282 [MH⁺]. HPLC: t_R = 3.03 min (ZQ2, polar_5min).

Example 10 : 3-(5,8-Difluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 5,8-difluoroisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8- dichloroisoquinolin-3-yl ester, affording the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.09-2.30 (m, 4H), 3.04-3.17 (m, 2H), 3.41 (d, J= 12.1 Hz, 2H), 4.48-4.59 (m, IH), 7.57-7.68 (m, IH), 7.79 (td, J= 8.8, 3.6 Hz, IH), 8.15 (s, IH), 8.47 (s, IH), 8.68 (s, IH), 8.83 (br. s., IH), 9.01 (br. s., IH), 9.65 (s, IH). MS (ES+): m/z = 407.16 [MH⁺]. HPLC: t_R = 1.76 min (ZQ2, polar_5min).

Trifluoromethanesulfonic acid 5,8-difluoroisoquinolin-3-yl ester

The same procedure as in the previous example was followed, except using 5,8-difluoroisoquinolin- 3-ol in place of 5,8-dichloroisoquinolin-3-ol, affording the title compound as a white solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.42 (d, J = 7.7 Hz, IH), 7.53 (t, J = 7.7 Hz, 2H), 7.57-7.63 (m, IH). 5,8-Difluoroisoquinolin-3-ol

The same procedure as in the previous example was followed, except using N-(2,5-difluorobenzyl)- 2,2-dimethoxyacetamide in place of N-(2,5-dichlorobenzyl)-2,2-dimethoxyacetamide, affording the title compound. MS (ES+): m/z: 181.65 [MH⁺]. HPLC: t_R = 2.34 min (ZQ2, polar_5min). N-^S-Difluorobenzyl^^-dimethoxyacetamide

The same procedure as in the previous example was followed, except using 2,5- difluorobenzylamine in place of 2,5-dichlorobenzylamine to afford the title compound as a clear oil. ¹H NMR (400 MHz, CDCl₃): δ = 3.4 (s, 6H), 4.1 (d, J= 6.2 Hz, 2H), 4.75 (s, IH), 6.93-7.08 (m, 3H). MS (ES+): m/z = 245.91 [MH⁺]. HPLC: t_R = 2.65 min (ZQ2, polar_5min). Example 11: 3-(5-Chloro-8-fhioroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride

The procedure for the preparation of 3-(4-fluoroisoquinolin-3-yl)-5-(l-piperidm-4-yl-lH-pyrazol-4- yl)-pyridin-2-ylamine trihydrochloride was followed, except using 4-{4-[6-amino-5-(5-chloro-8- fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester in place of 4- {4-[6-amino-5-(4-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.11-2.28 (m, 4H), 3.01-3.17 (m, 2H), 3.32-3.47 (m, 2H), 4.47-4.60 (m, IH), 7.66 (dd, J = 9.85, 8.59 Hz, IH), 8.08-8.15 (m, 2H), 8.34-8.51 (m, 3H), 8.56 (s, IH), 8.77 (d, J = 2.02 Hz, IH), 9.00 (br. s., IH), 9.16 (br. s., IH), 9.67 (s, IH). ¹H NMR (400 MHz, CD₃OD): δ = 2.29-2.44 (m, 4H), 3.20-3.30 (m, 2H), 3.60 (d, J = 12.6 Hz, 2H), 4.54-4.66 (m, IH), 7.39 (t, J = 9.1 Hz, IH), 7.91 (dd, J = 8.3, 4.8 Hz, IH), 7.94 (s, IH), 8.14 (s, IH), 8.18 (s, IH), 8.29 (s, IH), 8.43 (s, IH), 9.61 (s, IH). MS (ES+): m/z = 339.76/341.64 [MH⁺]. HPLC: t_R = 2.27 min (ZQ2, polar_5min).

4-{4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester 4-{4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-butyl ester (0.065 g, 0.14 mmol) (BB3), trifluoromethanesulfonic acid 5-chloro-8-fluoroisoquinolin-3-yl ester (0.040 g, 0.12 mmol), Cs₂CO₃ (75 mg, 0.23 mmol), and Pd(PPh₃ )₄ (7 mg, 0.006 mmol) were placed in a sealable microwave tube, taken up in 1,4-dioxane (2 mL, 30 mmol) and H₂O (0.54 mL, 30 mmol), flushed with nitrogen, sealed and heated in the microwave reactor at 100 ⁰C for 30 minutes. T he reaction mixture was diluted with EtOAc washed with water, brine, dried over Na₂SOz_I, filtered and concentrated. The compound was purified by prep- TLC with 5% 7M NH₃ in MeOH and DCM mixture yielding the title compound as pale yellow solid. MS (ES+): m/z = 523.15/525.12 (100/40) [MH⁺]. HPLC: t_R = 3.03 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 5-chloro-8-fluoroisoquinolin-3-yl ester To a solution of 5-chloro-8-fluoroisoquinorin-3-ol (6.6 g, 33.4 mmol) in CH₂Cl₂ (200 mL) under nitrogen at 0 ⁰C were added triethylamine (28 mL, 200 mmol) and triflic anhydride dropwise (11.2 mL, 66.8 mmol). The reaction mixture was stirred for 2 h. Water (50 mL) was added and the layers were separated. The organic layer was washed with aqueous satd. NaHCO₃ (50 mL) and water (40 mL), dried over Na₂SOzJ, filtered and concentrated under reduced pressure. The crude product was purified by passing through a short plug of silica gel using EtOAc/Hexanes (1 :9) as eluent to give the title compound as a yellow solid in 62%. ¹H NMR (CDCl₃, 300 MHz): δ = 7.25 (t, J = 8.1 Hz, IH), 7.06

(dd, J= 8.1, 4.2 Hz, IH), 7.93 (s, IH), 9.40 (s, IH). MS (ES+): m/z = 329.71/331.66 [MH⁺]. HPLC: fe = 3.97 min (ZQ2, polar_5min).

5-Chloro-8-fluoroisoquinolin-3-ol

To N-(5-chloro-2-fluorobenzyl)-2,2-dimethoxyacetamide (9.00 g, 34.3 mmol) were added cone. H₂SO₄ (25.0 mL, 465 mmol) and oleum (30%, 25.0 mL, 394 mmol). The mixture was heated at 85 ⁰C for 2 h. Then, the reaction mixture was cooled to RT and poured slowly into a cold aqueous satd. solution OfNaHCO₃ (2.0 L) in a beaker with efficient stirring (Note: frothing occurs). The solid formed was filtered off, washed with water (50 mL), and dried in vacuo to give the title compound as yellow solid. ¹H NMR (CDCl₃, 300 MHz): δ = 6.72 (t, J = 8.4 Hz, IH), 7.15 (s, IH), 7.43 (dd, J= 8.1, 4.2 Hz), 8.80 (s, IH), -OH not visible. MS (ES+): m/z 197.72/199.77 [MH⁺]. HPLC: t_R = 2.58 min (ZQ2, polar_5min).

A^S-Chloro-l-fluorobenzyl^l-dimethoxyacetamide

Equimolar amounts of 2-fluoro-5-chlorobenzylamine (10.0 g, 62.5 mmol) and methyl dimethoxyacetate (8.38 g, 62.5 mmol) were heated in a sealed tube at 100 ⁰C for 16 h. After cooling to RT, to the reaction mixture was added «-heptane (40 mL) and cooled at 4°C overnight. The solid formed was filtered off and dried in vacuo to give the title compound as off-white solid. ¹H NMR (CDCl₃, 300 MHz): δ = 3.40 (s, 6H), 4.52 (d, J= 5.8 Hz, 2H), 4.74 (s, IH), 6.89 (bs, IH), 7.01 (t, J = 8.4 Hz, IH), 7.20-7.25 (m, IH), 7.31-7.36 (m, IH). MS (ES+): m/z 261.90/263.78 [MH⁺]. HPLC: t_R = 2.85 min (ZQ2, polar_5min). Example 12: 4-{4-[6-Amino-5-(5-chloro-8-methoxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l- yl}-piperidine trihydrochloride

To a suspension of 4- {4-[6-amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l- yl}-piperidine-l-carboxylic acid tert-butyl ester (40 mg, 0.076 mmol) in MeOH (1.3 mL, 33 mmol), THF (1.3 mL, 16 mmol), and H₂O (0.13 mL, 7.4 mmol) was added sodium hydroxide (40.0 mg, 1.00 mmol), and the mixture was stirred at 55 ⁰C for 24 h. The reaction mixture was concentrated and then diluted with water, this was acidified with Acetic acid and the solid was filtered off and washed with more water and then dried to give the Boc-protected compound; MS (ES+): m/z = 535.12/537.13 [MH⁺]. This material was dissolved in DCM (1 mL) and stirred at ambient temperature with IM HCl in Et₂O (1.0 mL) for 4 h. The solid that formed was filtered off and dried in vacuo to yield the title compound as pale yellow solid. ¹H NMR (400 MHz, DMSO-</₆): δ = 2.11-2.30 (m, 4H), 3.03-3.18 (m, 2H), 3.34-3.43 (m, 2H), 4.08 (s, 3H), 4.48-4.61 (m, IH), 7.25 (d, J = 8.6 Hz, IH), 8.00 (d, J = 8.6 Hz, IH), 8.14 (s, IH), 8.47-8.50 (m, 3H), 8.59 (br. s., IH), 8.78 (d, J = 2.0 Hz, IH), 9.12 (br. s., IH), 9.28 (br. s., IH), 9.66 (s, IH). MS (ES+): m/z = 435.09/437.11 [MH⁺]. HPLC: t_R = 1.84 min (ZQ2, polar_5min).

Example 13 : 3-Isoquinolin-3-yl-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride

The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid isoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3-yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.39 (br. s., 4H), 3.22-3.31 (m, 2H), 3.57-3.66 (m, 2H), 4.61-4.74 (m, IH), 7.95 (t, J = 7.5 Hz, IH), 8.04-8.11 (m, 2H), 8.26 (d, J = 8.1 Hz, IH), 8.33 (s, IH), 8.38 (d, J = 8.3 Hz, IH), 8.41-8.46 (m, IH), 8.73 (s, IH), 8.80- 8.86 (m, IH), 9.64 (s, IH). MS (ES+): m/z = 370.94 [MH⁺]. HPLC: t_R = 2.21 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid isoquinolin-3-yl ester A DCM (5 mL) solution of 3-hydroxyisoquinoline (0.200 g, 1.38 mmol) and triethylamine (0.4 mL, 3 mmol) was cooled in an ice bath and charged with trifluoromethanesulfonic anhydride (0.5 mL, 3 mmol). This mixture was allowed to stir for 1 h while slowly warming to rt. The reaction was quenched with water and then diluted with more DCM, washed with NaHCO₃ solution, brine, dried over Na₂SOz_I, filtered and concentrated. The crude product was passed through a small silica gel plug eluting with 10% EtO Ac/Hex to yield the title compound as yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.59 (s, IH), 7.71 (t, J = 7.6 Hz, IH), 7.81 (dd, J= 8.1, 7.1 Hz, IH), 7.93 (d, J= 8.3 Hz, IH), 8.08 (d, J= 8.3 Hz, IH), 9.09 (s, IH). MS (ES+): m/z = 277.82 [MH⁺]. HPLC: t_R = 3.66 min (ZQ2, polar_5min).

Example 14: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(7-trifluoromethoxy-isoquinolin-3-yl)- pyridin-2-ylamine trihydrochloride A mixture of 4- {4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (BB3) (75 mg, 0.16 mmol), trifluoromethanesulfonic acid 7-trifluoromethoxyisoquinolin-3-yl ester (69 mg, 0.19 mmol), potassium carbonate (66 mg, 0.48 mmol), Pd(PPh₃)₄ (18 mg, 0.016 mmol) in DME (1.5 mL) and H₂O (0.5 mL) was evacuated and refilled with N₂ (3x), then it was heated at 100 ⁰C for 30 min using the microwave reactor. The reaction mixture was diluted with EtOAc (30 mL), washed with brine (10 mL), and dried over anhydrous sodium sulfate. The residue was purified by silica gel chromatography (Hex.:EtOAc = 30:70 → 15:85) to give a yellow solid. This material was dissolved in DCM (2 mL) and treated with IM HCl in diethyl ether (3 mL). The resulting mixture was stirred at room temperature overnight. The title compound was collected by filtration as a yellow solid and washed with DCM. MS (ES+): m/z = 455.12 [MH⁺]. Trifluoromethanesulfonic acid 7-trifluoromethoxyisoquinolin-3-yl ester

By following the procedure for the preparation of trifluoromethanesulfonic acid 5-chloro-8- fluoroisoquinolin-3-yl ester, the title compound was prepared from 7-trifluoromethoxyisoquinolin-3-ol (0.98 g, 4.3 mmol), triflic anhydride (0.17 mL, 1.0 mmol), NEt₃ (0.8 mL, 3.0 mmol) and CH₂Cl₂ (10 mL). ¹H NMR (CDCl₃, 300 MHz): δ = 7.63 (s, IH), 7.65 (d, J = 6.0 Hz, IH), 7.89 (s, IH), 7.98 (d, J = 9.0 Hz, IH), 9.10 (s, IH).

7-Trifluoromethoxyisoquinolin-3-ol

By following the procedure for the preparation of 5-chloro-8-fluoroisoquinolin-3-ol, the title compound was prepared from 2,2-dimethoxy-N-(3-trifluoromethoxybenzyl)-acetamide (5.0 g, 17 mmol), cone. H₂SO₄ (9.0 mL) and oleum (30%; 10.8 mL). ¹H NMR (CDCl₃, 300 MHz): δ = 6.80 (s, IH), 7.22 (d, J= 6.8 Hz, IH), 7.42 (s, IH), 7.43 (d, J= 7.2 Hz, IH), 8.44 (s, IH). 2,2-Dimethoxy-Λ'-(3-trifluoromethoxybenzyl)-acetamide

By following the procedure for the preparation of N-(5-chloro-2-fluorobenzyl)-2,2- dimethoxyacetamide, the title compound was prepared from 3-(trifluoromethoxy)benzylamine (4.0 g, 21 mmol) and methyl dimethoxyacetate (2.8 g, 21 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 3.40 (s, 6H), 4.44 (d, J= 4.2 Hz, 2H), 4.75 (s, IH), 6.95 (bs, IH), 7.11 (s, 2H), 7.20 (d, J= 2.4 Hz, IH), 7.35- 7.40 (m, IH).

Example 15: 3-(5-Chloro-6,8-difluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride salt

4- {4-[6-Amino-5-(5-chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester (0.0311 mmol) was dissolved in DCM (4.4 ml), and 1.0 M of HCl in Et₂O (8.8 ml) was added. The mixture was stirred at rt for 16 h. After that time, solvent was removed in vacuo to give the title compound as a yellow powder. ¹H NMR (400 MHz, DMSO-dβ): δ = 2.14- 2.30 (m, 4H), 3.03-3.18 (m, 2H), 3.36-3.42 (m, 2H), 4.50-4.60 (m, IH), 4.97 (brs, 2H), 8.07 (t, J = 10.0 Hz, IH), 8.14 (s, IH), 8.49 (s, IH), 8.53 (d, J= 2.4 Hz, IH), 8.63 (d, J= 0.8 Hz, IH), 8.81 (d, J = 2.4 Hz, IH), 9.14 (brs, IH), 9.31 (brs, IH), 9.66 (s, IH). MS(ES+): m/z = 440.84/442.79 (82/32) [MH⁺]. HPLC: t_R = 1.89 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(5-chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine-1-carboxylic acid tert-buty\ ester

To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-1-yl} -piperidine- 1 -carboxylic acid tert-butyl ester (BB3) (18.3 mg, 0.0391 mmol), trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester (0.0326 mmol), and Pd(PPh₃)₄ (2.51 mg, 0.00215 mmol) in 1,4-dioxane (0.90 ml) in a sealable microwave tube was added a solution of CS₂CO3 (21.4 mg, 0.0651 mmol) in H₂O (0.30 ml). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 100 ⁰C for 30 min. The reaction mixture was diluted with EtOAc (40 ml), washed with water (2x20 ml) and brine (20 ml), and dried over MgSO₄. After concentration in vacuo, a brown oil was obtained. It was then purified by prep. TLC eluting with 4% MeOH/CH₂Cl₂ to give the title compound as a brown oil. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.94-2.05 (m, 2H), 2.16-2.24 (m, 2H), 2.87-2.98 (m, 2H), 4.24-4.38 (m, 3H), 6.45 (brs, 2H), 7.18 (t, J = 9.6 Hz, IH), 7.68 (d, J = 0.8 Hz, IH), 7.79 (d, J= 0.8 Hz, IH), 7.99 (d, J= 2.4 Hz, IH), 8.32 (d, J= 2.4 Hz, IH), 8.34 (m, IH), 9.53 (d, J= 1.2 Hz, IH). MS(ES+): m/z = 540.92/542.87 (100/86) [MH⁺]. HPLC: t_R = 3.15 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester A DCM (2 ml) suspension of 5-chloro-6,8-difluoroisoquinolin-3-ol (42.9 mg, 0.199 mmol) and triethylamine (30.6 μl, 0.218 mmol) was charged slowly with N-phenylbis- (trifluoromethanesulfonimide) (73.8 mg, 0.204 mmol) at rt. This mixture was allowed to stir at rt for 24 h. After that time, the reaction mixture was purified by prep. TLC eluting with 40% EtOAc/hexane to give the title compound as an off-white solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.26 (t, J= 8.8 Hz, 1 H), 7.91-7.92 (m, 1 H), 9.34 (d, J= 0.4 Hz, 1 H). MS(ES+): m/z = 347.69/349.51 (82/42) [MH⁺]. HPLC: t_R = 3.98 min (polar_5min, ZQ3). 5-Chloro-6,8-difluoroisoquinolin-3-ol Sulfuric acid (18 M; 2.0 mL, 36 mmol.) was added to N-(5-chloro-2,4-difluorobenzyl)-2,2- dimethoxyacetamide (708 mg, 2.53 mmol) at rt. The solution was stirred at 90 ⁰C overnight. After that time, the mixture was poured into ice and basified with NaOH (10 N) until pH = 6-7 forming a solid. The solid was filtered off, washed with water, and dried in vacuo to give the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 6.94 (t, J= 9.2 Hz, IH), 7.48 (s, IH), 9.04 (s, IH). MS(ES+): m/z = 215.47/217.76 (45/100) [MH⁺]. HPLC: t_R = 2.67 min (polar_5min, ZQ3). Λ^S-Chloro-l^-difluorobenzylJ-ljl-dimethoxyacetamide

A mixture of methyl dimethoxyacetate (1.45 g, 10.7 mmol) and 5-chloro-2,4-difluorobenzylamine (1.78 g, 10.0 mmol) in a sealed tube was heated at 80 ⁰C for 20 h. After that time, the mixture was diluted with EtOAc (20 ml), washed with HCl (2 N, 10 ml), saturated Na₂CO₃ (10 ml), H₂O (10 ml) and brine (10 ml), and dried over MgSO₄. After concentrated in vacuo, the title compound was obtained as a brown oil. ¹H NMR (400 MHz, CDCl₃): δ = 3.41 (s, 6 H), 4.46 (d, J= 6.4 Hz, 2H), 4.74 (s, IH), 6.92 (t, J= 8.8 Hz, IH), 6.93 (brs, IH), 7.41 (t, J= 8.0 Hz, IH). MS(ES+): m/z = 280.03/282.01 (95/57) [MH⁺]. HPLC: t_R = 3.02 min (polar_5min, ZQ3).

Example 16: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(6-trifluoromethylisoquinolin-3-yl)- pyridin-2-ylamine trihydrochloride salt The title compound was obtained as yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(6-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.14-2.34 (m, 4H), 3.07-3.19 (m, 2H), 3.37-3.45 (m, 2H), 4.49-4.62 (m, IH), 4.70 (brs, 2H), 8.08 (dd, J= 2.0 & 8.8 Hz, IH), 8.16 (d, J = 0.4 Hz, IH), 8.51 (d, J= 2.0 Hz, IH), 8.52 (s, IH), 8.55 (d, J= 9.6 Hz, 2H), 8.71 (brs, IH), 8.87 (d, J = 2.0 Hz, IH), 8.93 (s, IH), 9.08 (brs, IH), 9.22 (brs, IH), 9.67 (s, IH). MS(ES+): m/z = 438.88(58) [MH⁺]. HPLC: t_R = 1.87 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(6-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-butyl ester The title compound was obtained as a brown oil following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 6-trifluoromethylisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.04 (m, 2H), 2.16-2.24 (m, 2H), 2.87-2.98 (m, 2H), 4.24-4.38 (m, 3H), 6.45 (brs, 2H), 7.67 (d, J= 0.8 Hz, IH), 7.77-7.81 (m, 2H), 7.96 (d, J= 2.0 Hz, IH), 8.16 (dd, J = 0.8 & 9.2 Hz, 2H), 8.24 (s, IH), 8.30 (d, J= 2.0 Hz, IH), 9.40 (s, IH). MS(ES+): m/z = 538.49/540.17 (82/100) [MH⁺]. HPLC: t_R = 3.01 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 6-trifluoromethylisoquinolin-3-yl ester The title compound was obtained as an off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 6- trifluoromethylisoquinolin-3-ol. ¹H NMR (400 MHz, CDCl₃): δ = 7.71 (s, IH), 7.88 (dd, J= 1.6 & 8.4 Hz, IH), 8.22-8.25 (m, 2H), 9.20 (s, IH). MS(ES+): m/z = 345.74 (100) [MH⁺]. HPLC: t_R = 3.92 min (polar_5min, ZQ3).

6-Trifluoromethylisoquinolin-3-ol

Sulfuric acid (18 M; 2.25 mL, 40.5 mmol) was added to 2,2-dimethoxy-N-(4- trifluoromethylbenzyl)-acetamide (828 mg, 2.96 mmol) at rt. The combined solution was stirred at 50 ⁰C overnight. The mixture was poured into ice, basified with NaOH (10 N) until pH > 12, and extracted with EtOAc (3><50 ml). The extracts were washed with water (20 ml), dried over MgSOzt, filtered, and concentrated in vacuo. The residue was triturated with 50% EtOAc/hexane (10 ml) to yield a yellow solid that was then purified by Gilson HPLC to give the title compound as yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.18 (s, IH), 7.45-7.51 (m, IH), 7.96-8.02 (m, 2H), 8.89 (brs, IH). MS(ES+): m/z = 214.32 (100) [MH⁺]. HPLC: t_R = 2.64 min (polar_5 min, ZQ3). 2,2-Dimethoxy-Λ'-(4-trifluoromethylbenzyl)-acetamide

The title compound was obtained as a yellow oil following the procedure for preparing N-(5-chloro- 2,4-difluorobenzyl)-2,2-dimethoxyacetamide, using 4-trifluoromethylbenzylamine. ¹H NMR (400 MHz, CDCl₃): δ = 3.42 (s, 6H), 4.54 (d, J= 6.0 Hz, 2H), 4.77 (s, IH), 6.97 (brs, IH), 7.39-7.43 (m, 2H), 7.60 (d, J = 8.0 Hz, 2H). MS(ES+): m/z = 278.12 (100) [MH⁺]. HPLC: t_R = 3.06 min (polar_5min, ZQ3).

Example 17: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(7-trifluoromethylisoquinolin-3-yl)- pyridin-2-ylamine tri-hydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(7-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.14-2.34 (m, 4H), 3.06-3.19 (m, 2H), 3.37-3.45 (m, 2H), 4.22 (brs, 2H), 4.50-4.60 (m, IH), 8.16 (dd, J = 1.6 & 8.4 Hz, IH), 8.17 (s, IH), 8.34 (d, J= 8.8 Hz, IH), 8.52 (d, J= 2.4 Hz, IH), 8.54 (s, IH), 8.75 (brs, IH), 8.84 (s, IH), 8.89 (s, IH), 8.91 (d, J= 2.0 Hz, IH), 9.16 (brs, IH), 9.31 (brs, IH), 9.69 (s, IH). MS(ES+): m/z 438.81(38) [MH⁺]. HPLC: t_R = 1.95 min (ZQ3, polar 5min).4-{4-[6-Amino-5-(7-trifluoromethylisoquinolin-3- yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester

The title compound was obtained as a brown foam following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 7-trifluoromethylisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.04 (m, 2H), 2.16-2.24 (m, 2H), 2.87-2.98 (m, 2H), 4.24-4.38 (m, 3H), 6.47 (brs, 2H), 7.67 (d, J= 0.4 Hz, IH), 7.78 (d, J= 0.8 Hz, IH), 7.90 (dd, J= 2.0 & 8.8 Hz, IH), 7.98 (d, J= 2.4 Hz, IH), 8.03 (d, J= 8.0 Hz, IH), 8.11 (s, IH), 8.30 (d, J= 2.4 Hz, IH), 8.34 (d, J= 0.8 Hz, IH), 9.41 (s, IH). MS(ES+): m/z = 539.97 (100) [MH⁺]. HPLC: t_R = 3.01 min (ZQ3, polar_5min). Trifluoromethanesulfonic acid 7-trifluoromethylisoquinolin-3-yl ester

The title compound was obtained as an off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- trifluoromethylisoquinolin-3-ol and 5-trifluoromethylisoquinolin-3-ol mixture followed by separation of the isomers by prep. TLC. ¹H NMR (400 MHz, CDCl₃): δ = 7.67 (s, IH), 7.97 (dd, J= 0.8 & 8.4 Hz, IH), 8.07 (d, J= 8.4 Hz, IH), 8.40 (d, J= 0.8 Hz, IH), 9.21 (s, IH). MS(ES+): m/z = 345.74 (100) [MH⁺]. HPLC: t_R = 3.90 min (polar_5min, ZQ3).

7-Trifluoromethylisoquinolin-3-ol and 5-Trifluoromethylisoquinolin-3-ol Sulfuric acid (18M; 4.0 mL, 72 mmol) was added to 2,2-dimethoxy-N-(3-trifluoromethylbenzyl)- acetamide (1.43 g, 5.16 mmol) at ambient temperature, and the solution was stirred at 50 ⁰C overnight. The solution was poured into ice, basified with NaOH (10 N), and extracted with ether (3><50 ml). The aqueous layer was neutralized with HCl until pH = 6-7 forming a precipitate that was filtered off, washed with water, and dried in vacuo to give a mixture of the title compounds as yellow powder. The mixture was used directly for the next step. ¹H NMR (400 MHz, CDCl₃): δ = 7.07 (s, IH), 7.33 (s, IH), 7.36 (t, J= 8.0 Hz, IH), 7.67 (dd, J= 1.6 & 8.8 Hz, IH), 7.74 (d, J= 8.8 Hz, IH), 7.96 (d, J= 7.2 Hz, IH), 8.01 (d, J = 8.0 Hz, IH), 8.11 (s, IH), 8.82 (s, IH), 8.84 (s, IH). MS(ES+): m/z = 214.06 (100) [MH⁺]. HPLC: t_R = 2.72 min (polar_5min, ZQ3).

2,2-Dimethoxy-Λ'-(3-trifluoromethylbenzyl)-acetamide

The title compound was obtained as a yellow oil following the procedure for N-(5-chloro-2,4- difluorobenzyl)-2,2-dimethoxyacetamide, using 3-trifluoromethylbenzylamine. ¹H NMR (400 MHz, CDCl₃): δ = 3.42 (s, 6H), 4.54 (d, J = 6.0 Hz, 2H), 4.77 (s, IH), 6.97 (brs, IH), 7.43-7.57 (m, 4H). MS(ES+): m/z = 278.12 (100) [MH⁺]. HPLC: t_R = 3.06 min (polar_5min, ZQ3).

Example 18: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(5-trifluoromethylisoquinolin-3-yl)- pyridin-2-ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(5-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.12-2.28 (m, 4H), 3.04-3.17 (m, 2H), 3.36-3.44 (m, 2H), 4.49-4.59 (m, IH), 4.91 (brs, 2H), 7.97 (t, J= 8.0 Hz, IH), 8.10 (s, IH), 8.26 (brs, IH), 8.31 (s, IH), 8.39 (d, J= 7.2 Hz, IH), 8.43 (s, IH), 8.49 (d, J= 2.4 Hz, IH), 8.57 (d, J= 2.0 Hz, IH), 8.65 (d, J= 8.4 Hz, IH), 9.06 (brs, IH), 9.25 (s, IH), 9.70 (s, IH). MS(ES+): m/z = 438.88 (42) [MH⁺]. HPLC: t_R = 1.81 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(5-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown foam following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 5-trifluoromethylisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.04 (m, 2H), 2.16-2.24 (m, 2H), 2.87-2.98 (m, 2H), 4.24-4.38 (m, 3H), 6.36 (brs, 2H), 7.66 (d, J= 0.4 Hz, IH), 7.69 (t, J= 8.0 Hz, IH), 7.77 (d, J= 0.8 Hz, IH), 7.92 (d, J= 2.4 Hz, IH), 8.12 (d, J= 7.2 Hz, IH), 8.21 (d, J= 8.4 Hz, IH), 8.27 (m, IH), 8.30 (d, J= 2.0 Hz, IH), 9.39 (d, J= 0.8 Hz, IH). MS(ES+): m/z 540.17 (100) [MH⁺]. HPLC: t_R = 2.91 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 5-trifluoromethylisoquinolin-3-yl ester The title compound was obtained as an off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- trifluoromethylisoquinolin-3-ol and 5-trifluoromethylisoquinolin-3-ol mixture followed by separation of the isomers by prep. TLC. ¹H NMR (400 MHz, CDCl₃): δ = 7.77 (dt, J= 0.4 & 8.0 Hz, IH), 7.84- 7.85 (m, IH), 8.19 (dd, J= 1.2 & 8.4 Hz, IH), 8.28 (d, J= 8.4 Hz, IH), 9.19 (d, J= 0.8 Hz, IH). MS(ES+): m/z = 345.74 (100) [MH⁺]. HPLC: t_R = 3.92 min (polar_5min, ZQ3). Example 19: 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-(8-trifluoromethylisoquinolin-3-yl)- pyridin-2-ylamine trihydrochloride salt

The title compound was obtained as a yellow oil following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(8-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.26-2.42 (m, 4H), 3.19-3.29 (m, 2H), 3.56-3.63 (m, 2H), 4.54-4.62 (m, IH), 7.89 (t, J = 8.0 Hz, IH), 7.96 (s, IH), 8.07 (d, J = 7.2 Hz, IH), 8.14 (s, IH), 8.26 (d, J= 9.2 Hz, 2H), 8.29 (d, J= 2.8 Hz, IH), 8.32 (brs, 2H), 8.47 (s, IH), 9.60 (brs, IH). MS(ES+): m/z = 438.88 (62) [MH⁺]. HPLC: t_R = 1.91 min (ZQ3, polar_5 min).

4-{4-[6-Amino-5-(8-trifluoromethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil following the procedure for 4-{4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 8-trifluoromethylisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.02 (m, 2H), 2.18-2.22 (m, 2H), 2.92 (t, J= 11.2 Hz, 2H), 4.24-4.38 (m, 3H), 6.54 (brs, 2H), 7.67 (d, J= 0.8 Hz, IH), 7.77 (t, J= 8.0 Hz, IH), 7.78 (d, J= 0.8 Hz, IH), 7.95 (d, J= 6.8 Hz, IH), 7.98 (d, J= 2.0 Hz, IH), 8.09 (d, J= 8.4 Hz, IH), 8.12 (s, IH), 8.29 (d, J= 2.0 Hz, IH), 9.65 (m, J= 2.0 Hz, IH). MS(ES+): m/z = 540.04(100) [MH⁺]. HPLC: t_R = 3.01 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 8-trifluoromethylisoquinolin-3-yl ester The title compound was obtained as a colorless oil following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 8- trifluoromethylisoquinolin-3-ol. ¹H NMR (400 MHz, CDCl₃): δ = 7.59 (s, IH), 7.86 (dt, J= 0.8 & 8.0 Hz, IH), 8.05 (td, J= 0.8 & 7.2 Hz, IH), 8.11 (d, J= 8.8 Hz, IH), 9.43-9.45 (m, IH). MS(ES+): m/z = 345.74 (100) [MH⁺]. HPLC: t_R = 3.96 min (polar_5min, ZQ3). 8-Trifluoromethylisoquinolin-3-ol

Sulfuric acid (18 M; 3.57 mL, 65.6 mmol) was added to 2,2-dimethoxy-N-(2- trifluoromethylbenzyl)-acetamide (1.33 g, 4.69 mmol) at rt. The solution was stirred at 40 ⁰C overnight. The mixture was poured into ice, basified with NaOH (10 N) until pH > 13, extracted with Et₂O (3x30 ml), and the extracts were back-washed with water (20 ml). The combined aqueous layers were neutralized with HCl until pH = 7-8 and extracted with EtOAc (3><30 ml). The EtOAc extract was washed with water (2x20ml), brine (20 ml), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound as yellow solid. The material was used in the next step without further purification; a small quantity (15 mg) was purified using the Gilson HPLC for characterization by NMR. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 7.13 (s, IH), 7.70 (t, IH, J= 8.0 Hz), 7.78 (d, IH, J= 7.2 Hz), 8.06 (d, IH, J= 8.4 Hz), 9.03 (t, IH, J= 1.0 Hz), 11.23 (brs, IH). MS(ES+): m/z = 213.38 (82) [MH⁺]. HPLC: t_R = 2.55 min (polar_5min, ZQ3).

2,2-Dimethoxy-Λ'-(2-trifluoromethylbenzyl)-acetamide

The title compound was obtained as a brown solid following the procedure for N-(5-chloro-2,4- difluorobenzyl)-2,2-dimethoxyacetamide, using 2-trifluoromethylbenzylamine. ¹H NMR (400 MHz, CDCl₃): δ = 3.39 (s, 6H), 4.66 (dd, J= 1.2 & 6.0 Hz, 2H), 4.74 (s, IH), 6.94 (brs, IH), 7.38-7.43 (m, IH), 7.51-7.59 (m, 2H), 7.66 (d, J= 8.0 Hz, IH).

Example 20: 3-(5,8-Dimethylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(5,8-dimethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.25-2.41 (m, 4H), 2.73 (s, 3H), 2.78 (s, 3H), 3.19-3.28 (m, 2H), 3.55-3.62 (m, 2H), 4.53^.62 (m, IH), 7.37 (dd, J= 0.8 & 7.2 Hz, IH), 7.50 (dd, J= 0.8 & 7.2 Hz, IH), 7.94 (d, J= 0.8 Hz, IH), 8.13 (d, J= 0.8, IH), 8.20 (s, IH), 8.21 (d, J= 6.8 Hz, IH), 8.26 (s, IH), 8.30 (brs, 2H), 9.49 (brs, IH). MS(ES+): m/z = 398.97 (100) [MH⁺]. HPLC: t_R = 1.84 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(5,8-dimethylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown solid following the procedure for 4-{4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 5,8-dimethylisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃) δ= 1.49 (s, 9H), 1.94-2.04 (m, 2H), 2.17-2.21 (m, 2H), 2.70 (s, 3H), 2.78 (s, 3H), 2.82-2.92 (m, 2H), 4.24-4.38 (m, 3H), 6.48 (brs, 2H), 7.29 (d, J= 6.8 Hz, IH), 7.43 (d, J= 7.2 Hz, IH), 7.66 (d, J = 0.8 Hz, IH), 7.77 (d, J= 0.8 Hz, IH), 7.94 (d, J= 2.0 Hz, IH), 8.08 (d, J= 0.8 Hz, IH), 8.26 (d, J = 2.0 Hz, IH), 9.47 (t, J= 0.8 Hz, IH). MS(ES+): m/z 498.62/500.24(76/100) [MH⁺]. HPLC: t_R = 2.84 min (ZQ3, polar_5 min).

Trifluoromethanesulfonic acid 5,8-dimethylisoquinolin-3-yl ester The title compound was obtained as an off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 5,8- dimethylisoquinolin-3-ol. ¹H NMR (400 MHz, CDCl₃): δ = 2.65 (s, 3H), 2.77 (s, 3H), 7.34 (dd, J= 0.8 & 7.2 Hz, IH), 7.48 (dd, J= 0.8 & 7.2 Hz, IH), 7.64 (d, J= 0.8 Hz, IH), 9.25 (d, J= 0.8 Hz, IH). MS(ES+): m/z = 305.80 (43) [MH⁺]. HPLC: t_R = 4.03 min (polar_5 min, ZQ3). 5,8-Dimethylisoquinolin-3-ol

Sulfuric acid (18 M; 3.8 mL, 68 mmol) was added to N-(2,5-dimethylbenzyl)-2,2- dimethoxyacetamide (1.17 g, 4.92 mmol) at rt, and the solution was stirred at rt overnight. The solution was poured into ice, basified with NaOH (10 N) until pH > 13, extracted with Et₂O (3><30 ml), and the extracts were back-extracted with water (20 ml). The aqueous layer was neutralized with HCl until pH = 7-8 and extracted with EtOAc (3><30 ml). The EtOAc extracts were washed with water (2x20ml), brine (20 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give a brown solid. It was purified by prep. TLC eluting with 4% MeOH in DCM to give the title compound as yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.46 (s, 3H), 2.55 (s, 3H), 6.84 (d, J = 7.6 Hz, IH), 6.98 (s, IH), 7.16 (d, J = 7.2 Hz, IH), 8.61 (s, IH). MS(ES+): m/z = 173.43 (100) [MH⁺]. HPLC: t_R = 2.35 min (polar_5 min, ZQ3).

N-^S-Dimethylbenzyl^l-dimethoxyacetamide

The title compound was obtained as a brown solid following the procedure for N-(5-chloro-2,4- difluorobenzyl)-2,2-dimethoxyacetamide, using 2,5-dimethylbenzylamine. ¹H NMR (400 MHz,

CDCl₃): δ = 3.28 (s, 3H), 3.31 (s, 3H), 3.40 (s, 6H), 4.43 (d, J= 5.6 Hz, 2H), 4.75 (s, IH), 6.68 (brs, IH), 7.01-7.09 (m, 3H).

Example 21 : 3-(7-Bromoisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(7-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.18-2.32 (m, 4H), 3.06-3.19 (m, 2H), 3.33- 3.42 (m, 2H), 4.50-4.60 (m, IH), 4.78 (brs, 2H), 8.03 (dd, J= 1.6 & 8.8 Hz, IH), 8.09 (d, J= 8.8 Hz, IH), 8.17 (s, IH), 8.51 (d, J= 1.2 Hz, IH), 8.58 (d, J= 9.2 Hz, 2H), 8.83 (s, IH), 8.88 (d, J= 1.2 Hz, IH), 9.41 (brs, IH), 9.47 (s, IH), 9.53 (s, IH). MS(ES+): m/z = 449.09/451.07(32/32) [MH⁺]. HPLC: ?_R = 1.86 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(7-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester The title compound was obtained as a yellow solid following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 7-bromoisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.94-2.04 (m, 2H), 2.17-2.21 (m, 2H), 2.86-2.98 (m, 2H), 4.20-4.38 (m, 3H), 6.44 (brs, 2H), 7.66 (d, J= 0.8 Hz, IH), 7.77-7.82 (m, 3H), 7.94 (d, J= 2.4 Hz, IH), 8.01 (s, IH), 8.18 (t, J = 0.8 Hz, IH), 8.28 (d, J= 2.4 Hz, IH), 9.23 (s, IH). MS(ES+): m/z = 549.20/551.15 (100/100) [MH⁺]. HPLC: t_R = 2.89 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 7-bromoisoquinolin-3-yl ester The title compound was obtained as beige solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- bromoisoquinolin-3-ol and 5-bromoisoquinolin-3-ol followed by separation of the isomers by prep. TLC. ¹H NMR (400 MHz, CDCl₃): δ = 7.57 (s, IH), 7.80 (d, J= 9.2 Hz, IH), 7.87 (dd, J= 2.0 & 8.8 Hz, IH), 8.24-8.25 (m, IH), 9.02 (s, IH). MS(ES+): m/z = 355.96/357.92 (35/45) [MH⁺]. HPLC: t_R = 3.90 min (polar_5min, ZQ3).

5-Bromoisoquinolin-3-ol and 7-Bromoisoquinolin-3-ol

A solution ofN-(3-bromobenzyl)-2,2-dimethoxyacetamide (565 mg, 1.96 mmol) and sulfuric acid (18 M; 1.5 mL, 27 mmol) was stirred at 40 ⁰C for 16 h. The mixture was poured into ice, neutralized with NaOH (10 N) until pH = 7-8, the solid was filtered off and washed with water. The filtrate was extracted with EtOAc (3><50 ml). The extracts were washed with water (2x20 ml), brine (20 ml), dried over MgSO4, filtered, and concentrated in vacuo. The residue was combined with the precipitate from the neutralization and dried in vacuo, giving a mixture of the two title compounds as yellow solid. Data for 5-bromoisoquinolin-3-ol: ¹H NMR (400 MHz, DMSO-^₆): δ = 6.93 (s, IH), 7.65-7.71 (m, 2H), 8.22-8.23 (m, IH), 8.91 (s, IH), 11.04 (brs, IH). Data for 7-bromoisoquinolin-3-ol: ¹H NMR (400 MHz, DMSO-^₆): δ = 7.01 (s, IH), 7.27 (dd, J= 8.0 & 8.0 Hz, IH), 7.96 (dd, J= 1.2 & 7.2 Hz, IH), 8.02 (d, J= 1.2 Hz, IH), 8.99 (d, J= 0.8 Hz, IH), 11.04 (brs, IH). Data for mixture: MS(ES+): m/z = 224/226 [MH⁺]. HPLC: t_R = 2.57 min (polar_5min, ZQ3). jY-^-Bromobenzyl^^-dimethoxyacetamide

The title compound was obtained as a brown oil following the procedure for N-(5-chloro-2,4- difluorobenzyl)-2,2-dimethoxyacetamide, using 3-bromobenzylamine. ¹H NMR (400 MHz, CDCI3): δ = 3.42 (s, 6H), 4.45 (d, J= 6.0 Hz, 2H), 4.76 (s, IH), 6.91 (brs, IH), 7.18-7.24 (m, 2H), 7.38-7.44 (m, 2H). MS(ES+): m/z = 287.97/289.95 (90/100) [MH⁺]. HPLC: t_R = 2.97 min (polar_5 min, ZQ3). Example 22: 3-(5-Bromoisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(5-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.11-2.28 (m, 4H), 3.05-3.17 (m, 2H), 3.36- 3.44 (m, 2H), 3.64 (brs, 2H), 4.48-4.57 (m, IH), 7.75 (t, J= 8.0 Hz, IH), 8.13 (d, J= 0.4 Hz, IH), 8.28 (dd, J= 1.2 & 7.2 Hz, IH), 8.36 (d, J= 8.4 Hz, IH), 8.42 (s, IH), 8.46 (d, J= 2.4 Hz, IH), 8.47 (s, IH), 8.72 (d, J= 2.4 Hz, IH), 8.93 (brs, IH), 9.11 (brs, IH), 9.55 (d, J= 0.8 Hz, IH). MS(ES+): m/z = 449.04/451.02 (46/46) [MH⁺]. HPLC: t_R = 1.78 min (ZQ3, polar_5min). 4-{4-[6-Amino-5-(5-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil following the procedure for 4-{4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 5-bromoisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCI3): δ = 1.49 (s, 9H), 1.94-2.04 (m, 2H), 2.16-2.25 (m, 2H), 2.86-2.98 (m, 2H), 4.22^.38 (m, 3H), 6.41 (brs, 2H), 7.50 (dd, J = 7.2 & 8.0 Hz, IH), 7.68 (d, J = 0.8 Hz, IH), 7.92 (d, J= 0.8 Hz, IH), 7.99-8.04 (m, 3H), 8.30 (d, J= 2.4 Hz, IH), 8.33 (s, IH), 9.28 (d, J= 0.8 Hz, IH). MS(ES+): m/z = 549.15/551.08 (99/100) [MH⁺]. HPLC: t_R = 2.84 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 5-bromoisoquinolin-3-yl ester

The title compound was obtained as beige solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- bromoisoquinolin-3-ol and 5-bromoisoquinolin-3-ol followed by separation of the isomers by prep. TLC. ¹H NMR (400 MHz, CDCl₃): δ = 7.57 (dd, J= 7.6 & 8.0 Hz, IH), 7.92 (t, J= 0.8 Hz, IH), 8.05 (td, J= 0.8 & 8.4 Hz, IH), 8.08 (dd, J= 0.8 & 7.2 Hz, IH), 9.08 (d, J= 0.4 Hz, IH). MS(ES+): m/z = 355.90/357.85 (36/22) [MH⁺]. HPLC: t_R = 3.96 min (polar_5min, ZQ3). Example 23: 3-(6-Bromoisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(6-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.40 (brs, 4H), 3.20-3.35 (m, 2H), 3.53-3.66 (m, 2H), 4.69 (brs, IH), 7.95-8.01 (m, IH), 8.05 (s, IH), 8.20-8.29 (m, IH), 8.30 (s, IH), 8.42-8.57 (m, 2H), 8.68 (s, IH), 8.79 (s, IH), 9.58 (brs, IH). MS(ES+): m/z = 449.17/451.09 (72/80) [MH⁺]. HPLC: t_R = 1.98 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(6-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a yellow solid following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 6-bromoisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.04 (m, 2H), 2.16-2.23 (m, 2H), 2.86-2.98 (m, 2H), 4.22^.38 (m, 3H), 6.42 (brs, 2H), 7.67 (d, J= 0.8 Hz, IH), 7.70 (dd, J= 2.0 & 8.8 Hz, IH), 7.77 (d, J= 0.8 Hz, IH), 7.89 (d, J = 8.8 Hz, IH), 7.93 (d, J= 2.4 Hz, IH), 7.95 (s, IH), 8.10 (m, IH), 9.29 (d, J= 2.0 Hz, IH), 9.27 (m, IH). MS(ES+): m/z = 549.12/551.08 (100/99) [MH⁺]. HPLC: t_R = 2.87 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 6-bromoisoquinolin-3-yl ester

The title compound was obtained as an off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 6-bromoisoquinolin-3- ol. ¹H NMR (400 MHz, CDCl₃): δ = 7.50 (s, IH), 7.78 (dd, J= 1.6 & 8.4 Hz, IH), 7.94 (d, J= 8.8 Hz, IH), 8.10-8.12 (m, IH), 9.06 (s, IH). MS(ES+): m/z = 355.96/357.92 (18/18) [MH⁺]. HPLC: f_R = 3.90 min (polar_5min, ZQ3).

6-Bromoisoquinolin-3-ol The title compounds was obtained as a yellow solid following the procedure for 5- bromoisoquinolin-3-ol and 7-bromoisoquinolin-3-ol, using N-(4-bromobenzyl)-2,2- dimethoxyacetamide. ¹H NMR (400 MHz, DMSO-iie): δ = 6.87 (s, IH), 7.42 (dd, J = 2.0 & 8.4 Hz, IH), 7.87 (d, J= 8.8 Hz, IH), 8.00 (d, J = 2.0 Hz, IH), 8.93 (s, IH), 11.07 (brs, IH). MS(ES+): m/z = 224.04/225.93 (88/100) [MH⁺]. HPLC: t_R = 2.41 min (polar_5min, ZQ3). jY-^-BromobenzylJ-ljl-dimethoxyacetamide

The title compound was obtained as a brown oil following the procedure for N-(5-chloro-2,4- difluorobenzyl)-2,2-dimethoxyacetamide, using 4-bromobenzylamine. ¹H NMR (400 MHz, CDCI3): δ = 3.40 (s, 6H), 4.43 (d, J= 6.4 Hz, 2H), 4.75 (s, IH), 6.89 (brs, IH), 7.16 (d, J= 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H). Example 24: 3-(8-Bromoisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedures for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt and 4- {4-[6-amino-5-(5-chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 8-bromoisoquinolin-3-yl ester. ¹H NMR (400 MHz, DMSO-d6): δ = 2.08-2.35 (m, 4H) 3.04-3.19 (m, 2H) 3.35-3.46 (m, 2H) 4.48-4.58 (m, IH) 7.80-7.86 (m, IH) 8.10-8.18 (m, 3H) 8.47 (d, J = 1.8 Hz, IH) 8.51 (s, IH) 8.71 (br. s., IH) 8.78 (s, IH) 8.88 (d, J = 2.0 Hz, IH) 8.99 (br. s., IH) 9.11 (br. s., IH) 9.60 (s, IH). MS (ES+): m/z = 449.05/451.06 [MH⁺]. HPLC: t_R = 1.89 min (ZQ2, polar_5min) Trifluoromethanesulfonic acid 8-bromoisoquinolin-3-yl ester

The title compound was obtained as an off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 8-bromoisoquinolin-3- ol. MS (ES+): m/z = 355.87/357.88 [MH⁺]. HPLC: t_R = 4.08 min (ZQ3, polar_5min). 8-Bromoisoquinolin-3-ol The title compounds was obtained as a yellow solid following the procedure for 5- bromoisoquinolin-3-ol and 7-bromoisoquinolin-3-ol, using N-(2-bromobenzyl)-2,2- dimethoxyacetamide. MS (ES+): m/z = 224.04/226.03 [MH⁺]. HPLC: t_R = 2.39 min (ZQ2, polar_5min).

Λ^-Bromobenzyl^^-dimethoxyacetamide Into a sealed tube were added methyl dimethoxyacetate (1.0 g, 7.5 mmol) and 2-bromobenzylamine

(1.1 g, 5.8 mmol), this mixture was stirred at 50 ⁰C for 16 h. The completed reaction was transferred to a flask and re-crystallized from heptane yielding the desired product as an off-white solid. MS (ES+): m/z = 288.04/289.69 [MH⁺]. HPLC: t_R = 2.93 min (ZQ3, polar_5min). Example 25: 3-(6-Phenylisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine tri-hydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4-{4-[6-amino-5-(6-phenylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.36 (brs, 4H), 3.21-3.32 (m, 2H), 3.53-3.62 (m, 2H), 4.67 (brs, IH), 7.55 (t, J = 7.2 Hz, IH), 7.61 (d, J = 7.2 Hz, 2H), 7.96 (d, J= 7.2 Hz, 2H), 8.05 (brs, IH), 8.42-8.49 (m, 3H), 8.63-8.72 (m, 2H), 8.73 (brs, IH), 8.81 (brs, IH), 9.95 (brs, IH). MS(ES+): m/z 447 ^'.17 (69) [MH⁺]. HPLC: t_R = 2.16 min (ZQ3, polar_5 min).

4-{4-[6-Amino-5-(6-phenylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil from 4- {4-[6-amino-5-(6-bromoisoquinolin-3-yl)- pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester and phenylboronic acid, following the Suzuki coupling procedure described for 4- {4-[6-amino-5-(5-chloro-6,8- difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.05 (m, 2H), 2.16-2.23 (m, 2H), 2.87-2.98 (m, 2H), 4.20-4.38 (m, 3H), 6.50 (brs, 2H), 7.43-7.48 (m, IH), 7.51-7.57 (m, 2H), 7.67 (d, J= 0.4 Hz, IH), 7.72-7.77 (m, 2H), 7.78 (d, J= 0.8 Hz, IH), 7.89 (dd, J= 1.6 & 8.8 Hz, IH), 7.98 (d, J= 2.4 Hz, IH), 8.07-8.12 (m, 3H), 8.27 (d, J= 2.4 Hz, IH), 9.31 (s, IH). MS(ES+): m/z = 547.23 (100) [MH⁺]. HPLC: t_R = 3.02 min (ZQ3, polar_5 min). Example 26: 3-(7-Phenylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine tri-hydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(7-phenylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.38 (brs, 4H), 3.21-3.35 (m, 2H), 3.55-3.65 (m, 2H), 4.66 (brs, IH), 7.48 (t, J= 7.2 Hz, IH), 7.56 (d, J= 7.2 Hz, 2H), 7.86 (d, J= 7.6 Hz, 2H), 8.04 (s, IH), 8.30-8.50 (m, 4H), 8.62 (s, IH), 8.75 (brs, 2H), 9.74 (s, IH). MS(ES+): m/z = 447 '.17 (100) [MH⁺]. HPLC: t_R = 2.17 min (ZQ3, polar_5 min).

4-{4-[6-Amino-5-(7-phenylisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil from 4- {4-[6-amino-5-(7-bromoisoquinolin-3-yl)- pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester and phenylboronic acid, following the Suzuki coupling procedure described for 4- {4-[6-amino-5-(5-chloro-6,8- difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.05 (m, 2H), 2.16-2.23 (m, 2H), 2.87-2.98 (m, 2H), 4.20-4.38 (m, 3H), 6.47 (brs, 2H), 7.41-7.46 (m, IH), 7.51-7.56 (m, 2H), 7.68 (d, J = 0.4 Hz, IH), 7.72-7.78 (m, 2H), 7.80 (d, J = 1.6 Hz, IH), 7.97-8.05 (m, 3H), 8.06 (s, IH), 8.20 (t, J= 0.8 Hz, IH), 8.28 (d, J= 2.4 Hz, IH), 9.35 (s, IH). MS(ES+): m/z 547.23 (100) [MH⁺]. HPLC: t_R = 3.03 min (ZQ3, polar_5 min).

General Procedure for Pd(O) Catalyzed OH Substitution:

Into a sealable tube containing a stir bar were added di-fert-butylmethyl-(2',4',6'-triisopropyl- 3,4,5,6-tetramethylbiphenyl-2-yl)-l(5)-phosphane (49.5 mg, 0.100 mmol) and tris(dibenzylideneacetone)dipalladium(0) (23.1 mg, 0.0250 mmol). The haloisoquinoline (0.500 mmol) dissolved in H₂O (1 ml) and 1,4-dioxane (1 ml) was added into the tube followed by addition of potassium hydroxide (66.0 mg, 1.00 mmol). The tube was evacuated and backfilled with nitrogen three times. The mixture was stirred in a 100 ⁰C preheated oil bath for 1 h. After that time, the mixture was treated with water (5 ml), neutralized with HCl until pH =7-8, and extracted with EtOAc (3><8 ml). The extracts were washed with water (3><8 ml), brine (8 ml), dried over MgSOzt, filtered, and concentrated in vacuo. The residue was purified by chromatography to give the target compound.

Example 27: 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-isoquinolin-5-ol tri-hydrochloride salt

The title compound was obtained as a light-yellow solid following the procedure for 3-(5-chloro- 6,8-difluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(5-hydroxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.35 (brs, 4H), 3.21-3.35 (m, 2H), 3.55-3.62 (m, 2H), 4.64 (brs, IH), 7.57 (d, J= 8.0 Hz, IH), 7.94 (dd, J= 7.6 & 8.0 Hz, IH), 8.02-8.06 (m, 2H), 8.38 (s, IH), 8.43 (s, IH), 8.65 (s, IH), 8.88 (s, IH), 9.86 (s, IH). MS(ES+): m/z = 387.14 (78) [MH⁺]. HPLC: t_R = 0.63 min (ZQ3, polar_5min). 4-{4-[6-Amino-5-(5-hydroxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil following the General Procedure for Pd(O) Catalyzed OH Substitution, using 4-{4-[6-amino-5-(5-bromoisoquinolm-3-yl)-pyridm-3-yl]-pyrazol-l- yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92- 2.04 (m, 2H), 2.13-2.19 (m, 2H), 2.86-2.98 (m, 2H), 4.22-4.38 (m, 3H), 7.20 (d, J= 6.8 Hz, IH),

7.47-7.55 (m, 2H), 7.59 (d, J= 5.6 Hz, 2H), 7.77 (s, IH), 8.04 (d, J= 2.0 Hz, IH), 8.41 (s, IH), 8.46 (brs, IH), 9.10 (s, IH). MS(ES+): m/z = 487.14 (100) [MH⁺]. HPLC: t_R = 2.35 min (ZQ3, polar_5min). Example 28: 3-[2-Amino-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-3-yl]-isoquinolin-6-ol tri-hydrochloride salt

The title compound was obtained as a brown oil following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(6-hydroxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.24-2.42 (m, 4H), 3.18-3.28 (m, 2H), 3.55-3.62 (m, 2H), 4.52-4.62 (m, IH), 7.20 (d, J= 2.0 Hz, IH), 7.25 (dd, J= 2.4 & 8.8 Hz, IH), 7.94 (s, IH), 7.98 (d, J= 9.2 Hz, IH), 8.01 (s, IH), 8.11 (s, IH), 8.14 (d, J= 2.4 Hz, IH), 8.21 (d, J= 2.4 Hz, IH), 8.35 (brs, 2H), 9.12 (s, IH). MS(ES+): m/z = 387.16 (30) [MH⁺]. HPLC: t_R = 1.57 min (ZQ3, polar_5min). 4-{4-[6-Amino-5-(6-hydroxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a yellow solid following the General Procedure for Pd(O) Catalyzed OH Substitution, using 4-{4-[6-amino-5-(6-bromoisoquinolm-3-yl)-pyridm-3-yl]-pyrazol-l- yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 1.48 (s, 9H), 1.88- 2.01 (m, 2H), 2.06-2.14 (m, 2H), 2.85-3.04 (m, 2H), 4.19-4.27 (m, 2H), 4.31-4.41 (m, IH), 7.18 (d, J = 2.0 Hz, IH), 7.21 (dd, J= 2.0 & 8.8 Hz, IH), 7.85 (s, IH), 7.94 (d, J= 9.2 Hz, IH), 7.98 (s, IH), 8.08 (s, IH), 8.09 (d, J= 2.4 Hz, IH), 8.18 (d, J= 2.4 Hz, IH), 9.08 (s, IH). MS(ES+): m/z = 487.21 (100) [MH⁺]. HPLC: t_R = 2.38 min (ZQ3, polar_5min).

Example 29: 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-isoquinolin-7-ol

Into the DCM (5 ml) solution of 4- {4-[6-amino-5-(7-methoxyisoquinolm-3-yl)-pyridm-3-yl]- pyrazol-1-yl} -piperidine- 1 -carboxylic acid tert-butyl ester (101 mg, 0.171 mmol), cooled in an ice/water bath, was added 1.00 M of boron tribromide in DCM (2.0 ml) over 5 min. The mixture was stirred at 0 ⁰C and warmed to rt overnight. After that time, the mixture was basified with saturated Na₂CO₃ until pH 10 and extracted with EtOAc (3x30 ml). The extracts were washed with brine (2x20 ml), dried over MgSOzt, filtered and concentrated in vacuo, giving the title compound as a light-yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 1.90-2.02 (m, 2H), 2.09-2.18 (m, 2H), 2.74-2.82 (m, 2H), 3.18-3.24 (m, 2H), 4.26-4.36 (m, IH), 7.27 (d, J= 2.4 Hz, IH), 7.36 (dd, J= 2.4 & 9.2 Hz, IH), 7.84- 7.87 (m, 2H), 8.06 (d, J= 0.8 Hz, IH), 8.07 (d, J= 3.2 Hz, IH), 8.10 (s, IH), 8.17 (d, J= 2.4 Hz, IH), 9.08 (s, IH). MS(ES+): m/z = 387.14 (100) [MH⁺]. HPLC: t_R = 0.66 & 1.85 min (ZQ3, polar_5min; peak splitting).

Example 30: 3-(l-Methoxyisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt The title compound was obtained as a light yellow oil following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(l-methoxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.25-2.41 (m, 4H), 3.19-3.28 (m, 2H), 3.55-3.62 (m, 2H), 4.16 (s, 3H), 4.52-4.62 (m, IH), 7.56-3.61 (m, IH), 7.71-7.76 (m, IH), 7.79 (s, IH), 7.89 (d, J= 8.0 Hz, IH), 7.93 (s, IH), 8.12 (s, IH), 8.16 (brs, IH), 8.20-8.22 (m, 2H), 8.36 (brs, 2H). MS(ES+): m/z = 401.19 (100) [MH⁺]. HPLC: t_R = 2.00 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(l-methoxyisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil following the procedure for 4-{4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using 3-chloro-l-methoxyisoquinoline. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.03 (m, 2H), 2.16-2.22 (m, 2H), 2.86-2.98 (m, 2H), 4.18 (s, 3H), 4.22-4.38 (m, 3H), 6.32 (brs, 2H), 7.53- 7.58 (m, IH), 7.59 (s, IH), 7.63 (d, J = 0.8 Hz, IH), 7.68-7.72 (m, IH), 7.77 (d, J = 0.4 Hz, IH), 7.81 (d, J= 8.0 Hz, IH), 7.93 (d, J= 2.4 Hz, IH), 8.24-8.27 (m, 2H). MS(ES+): m/z = 501.20 (100) [MH⁺]. HPLC: t_R = 3.13 min (ZQ3, polar_5min). 3-Chloro-l-methoxyisoquinoline

Into a sealed tube were added 1,3-dichloroisoquinoline (501 mg, 2.45 mmol), 2-aminopyridine (31 mg, 0.33 mmol), cuprous monochloride (37.2 mg, 0.162 mmol), MeONa (824 mg, 5.92 mmol), MeOH (3 ml) and diglyme (8 ml). The tube was sealed, evacuated and filled with N₂ three times. The combined mixture was heated at 125 ⁰C for 3 days under an atmosphere of nitrogen. After that time, the mixture was treated with water (20 ml) and extracted with EtOAc (3><50 ml). The organic extracts were washed with water (3><30 ml), brine (30 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give the title compound as light-yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 4.15 (s, 3H), 7.26 (d, J= 0.6 Hz, IH), 7.51 (ddd, J= 3.6, 4.6, 8.2 Hz, IH), 7.64-7.69 (m, 2H), 8.20 (dd, J= 8.4, 1.2 Hz, IH). MS(ES+): m/z = 194.08/196.01 (80/28) [MH⁺]. HPLC: t_R = 4.00 min (polar_5min, ZQ3). General Procedure for Conversion of Bromo(het)aryl to Cyano(het)aryl: Into a microwave vial were added the bromo(het)aryl compound (220 mg, 0.240 mmol), Pd(PPh₃ )₄ (38.9 mg, 0.0336 mmol), and zinc cyanide (28.2 mg, 0.240 mmol). The vial was sealed, and then DMF (6 ml) was added. The air was removed and N₂ was filled for 3 times. The reaction mixture was heated in the microwave reactor to 150 ⁰C for 5 min. The reaction mixture was diluted with EtOAc (30 ml), washed with water (2x50 ml), brine (50 ml), dried over MgSO₄, filtered, and concentrated in vacuo. The crude material thus obtained was purified by chromatography if needed.

Example 31 : 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-isoquinoline-6- carbonitrile trihydrochloride salt The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(6-cyanoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.26-2.44 (m, 4H), 3.19-3.32 (m, 2H), 3.56- 3.65 (m, 2H), 4.54-4.65 (m, IH), 7.85-7.92 (m, IH), 7.95-7.99 (m, IH), 8.11-8.14 (m, IH), 8.24-8.39 (m, 5H), 8.41-8.45 (m, IH), 8.52-8.56 (m, IH), 9.47-9.53 (m, IH). MS(ES+): m/z = 396.14(60) [MH⁺]. HPLC: t_R = 1.81 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(6-cyanoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester

Following the General Procedure for Conversion of Bromo(het)aryl to Cyano(het)aryl, 4-{4-[6- amino-5-(6-bromoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester (220 mg, 0.240 mmol) was reacted with Pd(PPh₃)₄ (38.9 mg, 0.0336 mmol) and zinc cyanide (28.2 mg, 0.240 mmol) in DMF (6 ml). The crude product was purified by chromatography on silica gel (8 g) eluting with DCM (100 ml), 1% (100 ml), 2% (100 ml), 3% (100 ml) and 4% (50 ml) MeOH/DCM to give the title compound as a yellow solid. MS(ES+): m/z = 496.22 (100) [MH⁺]. HPLC: t_R = 2.82 min (ZQ3, polar_5min).

Example 32: 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-isoquinoline-7- carbonitrile trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(7-cyanoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.30-2.44 (m, 4H), 3.21-3.33 (m, 2H), 3.56- 3.64 (m, 2H), 4.62-4.71 (m, IH), 8.05-8.09 (m, 2H), 8.29-8.34 (m, 2H), 8.48 (s, IH), 8.75 (s, IH), 8.34 (s, IH), 8.93 (s, IH), 9.56 (s, IH). MS(ES+): m/z = 396.13 (33) [MH⁺]. HPLC: t_R = 1.66 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(7-cyanoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester

The title compound was obtained as a brown solid following the procedure for 4-{4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 7-cyanoisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.03 (m, 2H), 2.16-2.22 (m, 2H), 2.86-2.98 (m, 2H), 4.22^.38 (m, 3H), 6.53 (brs, 2H), 7.67 (d, J = 0.8 Hz, IH), 7.77 (d, J= 0.4 Hz, IH), 7.85 (dd, J= 1.6 & 8.4 Hz, IH), 7.84 (d, J = 2.4 Hz, IH), 8.01 (d, J= 8.8 Hz, IH), 8.09 (s, IH), 8.30 (d, J= 2.4 Hz, IH), 8.42 (m, IH), 9.37 (d, J = 1.2 Hz, IH). MS(ES+): m/z = 496.18 (100) [MH⁺]. HPLC: t_R = 2.65 min (ZQ3, polar_5min). Trifluoromethanesulfonic acid 7-cyanoisoquinolin-3-yl ester The title compound was obtained as off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 3- hydroxyisoquinoline-5-carbonitrile and 3-hydroxyisoquinoline-7-carbonitrile followed by separation of the isomers by prep. TLC. ¹H NMR (400 MHz, CDCl₃): δ = 7.66 (s, IH), 7.93 (dd, J= 1.2 & 8.4 Hz, IH), 8.04 (d, J= 8.8 Hz, IH), 8.48 (s, IH), 9.19 (s, IH). MS(ES+): m/z = 303.08 (65) [MH⁺]. HPLC: t_R = 3.50 min (polar_5min, ZQ3).

3-Hydroxyisoquinoline-5-carbonitrile and 3-Hydroxyisoquinoline-7-carbonitrile Following the General Procedure for Conversion of Bromo(het)aryl to Cyano(het)aryl, using the mixture of 5-bromoisoquinolin-3-ol and 7-bromoisoquinolin-3-ol, one obtained the mixture of the title compounds as a brown solid. MS(ES+): m/z = 171.04 (100) [MH⁺]. HPLC: t_R = 2.13 min (polar_5min, ZQ3).

Example 33: 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-isoquinoline-5- carbonitrile trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(5-cyanoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.28-2.44 (m, 4H), 3.22-3.33 (m, 2H), 3.56- 3.65 (m, 2H), 4.62-4.72 (m, IH), 7.97 (t, J= 8.0 Hz, IH), 8.07 (s, IH), 8.33 (s, IH), 8.39 (s, IH), 8.46 (d, J = 6.4 Hz, IH), 8.60 (d, J= 8.4 Hz, IH), 8.65 (s, IH), 8.83 (s, IH), 9.67 (s, IH). MS(ES+): m/z = 396.13 (14) [MH⁺]. HPLC: t_R = 1.64 min (ZQ3, polar_5min)

4-{4-[6-Amino-5-(5-cyanoisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-buty\ ester

The title compound was obtained as a brown oil following the procedure for 4-{4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 5-cyanoisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.95-2.08 (m, 2H), 2.17-2.23 (m, 2H), 2.87-2.99 (m, 2H), 4.23^.38 (m, 3H), 6.49 (brs, 2H), 7.69-7.73 (m, 2H), 7.79 (d, J= 0.8 Hz, IH), 8.00 (d, J= 2.4 Hz, IH), 8.17 (dd, J= 1.2 & 6.8 Hz, IH), 8.28 (td, J= 0.8 & 8.0 Hz, IH), 8.32 (d, J= 2.0 Hz, IH), 8.34 (t, J= 0.8 Hz, IH), 9.40 (d, J= 0.8 Hz, IH). MS(ES+): m/z = 496.18 (100) [MH⁺]. HPLC: t_R = 2.58 min (ZQ3, polar_5 min). Trifluoromethanesulfonic acid 5-cyanoisoquinolin-3-yl ester

The title compound was obtained as off-white solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- cyanoisoquinolin-3-ol and 5-cyanoisoquinolin-3-ol followed by separation of the isomers by prep. TLC. ¹H NMR (400 MHz, CDCl₃): δ = 7.80 (dd, J= 7.2 & 8.0 Hz, IH). 7.92 (m, IH), 8.24 (dd, J= 1.2 & 7.6 Hz, IH), 8.35 (td, J= 1.2 & 8.4 Hz, IH), 9.22 (d, J= 0.8 Hz, IH). MS(ES+): m/z = 303.08 (100) [MH⁺]. HPLC: t_R = 3.50 min (polar_5 min, ZQ3).

Example 34: 3-(7-Fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine For the deprotection, IN HCl in diethyl ether (1.0 mL) was added to a solution of 4-{4-[6-amino-5-

(7-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (entire quantity isolated in the previous step) in DCM (1.0 mL) in a sealed test tube. The reaction stirred at rt for Ih. The mixture was concentrated in vacuo to give the title compound as yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.37 (4H, br.s), 3.54-3.68 (3H, m), 4.20 (IH, d, J= 5.6 Hz), 4.64 (IH, br.s), 7.58-7.72 (IH, m), 7.81 (IH, br.s), 7.98 (IH, br.s), 8.06 (IH, br.s), 8.27 (2H, br.s), 8.69-

8.90 (2H, m), 9.48 (IH, br.s). HPLC: t_R = 1.74 min. (ZQ2, polar_5min.). MS (ES⁺): m/z = 389.18 (95) [MH⁺].

4-{4-[6-Amino-5-(7-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-butyl ester A mixture of 4-4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-pyrazol-

1 -ylpiperidine- 1 -carboxylic acid tert-butyl ester (BB3) (30.0 mg, 0.0639 mmol), trifluoromethanesulfonic acid 7-fluoroisoquinolin-3-yl ester (22.6 mg, 0.0767 mmol), KF (7.4 mg, 0.13 mmol), and Pd(PPh₃)₄ (4 mg, 0.003 mmol) in 1,4-dioxane (1.5 mL) and H₂O (0.12 mL) was degassed and refilled with nitrogen (3x). The reaction was heated in the microwave reactor to 100 ⁰C for 30 min. The reaction mixture was concentrated in vacuo to a solid and purified by chromatography on silica gel (25 g prepacked column, eluting with DCM to 5% MeOH in DCM] to give the title compound. MS (ES⁺): m/z = 489.19 (100) [MH⁺]

Trifluoromethanesulfonic acid 7-fluoroisoquinolin-3-yl ester

A DCM (10 mL, 0.2 mol) solution of 7-Fluoroisoquinolin-3-ol (0.476 g, 2.92 mmol) and triethylamine (0.813 mL, 5.84 mmol) was cooled in an ice bath and charged with trifluoromethanesulfonic anhydride (0.982 mL, 5.84 mmol); this mixture was allowed to stir for 1 h while slowly warming to rt. The reaction was quenched with water and then diluted with more DCM, washed with NaHCO₃ solution, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by prep. TLC [1000 μm layer of 60 A silica gel on glass-backed 20x20 cm TLC plate, eluting with 2% 7N (NH₃) MeOH in DCM], which afforded the title compound. ¹H NMR (400 MHz, CD₃OD): δ = 7.72 (IH, td, J= 8.8, 2.5 Hz), 7.87 (IH, s), 7.90 (IH, dd, J= 9.0, 2.7 Hz), 8.13 (IH, dd, J= 9.2, 5.2 Hz), 9.12 (1H, s). HPLC: t_R = 3.70 min. (ZQ2, polar_5min.). MS (ES⁺): m/z = 295.76 (45) [MH⁺].

7-Fluoroisoquinolin-3-ol Into a RBF was added N-(3-Fluorobenzyl)-2,2-dimethoxyacetamide (1.53 g, 6.73 mmol) and sulfuric acid (18M; 3.4 mL, 61 mmol); this mixture was stirred at 85 ⁰C for 5 min. Ice water was added and stirred, and then solid NaHCθ3 was carefully added until the solution was neutralized. The aqueous layer was extracted with DCM. The DCM layer was dried over Na₂SO₄, filtered, and concentrated in vacuo to give the title compound. It was carried onto the next step without any further purification. HPLC: t_R = 2.13 min. (ZQ2, polar_5min.). MS (ES⁺): m/z = 164.69 (100) [MH⁺]. A^-FluorobenzylJ-l^-dimethoxyacetamide

Into a sealable tube were added methyl dimethoxyacetate (0.98 g, 7.3 mmol) and 3- fluorobenzylamine (0.91 g, 7.3 mmol); this mixture was stirred at 60 ⁰C for 2 days. The compound was purified by chromatography on silica gel (10 g / 70 mL prepacked column, eluting with 5% EtOAc in hexanes → 5% MeOH in hexanes), affording the title compound. HPLC: t_R = 2.59 min. (ZQ2, polar_5min.). MS (ES⁺): m/z = 249.92 (29) [MNa⁺], 227.91 (100) [MH⁺].

Example 35: 3-(6-Fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine Following the procedure for 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-(7-trifluoromethoxy- isoquinolin-3-yl)-pyridin-2-ylamine trihydrochloride, using trifluoromethanesulfonic acid 6- fluoroisoquinolin-3-yl ester, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.27-2.39 (m, 4H), 3.18-3.26 (m, 2H), 3.51-3.60 (m, 2H), 4.57-4.70 (m, IH), 7.79-7.86 (m, IH), 7.96-8.04 (m, 2H), 8.36 (s, IH), 8.40 (s, IH), 8.56 (dd, J = 9.2, 5.4 Hz, IH), 8.70 (s, IH), 8.74 (s, IH), 9.77 (s, IH). MS (ES+): m/z = 389.18 [MH⁺]. HPLC: t_R = 1.68 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 6-fluoroisoquinolin-3-yl ester

A DCM (5 mL) solution of 6-fluoroisoquinolin-3-ol (225 mg, 1.38 mmol) and Triethylamine (0.42 mL, 3.0 mmol) was cooled in an ice bath and charged with trifluoromethanesulfonic anhydride (0.85 g, 3.0 mmol); this mixture was allowed to stir for Ih while slowly warming to rt. The reaction was quenched with some water and then diluted with more DCM, washed with NaHCO₃ solution, brine, dried over Na₂SO₄, filtered and concentrated. The crude product was passed through a small SiO₂ plug eluting with 10% EtOAc/Hexanes to yield the title compound as a yellow solid. MS (ES+): m/z = 296.05 [MH⁺]. HPLC: t_R = 3.63 min (ZQ2, polar_5min). 6-Fluoroisoquinolin-3-ol Into a RBF were added N-(4-Fluorobenzyl)-2,2-dimethoxyacetamide (1.53 g, 6.73 mmol) and sulfuric acid (18M; 3.4 mL, 61 mmol). This mixture was stirred at 85 ⁰C for 5 min. Ice water was added and stirred; then solid NaHCO₃ was added until the pH was 7-8. This was allowed to stir, then DCM was added and stirred to dissolve product. A solid precipitated out of the solution after 16 h. It was filtered off and dried in vacuo to give the title compound as yellow solid. HPLC: t_R = 2.07 min. (ZQ2, polar_5min.). MS (ES⁺): m/z 164.24 (100) [MH⁺]. jY-^-FluorobenzylJ-ljl-dimethoxyacetamide

Into a sealable tube were added methyl dimethoxyacetate (0.98 g, 7.3 mmol) and 4- fluorobenzylamine (0.91 g, 7.3 mmol); mixture was stirred at 60 ⁰C for 2 days. The compound was purified by column chromatography on silica gel (10 g / 70 mL prepacked cartridge, eluting with 5% EtOAc in hexanes → 5% MeOH in hexanes), affording the title compound. HPLC: t_R = 2.58 min. (ZQ2, polar_5min.). MS (ES⁺): m/z = 249.92 (24) [MNa⁺], 227.91 (100) [MH⁺].

Example 36: 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-isoquinoline-8- carbonitrile trihydrochloride salt

The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 8-cyanoisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3- yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.30- 2.42 (m, 4H), 3.21-3.27 (m, 2H), 3.59 (d, J = 13.4 Hz, 2H), 4.59-4.71 (m, IH), 7.97-8.04 (m, IH), 8.08 (s, IH), 8.25-8.30 (m, 2H), 8.42-8.49 (m, 2H), 8.86 (s, IH), 8.93 (d, J = 2.0 Hz, IH), 9.70 (s, IH). MS (ES+): m/z = 396.19 [MH⁺]. HPLC: t_R = 1.67 min (ZQ2, polar_5min).

Trifluoromethanesulfonic acid 8-cyanoisoquinolin-3-yl ester

Following the procedure for trifluoromethanesulfonic acid 6-fluoroisoquinolin-3-yl ester, using 3- hydroxyisoquinoline-8-carbonitrile in place of 6-fluoroisoquinorm-3-ol, the title compound was obtained as a yellow solid. MS (ES+): m/z = 303.04 [MH⁺]. HPLC: t_R = 3.55 min (ZQ2, polar_5min). 3-Hydroxyisoquinoline-8-carbonitrile

The General Procedure for Conversion of Bromo(het)aryl to Cyano(het)aryl was followed, using 8- bromoisoquinolin-3-ol. The crude material was purified by trituration from hexane yielding the title compound as a yellow solid. MS (ES+): m/z = 171.04 [MH⁺]. HPLC: t_R = 2.22 min (ZQ3, polar_5min)

Example 37: 3-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-8-fluoro- isoquinoline-5-carbonitrile trihydrochloride

The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 5-cyano-8-fluoroisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8- dichloroisoquinolin-3-yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400

MHz, CD₃OD): δ = 2.26-2.42 (m, 4H), 3.20-3.29 (m, 2H), 3.55-3.63 (m, 2H), 4.55-4.67 (m, IH), 7.54 (dd, J = 9.7, 8.2 Hz, IH), 7.95 (s, IH), 8.15 (s, IH), 8.26 (d, J = 2.0 Hz, IH), 8.30 (d, J = 2.3 Hz, IH), 8.35 (dd, J = 8.1, 5.1 Hz, IH), 8.39 (s, IH), 9.70 (d, J = 1.0 Hz, IH). MS (ES+): m/z = 414.13 [MH⁺]. HPLC: t_R = 1.70 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 5-cyano-8-fluoroisoquinolin-3-yl ester Following the procedure for trifluoromethanesulfonic acid 6-fluoroisoquinolin-3-yl ester, using 8- fluoro-3-hydroxyisoquinoline-5-carbonitrile in place of 6-fluoroisoquinolin-3-ol, the title compound was obtained as a yellow solid. MS (ES+): m/z = 321.06 [MH⁺]. HPLC: t_R = 3.58 min (ZQ2, polar_5min).

8-Fluoro-3-hydr<)xyisoquinoline-5-carbonitrile The General Procedure for Conversion of Bromo(het)aryl to Cyano(het)aryl was followed, using 5- bromo-8-fluoroisoquinolin-3-ol. The crude material was purified by trituration from hexane yielding the title compound as a yellow solid. MS (ES+): m/z = 189.05 [MH⁺]. HPLC: t_R = 2.30 min (ZQ3, polar_5min).

Example 38: 3-(8-Chloro-7-fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(8-chloro-7-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.14-2.31 (m, 4H), 3.07-3.18 (m, 2H), 3.37-3.44 (m, 2H), 3.59 (brs, 2H), 4.49-4.59 (m, IH), 8.05 (t, J = 9.2 Hz, IH), 8.16 (s, IH), 8.23 (dd, J = 4.8 & 8.8 Hz, IH), 8.49 (d, J= 2.0 Hz, IH), 8.52 (s, IH), 8.70 (brs, 2H), 8.88 (s, 2H), 9.09 (brs, 2H), 9.22 (brs, IH), 9.68 (s, IH). MS(ES+): m/z = 423.09/425.11 (82/35) [MH⁺]. HPLC: t_R = 1.86 min (ZQ3, polar_5min). 4-{4-[6-Amino-5-(8-chloro-7-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a yellow solid following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 8-chloro-7-fluoroisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.88-2.04 (m, 2H), 2.15-2.22 (m, 2H), 2.86-2.98 (m, 2H), 4.20-4.38 (m,

3H), 6.50 (brs, 2H), 7.58 (t, J= 8.8 Hz, IH), 7.67 (s, IH), 7.77 (d, J= 0.4 Hz, IH), 7.84 (dd, J= 4.4 & 8.8 Hz, IH), 7.94 (d, J= 2.4 Hz, IH), 8.03 (s, IH), 8.28 (d, J= 2.4 Hz, IH), 9.68 (s, IH). MS(ES+): m/z = 523.17/525.15 (100/88) [MH⁺]. HPLC: t_R = 3.36 min (ZQ3, polar_5min). Trifluoromethanesulfonic acid 8-chloro-7-fluoroisoquinolin-3-yl ester The title compound was obtained as a beige oil following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 8-chloro-7- fluoroisoquinolin-3-ol. ¹H NMR (400 MHz, CDCl₃): δ = 7.61 (s, IH), 7.66 (dd, J= 8.4 & 8.8 Hz, IH), 7.84-7.88 (m, IH), 9.47 (t, J= 0.8 Hz, IH). MS(ES+): m/z = 329.91/331.89 (100/40) [MH⁺]. HPLC: t_R = 4.03 min (polar_5min, ZQ3). 8-Chloro-7-fluoroisoquinolin-3-ol Sulfuric acid (18M; 0.19 mL, 3.4 mmol) was added to N-(2-chloro-3-fluorobenzyl)-2,2- dimethoxyacetamide (72.6 mg, 0.250 mmol) at ambient temperature. The mixture was stirred at 50 °C for 16 h. After cooling to rt, the mixture was poured into ice, basified with saturated Na₂COs until pH = 8, and extracted with EtOAc (3><30 ml). The extracts were washed with water (3x20 ml), brine (20 ml), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound as yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 7.05 (s, IH), 7.41 (dd, J = 8.4 & 9.2 Hz, IH), 7.56-7.60 (m, IH), 9.11 (s, IH). MS(ES+): m/z = 198.14/200.02 (100/88) [MH⁺]. HPLC: t_R = 2.48 min (polar_5min, ZQ3). Λ^l-Chloro-S-fluorobenzylJ-ljl-dimethoxyacetamide

A mixture of 2-chloro-3-fluorobenzylamine (575 mg, 3.53 mmol), methyl dimethoxyacetate (512 mg, 3.78 mmol), triethylamine (0.62 mL, 4.4 mmol) and MeOH (1 mL, 20 mmol) in a sealed tube was heated at 80 ⁰C for 20 h. After cooling to rt, the mixture was diluted with EtOAc (40 ml), washed with HCl (2N, 2x30 ml), water (2x30 ml), brine (30 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give the title compound as a brown oil. ¹H NMR (400 MHz, CDCl₃): δ = 3.40 (s, 6H), 4.59 (d, J = 6.0 Hz, 2H), 4.74 (s, IH), 6.99 (brs, IH), 7.07-7.12 (m, IH), 7.17-7.25 (m, 2H). MS(ES+): m/z = 262.06/264.04 (100/62) [MH⁺]. HPLC: t_R = 2.91 min (ZQ3, polar_5min). 2-Chloro-3-fluorobenzylamine

BH₃-THF in THF (1.0 M, 50.0 ml) was carefully added into the THF (40.0 ml) solution of 2-chloro- 3-fluorobenzonitrile (662 mg, 4.17 mmol) at rt. The resulting mixture was heated at 70 ⁰C under an atmosphere of nitrogen for 16 h. After cooling to ambient temperature, cone. HCl (5.18 ml, 62.5 mmol) was added slowly. The combined mixture was heated at 70 ⁰C for 30 min. After that time, the mixture was concentrated in vacuo to remove most of solvent, water (20 ml) was added, and the mixture was extracted with Et₂O (3x30 ml). The extracts were washed with water (20 ml). The combined aqueous layers were basified by saturated Na₂CO₃ until pH = 9 and extracted with EtOAc (3x50 ml). These EtOAc extracts were washed with brine (50 ml) dried over MgSO₄, filtered, and concentrated in vacuo to give the title compound as colorless oil. ¹H NMR (400 MHz, CDCl₃): δ = 1.67 (brs, 2H), 3.97 (s, 2H), 7.03-7.09 (m, IH), 7.17-7.26 (m, 2H). MS(ES+): m/z = 160.14/162.09 (64/32) [MH⁺]. HPLC: t_R = 0.40 & 0.70 min (polar_5min, ZQ3; peak splitting).

Example 39: 3-(8-Fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine 4- {4-[6-Amino-5-(5-bromo-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester (0.030 g, 0.053 mmol), 2-propaneboronic acid (10 mg, 0.1 mmol), Cs₂CO₃ (70 mg, 0.22 mmol) and Pd(PPh₃)₄ (6 mg, 0.005 mmol) were placed in a sealable microwave tube and taken up in 1,4-dioxane (2 mL, 20 mmol) and H₂O (0.50 mL, 28 mmol), flushed with nitrogen, sealed and heated in the microwave reactor at 100 ⁰C for 30 min. Pd(dppf)Cl₂-DCM (10 mg) was added, and the mixture was heated in the microwave reactor at 100 ⁰C for 30 min. The reaction mixture was diluted with EtOAc washed with water, brine, dried over Na₂SOz_I, filtered and concentrated. The residue was purified on prep-TLC eluting with 5% 7M NH₃ in MeOH and DCM to give the Boc- protected title compound; MS (ES+): m/z = 488.93 [MH⁺]. This material was dissolved in DCM (1 mL) and charged with IM HCl in ether (2.0 mL) and stirred at ambient temperature for 1 h. The solid that formed was filtered off and dried in vacuo overnight, giving the title compound as yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.34-2.43 (m, 4H), 2.81 (s, 3H), 2.85-2.89 (m, 2H), 3.56-3.65 (m, 2H), 4.60-4.70 (m, IH), 7.37 (dd, J = 10.1, 7.8 Hz, IH), 7.70 (dd, J = 7.5, 5.4 Hz, IH), 8.08 (s, IH), 8.26 (d, J = 1.5 Hz, IH), 8.38 (s, IH), 8.59 (s, IH), 8.86 (d, J = 1.5 Hz, IH), 9.62 (s, IH). MS (ES+): m/z = 388.92 (100) [MH⁺]. HPLC: t_R = 1.75 min (ZQ2, polar_5min).

Example 40: 3-(6-Chloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 6-chloroisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3- yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.14- 2.31 (m, 4H), 3.04-3.16 (m, 2H), 3.33-3.41 (m, 2H), 4.47-4.62 (m, 3H), 7.83 (dd, J = 8.8, 2.0 Hz, IH), 8.15 (s, IH), 8.21 (d, J = 1.8 Hz, IH), 8.34 (d, J = 8.8 Hz, IH), 8.50 (d, J = 2.0 Hz, IH), 8.54 (s, IH), 8.73 (s, IH), 8.84 (d, J = 2.0 Hz, IH), 9.22 (br. s., IH), 9.34 (br. s., IH), 9.52 (s, IH). MS (ES+): m/z = 404.90/406.78 [MH⁺]. HPLC: t_R = 1.80 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 6-chloroisoquinolin-3-yl ester

Following the procedure for trifluoromethanesulfonic acid 6-fluoroisoquinolin-3-yl ester, using 6- chloroisoquinolin-3-ol in place of 6-fluoroisoquinolin-3-ol, the title compound was obtained as a yellow solid. MS (ES+): m/z = 311.69/313.63 [MH⁺]. HPLC: t_R = 3.88 min (ZQ2, polar_5min).

6-Chloroisoquinolin-3-ol The title compound was obtained as a yellow solid following the procedure for 5-chloro-6,8- difluoroisoquinolin-3-ol, using N-(4-chlorobenzyl)-2,2-dimethoxyacetamide. MS (ES+): m/z = 179.90/181.83 [MH⁺]. HPLC: t_R = 2.34 min (ZQ3, polar_5min).

Λ'-(4-chlorobenzyl)-2,2-dimethoxyacetamide

Into a vial was added methyl dimethoxyacetate (0.98 g, 7.3 mmol) and 4-chlorobenzylamine (1.0 g, 7.3 mmol), this mixture was stirred at 50 ⁰C for 2 d. The product was recrystallized from Heptane to yield the desired product as an oil that solidified over time. MS (ES+): m/z = 244.09/246.05 [MH⁺]. HPLC: t_R = 2.80 min (ZQ2, polar_5min).

Example 41 : 3-(7-Chloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l -piperidin-4-yl- IH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 7-chloroisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3- yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.29- 2.46 (m, 4H), 3.24-3.31 (m, 2H), 3.59-3.67 (m, 2H), 4.61-4.72 (m, IH), 7.91 (dd, J = 8.8, 2.0 Hz, IH), 8.10 (s, IH), 8.18 (d, J = 9.0 Hz, IH), 8.28 (d, J = 2.0Hz, IH), 8.30 (d, J = 2.0 Hz, IH), 8.43 (s, IH), 8.73 (s, IH), 8.90 (d, J = 2.3 Hz, IH), 9.43 (s, IH). MS (ES+): m/z = 405.09/407.03 [MH⁺]. HPLC: fe = 1.95 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 7-chloroisoquinolin-3-yl ester The title compound was obtained as beige solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- chloroisoquinolin-3-ol and S-chloroisoquinolm-S-ol. Isomers were separated via column chromatography eluting with heptane — > 10% EtO Ac/heptane. The higher, less polar spot was the title compound. ¹H NMR (400 MHz, CDCl₃): δ = 7.59 (s, IH), 7.75 (dd, J = 8.8, 2.0 Hz, IH), 7.88 (d, J = 8.8 Hz, IH), 8.07 (d, J = 2.0 Hz, IH), 9.02 (s, IH). MS (ES+): m/z = 311.75/313.70 [MH⁺]. HPLC: t_R = 3.87 min (ZQ2, polar_5min).

5-Chloroisoquinolin-3-ol and 7-Chloroisoquinolin-3-ol

Following the procedure for 5-bromoisoquinolin-3-ol and 7-bromoisoquinolin-3-ol, using N-(3- chlorobenzyl)-2,2-dimethoxyacetamide, the mixture of the title compounds was obtained as a yellow solid. MS (ES+): m/z = 311.76/313.68 [MH⁺]. HPLC: t_R = 3.86 min (ZQ2, polar_5min). A^-Chlorobenzy^-l^-dimethoxyacetamide

Into a vial were added methyl dimethoxyacetate (1.9 g, 14 mmol) and 3-chlorobenzylamine (2.0 g, 14 mmol), this mixture was stirred at room temperature over two days. The product was triturated with hexane (3x) and re-crystallized from hexane, affording the desired product as oil that solidified over time. ¹H NMR (400 MHz, CDCl₃): δ = 3.43 (s, 6H), 4.47 (d, J = 6.1 Hz, 2H), 4.77 (s, IH), 6.91 (br. s., IH), 7.15-7.21 (m, IH), 7.25 -7.30 (m, 3H). MS (ES+): m/z = 243.93/245.81 [MH⁺]. HPLC: t_R = 2.80 min (ZQ2, polar_5min).

Example 42: 3-(5-Chloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l -piperidin-4-yl- IH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 5-chloroisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin-3- yl ester. This afforded the title compound as a yellow solid. MS (ES+): m/z = 405.05/407.03 [MH⁺]. HPLC: t_R = 1.91 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 5-chloroisoquinolin-3-yl ester The title compound was obtained as beige solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 7- chloroisoquinolin-3-ol and S-chloroisoquinolin-S-ol. Isomers were separated via column chromatography eluting with heptane — > 10% EtO Ac/heptane. The lower, more polar spot was the title compound. ¹H NMR (400 MHz, CDCl₃): δ = 7.65 (dd, J = 8.1, 1.0 Hz, IH), 7.89 (dd, J = 7.6, 1.0 Hz, IH), 7.95 (s, IH), 8.02 (d, J = 8.1 Hz, IH), 9.11 (s, IH). MS (ES+): m/z = 311.74/313.72 [MH⁺]. HPLC: t_R = 3.91 min (ZQ2, polar_5min).

Example 43 : 3-(6,8-Dichloroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l -piperidin-4-yl- IH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 6,8-dichloroisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8- dichloroisoquinolin-3-yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.10-2.31 (m, 4H), 3.04-3.18 (m, 2H), 3.33-3.46 (m, 2H), 4.45-4.59 (m, IH), 8.11 (d, J = 1.8 Hz, IH), 8.14 (s, IH), 8.22 (d, J = 1.3 Hz, IH), 8.48 (d, J = 2.0 Hz, IH), 8.50 (s, IH), 8.63 (br. s., IH), 8.75 (s, IH), 8.83 (d, J = 2.0 Hz, IH), 8.95 (br. s., IH), 9.07 (br. s., IH), 9.65 (s, IH). MS (ES+): m/z = 439.07/441.07/443.06 [MH⁺]. HPLC: t_R = 2.00 min (ZQ2, polar_5min). Trifluoromethanesulfonic acid 6,8-dichloroisoquinolin-3-yl ester The title compound was obtained as yellow solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 6,8- dichloroisoquinolin-3-ol. MS (ES+): m/z = 345.96/347.96/349.94 [MH⁺]. HPLC: t_R = 4.16 min (ZQ3, polar_5min).

6,8-Dichloroisoquinolin-3-ol

The title compound was obtained as a yellow solid following the procedure for 5-chloro-6,8- difluoroisoquinolin-3-ol, using N-(2,4-dichlorobenzyl)-2,2-dimethoxyacetamide. MS (ES+): m/z = 214.08/216.10/218.08 [MH⁺]. HPLC: t_R = 2.73 min (ZQ2, polar_5min). Λ^l^-DichlorobenzylJ-ljl-dimethoxyacetamide

Into a sealed tube were added methyl dimethoxyacetate (0.78 g, 5.8 mmol) and 2,4- dichlorobenzylamine (1.0 g, 5.8 mmol). This mixture was stirred at 50 ⁰C for 36 h. The completed reaction mixture was transferred to a flask and re-crystallized from heptane yielding the desired product as an off-white solid. MS (ES+): m/z = 278.10/280.09/282.08 [MH⁺]. HPLC: t_R = 3.03 min (ZQ2, polar_5min).

Example 44: 3-(7-Methoxyisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l -piperidin-4-yl- IH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 7-methoxyisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin- 3-yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.32- 2.44 (m, 4H), 3.23-3.31 (m, 2H), 3.58-3.67 (m, 2H), 4.08 (s, 3H), 4.61-4.72 (m, IH), 7.67-7.74 (m, 2H), 8.08 (s, IH), 8.16 (d, J = 8.8 Hz, IH), 8.31 (d, J = 2.0 Hz, IH), 8.40 (s, IH), 8.65 (s, IH), 8.79 (d, J = 2.0 Hz, IH), 9.51 (s, IH). MS (ES+): m/z = 401.14 [MH⁺]. HPLC: t_R = 1.88 min (ZQ3, polar_5min).

Trifluoromethanesulfonic acid 7-Methoxyisoquinolin-3-yl ester The title compound was obtained as yellow solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 7-methoxyisoquinolin- 3-ol. ¹H NMR (400 MHz, CDCl₃): δ = 3.98 (s, 3H), 7.29 (d, J = 2.5 Hz, IH), 7.46 (dd, J = 9.1, 2.5 Hz, IH), 7.52 (s, IH), 7.81 (d, J = 9.1 Hz, IH), 8.95 (s, IH). MS (ES+): m/z = 307.76 [MH⁺]. HPLC: t_R = 3.70 min (ZQ2, polar_5min).

7-Methoxyisoquinolin-3-ol The title compound was obtained as a yellow solid following the procedure for 5-chloro-6,8- difluoroisoquinolin-3-ol, using N-(2,4-dichlorobenzyl)-2,2-dimethoxyacetamide. MS (ES+): m/z = 176.09 [MH⁺]. HPLC: t_R = 2.19 min (ZQ3, polar_5min). 2,2-Dimethoxy-Λ'-(3-methoxybenzyl)-acetamide

Into a vial was added methyl dimethoxyacetate (2.0 g, 14 mmol) and 3-methoxybenzylamine (2.0 g, 14 mmol), this mixture was stirred at room temperature for 8 d. The product was triturated with heptane (3x) and then dried in vacuo, yielding the desired product as an off-white solid. MS (ES+): m/z = 240.84 [MH⁺]. HPLC: t_R = 2.55 min (ZQ2, polar_5min).

Example 45: 3-(6-Methoxyisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride

The procedure for the preparation of 3-(5,8-dichloroisoquinolin-3-yl)-5-(l -piperidin-4-yl- IH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride was followed, except using trifluoromethanesulfonic acid 6-methoxyisoquinolin-3-yl ester in place of trifluoromethanesulfonic acid 5,8-dichloroisoquinolin- 3-yl ester. This afforded the title compound as a yellow solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.16-2.29 (m, 4H), 3.05-3.17 (m, 2H), 3.38 (d, J = 12.6 Hz, 2H), 4.00 (s, 3H), 4.48-4.59 (m, IH),

7.46-7.54 (m, 2H), 8.13 (s, IH), 8.27 (d, J = 8.8 Hz, IH), 8.48-8.51 (m, 2H), 8.59 (s, IH), 8.80 (d, J = 2.3 Hz, IH), 9.19 (br. s., IH), 9.28 (br. s., IH), 9.45 (s, IH). MS (ES+): m/z = 318.16 [MH⁺]. HPLC: t_R = 1.70 min (ZQ2, polar_5min).

Trifluoromethanesulfonic acid 6-Methoxyisoquinolin-3-yl ester The title compound was obtained as yellow solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 6-methoxyisoquinolin- 3-ol. MS (ES+): m/z = 308.07 [MH⁺]. HPLC: t_R = 3.68 min (ZQ2, polar_5min). 6-Methoxyisoquinolin-3-ol

The title compound was obtained as a yellow solid following the procedure for 5-chloro-6,8- difluoroisoquinolin-3-ol, using N-formyl-3-methoxyphenylacetamide. MS (ES+): m/z = 176.21 [MH⁺]. HPLC: t_R = 2.70 min (ZQ2, polar_5min). jy-formyl-3-methoxyphenylacetamide

To a stirring solution of (4-methoxyphenyl)acetyl chloride (0.500 g, 2.71 mmol) in acetone (1.0 mL) at 0 ⁰C was added a solution of formamide (0.28 mL, 7.0 mmol) and pyridine (0.28 mL, 3.5 mmol) in acetone (1.0 mL). The resulting solution was stirred at 0 ⁰C for 30 min and then overnight at rt. The reaction mixture was diluted with EtOAc and washed with IM HCl, sat. NaHCθ3 solution, brine, dried over Na₂SOz_I, filtered and concentrated in vacuo. The crude material was purified by column chromatography eluting with 1% MeOH in DCM yielding the title compound as an off- white solid. MS (ES+): m/z = 194.11 [MH⁺]. HPLC: t_R = 2.57 min (ZQ3, polar_5min). General Procedure for the Synthesis of Λ'-Formyl Acetamides:

A mixture of (substituted)-phenylacetic acid (2.00 mmol), oxalyl chloride (1.38 ml, 16.0 mmol), and toluene (10 ml) was stirred at 110 ⁰C for 2 h. After that time, the excess reagent and solvent were removed in vacuo to give a light-brown oil. A solution of this oil in acetone (1 ml) was cooled in ice/water, and a solution of formamide (209 μl, 5.20 mmol) and pyridine (212 μl, 2.60 mmol) in acetone (1 ml) was added. The reaction mixture was stirred at 5 ⁰C for 30 min and then at room temperature overnight. After that time, the mixture was diluted with EtOAc (50 ml), washed with HCl (2N; 30 ml), water (2x30 ml), brine (30 ml), dried over MgSOzt, filtered, and concentrated in vacuo to give a light-yellow solid. It was then purified by chromatography on silica gel eluting with 10% (100 ml), 20% (100 ml), 30% (100 ml), 40% (100 ml) and 50% (100 ml) EtOAc/hexane to give a light yellow solid that was further purified by trituration with 10% EtOAc/Hexane to give the N-formyl- [(substituted)-phenyl]-acetamide.

Example 46: 3-(6,8-Difluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine trihydrochloride salt The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4-{4-[6-ammo-5-(6,8-difluoroisoqumolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.14-2.31 (m, 4H), 3.07-3.18 (m, 2H), 3.37-3.44 (m, 2H), 3.45 (brs, 2H), 4.49-4.59 (m, IH), 7.75-7.81 (m, 2H), 8.13 (s, IH), 8.49-8.51 (m, 2H), 8.74 (s, IH), 8.78 (s, IH), 9.00 (brs, IH), 9.15 (brs, IH), 9.58 (s, IH). MS(ES+): m/z = 407.11(82) [MH⁺]. HPLC: t_R = 1.78 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained as a yellow solid following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 6,8-difluoroisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.05 (m, 2H), 2.16-2.23 (m, 2H), 2.86-2.98 (m, 2H), 4.20-4.38 (m, 3H), 6.48 (brs, 2H), 7.05-7.11 (m, IH), 7.33-7.35 (m, IH), 7.66 (d, J= 0.8 Hz, IH), 7.77 (d, J = 0.4 Hz, IH), 7.94 (d, J= 2.0 Hz, IH), 7.99 (d, J= 1.6 Hz, IH), 8.29 (d, J= 2.0 Hz, IH), 9.51 (t, J= 1.2 Hz, IH). MS(ES+): m/z = 507.20 (100) [MH⁺]. HPLC: t_R = 3.32 min (ZQ3, polar_5min). Trifluoromethanesulfonic acid 6,8-Difluoroisoquinolin-3-yl ester The title compound was obtained as yellow solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using 6,8- difluoroisoquinolin-3-ol. ¹H NMR (400 MHz, CDCl₃): δ = 7.12-7.17 (m, IH), 7.34-7.37 (m, IH), 7.54 (s, IH), 9.30 (s, IH). MS(ES+): m/z = 314.02 (9) [MH⁺]. HPLC: t_R = 3.87 min (polar_5min, ZQ3). 6,8-Difluoroisoquinolin-3-ol

The title compound was obtained as a yellow solid following the procedure for 5-chloro-6,8- difluoroisoquinolin-3-ol, using N-formyl-(3,5-difluorophenyl)acetamide. MS (ES+): m/z = 176.21 [MH⁺]. HPLC: t_R = 2.70 min (ZQ2, polar_5min). N-Formyl-(3,5-difluorophenyl)acetamide

The title compound was obtained as an off-white solid following the General Procedure for the Synthesis of N-Formyl Acetamides, using (3,5-difluorophenyl)acetic acid. ¹H NMR (400 MHz, CDCl₃): δ = 3.71 (s, 2H), 6.78-6.85 (m, 3H), 8.00 (brs, IH), 9.10 (d, J= 10.0 Hz, IH). HPLC: t_R = 2.67 min (polar_5min, ZQ3).

Example 47: 3-(8-Chloro-6-fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride salt

The title compound was obtained as a yellow solid following the procedure for 3-(5-chloro-6,8- difluoroisoquinolin-3-yl)-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride salt, using 4- {4-[6-amino-5-(8-chloro-6-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 - carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.14-2.31 (m, 4H), 3.07-3.18 (m, 2H), 3.35-3.43 (m, 2H), 4.49-4.59 (m, IH), 4.97 (brs, 2H), 7.92 (dd, J= 2.4 & 8.2 Hz, IH), 8.07 (dd, J = 2.4 & 8.4 Hz, IH), 8.16 (s, IH), 8.52 (d, J= 1.6 Hz, IH), 8.55 (s, IH), 8.76 (brs, IH), 8.84 (s, IH), 8.88 (A, J= 2.0 Hz, IH), 9.20 (brs, IH), 9.33 (brs, IH), 9.64 (s, IH). MS(ES+): m/z = 423.09/425.04 (58/24) [MH⁺]. HPLC: t_R= 1.89 min (ZQ3, polar_5min). 4-{4-[6-Amino-5-(8-chloro-6-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-butyl ester

The title compound was obtained as a yellow solid following the procedure for 4- {4-[6-amino-5-(5- chloro-6,8-difluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -piperidine- 1 -carboxylic acid tert-butyl ester, using trifluoromethanesulfonic acid 8-chloro-6-fluoroisoquinolin-3-yl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.49 (s, 9H), 1.92-2.05 (m, 2H), 2.16-2.23 (m, 2H), 2.86-2.98 (m, 2H), 4.20-4.38 (m,

3H), 6.55 (brs, 2H), 7.43-7.48 (m, 2H), 7.66 (d, J = 0.8 Hz, IH), 7.77 (d, J = 0.8 Hz, IH), 7.94 (d, J = 2.4 Hz, IH), 7.98 (d, J= 0.8 Hz, IH), 8.29 (d, J= 2.0 Hz, IH), 9.64 (t, J= 0.8 Hz, IH). MS(ES+): m/z = 523.15/525.11 (100/62) [MH⁺]. HPLC: t_R = 3.08 min (ZQ3, polar_5min). Trifluoromethanesulfonic acid 8-Chloro-6-fluoroisoquinolin-3-yl ester The title compound was obtained as yellow solid following the procedure for trifluoromethanesulfonic acid 5-chloro-6,8-difluoroisoquinolin-3-yl ester, using the mixture of 8- chloro-6-fluoroisoquinolin-3-ol and 6-chloro-8-fluoroisoquinolm-3-ol mixture. ¹H NMR (400 MHz, CDCl₃): δ = 7.46 (dd, J= 2.4 & 8.4 Hz, IH), 7.53 (dd, J= 2.4 & 8.4 Hz, IH), 7.54 (s, IH), 9.34 (s, IH). MS(ES+): m/z = 329.98/332.00 (27/9) [MH⁺]. HPLC: t_R = 4.05 min (polar_5min, ZQ3). 8-Chloro-6-fluoroisoquinolin-3-ol and 6-Chloro-8-fluoroisoquinolin-3-ol

The mixture of title compounds was obtained as yellow solid following the procedure for 5-chloro- 6,8-difluoroisoquinolin-3-ol, using N-formyl-(3-chloro-5-fluorophenyl)acetamide. MS(ES+): m/z = 198.04/200.01 (100/85) [MH⁺]. HPLC: t_R = 2.57 and 2.68 min (polar_5min, ZQ3). N-Formyl-(3-chloro-5-fluorophenyl)acetamide The title compound was obtained as a white solid following the General Procedure for the

Synthesis of N-Formyl Acetamides, using (3-chloro-5-fluorophenyl)acetic acid. ¹H NMR (400 MHz, CDCl₃): δ = 3.69 (s, 2H), 6.90-6.95 (m, IH), 7.06-7.12 (m, 2H), 8.30 (brs, IH), 9.10 (d, J= 9.2 Hz, IH). HPLC: t_R = 2.87 min (polar_5min, ZQ3).

General Procedure S: Suzuki & Stille couplings on 4-{4-[6-Amino-5-(5-bromo-8- fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester:

To a microwave vial were added 4- {4-[6-Amino-5-(5-bromo-8-fluoro-isoquinolin-3-yl)-pyridin-3- yl]-pyrazol-l-yl} -piperidine- 1 -carboxylic acid tert-butyl ester (0.0881 mmol), appropriate boronic acid (1.74 mmol), Cs₂CO₃ (3.3 mmol), and Palladium(O) tetrakis(triphenylphosphine) (0.08 mmol). The mixture was dissolved in 1,4-dioxane (4.0 mL, 63 mmol) and H₂O (1.0 mL, 90 mmol) and flushed with nitrogen. The vial was sealed and heated in the microwave reactor at 100 ⁰C for 30 min. For reactions with tributyltin reagents (1.74 mmol), KF (3.3 mmol) was used in place Of Cs₂CO₃, and no water was used. The completed reaction was diluted with EtOAc (25 mL) and washed with water, brine, drying over Na₂SOzJ, filtered and concentrated in vacuo. The product was purified on prep-TLC eluting with 5% 7M NH₃ in MeOH/DCM and concentrated. The pure product was dissolved in DCM and charged with excess IM HCl in Et₂O. This mixture was stirred at rt for 30 min to overnight, the solid that formed was filtered off and dried in vacuo, giving the desired pure final compound.

Example 48: 3-(8-Fluoro-5-furan-2-ylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine The title compound was obtained as a yellow solid, following General Procedure S with an extra purification step, passing product through SCX column and elute off of column with 3% 7M NH₃ in MeOH/MeOH (l :3). Η NMR (400 MHZ, DMSO-(Z₆): δ = 1.81-2.08 (m, 4H), 2.70 (t, J = 11.4 Hz, 2H), 3.12 (d, J = 12.6 Hz, 2H), 4.19-4.31 (m, IH), 6.72-6.78 (m, 3H), 7.16 (d, J = 3.3 Hz, IH), 7.54- 7.66 (m, 2H), 7.87 (s, IH), 7.96 (d, J = 1.3 Hz, IH), 8.03-8.10 (m, 2H), 8.19 (s, IH), 8.35 (d, J = 2.0 Hz, IH), 8.58 (s, IH), 9.64 (s, IH). MS (ES+): m/z = 455.15 [MH⁺]. HPLC: f_R = 2.09 min (ZQ3, polar_5min).

Example 49: 3-(8-Fluoro-5-furan-3-ylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride The title compound was obtained as a yellow solid, following General Procedure S. ¹H NMR (400

MHz, DMSO-(Z₆): δ = 2.09-2.27 (m, 4H), 3.03-3.16 (m, 2H), 3.34-3.44 (m, 2H), 4.46-4.60 (m, IH), 7.08 (d, J = 1.0 Hz, IH), 7.68 (dd, J = 10.1, 8.1 Hz, IH), 7.89-7.97 (m, 2H), 8.10 (s, IH), 8.27-8.34 (m, 2H), 8.42 (s, IH), 8.45 (d, J = 1.8 Hz, 2H), 8.66 (d, J = 2.0 Hz, IH), 8.94 (br. s., IH), 9.08 (br. s., IH), 9.68 (s, IH). MS (ES+): m/z = 455.13 [MH⁺]. HPLC: tR = 2.10 min (ZQ3, polar_5min).

Example 50: 3-(8-Fluoro-5-phenylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine

The title compound was obtained as a yellow solid, following General Procedure S with an extra purification step, passing product through SCX column and elute off of column with 3% 7M NH₃ in MeOH/MeOH (l :3). ¹H NMR (400 MHz, CD₃OD): δ = 1.98 (dd, J = 12.4, 3.8 Hz, IH), 2.14 (dd, J = 12.4, 2.3 Hz, 2H), 2.82 (td, J = 12.6, 2.5 Hz, 2H), 3.24 (d, J = 12.9 Hz, 2H), 4.26-4.37 (m, IH), 7.42 (dd, J = 10.1, 8.1 Hz, IH), 7.46-7.52 (m, IH), 7.52-7.59 (m, 4H), 7.67-7.74 (m, 2H), 7.82 (d, J = 2.3 Hz, IH), 7.95 (s, IH), 8.06 (s, IH), 8.18 (d, J = 2.3 Hz, IH), 9.59 (s, IH). MS (ES+): m/z = 465.16 [MH⁺]. HPLC: t_R = 2.03 min (ZQ2, polar_5min).

Example 51: 3-[8-Fluoro-5-(lH-pyrazol-4-yl)-isoquinolin-3-yl]-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride

The title compound was obtained as a yellow solid, following General Procedure S. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.15-2.27 (m, 4H), 3.03-3.15 (m, 2H), 3.38 (d, J = 12.4 Hz, 2H), 4.48-4.60 (m, IH), 7.66 (dd, J = 10.0, 8.2 Hz, IH), 7.91 (dd, J = 8.1, 5.6 Hz, IH), 8.11 (s, IH), 8.24 (s, 2H), 8.37 (br. s., IH), 8.44 (s, IH), 8.48 (s, 2H), 8.69 (d, J = 1.8 Hz, IH), 9.19 (br. s., IH), 9.32 (br. s., IH), 9.66 (s, IH). MS (ES+): m/z = 455.15 [MH⁺]. HPLC: t_R = 1.91 min (ZQ3, polar_5min).

Example 52: 3-[8-Fluoro-5-(l-methyl-l//-pyrazol-4-yl)-isoquinolin-3-yl]-5-(l-piperidin-4-yl- l//-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride The title compound was obtained as a yellow solid, following General Procedure S. ¹H NMR (400

MHz, DMSO-(Z₆): δ = 2.14-2.29 (m, 4H), 3.04-3.15 (m, 2H), 3.38 (d, J = 12.6 Hz, 2H), 3.96 (s, 3H), 4.47-4.58 (m, IH), 7.65 (dd, J = 10.1, 8.1 Hz, IH), 7.88 (dd, J = 8.2, 5.4 Hz, IH), 7.96 (s, IH), 8.11 (s, IH), 8.35 (s, IH), 8.39 (br. s., IH), 8.46 (s, IH), 8.47 (d, J = 2.0 Hz, IH), 8.49 (s, IH), 8.68 (d, J = 2.0 Hz, IH), 9.07 (br. s., IH), 9.20 (br. s., IH), 9.65 (s, IH). MS (ES+): m/z = 469.20 [MH⁺]. HPLC: t_R = 1.78 min (ZQ2, polar_5min).

Example 53 : 3- [8-Fluoro-5-(l//-pyrrol-2-yl)-isoquinolin-3-yl] -5-(l-piperidin-4-yl-l//-pyrazol- 4-yl)-pyridin-2-ylamine

The title compound was obtained as a yellow solid, following General Procedure S with additional purification: The product was passed through an SCX column eluting with 4M NH₃ in MeOH, concentrated in vacuo, and then purified on Prep-TLC eluting with 5% 7MNH₃ in MeOH/DCM. ¹H NMR (400 MHz, CD₃OD): δ = 1.88-2.01 (m, 2H), 2.08-2.17 (m, 2H), 2.71-2.82 (m, 2H), 3.16-3.24 (m, 2H), 4.24-4.37 (m, IH), 6.34 (t, J = 3.0 Hz, IH), 6.49 (dd, J = 3.4, 1.4 Hz, IH), 7.00 (dd, J = 2.7, 1.4 Hz, IH), 7.37 (dd, J = 10.1, 8.1 Hz, IH), 7.74 (dd, J = 8.1, 5.3 Hz, IH), 7.78 (s, IH), 7.97-8.01 (m, 2H), 8.20 (d, J = 2.0 Hz, IH), 8.51 (s, IH), 9.54 (s, IH). MS (ES+): m/z = 454.19 [MH⁺]. HPLC: t_R = 1.96 min (ZQ3, polar_5min).

Example 54: 3-(8-Fluoro-5-pyridin-3-ylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride The title compound was obtained as a yellow solid, following General Procedure S. ¹H NMR (400

MHz, DMSO-(Z₆): δ = 1.85 (dd, J = 12.0, 3.7 Hz, 2H), 1.97-2.04 (m, 2H), 2.69 (t, J = 11.9 Hz, 2H), 3.11 (d, J = 12.4 Hz, 2H), 4.22 (dd, J = 15.4, 7.3 Hz, IH), 4.44 (br. s., IH), 6.66 (br. s., 2H), 7.63 (dd, J = 10.6, 8.6 Hz, 2H), 7.78 (s, IH), 7.86 (dd, J = 8.1, 5.6 Hz, IH), 7.90 (d, J = 2.3 Hz, IH), 7.98 (s, IH), 8.08-8.10 (m, IH), 8.11 (s, IH), 8.30 (d, J = 2.3 Hz, IH), 8.70 (dd, J = 4.8, 1.5 Hz, IH), 8.82 (d, J = 1.5 Hz, IH), 9.68 (s, IH). MS (ES+): m/z = 466.17 [MH⁺]. HPLC: t_R = 2.00 min (ZQ3, polar_5min).

Example 55: 3-(8-Fluoro-5-thiazol-2-ylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride

The title compound was obtained as a yellow solid, following General Procedure S using 2- tributylstannylthiazole. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.08-2.29 (m, 4H), 3.02-3.17 (m, 2H), 3.34-3.43 (m, 2H), 4.44-4.58 (m, IH), 7.05-7.36 (m, IH), 7.76 (d, J = 8.3 Hz, IH), 8.00 (d, J = 3.3 Hz, IH), 8.07 (s, IH), 8.15 (d, J = 3.3 Hz, IH), 8.26 (br. s., IH), 8.34-8.42 (m, 2H), 8.46 (d, J = 2.0 Hz, IH), 8.57 (d, J = 1.8 Hz, IH), 8.97 (br. s., IH), 9.10 (br. s., IH), 9.36 (s, IH), 9.72 (s, IH). MS (ES+): m/z = 412.13 [MH⁺]. HPLC: t_R = 2.27 min (ZQ3, polar_5min).

Example 56: 3-(8-Fluoro-5-thiazol-5-ylisoquinolin-3-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride

The title compound was obtained as a yellow solid, following General Procedure S using 5- tributylstannylthiazole. ¹H NMR (400 MHz, CD₃OD): δ = 2.28-2.41 (m, 4H), 3.20-3.27 (m, 2H), 3.55-3.64 (m, 2H), 4.58-4.74 (m, IH), 7.56-7.67 (m, IH), 7.97 (s, IH), 8.01-8.10 (m, IH), 8.22-8.31 (m, 2H), 8.35 (s, IH), 8.51 (s, IH), 8.64 (s, IH), 9.42 (s, IH), 9.74 (s, IH). MS (ES+): m/z = 472.41 [MH⁺]. HPLC: t_R = 2.41 min (ZQ3, polar_5min).

Example 57: 4-4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l- ylpiperidine-1-carbaldehyde To a solution of 3-(5-chloro-8-fluoroisoquinolin-3-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride (100 mg, 0.188 mmol), EDCI (56.5 mg, 0.295 mmol), DMAP (10 mg, 0.085 mmol), and diisopropylethylamine (160 μL, 0.94 mmol) in DCM (5.1 mL, 80 mmol) was added formic acid (19.9 mg, 0.432 mmol) at ambient temperature, and the reaction mixture was stirred for 1 h at ambient temperature. The reaction was diluted with DCM, washed with NaHCO₃ and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified on prep- TLC developing with 5% 7N NH₃(MeOH):DCM solvent system, giving the title compound. ¹H NMR (400 MHz, CD₃OD): δ = 2.18-2.32 (m, 2H), 2.89-3.00 (m, IH), 3.95 (dd, IH), 4.25 (dd, J = 5.6, 1.8 Hz, 3H), 4.46-4.61 (m, 2H), 7.63-7.68 (m, IH), 7.71-7.77 (m, IH), 7.90-7.97 (m, IH), 8.11 (s, IH), 8.17 (s, IH), 8.22 (d, J = 2.3 Hz, IH), 8.32 (d, J = 2.3 Hz, IH), 8.48 (s, IH), 9.64 (s, IH). MS (ES+): m/z = 450.79 [MH⁺]. HPLC: t_R = 2.41 min (ZQ2, polar_5min).

Example 58: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-[l-(l-methylpiperidin-4-yl)-l//-pyrazol- 4-yl] -pyridin-2-ylamine

To a solution of 4-{4-[6-amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine-1-carbaldehyde (50.0 mg, 0.111 mmol) in THF (5 mL, 60 mmol), cooled to « 0 ⁰C, LiAlH₄ (1.0M solution in THF; 0.27 mL, 0.27 mmol) was added, and the reaction mixture was stirred at 0 ⁰C → rt for 30 min. Sodium sulfate decahydrate (0.1 g, 0.4 mmol) and EtOAc were added and the reaction mixture was stirred for 10 min at rt. The solids were filtered off, and the filtrate was concentrated and purified on prep-TLC eluting with 5% 7M NH₃ (MeOH)/DCM to give the title compound as pale yellow oil. MS (ES+): m/z = 436.79/438.74 [MH⁺]. HPLC: t_R = 2.24 min (ZQ2, polar_5min). Example 59: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-[l-(l-methylpiperidin-4-yl)-lH-pyrazol- 4-yl] -pyridin-2-ylamine trihydrochloride

To a solution of 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-[l-(l-methylpiperidm-4-yl)-lH-pyrazol-4- yl] -pyridin-2-ylamine (25 mg, 0.057 mmol) in DCM (2.8 mL) was added 1.0 M of HCl in Et₂O (2.8 mL, 2.8 mmol), causing a solid to precipitate. The solid was filtered off, washed with DCM and heptane, and dried in vacuo, yielding the title compound as yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.36-2.47 (m, 4H), 3.67-3.76 (m, 2H), 4.19-4.24 (m, IH), 4.58-4.69 (m, IH), 4.70 (s, IH), 7.47-7.54 (m, IH), 8.00 (dd, J = 8.3, 4.8 Hz, IH), 8.05-8.09 (m, IH), 8.29 (s, IH), 8.38 (s, IH), 8.71 (s, IH), 8.83 (s, IH), 9.68 (s, IH). General Procedure for the Preparation of Pinacol Boronates

To degassed dioxane (200 mL) were added Pd₂(dba)₃ (1.2 g, 2 mol%) and tricyclohexylphosphine (1.47 g, 8 mol %) and stirred for 30 minutes. To this mixture were added the (het)aryl bromide or - iodide (69.3 mmol), bis(pinacolato)diboron (23.0 g, 90.2 mmol), and potassium acetate (10.9 g, 111 mmol), and the mixture was heated under nitrogen at 100 ⁰C for 16 h. After cooling back to RT, the solid that had formed was filtered off. The filtrate was evaporated to give the crude pinacol boronate solid, which was purified by trituration with diisopropyl ether (3x40 mL). General Procedure for the Bromination of Aminopyridines with NBS

To a solution of the substituted aminopyridine (15.4 mmol) in CH₂Cl₂ (200 mL) under nitrogen at 0 ⁰C was added N-bromosuccinimide (2.73 g, 15.4 mmol) portionwise. The mixture was stirred for 30 min, washed with water (2x40 mL), dried over MgSO4, filtered, and concentrated to give the crude material, which was purified by trituration with diisopropyl ether (30 mL).

3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- pyridin-2-ylamine (BB5)

The title compound was prepared by following the General Procedure for the Preparation of Pinacol Boronates, using 5-bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-2-ylamine (BB4) (2.0 g, 5.7 mmol), bis(pinacolato)diboron (1.87 g, 7.4 mmol), Pd₂(dba)₃ (2 mol%), tricyclohexylphosphine (8 mol %), and KOAc (0.89 g, 9 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 1.38 (s, 12H), 7.19 (t, J = 3.8 Hz, IH), 7.62 (bs, 2H), 7.71 (dd, 6.8, 3.8 Hz, IH), 8.31 (d, J= 1.2 Hz, IH), 8.38 (d, J= 1.2 Hz, IH), 8.42 (s, IH), 9.55 (s, IH). MS(ES+): m/z = 399.08/400.10/401.09/402.08 (17/100/25/39) [MH⁺]. HPLC: t_R = 3.46 min (polar_5min, ZQ3).

Data for the corresponding boronic acid: MS(ES+): m/z = 317.06/318.04/319.04/320.03 (32/100/15/50) [MH⁺]. HPLC: t_R = 2.29 min (polar_5min, ZQ3).

5-Bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-2-ylamine (BB4) The title compound was obtained as a light orange solid following the General Procedure for the Bromination of Aminopyridines with NBS, using 3-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-2- ylamine (4.2 g, 15.4 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 6.77 (brs, 2H), 7.22 (t, J = 3.9 Hz, IH), 7.76 (dd, J= 6.8, 3.9 Hz, IH), 8.07 (d, J= 1.5 Hz, IH), 8.17 (d, J= 1.5 Hz, IH), 8.30 (s, IH), 9.56 (s, IH). MS(ES+): m/z = 351.94/353.92/355.95 (82/100/35) [MH⁺]. HPLC: t_R = 3.59 min (nonpolar_5min, ZQ3).

3-(5-Chloro-8-fluoroisoquinolin-3-yl)-pyridin-2-ylamine A mixture of trifluoromethanesulfonic acid 5-chloro-8-fluoroisoquinolin-3-yl ester (9.00 g, 27.4 mmol), 3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine (8.42 g, 38.3 mmol), Pd(PPh₃)₄ (0.63 g, 2 mol %), and Cs₂CO₃ (20.5 g, 62.9 mmol) in dioxane/H₂O (4: 1, 300 mL) were heated under nitrogen at 100 ⁰C for 16 h. Solvents were evaporated in vacuo, water (100 mL) was added to the residue, and the mixture was extracted with EtOAc (3><75 mL). The EtOAc extract was dried over MgSO₄, filtered, and concentrated in vacuo to give the crude product. It was purified by column chromatography on silica gel using EtOAc/Hexanes (1 :3) to give the title compound. ¹H NMR (CDCl₃, 300 MHz): δ = 6.87 (brs, 2H), 6.81 (dd, J= 8.7, 4.8 Hz, IH), 7.18 (dd, J= 9.3, 9.0 Hz, IH), 7.22 (dd, J = 8.1, 4.2 Hz, IH), 7.99 (dd, J= 7.5, 2.1 Hz, IH), 8.15 (dd, J= 6.8, 1.8 Hz, IH), 8.31 (t, J = 1.2 Hz, IH), 9.56 (d, J= 1.2 Hz, IH). 3-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine

The title compound was obtained following the General Procedure for the Preparation of Pinacol Boronates, using 2-amino-3-bromopyridine (12.0 g, 69.3 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 1.42 (s, 12H), 6.65 (dd, J= 5.1, 3.6 Hz, IH), 7.91 (d, J= 5.1 Hz, IH), 8.10 (d, J= 3.6 Hz, IH).

Example 60: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-[2-(4-methylpiperazin-l-yl)-thiazol-5- yl] -pyridin-2-ylamine trihydrochloride

A solution of l-(5-bromothiazol-2-yl)-4-methylpiperazine (45 mg, 0.17 mmol), 3-(5-chloro-8- fluoroisoquinolin-3-yl)-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (BB5) (89.2 mg, 0.223 mmol), potassium carbonate (71.2 mg, 0.515 mmol), and Pd(PPh₃)₄ (11.9 mg, 0.0103 mmol) in previously degassed DME/Water (4: 1) (3.0 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 45 min. The reaction mixture was partitioned between CHCl₃ and H₂O, and the layers were separated. The aqueous layer was re-extracted with CHCl₃ (3x), and the combined organic fractions were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by chromatography on silica gel [eluting with 1% MeOH in CHCl₃] resulting in a pure yellow solid. This sample was then dissolved in a minimum of DCM then charged with 3 equiv of IM HCl in ether and the reaction mixture was concentrated in vacuo resulting in the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ =2.83 (d, J= 4.0 Hz, 3H), 3.13-3.28 (m, 2H), 3.45-3.60 (m, 4H), 4.07 (d, J= 14.3 Hz, 2H), 7.67 (t, J= 8.0 Hz, IH), 7.84 (s, IH), 8.11 (dd, J= 8.4, 4.8 Hz, IH), 8.27 (d, J= 2.2 Hz, IH), 8.54 (s, IH), 8.61 (s, IH), 9.67 (s, IH), 11.05 (br. s., IH). MS (ES+): m/z = 455.07/457.08 (76/24) [MH⁺]. HPLC: t_R = 1.99 min (ZQ2, polar_5min). l-(5-Bromothiazol-2-yl)-4-methylpiperazine

A solution of 2,5-dibromothiazole (1.000 g, 4.116 mmol) in DIPEA (3.00 mL) was charged with 1- methylpiperazine (0.457 mL, 4.12 mmol) and heated to 110 ⁰C for 3 h then an additional 48 h at rt. The reaction mixture was partitioned between CHCl₃ and H₂O, and the layers were separated. The aqueous layer was re-extracted with CHCl₃ (3x) and the combined organic fractions were dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by chromatography on silica gel [eluting with 5% EtOAc in CHCl₃ → 20% EtOAc in CHCl₃] resulting in the title compound as an off- white solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.34 (s, 3H), 2.48-2.56 (m, 4H), 3.42-3.51 (m, 4H), 7.07 (s, IH). MS (ES+): m/z = 262.09/264.06 (51/49) [MH⁺]. HPLC: t_R = 1.57 & 0.53 min (peak splitting; ZQ2, polar_5min).

Example 61 : 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(2-morpholin-4-ylthiazol-5-yl)-pyridin- 2-ylamine A solution of 4-(5-bromo-thiazol-2-yl)-morpholine (52.4 mg, 0.210 mmol), 3-(5-chloro-8- fluoroisoquinolin-3-yl)-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (BB5) (70 mg, 0.18 mmol), potassium carbonate (77.5 mg, 0.560 mmol), and Pd(PPh₃)₄ (0.01 g, 0.01 mmol) in previously degassed DME/water (4:1) (1.95 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 45 min. The reaction mixture was partitioned between CHCl₃ and H₂O, and the layers were separated. The aqueous layer was re-extracted with CHCl₃ (3x) and the combined organic fractions were washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by chromatography on silica gel [eluting with 1.5% MeOH in CHCl₃] resulting in a yellow solid slightly contaminated with triphenylphosphine oxide. Therefore, this material was dissolved in MeOH/THF and passed through a prewashed 5 g SCX column. The column was washed with 2 volumes of MeOH and 2 volumes of THF then was washed with IM NH₄OH in MeOH upon which the product was released from the resin. The filtrate was concentrated in vacuo, and the resulting material was chromatographed on silica gel [eluting with 0.5% MeOH in CHCl₃] resulting in the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 3.37-3.49 (m, 4H), 3.68-3.81 (m, 4H), 7.05 (s, 2H), 7.51-7.62 (m, 2H), 8.03 (dd, J = 8.4, 4.8 Hz, IH), 8.07 (d, J = 2.2 Hz, IH), 8.23 (d, J= 2.2 Hz, IH),

8.36 (s, IH), 9.64 (s, IH). MS (ES+): m/z = 442.06/444.03 (76/24) [MH⁺]. HPLC: t_R = 3.06 min (ZQ2, polar_5min).

4-(5-Bromothiazol-2-yl)-morpholine

A solution of 2,5-dibromothiazole (0.500 g, 2.06 mmol) in DIPEA (1.50 mL) was charged with morpholine (0.179 mL, 2.06 mmol) and heated to 110 ⁰C for 2 h. The reaction mixture was allowed to cool then partitioned between EtOAc and H₂O, and the layers were separated. The aqueous layer was re-extracted with EtOAc (3x), and the combined organic extracts were washed with brine (2x), dried over Na₂SOz_I, filtered and concentrated in vacuo. The crude material was purified by chromatography on silica gel [eluting with 5% EtOAc in CHCl₃] resulting in the title compound as an off-white solid. ¹H NMR (400 MHz, CDCl₃): δ = 3.35-3.47 (m, 4H), 3.74-3.86 (m, 4H), 7.09 (s, IH). MS (ES+): m/z = 249.06/251.03 (51/49) [MH⁺]. HPLC: t_R = 2.98 min (ZQ2, polar_5min).

Example 62: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-((Λ)-l-pyrrolidin-3-yl-l//-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride

A solution of (R)-3-[4-(4,4,5,5-tetramethyl-[l ,3,2]dioxaborolan-2-yl)-pyrazol- 1 -yl]-pyrrolidine- 1 - carboxylic acid tert-butyl ester (0.0804 g, 0.221 mmol), 5-bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)- pyridin-2-ylamine (0.065 g, 0.18 mmol), potassium carbonate (0.0815 g, 0.590 mmol), and Pd(PPh₃)₄ (0.015 g, 0.013 mmol) in previously degassed DME/Water (4: 1) (2.05 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 45 min. The reaction mixture was diluted with EtOAc and washed with H₂O (2x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo to give a brown oil. This material was purified by chromatography on silica gel [eluting with 1% MeOH in CHCl₃] resulting in (R)-3-{4- [6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -pyrrolidine- 1 -carboxylic acid tert-butyl ester, MS (ES+): m/z = 508.9/510.8 (76/24) [MH⁺]. This compound was dissolved in DCM (2.0 mL) and charged with 1.0 M of HCl in Et₂O (1.1 mL) and stirred at 40 ⁰C for 5 h then at rt for an additional 16 h. The solid that formed was filtered off and washed with diethyl ether (3x), yielding the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.23-2.36 (m, IH), 2.39-2.49 (m, IH), 3.33-3.48 (m, IH), 3.51-3.62 (m, 2H), 3.62-3.82 (m, 2H), 5.14-5.28 (m, IH), 7.66 (t, J = 9.2 Hz, IH), 8.11 (dd, J = 8.4, 4.8 Hz, IH), 8.17 (s, IH), 8.47 (d, J= 1.8 Hz, IH), 8.54 (d, J= 11.7 Hz, 2H), 8.67 (br. s., IH), 9.41 (br. s., IH), 9.54 (br. s., IH), 9.68 (s, IH). MS (ES+): m/z = 408.88/410.77 (76/24) [MH⁺]. HPLC: t_R = 1.84 min (ZQ2, polar_5min).

(Λ)-3-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-pyrrolidine-l-carboxylic acid tert-buty\ ester

A solution of 4-(4,4,5,5-tetramethyl[l,3,2]dioxaborolan-2-yl)-lH-pyrazole (0.856 g, 4.41 mmol), (S)-3-methanesulfonyloxypyrrolidine-l -carboxylic acid tert-butyl ester (1.17 g, 4.41 mmol), and Cs₂CO₃ (2.16 g, 6.61 mmol) in anhydrous DMF (11.7 mL) was heated to 100 ⁰C for 16 h. The reaction mixture was allowed to cool to rt and was partitioned between EtOAc and H₂O and separated. The aqueous layer was re-extracted with EtOAc (3 x) and the combined organic fractions were washed with H₂O (3x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo resulting in a crude brown oil. The reaction mixture was purified by chromatography on silica gel [eluting with 12% EtOAc in CHCl₃] resulting in the title compound as a light yellow oil. ¹H NMR (400 MHz, CDCl₃): δ = 1.31 (s, 12H), 1.46 (s, 9H), 2.36 (q, J= 7.0 Hz, 2H), 3.46-3.78 (m, 3H), 3.80-3.91 (m, IH), 4.89 (quint, J = 6.1 Hz, IH), 7.73 (s, IH), 7.80 (s, IH).

(5)-3-Methanesulfonyloxypyrrolidine-l-carboxylic acid tert-buty\ ester

A solution of (S)^ -hydroxypyrrolidine-1 -carboxylic acid tert-butyl ester (0.750 g, 4.00 mmol) in DCM (10 mL) was cooled to 0 ⁰C and charged with triethylamine (0.67 mL, 4.8 mmol), methanesulfonyl chloride (0.34 mL, 4.4 mmol), and 4-dimethylaminopyridine (0.005 g, 0.04 mmol) and stirred at ambient temperature for 6 h. The reaction mixture was partitioned between CHCl₃ and sat. NaHCO₃ and separated. The aqueous layer was re-extracted with CHCl₃ (3x) and the combined organic fractions were washed with sat. NaHCO₃ (2x), brine (2x), dried over Na₂SOz_I, filtered and concentrated in vacuo to give the title compound as a pale yellow oil. This material was taken on to the next step without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 1.47 (s, 9H), 2.05-2.36 (m, 2H), 3.05 (s, 3H), 3.43-3.74 (m, 4H), 5.24-5.30 (m, IH).

Example 63 : 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-((5)-l-pyrrolidin-3-yl-lH-pyrazol-4-yl)- pyridin-2-ylamine trihydrochloride A solution of (S)-3-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-pyrrolidine-l- carboxylic acid tert-butyl ester (0.0804 g, 0.221 mmol), 5-bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)- pyridin-2-ylamine (0.065 g, 0.18 mmol), potassium carbonate (0.0815 g, 0.590 mmol), and Pd(PPh₃)₄ (0.015 g, 0.013 mmol) in previously degassed DME/Water (4: 1) (2.05 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 45 min. The reaction mixture was diluted with EtOAc and washed with H₂O (2x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo to give a brown oil. This material was purified by chromatography on silica gel [eluting with 1% MeOH in CHCl₃] resulting in (R)-3-{4- [6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -pyrrolidine- 1 -carboxylic acid tert-butyl ester, MS (ES+): m/z = 508.9/510.8 (76/24) [MH⁺]. This compound was dissolved in DCM (2.0 mL) and charged with 1.0 M of HCl in Et₂O (1.1 mL) and stirred at 40 ⁰C for 5 h then at rt for an additional 16 h. The solid that formed was filtered off and washed with diethyl ether (3x), yielding the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.23-2.36 (m, IH), 2.39-2.49 (m, IH), 3.33-3.48 (m, IH), 3.51-3.62 (m, 2H), 3.62-3.82 (m, 2H), 5.14-5.28 (m, IH), 7.66 (t, J= 9.2 Hz, IH), 8.11 (dd, J= 8.4, 4.8 Hz, IH), 8.17 (s, IH), 8.47 (d, J= 1.8 Hz, IH), 8.54 (d, J= 11.7 Hz, 2H), 8.67 (br. s., IH), 9.41 (br. s., IH), 9.54 (br. s., IH), 9.68 (s, IH). MS (ES+): m/z = 408.88/410.77 (76/24) [MH⁺]. HPLC: t_R = 1.84 min (ZQ2, polar_5min).

(5)-3-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-pyrrolidine-l-carboxylic acid tert-butyl ester

A solution of 4-(4,4,5,5-tetramethyl[l,3,2]dioxaborolan-2-yl)-lH-pyrazole (0.375 g, 1.93 mmol), (R)-3-methanesulfonyloxypyrrolidine-l -carboxylic acid tert-butyl ester (0.513 g, 1.93 mmol), and Cs₂CO₃ (0.943 g, 2.90 mmol) in anhydrous DMF (5.1 mL) was heated to 100 ⁰C for 6 h. The reaction mixture was partitioned between EtOAc and H₂O and separated. The aqueous layer was re-extracted with EtOAc (3x) and the combined organic fractions were washed with H₂O (3x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo resulting in a brown oil. This material crude was purified by chromatography on silica gel [eluting with 12% EtOAc in CHCl₃] resulting in the title compound as a viscous oil. ¹H NMR (400 MHz, CDCl₃): δ = 1.32 (s, 12H), 1.47 (s, 9H), 2.36 (q, J = 7.0 Hz, 2H), 3.46-3.79 (m, 3H), 3.81-3.92 (m, IH), 4.90 (quint, J = 6.1 Hz, IH), 7.73 (s, IH), 7.81 (s, IH).

(Λ)-3-Methanesulfonyloxypyrrolidine-l-carboxylic acid tert-buty\ ester

A solution of (R)-3-hydroxypyrrolidine-l-carboxylic acid tert-butyl ester (0.500 g, 2.67 mmol) in DCM (6.7 mL) was cooled to 0 ⁰C and charged with triethylamine (0.45 mL, 3.20 mmol), methanesulfonyl chloride (0.23 mL, 2.90 mmol), and 4-dimethylaminopyridine (3.0 mg, 0.03 mmol) and stirred at rt for 6 h. The reaction mixture was partitioned between CHCl₃ and sat. NaHCO₃ and separated. The aqueous layer was re-extracted with CHCl₃ (3x) and the combined organic fractions were washed with sat. NaHCO₃ (2x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo resulting in the title compound as a pale yellow oil. This material was taken on to the next step without further purification. ¹H NMR (400 MHz, CDCl₃): δ =1.47 (s, 9H), 2.06-2.39 (m, 2H), 3.05 (s, 3H), 3.38-3.82 (m, 4H), 5.27 (t, J= 4.4 Hz, IH).

Example 64: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-[l-(8-methyl-8-azabicyclo[3.2.1]oct-3- yl)-l//-pyrazol-4-yl] -pyridin-2-ylamine

A solution of 3-(4-iodopyrazol-l-yl)-8-methyl-8-azabicyclo[3.2.1]octane (42.7 mg, 0.135 mmol), 3-(5-chloro-8-fluoroisoquinolin-3-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyridin-2- ylamine (0.070 g, 0.18 mmol), potassium carbonate (55.9 mg, 0.404 mmol), and Pd(PPh₃ )₄ (9 mg, 0.008 mmol) in previously degassed DME/Water (4:1) (3.0 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 45 min. The reaction mixture was diluted with EtOAc and washed with H₂O (2x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by chromatography on silica gel [eluting with 10% MeOH in CHCl₃], passing through an SCX cartridge, and finally by the MDP. The fractions containing product were combined, concentrated in vacuo, and partitioned between CHCl₃ and sat. NaHCO₃. The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo resulting in the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO- d₆): δ = 1.64-1.72 (m, 2H), 1.77-1.86 (m, 2H), 1.97-2.06 (m, 2H), 2.07-2.17 (m, 2H), 2.26 (s, 3H), 3.20 (br. s., 2H), 4.47 (tt, J= 11.7, 5.9 Hz, IH), 6.89 (br. s., 2H), 7.54 (dd, J= 9.9, 8.4 Hz, IH), 7.87 (s, IH), 8.03 (dd, J= 8.4, 4.8 Hz, IH), 8.15 (d, J= 2.2 Hz, IH), 8.25 (s, IH), 8.35 (d, J= 2.2 Hz, IH), 8.37 (s, IH), 9.64 (s, IH). MS (ES+): m/z = 463.13/465.15 (76/24) [MH⁺]. HPLC: t_R = 1.88 min (ZQ2, polar_5min).

3-(4-Iodopyrazol-l-yl)-8-methyl-8-azabicyclo[3.2.1]octane

Method C was followed, using methanesulfonic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester (1 eq). After a reaction time of 6.5 h, H₂O was added and an aqueous workup, using CH₂Cl₂ as extracting solvent, was conducted. The crude material was purified by silica gel column chromatography

[0.5"x l0" column, eluting with 1%→5% 7N NH₃(MeOH): CH₂Cl₂]. The residue was dissolved in minimal CH₂Cl₂ and heptane was added. The solution was heated until boiling and then chilled to -20 ⁰C. Needles had recrystallized after 16 h and all solvent was decanted. The needles were swirled with fresh heptane, which was decanted, and then allowed to dry in vacuo, to afford the title material. ¹H NMR (400 MHz, CDCl₃): δ = 1.66-1.73 (m, 2H), 1.95 (ddd, J = 13.0, 5.9, 3.5 Hz, 2H), 2.04-2.17 (m, 4H), 2.37 (s, 3H), 3.30 (dd, J = 3.8, 3.0 Hz, 2H), 4.49 (tt, J= 11.9, 6.0 Hz, IH), 7.47 (s, IH), 7.48 (s, IH). MS (ES⁺): m/z = 318.03 (87) [MH⁺]. HPLC: t_R = 1.55 min (ZQ2, polar_5min). Methanesulfonic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester

A solution of tropine (10.0 g, 70.8 mmol), 4-dimethylaminopyridine (80 mg, 0.60 mmol), and triethylamine (11.0 mL, 78.9 mmol) in DCM (125 mL) was cooled to 0 ⁰C, charged with methanesulfonyl chloride (5.50 mL, 71.0 mmol), slowly allowed to warm to rt, and stirred for an additional 16 h at rt. The reaction mixture was partitioned between CHCl₃ and sat. NaHCO₃, and the layers were separated. The aqueous layer was extracted with CHCl₃ (3x) and the combined organic fractions were washed with sat. NaHCO₃ (2x), brine (2x), dried over Na₂SO₄, filtered, and concentrated in vacuo resulting in the title compound as a pale brown solid. This material was taken on to the next step without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 1.94-2.09 (m, 6H), 2.20 (dt, J = 15.4, 4.2 Hz, 2H), 2.28 (s, 3H), 2.99 (s, 3H), 3.10-3.17 (m, 2H), 4.94 (t, J= 5.1 Hz, IH).

Method A: General procedure for HCl salt formation of 2-aminopyridine free base precursor A solution of the free base (0.21 mmol) in dioxane (3 mL) was charged with 4.0 M of HCl in dioxane (1 mL) at rt. Upon addition, a solid precipitated and all solvent was removed in vacuo. MeOH and heptane were added and the solid was filtered off and dried, giving the title material.

Method B: General procedure for the Suzuki coupling of the brominated 2-aminopyridine core and the desired (het)arylboronate

A suspension of 3-Rl-5-bromopyridin-2-ylamine (0.226 mmol, 1 eq), the (het)arylboronate / boronic acid (0.272 mmol, 1.2 eq), Pd(PPh₃ )₄ (18.6 mg, 0.0161 mmol, 7 mol%), and potassium carbonate (101.1 mg, 0.732 mmol, 3.2 eq) in a 4: 1 mixture of DME:H2O (2.5 mL) was evacuated and charged with nitrogen several times, after which the sample was heated in the microwave reactor to 100 ⁰C for 45 min. EtOAc was added to dilute the reaction, which was then washed with water (2x) and brine (Ix), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo to dryness. The crude material was purified by column chromatography on silica gel [0.5"xl0" glass column, eluting with CH₂Cl₂:Et0Ac 1 :0 → 4: 1 → 1 : 1 → 2:3 → 3:7 → 1 :9 → 0: 1]. Fractions containing product were combined and concentrated in vacuo. DCM and heptane were added to the residue and the solvent was concentrated in vacuo until all CH₂Cl₂ had been removed; a solid precipitated at this point. The solid was triturated in hot heptane and filtered off, giving the title material.

Method C: General procedure for iV-alkylation of substituted pyrazoles, using halogenated (Bromo- or Iodo-) and mesylated species

In a sealed tube, to a suspension of 4-(4,4,5,5-tetramethyl[l,3,2]dioxaborolan-2-yl)-lH-pyrazole (567 mg, 2.92 mmol, 1.0 eq) and Cs₂CO₃ (1.544 g, 4.739 mmol, 1.6 eq) in DMF (6 mL), the halide or mesylate (4.43 mmol, 1.5 eq) was added and the reaction was allowed to stir at 100 ⁰C for 19 h. Water was added to dilute the reaction and dissolve all salts that had formed, after which EtOAc was added and the two layers were separated. The organic layer was washed with water (2x) and brine (1 x). The combined aqueous layers were back extracted with EtOAc (1 x), and the combined EtOAc extracts were dried over anhydrous Na₂SOz_I, filtered, and concentrated in vacuo to give the target material.

Method D: General procedure for JV-alkylation/acylation, using carbamoyl chloride, isocyanate, and triflate species: To a solution of 4-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine hydrochloride (253.6 mg, 0.809 mmol, 1 eq) in DMF (6 mL), DIPEA (0.7 mL, 4 mmol, 5 eq) was added at rt. The solution was cooled to 0 ⁰C and the carbamoyl chloride / isocyanate / triflate (1.002 mmol, 1.2 eq) in DMF (1 mL) was added. The reaction was stirred from 0 ⁰C — > rt for 30 min. MeOH was added and all organic solvent was concentrated in vacuo to dryness. The residue was dissolved in CH₂Cl₂, washed with water (Ix) and brine (Ix), dried over anhydrous Na₂SOz_I, filtered, and concentrated in vacuo, giving the title compound.

Method E: General procedure for the Suzuki coupling of the borylated 2-aminopyridine core and the desired iodo-/bromo-het(aryl) building block

A solution of the 3-Rl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (0.155 mmol, 1.0 eq), the iodo-/bromo-het(aryl) building block (0.183 mmol, 1.2 eq), Pd(PPh₃)₄ (12.8 mg,

0.0111 mmol, 7 mol%), and K₂CO₃ (68.1 mg, 0.493 mmol, 3.2 eq) in a 4:1 mixture of dioxane to H₂O (5 mL) was evacuated and charged with nitrogen several times, after which the sample was heated in the microwave reactor to 100 ⁰C for 45 min. EtOAc and water were added to the reaction mixture and the layers were separated. The organic phase was washed with water (2^χ) and brine (1 x), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The crude material was purified by pTLC or column chromatography on silica gel.

Example 65: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(l-methyl-l//-pyrazol-4-yl)-pyridin-2- ylamine bis-hydrochloride Method A was followed. ¹H NMR (400 MHz, OMSO-d₆): δ = 3.90 (s, 3H), 7.67 (dd, J= 9.9, 8.3

Hz, IH), 8.04 (s, IH), 8.12 (dd, J = 8.3, 4.8 Hz, IH), 8.34 (s, IH), 8.42 (d, J= 2.3 Hz, IH), 8.57 (s, IH), 8.73 (A, J= 2.0 Hz, IH), 9.67 (A, J= 0.8 Hz, IH). MS (ES⁺): m/z = 354.06/356.04 (100/87) [MH⁺]. HPLC: t_R = 2.48 min (ZQ3, polar_5min).

3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(l-methyl-l//-pyrazol-4-yl)-pyridin-2-ylamine Method B was followed, except the crude material was purified by pTLC [Silicycle, 1000 μm,

20x20 plate, developed once in 3% 7N NH₃ (MeOH): CH₂Cl₂ solvent system]; the desired band was scraped from the plate, the silica gel was rinsed well with copious amounts of the same solvent system, and the filtrate was concentrated in vacuo. ¹H NMR (400 MHz, CDCl₃): δ = 3.99 (s, 3H), 6.43 (br s, 2H), 7.21 (dd, J= 9.4, 8.3 Hz, IH), 7.64 (s, IH), 7.75 (dd, J= 8.3, 4.6 Hz, IH), 7.78 (s, IH), 8.01 (d, J = 2.3 Hz, IH), 8.32 (d, J= 2.0 Hz, IH), 8.34 (s, IH), 9.59 (d, J= 0.8 Hz, IH). MS (AP⁺): m/z = 354.06/356.04 (100/37) [MH⁺]. HPLC: t_R = 2.45 min (ZQ3, polar_5min).

Example 66: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(l-isopropyl-l//-pyrazol-4-yl)-pyridin- 2-ylamine bis-hydrochloride Method A was followed, except heptane was the only solvent used for recrystallization of the title compound. ¹H NMR (400 MHz, OMSO-d₆): δ = 1.46 (d, J= 6.6 Hz, 6H), 4.53 (septet, J= 6.7 Hz, IH), 7.67 (dd, J= 9.7, 8.5 Hz, IH), 8.05 (s, IH), 8.12 (dd, J= 8.5, 4.7 Hz, IH), 8.31 (br s, IH), 8.43 (d, J= 2.0 Hz, IH), 8.44 (s, IH), 8.56 (s, IH), 8.75 (d, J= 2.0 Hz, IH), 9.68 (d, J= 0.8 Hz, IH). MS (AP⁺): m/z = 382.09/384.07 (100/37) [MH⁺]. HPLC: t_R = 2.78 min (ZQ3, polar_5min). 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(l-isopropyl-l//-pyrazol-4-yl)-pyridin-2-ylamine

Method B was followed, except 1% MeOH was added to the CH₂Cl₂:Et0Ac mixtures for better separation. ¹H NMR (400 MHz, CDCl₃): δ = 1.58 (s, 6H), 4.58 (septet, J= 6.7 Hz, IH), 6.40 (br s, 2H), 7.21 (dd, J= 9.4, 8.3 Hz, IH), 7.69 (d, J= 0.8 Hz, IH), 7.75 (dd, J= 8.3, 4.8 Hz, IH), 7.79 (d, J= 0.5 Hz, IH), 8.01 (d, J= 2.0 Hz, IH), 8.33 (d, J= 2.3 Hz, IH), 8.34-8.36 (m, IH), 9.59 (d, J= 0.8 Hz, IH). MS (AP⁺): m/z = 382.09/384.09 (100/35) [MH⁺]. HPLC: t_R = 2.75 min (ZQ3, polar_5min). l-Isopropyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-l//-pyrazole Method C was followed, using isopropyl iodide (753.3 mg, 4.431 mmol, 1.5 eq). The title compound was obtained as a yellow oil that was used without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 1.33 (s, 12H), 1.51 (d, J= 6.8 Hz, 6H), 4.53 (septet, J= 6.7 Hz, IH), 7.75 (s, IH), 7.80 (s, IH). MS (AP⁺): m/z = 235.98 (76) [MH⁺]. HPLC: t_R = 3.22 min (ZQ3, polar_5min).

Example 67: 4-4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l- ylpiperidine-1-carboxylic acid dimethylamide bis-hydrochloride

Method A was followed, except a mixture of CH₂Cl₂ and heptane was used to recrystallize the title compound. ¹H NMR (400 MHz, OMSO-d₆): δ = 1.89 (qd, J= 12.1, 3.9 Hz, 2H), 2.05 (dd, J= 12.3, 2.4 Hz, 2H), 2.76 (s, 6H), 2.90 (t, J = 11.8 Hz, 2H), 3.66 (d, J = 13.4 Hz, 2H), 4.33-4.45 (m, IH), 7.66 (dd, J= 9.9, 8.6 Hz, IH), 8.07 (s, IH), 8.12 (dd, J= 8.5, 4.7 Hz, IH), 8.30 (br s, 2H), 8.42 (d, J= 2.0 Hz, IH), 8.49 (s, IH), 8.55 (s, IH), 8.74 (d, J= 2.0 Hz, IH), 9.68 (d, J= 0.8 Hz, IH). MS (AP⁺): m/z = 494.12/496.12 (100/39) [MH⁺]. HPLC: t_R = 2.59 min (ZQ3, polar_5min).

4-4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-ylpiperidine-l- carboxylic acid dimethylamide

Method B was followed, except 7N NH₃(MeOH):EtOAc mixtures were necessary for silica gel chromatography. ¹H NMR (400 MHz, CDCl₃): δ = 2.01-2.16 (m, 2H), 2.18-2.27 (m, 2H), 2.88 (s, 6H), 2.91-3.01 (m, 2H), 3.84 (d, J= 13.4 Hz, 2H), 4.29-4.40 (m, IH), 6.42 (br s, 2H), 7.21 (dd, J= 9.4, 8.3 Hz, IH), 7.70 (d, J= 0.5 Hz, IH), 7.75 (dd, J= 8.3, 4.8 Hz, IH), 7.80 (d, J= 0.5 Hz, IH), 8.00 (d, J = 2.3 Hz, IH), 8.32 (d, J= 2.3 Hz, IH), 8.34-8.37 (m, IH), 9.59 (d, J= 0.8 Hz, IH). MS (ES⁺): m/z = 493.97/496.11 (78/100) [MH⁺]. HPLC: t_R = 2.53 min (ZQ3, polar_5min).

4-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid dimethylamide

To a solution of 4-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine hydrochloride (253.6 mg, 0.809 mmol, 1 eq) in DMF (6 mL), DIPEA (0.7 mL, 4 mmol, 5 eq) was added at rt. The solution was cooled to 0 ⁰C and N, N-dimethylcarbamoyl chloride (107.7 mg, 1.002 mmol, 1.2 eq) in DMF (1 mL) was added. The reaction was stirred from 0 ⁰C — > rt for 30 min. MeOH was added and all organic solvent was concentrated in vacuo to dryness. The residue was dissolved in CH₂Cl₂, washed with water (1 x) and brine (1 x), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo, giving 292.5 mg (98%, 0.798 mmol) of the title compound, as a waxy white solid that had solidified upon drying. ¹H NMR (400 MHz, CDCl₃): δ = 1.32 (s, 12H), 1.94-2.07 (m, 2H), 2.16 (dd, J= 12.3, 2.4 Hz, 2H), 2.85 (s, 6H), 2.87-2.95 (m, 2H), 3.78 (d, J= 13.4 Hz, 2H), 4.24- 4.34 (m, IH), 7.76 (s, IH), 7.80 (s, IH). MS (AP⁺): m/z = 349.13 (100) [MH⁺]. HPLC: t_R = 2.91 min (ZQ3, polar_5min). 4-[4-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine hydrochloride

To a solution of 4-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine-l- carboxylic acid tert-butyl ester (1.011 g, 2.68 mmol, 1 eq.) in dioxane (5 mL), 4.0 M of HCl in dioxane (10 mL, 20 eq) was added and the reaction was stirred at 35 ⁰C for 2.5 h. The reaction mixture was concentrated in vacuo, yielding the title material, as a white solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.32 (s, 12H), 2.46 (br s, 4H), 3.18 (br s, 2H), 3.57-3.70 (m, 2H), 4.48 (br s, IH), 7.78 (s, IH), 7.79 (s, IH), 9.54-10.04 (m, 2H). MS (ES⁺): m/z = 278.14 (100) [MH⁺]. HPLC: t_R = 1.89 min (ZQ2, polar_5min).

Example 68: 4-4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l- ylpiperidine-1-carboxamide bis-hydrochloride Method A was followed, except a mixture of CH₂Cl₂ and heptane was used to recrystallize the title compound. ¹H NMR (400 MHz, DMSO-^₆): δ = 1.77 (qd, J = 12.1, 4.0 Hz, 2H), 2.01 (dd, J = 11.8, 2.4 Hz, 2H), 2.87 (t, J = 11.9 Hz, 2H), 4.06 (d, J= 13.4 Hz, 2H), 4.33-4.44 (m, IH), 6.04 (br s, IH), 7.66 (dd, J= 9.9, 8.6 Hz, IH), 8.06 (d, J= 0.5 Hz, IH), 8.12 (dd, J= 8.3, 4.8 Hz, IH), 8.27 (br s, IH), 8.41 (d, J= 2.0 Hz, IH), 8.48 (s, IH), 8.55 (s, IH), 8.73 (d, J= 1.5 Hz, IH), 9.68 (d, J= 0.8 Hz, IH). MS (ES⁺): m/z = 466.12/468.04 (100/63) [MH⁺]. HPLC: t_R = 2.33 min (ZQ3, polar_5min).

4-4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol-l-ylpiperidine-l- carboxamide

Method B was followed, except 7N NH₃(MeOH):EtOAc mixtures were necessary for silica gel chromatography. ¹H NMR (400 MHz, CDCl₃): δ = 2.07 (qd, J= 12.3, 4.0 Hz, 2H), 2.26 (dd, J= 12.4, 2.5 Hz, 2H), 3.01-3.11 (m, 2H), 4.13 (d, J= 13.4 Hz, 2H), 4.38 (tt, J= 11.4, 4.1 Hz, IH), 4.50 (br s, 2H), 6.44 (br s, 2H), 7.21 (dd, J= 9.4, 8.3 Hz, IH), 7.69 (d, J= 0.5 Hz, IH), 7.75 (dd, J= 8.3, 4.8 Hz, IH), 7.80 (d, J= 0.8 Hz, IH), 8.00 (d, J= 2.3 Hz, IH), 8.32 (d, J= 2.3 Hz, IH), 8.33-8.35 (m, IH), 9.59 (d, J= 0.8 Hz, IH). MS (ES⁺): m/z = 466.11/468.09 (100/72) [MH⁺]. HPLC: t_R = 2.33 min (ZQ3, polar_5min). 4-[4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine-l-carboxamide

Method D was followed, using trimethylsilyl isocyanate (2.3 eq) and DIPEA (3 eq). After a total reaction time of 3.5 h, EtOAc was added and a standard aqueous workup was performed. ¹H NMR (400 MHz, CDCl₃): δ = 1.31 (s, 12H), 1.88-2.02 (m, 2H), 2.17 (dd, J= 12.3, 2.4 Hz, 2H), 2.92-3.05 (m, 2H), 4.06 (d, J= 13.6 Hz, 2H), 4.31 (U, J= 11.3, 3.9 Hz, IH), 4.77 (br s, 2H), 7.73 (s, IH), 7.78 (s, IH). MS (ES⁺): m/z = 321.18 (100) [MH⁺]. HPLC: t_R = 2.57 min (ZQ3, polar_5min).

Example 69: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-l-[l-(2,2,2-trifluoroethyl)-piperidin-4- yl] -l//-pyrazol-4-yl-pyridin-2-ylamine bis-hydrochloride

Method A was followed, except a mixture of CH₂Cl₂ and heptane was used to recrystallize the title compound. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.15 (br s, 4H), 2.86 (br s, 2H), 3.23 (d, J= 8.8 Hz, 2H), 3.57-3.71 (m, 2H), 4.26-4.39 (m, IH), 7.67 (dd, J= 9.9, 8.6 Hz, IH), 8.07-8.14 (m, 2H), 8.46 (d, J= 2.0 Hz, IH), 8.51 (s, IH), 8.56 (s, IH), 8.76 (d, J= 2.0 Hz, IH), 9.67 (d, J= 0.8 Hz, IH). MS (ES⁺): m/z = 505.12/507.09 (100/79) [MH⁺]. HPLC: t_R = 3.08 min (ZQ3, polar_5min).

3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-l-[l-(2,2,2-trifluoroethyl)-piperidin-4-yl]-lH-pyrazol- 4-yl-pyridin-2-ylamine

Method B was followed, except 1% 7N NH₃(MeOH) was added to the CH₂Cl₂:Et0Ac mixtures for better separation. ¹H NMR (400 MHz, CDCl₃): δ = 2.09-2.27 (m, 4H), 2.62 (td, J= 11.5, 3.0 Hz, 2H), 3.07 (q, J= 9.6 Hz, 2H), 3.11-3.18 (m, 2H), 4.15-4.26 (m, IH), 6.43 (br s, 2H), 7.21 (dd, J= 9.4, 8.3 Hz, IH), 7.70 (s, IH), 7.75 (dd, J= 8.2, 4.7 Hz, IH), 7.79 (d, J= 0.8 Hz, IH), 8.00 (d, J= 2.3 Hz, IH), 8.32 (d, J = 2.3 Hz, IH), 8.34-8.36 (m, IH), 9.59 (d, J = 0.8 Hz, IH). MS (AP⁺): m/z = 505.09/507.10 (83/29) [MH⁺]. HPLC: t_R = 3.05 min (ZQ3, polar_5min).

4-[4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-pyrazol-l-yl]-l-(2,2,2-trifluoroethyl)- piperidine

Method D was followed, using 2,2,2-trifluoroethyl triflate (1.6 eq). After reacting for 3 h, EtOAc was added and a standard aqueous workup was performed. The crude was purified using a short silica gel plug [eluting with 2: 1 CH₂Cl₂:Et0Ac]. ¹H NMR (400 MHz, CDCl₃): δ = 1.33 (s, 12H), 1.58 (s, 2H), 2.00-2.11 (m, 2H), 2.11-2.19 (m, 2H), 2.59 (td, J= 11.7, 2.2 Hz, 2H), 3.06-3.12 (m, 2H), 4.15 (tt, J= 11.3, 4.3 Hz, IH), 7.75 (s, IH), 7.80 (s, IH). MS (AP⁺): m/z = 360.14 (100) [MH⁺]. HPLC: t_R = 3.54 min (ZQ3, polar_5min).

Example 70: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-l-[l-(2-methoxyethyl)-piperidin-4-yl]- l//-pyrazol-4-yl-pyridin-2-ylamine

Method B was followed, except the crude material was purified by pTLC [Silicycle, 1000 μm, 20x20 cm plate, developed once in 4% 7N NH₃(MeOH):EtOAc solvent system]; the desired band was scraped from the plate, the silica gel was rinsed well with copious amounts of the same solvent system, and the filtrate was concentrated in vacuo. The title compound was recrystallized from hot heptane. ¹H NMR (400 MHz, CDCl₃): δ = 2.08-2.28 (m, 6H), 2.65 (t, J= 5.6 Hz, 2H), 3.14 (d, J= 11.4 Hz, 2H), 3.39 (s, 3H), 3.55 (t, J= 5.6 Hz, 2H), 4.15-4.28 (m, IH), 6.43 (br s, 2H), 7.20 (dd, J= 9.4, 8.3 Hz, IH), 7.70 (s, IH), 7.75 (dd, J= 8.3, 4.8 Hz, IH), 7.78 (d, J= 0.8 Hz, IH), 8.00 (d, J= 2.3 Hz, IH), 8.32 (d, J = 2.3 Hz, IH), 8.35 (s, IH), 9.59 (d, J= 0.8 Hz, IH). MS (ES⁺): m/z = 481.14/483.12 (60/35) [MH⁺]. HPLC: t_R = 2.02 min (ZQ3, polar_5min). l-(2-Methoxyethyl)-4-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyrazol-l-yl]- piperidine

Method C was followed, using 1 -bromo-2-methoxyethane (2 eq) and Cs₂CO₃ (3 eq). The crude material was also quickly purified over a short plug of silica gel. ¹H NMR (400 MHz, CDCl₃): δ = 1.32 (s, 12H), 2.06 (td, J= 11.9, 3.7 Hz, 2H), 2.11-2.24 (m, 4H), 2.59-2.64 (m, 2H), 3.07 (d, J= 12.1 Hz, 2H), 3.37 (s, 3H), 3.53 (t, J= 5.6 Hz, 2H), 4.15 (tt, J= 11.4, 4.1 Hz, IH), 7.74 (s, IH), 7.79 (s, IH).

Example 71 : (25',45)-4-{4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]- pyrazol-l-yl}-pyrrolidine-2-carboxylic acid dimethylamide

To a solution of (2S,4S)-4-{4-[6-amino-5-(5-chloro-8-fluoroisoqumoh^'n-3-yl)-pyridm-3-yl]- pyrazol-l-yl}-pyrrolidine-2-carboxylic acid (5.00 mg, 0.00889 mmol) in DCM (2 mL, 0.02 mol) was added dimethylamine hydrochloride (20 mg, 0.2 mmol) and DIPEA (0.2 mL, 1.0 mmol), and stirred for 1 min. TBTU (5.71 mg, 0.0178 mmol) was then added, and the solution was stirred at rt for 10 min. The material was transferred to a separatory funnel. The organic layer was washed with water, and concentrated in vacuo. The material was loaded onto a prep TLC plate, eluting with 6% (7N NH₃ in MeOH) / DCM. The band containing the product was collected and the product was eluted with 1 : 1 MeOH / DCM. The solution was concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.15-2.22 (m, IH), 2.82-2.90 (m, IH), 2.99 (s, 3H), 3.10-3.13 (m, 3H), 3.21-3.26 (m, IH), 3.49 (dd, J = 12.3, 3.2 Hz, IH), 4.15 (t, J = 8.2 Hz, IH), 4.99-5.05 (m, IH), 7.38 (dd, J = 9.6, 8.3 Hz, IH), 7.84-7.91 (m, 2H), 8.13-8.17 (m, 2H), 8.27 (d, J = 2.3 Hz, IH), 8.43 (s, IH), 9.60 (s, IH). MS (ES⁺): m/z = 480.13/482.11 (100/36) [MH⁺]. HPLC: t_R = 1.89 min (ZQ2, polar_5min).

Example 72: ((25',45)-4-{4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]- pyrazol-l-yl}-pyrrolidin-2-yl)-morpholin-4-ylmethanone

The title compound was prepared according to the procedures described for (2S,4S)-4-{4-[6-amino- 5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.23 (s, IH), 2.79-2.86 (m, IH), 3.23 (dd, J = 12.3, 6.4 Hz, IH), 3.46-3.51 (m, IH), 3.57-3.70 (m, 8H), 4.13 (t, J = 8.3 Hz, IH), 4.99-5.04 (m, IH), 7.38 (dd, J = 9.6, 8.3 Hz, IH), 7.85-7.92 (m, 2H), 8.12-8.18 (m, 2H), 8.27 (d, J = 2.3 Hz, IH), 8.43 (s, IH), 9.60 (s, IH). MS (ES⁺): m/z = 522.14/524.13 (100/40) [MH⁺]. HPLC: t_R = 1.95 min (ZQ2, polar_5min).

Example 73: ((25',45)-4-{4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]- pyrazol-l-yl}-pyrrolidin-2-yl)-pyrrolidin-l-ylmethanone

The title compound was prepared according to the procedures described for (2S,4S)-4-{4-[6-amino- 5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.91-2.02 (m, 4H), 2.78-2.86 (m, IH), 3.21-3.26 (m, IH), 3.45-3.52 (m, 4H), 3.61-3.67 (m, IH), 4.01 (t, J = 8.2 Hz, IH), 4.21 (dd, J = 5.6, 1.8 Hz, IH), 4.99-5.03 (m, IH), 7.38 (dd, J = 9.6, 8.3 Hz, IH), 7.87 (s, IH), 7.90 (dd, J = 8.3, 4.8 Hz, IH), 8.17 (s, 2H), 8.27 (d, J = 2.3 Hz, IH), 8.44 (s, IH), 9.60 (d, J = 1.0 Hz, IH). MS (ES⁺): m/z = 506.16/507.15 (100/41) [MH⁺]. HPLC: t_R = 2.23 min (ZQ2, polar_5min).

Example 74: (25',45)-4-{4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]- pyrazol-1-yl} -pyrrolidine-2-carboxylic acid (2-methoxyethyl)-amide

The title compound was prepared according to the procedures described for (2S,4S)-4-{4-[6-amino- 5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-pyrazol- 1 -yl} -pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.33-2.40 (m, IH), 2.76-2.82 (m, IH), 3.27 (s, 3H), 3.37 (d, J = 4.8 Hz, 2H), 3.41 (d, J = 4.5 Hz, 2H), 3.81-3.90 (m, IH), 4.22 (dd, J = 5.6, 1.8 Hz, 2H), 4.96 (br. s., IH), 7.38 (dd, J = 9.9, 8.3 Hz, IH), 7.87 (s, IH), 7.90 (dd, J = 8.3, 4.8 Hz, IH), 8.14 (s, IH), 8.18 (d, J = 2.3 Hz, IH), 8.29 (d, J = 2.3 Hz, IH), 8.45 (d, J = 1.8 Hz, IH), 9.61 (s, IH). MS (ES⁺): m/z = 510.14/512.16 (100/43) [MH⁺]. HPLC: t_R = 2.05 min (ZQ2, polar_5min).

Example 75: (25',45)-4-{4-[6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]- pyrazol-l-yl}-pyrrolidine-2-carboxylic acid A mixture of 3-(5-chloro-8-fluoroisoquinolin-3-yl)-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2- yl)-pyridin-2-ylamine (100 mg, 0.250 mmol), (2S,4S)-4-(4-iodopyrazol-l-yl)-pyrrolidine-l,2- dicarboxylic acid 1-benzyl ester 2-methyl ester (137.0 mg, 0.300 mmol), Pd(PPh₃)₄ (29 mg, 0.025 mmol), potassium fluoride (43.6 mg, 0.751 mmol) and 4: 1 dioxane:water (3 mL) was heated in the microwave reactor to 85 ⁰C for 30 min. The material was concentrated in vacuo, then dry-loaded onto silica gel for column chromatography. The product was eluted with 2— >5% MeOH / DCM, and the fractions containing the product were concentrated in vacuo. The material was dissolved in cone. HCl, transferred to a sealed tube and heated at 60 ⁰C for 2 h. The solvent was removed in vacuo to afford the title compound as a brown solid. MS (ES⁺): m/z = 453.09/455.10 (100/37) [MH⁺]. HPLC: t_R = 1.94 min (ZQ2, polar_5min).

Example 76 : 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-thiophen-3-ylpyridin-2-amine A mixture of 5-bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-2-ylamine (BB4) (25 mg, 0.070 mmol), 3-thienylboronic acid (20 mg, 0.10 mmol) and potassium carbonate (29 mg, 0.21 mmol) in 1,4-dioxane (1.0 mL) and H₂O (0.4 mL) was degassed and refilled with argon (3x) prior to the addition of Pd(dppf)Cl₂ (5 mg, 0.01 mmol). The reaction mixture was degassed and refilled with argon (2x) and left to stir at 100 ⁰C in the microwave reactor for 30 min. Then, the mixture was passed through PL-Thiol MP SPE resin and concentrated in vacuo. The residual oil was partitioned between DCM and H₂O. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. Purification via MDP afforded the title compound as a yellow solid. MS (ES+): m/z = 356.03/358.05 (100/50) [MH⁺]. HPLC: t_R = 3.22 min (ZQ2, polar_5min). The following examples 77-89 were prepared following the same procedure.

Example 77: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-phenylpyridin-2-amine

MS (ES+): m/z = 350.03/352.05 (100/45) [MH⁺]. HPLC: t_R = 3.37 min (ZQ2, polar_5min).

Example 78: 5-(5-Chloro-8-fluoroisoquinolin-3-yl)-3,3'-bipyridin-6-amine

MS (ES+): m/z = 351.04/353.07 (100/40) [MH⁺]. HPLC: t_R = 2.66 min (ZQ2, polar_5min).

Example 79: 5-(5-Chloro-8-fluoroisoquinolin-3-yl)-3,4'-bipyridin-6-amine MS (ES+): m/z = 351.04/353.07 (100/30) [MH⁺]. HPLC: t_R = 2.35 min (ZQ2, polar_5min).

Example 80: 5-(5-Chloro-8-fluoroisoquinolin-3-yl)-l',2',3',6'-tetrahydro-3,4'-bipyridin-6-yl- tert-buty\ carboxylate

MS (ES+): m/z = 455.15/457.06 (100/55) [MH⁺]. HPLC: t_R = 3.87 min (ZQ3, polar_5min).

Example 81 : 5-(5-Chloro-8-fluoroisoquinolin-3-yl)-3,3'-bipyridine-6,6'-diamine

MS (ES+): m/z = 366.06/368.04 (100/35) [MH⁺]. HPLC: t_R = 3.37 min (ZQ2, polar_5min).

Example 82 : iV-4- [6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)pyridin-3- yl]phenylacetamide

MS (ES+): m/z = 407.06/409.04 (100/50) [MH⁺]. HPLC: t_R = 3.01 min (ZQ3, polar_5min).

Example 83 : Ethyl- [4-(6-amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)pyridin-3- yl)phenoxy] acetate MS (ES+): m/z = 452.08/454.06 (100/90) [MH⁺]. HPLC: t_R = 3.48 min (ZQ3, polar_5min).

Example 84: 6'-Amino-5'-(5-chloro-8-fluoroisoquinolin-3-yl)-3,3'-bipyridin-6-ol

MS (ES+): m/z = 367.09/369.06 (100/50) [MH⁺]. HPLC: t_R = 2.49 min (ZQ3, polar_5min).

Example 85: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-furan-3-ylpyridin-2-amine

MS (ES+): m/z = 340.08/341.99 (100/80) [MH⁺]. HPLC: t_R = 3.26 min (ZQ3, polar_5min).

Example 86 : 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-furan-2-ylpyridin-2-amine

MS (ES+): m/z = 340.08/341.99 (100/70) [MH⁺]. HPLC: t_R = 3.72 min (ZQ3, polar_5min).

Example 87: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(l//-pyrazol-4-yl)pyridin-2-amine

MS (ES+): m/z = 340.08/341.99 (100/80) [MH⁺]. HPLC: t_R = 2.49 min (ZQ3, polar_5min).

Example 88: 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-iV6'-(2-morpholin-4-ylethyl)-3,3'- bipyridine-6,6'-diamine

MS (ES+): m/z = 479.16/481.07 (100/75) [MH⁺]. HPLC: t_R = 2.18 min (ZQ3, polar_5min).

Example 89 : 3-(5-Chloro-8-fluoroisoquinolin-3-yl)-5-(l//-indol-2-yl)pyridin-2-amine l-Boc-indole-2-boronic acid was used. The resulting Boc-protected intermediate was treated with

(1 : 1) DCM:TFA mixture at rt for 15 min. Filtration and drying in vacuo afforded the title compound. MS (ES+): m/z = 389.12/391.10 (100/60) [MH⁺]. HPLC: t_R = 3.72 min (ZQ3, polar_5min).

Example 90: 4- [6-Amino-5-(5-chloro-8-methoxyisoquinolin-3-yl)-pyridin-3-yl] benzoic acid To a solution of methyl 4-[6-amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-benzoate

(0.13 g, 0.32 mmol) in methanol (5 mL) and water (0.5 mL) was added NaOH (0.24 g, 6 mmol), and the mixture was heated at 50 ⁰C for 16 h. The solvents were evaporated at reduced pressure, and the residue was neutralized with acetic acid. The solid formed was filtered off and dried in vacuo to give the title compound. ¹H NMR (400 MHz, DMSO-^₆): δ = 12.82 (very brs, IH), 9.63 (s, IH), 8.51 (d, J = 2.4 Hz, IH), 8.35 (s, IH), 8.31 (d, J = 2.4 Hz, IH), 8.03-7.98 & 7.90-7.85 (AA¹BB', 4H), 7.92 (d, J = 8.0 Hz, IH), 7.27 (brs, 2H), 7.15 (d, J= 8.0 Hz, IH), 4.07 (s, 3H). MS(ES+): m/z = 406.08/408.03 (100/53) [MH⁺]. HPLC: t_R = 3.00 min (polar_5min, ZQ3).

Methyl 4- [6-Amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl] -benzoate

A mixture of 5-bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-2-ylamine (BB4) (0.40 g, 1.1 mmol), 4-(carbomethoxyphenyl)boronic acid (0.21 g, 1.2 mmol), Pd(PPh₃ )₄ (5 mol%) and CS₂CO3 (0.89 g, 2.3 mmol) in dioxane/H₂O (4: 1, 5.0 mL) was heated under nitrogen at 90 ⁰C for 5 h. The solvents were removed under reduced pressure. The residue was dissolved in EtOAc (30 mL) and washed with water (20 mL). The EtOAc solution was dried over MgSO₄, filtered, and concentrated. The crude material was purified by column chromatography on silica gel using EtOAc/Hexanes (1 :4) to give the title compound.

Example 91: 3-[6-Amino-5-(5-chloro-8-methoxyisoquinolin-3-yl)-pyridin-3-yl]benzoic acid

To a solution of methyl 4-[6-amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3-yl]-benzoate (0.13 g, 0.32 mmol) in methanol (5 mL) and water (0.5 mL) was added NaOH (0.24 g, 6 mmol), and the mixture was heated at 50 ⁰C for 16 h. The solvents were evaporated at reduced pressure, and the residue was neutralized with acetic acid. The solid formed was filtered off and dried in vacuo to give the title compound. ¹H NMR (400 MHz, DMSO-^₆): δ = 12.99 (very brs, IH), 9.64 (d, J= 1.2 Hz, IH), 8.44 (d, J= 2.4 Hz, IH), 8.34 (d, J= 0.4 Hz, IH), 8.26 (d, J= 2.4 Hz, IH), 8.20 (t, J= 1.6 Hz, IH), 7.99 (dt, J= 8.0, 1.0 Hz, IH), 7.91 (d, J= 8.0 Hz, IH), 7.90 (dt, J= 8.0, 1.4 Hz, IH), 7.59 (t, J= 8.0 Hz, IH), 7.17 (brs, 2H), 7.15 (d, J= 8.0 Hz, IH), 4.07 (s, 3H). MS(ES+): m/z = 406.09/408.07 (100/45) [MH⁺]. HPLC: t_R = 3.00 min (polar_5min, ZQ3).

Methyl 3- [6-Amino-5-(5-chloro-8-fhioroisoquinolin-3-yl)-pyridin-3-yl] -benzoate Following the procedure for methyl 4-[6-amino-5-(5-chloro-8-fluoroisoquinolin-3-yl)-pyridin-3- yl]-benzoate, the title compound was prepared from 5-bromo-3-(5-chloro-8-fluoroisoquinolin-3-yl)- pyridin-2-ylamine (BB4) (0.4 g, 1.13 mmol), 3-(carbomethoxy)phenylboronic acid (0.214 g, 1.2 mmol), Pd(PPh₃)₄ (5 mol %) and Cs₂CO₃ (0.89 g, 2.3 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 6.59 (bs, 2H), 7.20 (dd, J = 8.4, 7.8 Hz, IH), 7.55 (t, J = 7.8 Hz, IH), 7.43 (dd, J= 5.2, 4.8 Hz, IH), 7.80 (dd, J= 6.8, 2.4 Hz, IH), 8.01 (dd, J= 6.8, 2.4 Hz, IH), 8.17 (d, J= 2.1 Hz, IH), 8.28 (t, J= 1.8 Hz, IH), 8.44 (d, J = 2.4 Hz, IH), 9.59 (s, IH).

Example 92: 3-Benzofuran-2-yl-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine dihydrochloride

To a solution of 4-[4-(6-amino-5-benzofuran-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidine-l- carboxylic acid fert-butyl ester (83.2 mg, 0.181 mmol) in DCM (2 mL) was added IM HCl in Et₂O (3.0 mL, 3.0 mmol), and the mixture was stirred at ambient temperature for 30 min to overnight. The solid that formed was filtered off and dried in vacuo to give the title compound. ¹H NMR (400 MHz,

DMSO-(Z₆): δ = 2.11-2.30 (m, 4H), 3.04-3.16 (m, 2H), 3.39 (d, J= 12.1 Hz, 2H), 4.47-4.57 (m, IH), 7.35 (t, J= IA Hz, IH), 7.43 (t, J= IA Hz, IH), 7.63 (s, IH), 7.71 (d, J= 8.4 Hz, IH), 7.77 (d, J= 7.6 Hz, IH), 8.00 (brs, IH), 8.11 (s, IH), 8.47 (s, IH), 8.48 (d, J= 1.8 Hz, IH), 8.67 (d, J= 1.8 Hz, IH), 9.07 (brs, IH), 9.21 (brs, IH). MS (ES+): m/z 360.16 [MH⁺]. HPLC: t_R = 2.02 min (ZQ3, polar_5min). 4-[4-(6-Amino-5-benzofuran-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert- butyl ester

To a solution of 3-Benzofuran-2-yl-5-bromopyridin-2-ylamine (61.1 mg, 0.211 mmol) and 4-[4- (4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-pyrazol- 1 -yl]-piperidine- 1-carboxylic acid tert-bxAy\ ester (94.4 mg, 0.250 mmol) in 1,4-dioxane (2.9 mL, 38 mmol) in a microwave reactor tube were added PS- PPh₃-Pd (0.10 mmol/g loading; 120 mg, 0.0120 mmol; Argonaut) and a solution Of Cs₂CO₃ (142 mg, 0.436 mmol) in H₂O (0.90 mL, 50 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 60 min. The resin was filtered off and washed with DCM. The combined filtrate and washings were diluted with DCM to « 50 mL, washed with water and brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed on silica gel [10 g / 70 mL prepacked cartridge, eluting with DCM → 1% MeOH in DCM → 2% MeOH in DCM]. Fractions containing product were combined and dried in vacuo. One obtained the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 8.26 (d, J= 2.4 Hz, IH), 7.98 (d, J= 2.4 Hz, IH), 7.77 (s, IH), 7.66 (s, IH), 7.62 (dd, J= 7.6, 0.8 Hz, IH), 7.55 (d, J= 8.4 Hz, IH), 7.33 (ddd, J= 1.6, 7.2, 8.2 Hz, IH), 7.28 (ddd, J= 1.0, 7.8, 8.4 Hz, IH), 7.05 (d, J= 0.8 Hz, IH), 5.27 (brs, 2H), 4.40-4.16 (m, 3H), 2.92 (brt, J= 11.4 Hz, 2H), 2.19 (brdd, J= 2.2, 12.6 Hz, 2H), 1.97 (dq, J= 4.4, 12.4 Hz, 2H), 1.49 (s, 9H). MS(ES+): m/z = 460.20 (100) [MH⁺]. HPLC: t_R = 2.92 min (nonpolar_5min, ZQ3).

In an alternative synthesis of the title compound, 4-[4-(6-Amino-5-bromopyridin-3-yl)-pyrazol-l- yl]-piperidine- 1-carboxylic acid tert-butyl ester (70 mg, 0.17 mmol), 1 -benzofuran-2-ylboronic acid (40 mg, 0.25 mmol), Cs₂CO₃ (110 mg, 0.33 mmol), and Pd(PPh₃)₄ (10 mg, 0.0087 mmol) were placed in a sealable microwave tube, taken up in 1,4-dioxane (3 mL) and H₂O (0.8 mL), flushed with nitrogen, sealed and irradiated in a microwave reactor at 100 ⁰C for 30 min. The reaction mixture was diluted with EtOAc and washed with water (2^χ), brine, dried over Na₂SOz_I, filtered, and concentrated. The crude product was purified via prep-TLC eluting with 5% NH₃ in MeOH and (1 : 1) EtO Ac/Hep mixtures to give the title compound. 3-Benzofuran-2-yl-5-bromopyridin-2-ylamine (BB6)

To a mixture of 5-bromo-3-(3-bromobenzofuran-2-yl)-pyridin-2-ylamine (2.5 g, 6.8 mmol) in ethanol (95%, 75 mL), CH₂Cl₂ (25 mL) and NH₄Cl (9.0 g) in water (20 mL) at 60⁰C was added Zinc (8.0 g) portion wise. After 30 minutes, the reaction mixture was filtered while hot and the filtrate was evaporated in vacuo. The crude material was chromatographed on silica gel using EtOAc/Hexanes (1 :4) to give the title compound as a pale yellow solid. ¹H NMR (CDCl₃, 300 MHz): δ = 7.02 (s, IH), 7.28-7.37 (m, 2H), 7.35 (d, J= 8.1 Hz, IH), 7.62 (d, J= 8.1 Hz, IH), 7.99 (d, J = 2.4 Hz, IH), 8.13 (d, J = 2.4 Hz, IH). MS(ES+): m/z = 288.99/290.92 (90/100) [MH⁺]. HPLC: t_R = 3.30 min. 5-Bromo-3-(3-bromobenzofuran-2-yl)-pyridin-2-ylamine Following the General Procedure for the Bromination of Aminopyridines with N- bromosuccinimide, but using 2.0 equivalents of ΝBS, the title compound was prepared from 3- benzofuran-2-ylpyridin-2-ylamine. ¹H ΝMR (CDCl₃, 300 MHz): δ = 5.56 (brs, 2H), 7.36-7.44 (m, 2H), 7.52 (d, J= 7.5 Hz, IH), 7.60 (d, J= 7.5 Hz, IH), 8.12 (d, J= 2.4 Hz, IH), 8.18 (d, J= 2.4 Hz, IH).

3-Benzofuran-2-ylpyridin-2-ylamine

A mixture of 2-amino-3-bromopyridine (1.0 g, 5.7 mmol), benzofuran-2-boronic acid (1.03 g, 6.4 mmol), Pd(dppf)₂Cl₂ (50 mg) and K₂CO₃ (1.83 g, 13.3 mmol) in dioxane/H₂O (4: 1, 5 mL) was heated under nitrogen at 80 ⁰C for 16 h, cooled to RT, and concentrated in vacuo. The solid residue thus obtained was dissolved in EtOAc (30 mL) and washed with water (20 mL) and dried in vacuo. The crude material was purified by chromatography on silica gel using EtOAc/Hexanes (1 :4) to give the title compound. ¹H ΝMR (CDCl₃, 300 MHz): δ = 5.61 (brs, 2H), 6.82 (dd, J= 7.2, 4.1 Hz, IH), 7.05 (s, IH), 7.25-7.28 (m, 2H), 7.60 (d, J= 7.2 Hz, IH), 7.66 (d, J= 7.2 Hz, IH), 7.94 (d, J= 2.4 Hz, IH), 8.19 (d, 2.4 Hz).

Example 93: 3-(3-Chlorobenzofuran-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine dihydrochloride

To a solution of 4-{4-[6-Ammo-5-(3-chlorobenzofuran-2-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine- 1 -carboxylic acid tert-buiyl ester (78.0 mg, 0.158 mmol) in DCM (2.5 mL, 39 mmol) was added 1.0 M of HCl in Et₂O (1.5 mL; 1.5 mmol), and the mixture was stirred at ambient temperature for 8.5 h. The solid formed was filtered off, washed with DCM, and dried in vacuo overnight, yielding the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 9.20-9.09 (brm, IH), 9.02-8.91 (brm, IH), 8.57 (d, J = 2.0 Hz, IH), 8.52 (d, J = 2.0 Hz, IH), 8.39 (s, IH), 8.05 (s, IH), 7.96 (very brs, 2H), 7.76 (d, J= 8.4 Hz, IH), 7.74 (dd, J= 8.4, 0.8 Hz, IH), 7.55 (ddd, J= 1.2, 7.2, 8.4 Hz, IH), 7.48 (ddd, J= 0.8, 7.2, 8.4 Hz, IH), 4.55-4.46 (m_c, IH), 3.38 (brd, J= 12.8 Hz, 2H), 3.08 (q, J= 12.2 Hz, 2H), 2.26-2.08 (m, 4H). MS(ES+): m/z = 394.10/396.09 (65/21) [MH⁺], 311.04/313.07 (100/34) [MH⁺ - piperidine]. HPLC: t_R = 2.28 min (polar_5min, ZQ3).

4-{4-[6-Amino-5-(3-chlorobenzofuran-2-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To a solution of 5-Bromo-3-(3-chlorobenzofuran-2-yl)-pyridin-2-ylamme (57.9 mg, 0.179 mmol) and 4-[4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-pyrazol- 1 -yl]-piperidine- 1 -carboxylic acid tert- butyl ester (69.5 mg, 0.184 mmol) in 1,4-dioxane (2.5 mL, 32 mmol) in a microwave reactor tube were added PS-PPh₃-Pd (0.10 mmol/g loading; 100 mg, 0.0100 mmol; Argonaut) and a solution Of Cs₂CO₃ (117 mg, 0.358 mmol) in H₂O (0.75 mL, 42 mmol). The tube was sealed, evacuated and refilled with nitrogen (3x), and heated in the microwave reactor to 105 ⁰C for 30 min. More 4-[4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (21 mg, 0.056 mmol) was added, the tube was evacuated and refilled with nitrogen again (3x) and heated in the microwave reactor to 105 ⁰C for 45 min. The resin was filtered off and washed with DCM. The combined filtrate and washings were diluted with DCM to « 50 mL, washed with water and brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was chromatographed on silica gel [1O g / 70 mL prepacked cartridge, eluting with DCM → 1% MeOH in DCM → 2% MeOH in DCM]. Fractions containing product were combined and dried in vacuo. One obtained the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 8.30 (d, J= 2.4 Hz, IH), 8.09 (d, J= 2.4 Hz, IH), 7.74 (s, IH), 7.65 (dd, J= 7.2, 1.2 Hz, IH), 7.63 (s, IH), 7.52 (dd, J= 7.0, 1.4 Hz, IH), 7.41 (ddd, J= 1.6, 7.2, 7.2 Hz, IH), 7.38 (ddd, J= 1.4, 7.0, 7.0 Hz, IH), 5.27 (brs, 2H), 4.37-4.17 (m, 3H), 2.91 (bit, J = 11.2 Hz, 2H), 2.18 (brdd, J= 2.2, 12.8 Hz, 2H), 1.97 (dq, J= 12.4, 4.0 Hz, 2H), 1.48 (s, 9H). MS(ES+): m/z = 494.15/496.08 (100/48) [MH⁺]. HPLC: t_R = 3.23 min (nonpolar_5min, ZQ3). 5-Bromo-3-(3-chlorobenzofuran-2-yl)-pyridin-2-ylamine

A solution of 3-Benzofuran-2-yl-5-bromopyridin-2-ylamine (76.1 mg, 0.263 mmol) and NCS (37.3 mg, 0.279 mmol) in DCM (5.0 mL, 78 mmol) was stirred at ambient temperature for 2 d and then at reflux for 3 d. The reaction mixture was diluted with DCM to 50 mL, washed with IM NaOH, water containing Na₂S₂O₃, and brine, and dried over MgSO₄. The DCM solution was filtered through a plug of silica gel (~ 1 " in a 60 mL fritted funnel) that was washed with more DCM until no more product eluted. The filtrate containing product was concentrated in vacuo. The residue was triturated with Et₂O. The solid was filtered off, rinsed with Et₂O, and dried in vacuo overnight. One obtained the title compound as light beige solid. ¹H NMR (400 MHz, CDCl₃): δ = 8.19 (d, J= 2.2 Hz, IH), 8.10 (d, J = 2.2 Hz, IH), 7.64 (dd, J= 1.2, 7.2 Hz, IH), 7.52 (dd, J= 1.4, 7.4 Hz, IH), 7.41 (ddd, J= 1.4, 7.4, 7.4 Hz, IH), 7.38 (ddd, J = 1.2, 7.2, 7.2 Hz, IH), 5.32 (brs, 2H). MS(ES+): m/z = 322.96/324.94/326.91 (87/100/29) [MH⁺]. HPLC: t_R = 3.56 min (nonpolar_5min, ZQ3).

Example 94: 3-(3-Methylbenzofuran-2-yl)-5-(l-piperidin-4-yl-7//-pyrazol-4-yl)pyridin-2- ylamine bishydrochloride To the powder of Boc protected compound was added 2 mL of 1.0M HCl in ether. The mixture was shaken at room temperature overnight. Evaporation of solvents yielded the hydrochloride salt of the title compound as yellow powder. ¹H NMR (400 MHz, CD₃OD): δ = 2.36 (br. s., 4H), 2.41 (s, 3H), 3.22 (br. s., 2H), 3.58 (br. s., 2H), 4.63 (br. s., IH), 7.31-7.38 (m, IH), 7.43 (td, J= 7.7, 1.3 Hz, IH), 7.57 (d, J = 8.1 Hz, IH), 7.70 (d, J= 6.6 Hz, IH), 8.00 (s, IH), 8.25 (d, J= 2.0 Hz, IH), 8.29 (s, IH), 8.40 (d, J= 2.0 Hz, IH). MS (ES+): m/z= 374.26 (100) [MH⁺]. HPLC: t_R = 0.52 min (UPLC- ACQUITY, Analytical).

4-{4-[6-Amino-5-(3-methylbenzofuran-2-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To the DME solution of 3-methyl-2-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)benzofuran (2.3 mL, 0.58 mmol, 2 eq.) from the previous step were added 4-[4-(6-amino-5-bromopyridin-3-yl)-pyrazol- l-yl]piperidine-l-carboxylic acid tert-butyl ester (BB3) (120 mg, 0.29 mmol, 1 eq.), potassium carbonate (120 mg, 0.87 mmol, 3 eq.), water (0.5 mL), and 1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium ^• DCM (10 mg, 0.01 mmol, 0.05 eq.). The mixture was evacuated and filled with nitrogen (3x) and heated in a microwave reactor to 100 ⁰C for 30 min. The crude was passed through Thiol-SPE to remove Pd. The clear solution was purified with the

MDPS. ¹H NMR (400 MHz, CD₃OD): δ = 1.48 (s, 9H), 1.96 (dq, J= 4.3, 12.3 Hz, 2H), 2.09 (br. s., 2H), 2.35 (s, 3 H), 2.96 (br. s., 2H), 4.21 (br. s., 2H), 4.33-4.43 (m, IH), 7.29 (dt, J= 0.8, 7.4 Hz, IH), 7.34 (dt, J= 1.4, 7.2 Hz, IH), 7.51 (d, J= 7.8 Hz, IH), 7.59-7.65 (m, IH), 7.82 (s, IH), 7.85 (d, J= 2.3 Hz, IH), 8.07 (s, IH), 8.26 (d, J= 2.3 Hz, IH). MS (ES+): m/z = 474.38 (100) [MH⁺]. HPLC: t_R = 0.94 min (UPLC-ACQUITY, Analytical).

3-Methyl-2-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)benzofuran

A flask containing [Ir(OMe)(COD)]₂ (20 mg, 0.030 mmol), 4,4'-di-tert-butyl-[2,2']bipyridinyl (20 mg, 0.060 mmol) and 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l,3,2]dioxaborolane (250 mg, 1.0 mmol) was evacuated and refilled with argon (3x), then charged with anhydrous DME (5 mL) and 3- methylbenzofuran (264 mg, 2.0 mmol). The resulting mixture was evacuated and refilled with argon (3x) again and kept stirring under argon at ambient temperature overnight. The resulting boronate was not isolated, but the reaction solution was used directly in the Suzuki coupling step. MS (ES+): m/z = 259.20 (100) [MH⁺]. HPLC: t_R = 1.39 min (UPLC-ACQUITY, Analytical). Example 95: 3-(3-Bromobenzofuran-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine trifluoroacetate

A solution of 4-[4-(6-amino-5-benzofuran-2-yl-pyridin-3-yl)pyrazol- 1 -yl]piperidine- 1 -carboxylic acid tert-butyl ester (10 mg, 0.020 mmol) and NBS (8.6 mg, 0.048 mmol) in acetonitrile (1 mL) was left to stir at 55 ⁰C for 2 h. The mixture was concentrated in vacuo, and the residue was partitioned between EtOAc and an aqueous saturated solution OfNa₂S₂O₃ (2x). The organic layer was washed with water (1 x). The combined organic extracts were treated with brine, dried over sodium sulfate and concentrated in vacuo. Purification via prep TLC (5% MeOH in DCM) afforded 4-{4-[6-amino-5-(3- bromobenzofuran-2-yl)pyridine-3-yl]pyrazol-l-yl}piperidine-l -carboxylic acid tert-butyl ester. This compound was left to stir in a 1 : 1 DCM/TFA mixture (1 mL) for 15 min at rt. The mixture was concentrated in vacuo, affording the title compound as a tan solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.23-2.38 (m, 4H), 3.18-3.26 (m, 2H), 3.57 (dd, J= 9.5, 3.9 Hz, 2H), 4.57 (dd, J= 10.1, 5.1 Hz, IH), 7.46 (dd, J= 8.2, 1.4 Hz, 2H), 7.62 (d, J= 8.6 Hz, IH), 7.90 (s, IH), 8.09 (s, IH), 8.26-8.31 (m, 2H). MS (ES+): m/z = 438.03/440.01 (60/70) [MH⁺]. HPLC: t_R = 2.50 min (ZQ3, polar_5min).

4-{4-[6-Amino-5-(3-bromobenzofuran-2-yl)pyridine-3-yl]pyrazol-l-yl}piperidine-l-carboxylic acid tert-butyl ester

A solution of 4-[4-(6-Amino-5-benzofuran-2-ylpyridin-3-yl)pyrazol-l-yl]piperidine-l -carboxylic acid tert-butyl ester (795 mg, 1.73 mmol) and NBS (616 mg, 3.46 mmol) in acetonitrile (30 mL) was left to stir at rt for 16 h. The mixture was quenched with Na₂S₂O₃ saturated solution (15 mL) and left to stir for an additional 5 min at rt. The mixture was partitioned between EtOAc and H₂O (3x). The combined organic extracts were treated with brine, dried over Na₂SOzJ, and concentrated in vacuo.

Purification via silica gel chromatography (5% MeOH in DCM) afforded the title compound as a brown solid. ¹H NMR (400 MHz, DMSO-4): δ = 1.42 (s, 9H), 1.71-1.85 (m, 2H), 1.97-2.08 (m, 2H), 2.83- 3.03 (m, 2H), 3.99-4.11 (m, 2H), 4.31-4.40 (m, IH), 6.21 (br. s., 2H), 7.42 (dd, J= 7.5, 1.1 Hz, IH), 7.45 (td, J= 7.6, 1.6 Hz, IH), 7.58 (dd, J= 7.6, 1.0 Hz, IH), 7.69 (d, J= 7.8 Hz, IH), 7.83 (s, IH), 7.95 (d, J= 2.3 Hz, IH), 8.22 (s, IH), 8.38 (d, J= 2.3 Hz, IH). MS (ES+): m/z = 538.11/540.09 (90/100) [MH⁺]. HPLC: t_R = 3.84 min (ZQ3, polar_5min).

Example 96: 3-(3-Phenylbenzofuran-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)pyridine-2- ylamine A mixture of 4-{4-[6-amino-5-(3-bromobenzofuran-2-yl)pyridine-3-yl]pyrazol-l-yl}piperidine-l- carboxylic acid tert-butyl ester (50 mg, 0.093 mmol), phenylboronic acid (28 mg, 0.23 mmol), potassium fluoride (16 mg, 0.28 mmol), and palladium acetate (1.0 mg, 0.0050 mmol) in 1,4-dioxane (2.25 mL) and H₂O (0.75 mL) was degassed and refilled with argon (2x). The reaction mixture was left to stir at 100 ⁰C in the microwave reactor for 30 min. Then, the mixture was passed through PL-Thiol MP SPE+ resin and concentrated in vacuo. The residual oil was partitioned between DCM and H₂O. The organic layers were treated with brine, dried over anhydrous Na₂SC^ and concentrated in vacuo to give 4- {4-[5-(3-Phenylbenzofuran-2-yl)pyridin-3-yl]pyrazol-l-yl}piperidine-l-carboxylic acid tert- butyl ester, MS (ES+): m/z= 536.13 (100) [MH⁺]; HPLC: t_R = 3.38 min (ZQ3, polar_5min). This compound was left to stir in a 1 : 1 DCM/TFA mixture (1 mL) for 30 min at rt. Purification via MDP afforded the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.13-2.22 (m, 2H), 2.23-2.30 (m, 2H), 3.10-3.19 (m, 2H), 3.47-3.54 (m, 2H), 4.43-4.53 (m, IH), 7.33 (td, J= 7.5, 0.8 Hz, IH), 7.38-7.46 (m, 3H), 7.47-7.52 (m, 3H), 7.53 (s, IH), 7.62 (d, J = 8.3 Hz, IH), 7.64 (d, J= 2.3 Hz, IH), 7.67 (d, J= 7.8 Hz, IH), 7.82 (s, IH), 8.20 (d, J= 2.5 Hz, IH), 8.53 (br. s., 2H). MS (ES+): m/z = 436.12 (60) [MH⁺]. HPLC: t_R = 2.56 min (ZQ3, polar_5min).

Example 97: 3-[3-(3-Chloro-2-fluorophenyl)benzofuran-2-yl]-5-(l-piperidin-4-yl-lH-pyrazol-

4-yl)pyridine-2-ylamine

The title compound was obtained following the procedure for 3-(3-phenylbenzofuran-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)pyridine-2-ylamine, using 4-(4- {5-[3-(3-chloro-2-fluorophenyl)- benzofuran-2-yl]pyridin-3-yl}pyrazol- 1 -yl)-piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.13-2.18 (m, 2H), 2.22-2.28 (m, 2H), 3.07-3.11 (m, 2H), 3.42-3.49 (m, 2H),

4.40-4.49 (m, IH), 7.28 (dd, J= 15.8, 0.9 Hz, IH), 7.32-7.37 (m, IH), 7.41-7.47 (m, 2H), 7.51 (d, J = 7.8 Hz, IH), 7.54 (s, IH), 7.56 (d, J= 1.3 Hz, IH), 7.58 (d, J= 2.3 Hz, IH), 7.66 (d, J= 8.1 Hz, IH), 7.85 (s, IH), 8.22 (d, J= 2.3 Hz, IH), 8.54 (br. s., 2H). MS (ES+): m/z = 488.03/490.01 (60/20) [MH⁺]. HPLC: t_R = 2.63 min (ZQ3, polar_5min). 4-(4-{5-[3-(3-Chloro-2-fluorophenyl)-benzofuran-2-yl]pyridin-3-yl}pyrazol-l-yl)-piperidine-l- carboxylic acid tert-butyl ester

The title compound was obtained following the procedure for 4-{4-[5-(3-phenylbenzofuran-2- yl)pyridin-3-yl]pyrazol-l-yl}piperidine-l -carboxylic acid tert-butyl ester in the previous example, using 3-chloro-2-fluorophenylboronic acid. It was used in the next step without further purification. MS (ES+): m/z = 588.12/590.03 (100/50) [MH⁺]. HPLC: t_R = 3.55 min (ZQ3, polar_5min).

Example 98: 3-[3-(2,3-Difluorophenyl)benzofuran-2-yl]-5-(l-piperidin-4-yl-l//-pyrazol-4- yl)pyridine-2-ylamine

The title compound was obtained following the procedure for 3-(3-phenylbenzofuran-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)pyridine-2-ylamine, using 4-(4- {5-[3-(2,3-difluorophenyl)benzofuran-2- yl]pyridin-3-yl}pyrazol- 1 -yl)-piperidine- 1 -carboxylic acid tert-butyl ester. ¹H NMR (400 MHz, CD₃OD): δ = 2.12-2.23 (m, 2H), 2.24-2.31 (m, 2H), 3.07-3.16 (m, 2H), 3.45-3.51 (m, 2H), 4.47-4.55 (m, IH), 7.28 (td, J= 8.4, 3.4 Hz, 2H), 7.32-7.38 (m, 2H), 7.44 (dd, J= 15.4, 1.3 Hz, IH), 7.53 (d, J = 7.6 Hz, IH), 7.56 (s, IH), 7.60 (d, J= 2.3 Hz, IH), 7.66 (d, J= 8.3 Hz, IH), 7.86 (s, IH), 8.22 (d, J = 2.3 Hz, IH), 8.54 (br. s., 2H). MS (ES+): m/z = 472.07 (50) [MH⁺]. HPLC: t_R = 2.60 min (ZQ3, polar_5min).

4-(4-{5-[3-(2,3-Difluorophenyl)benzofuran-2-yl]pyridin-3-yl}pyrazol-l-yl)piperidine-l- carboxylic acid tert-buty\ ester

The title compound was obtained following the procedure for 4-{4-[5-(3-phenylbenzofuran-2- yl)pyridin-3-yl]pyrazol- 1 -yljpiperidine- 1 -carboxylic acid tert-buiyl ester in the previous example, using 2,3-difluorophenylboronic acid. It was used in the next step without further purification. MS (ES+): m/z= 572.15 (100) [MH⁺]. HPLC: t_R = 3.92 min (ZQ3, polar_5min).

Example 99: 3-Benzofuran-2-yl-5-((i?)-l-pyrrolidin-3-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine dihydrochloride

A solution of (R)-3-[4-(4,4,5,5-tetramethyl-[l ,3,2]dioxaborolan-2-yl)-pyrazol- 1 -yl] -pyrrolidine- 1 - carboxylic acid tert-butyl ester (0.0980 g, 0.270 mmol), 3-benzofuran-2-yl-5-bromopyridin-2-ylamme (0.065 g, 0.220 mmol), potassium carbonate (0.0994 g, 0.719 mmol), and Pd(PPh₃)₄ (0.02 g, 0.020 mmol) in previously degassed DME/H₂O (4: 1) (2.5 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in a microwave reactor to 100 ⁰C for 45 min. The reaction mixture was diluted with EtOAc and washed with H₂O (2x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was further purified by chromatography on silica gel [eluting with 3% MeOH in CHCI₃] resulting in 50 mg of a yellow oil which was still slightly impure with triphenylphosphine oxide. Therefore the material was purified again by chromatography on silica gel [eluting with 1% MeOH in CHCI3] to give (R)-3-[4-(6-amino-5- benzofuran-2-ylpyridin-3-yl)-pyrazol-l-yl] -pyrrolidine- 1 -carboxylic acid tert-butyl ester. This material was dissolved in DCM (1.0 mL), charged with HCl (1.0 M solution in Et₂O; 0.67 mL, 0.67 mmol) and stirred at ambient temperature for 3 h. The reaction was charged with another portion of DCM (1 mL) and HCl (1.0 M solution in Et₂O; 0.67 mL, 0.67 mmol) and was heated to 40 ⁰C for 7 h and then stirred at ambient temperature for an additional 16 h. The precipitate that had formed was filtered off, washed with diethyl ether (4x), and dried in vacuo to give the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.26-2.37 (m, IH), 2.39-2.48 (m, IH), 3.33-3.60 (m, 3H), 3.62-3.74 (m, IH), 5.15-5.26 (m, IH), 7.35 (t, J= 7.5 Hz, IH), 7.43 (t, J= 7.2 Hz, IH), 7.60 (s, IH), 7.71 (d, J= 8.1 Hz, IH), 7.76 (d, J = 7.7 Hz, IH), 8.15 (s, IH), 8.44 (d, J = 2.2 Hz, IH), 8.55 (s, IH), 8.59 (s, IH), 9.36 (broad s, 2H). MS (ES+): m/z = 263.90 (100) [MH⁺]. HPLC: t_R = 2.63 min (ZQ2, polar_5min).

Example 100: 3-Benzofuran-2-yl-5-((5)-l-pyrrolidin-3-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine dihydrochloride

A solution of (ιS)-3-[4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-pyrazol- 1 -yl] -pyrrolidine- 1 - carboxylic acid tert-butyl ester (0.0980 g, 0.270 mmol), 3-benzofuran-2-yl-5-bromopyridin-2-ylamme (0.0650 g, 0.225 mmol), potassium carbonate (0.0994 g, 0.719 mmol), and Pd(PPh₃)₄ (0.02 g, 0.02 mmol) in previously degassed DME/Water (4: 1) (2.50 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in a microwave reactor to 100 ⁰C for 45 min. Another portion of (S)-3-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyrazol-l-yl]- pyrrolidine- 1 -carboxylic acid tert-butyl ester (0.0163 g, 0.0450 mmol) was added, and heating to 100 ⁰C was continued for 30 min. The reaction mixture was diluted with EtOAc and washed with H₂O (2x), brine (2x), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude oil was purified by chromatography on silica gel [eluting with 1% MeOH in CHCI3] to give (ιS)-3-[4-(6-amino-5- benzofuran-2-ylpyridin-3-yl)-pyrazol-l-yl] -pyrrolidine- 1 -carboxylic acid tert-butyl ester. This material was dissolved in DCM (2.0 mL, 31 mmol) and charged with 1.00 M of HCl in Et₂O (1.35 mL, 1.35 mmol) and stirred at 40° C for 5 h then at rt for an additional 16 h. The solid that had formed was filtered off, washed with diethyl ether (3x), and dried in vacuo to give the title compound as a yellow solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.25-2.37 (m, IH), 2.39-2.49 (m, IH), 3.32-3.50 (m, 2H), 3.62-3.74 (m, IH), 5.15-5.25 (m, IH), 7.37 (d, J= 8.4 Hz, IH), 7.44 (t, J= 7.2 Hz, IH), 7.63 (s, IH), 7.71 (d, J = 8.0 Hz, IH), 7.77 (d, J = 7.3 Hz, IH), 8.17 (s, IH), 8.46 (d, J= 1.8 Hz, IH), 8.58 (s, IH), 8.64 (s, IH), 9.34-9.68 (m, 2H). MS (ES+): m/z = 345.92 (100) [MH⁺]. HPLC: t_R = 1.84 min (ZQ2, nonpolar_5min) .

Example 101: 3-Benzofuran-2-yl-5-(l-methyl-l//-pyrazol-4-yl)-pyridin-2-ylamine bis- hydrochloride A solution of 3-benzofuran-2-yl-5-(l-methyl-lH-pyrazol-4-yl)-pyridin-2-ylamine (60 mg, 0.207 mmol) in dioxane (3 mL) was charged with 4.0 M of HCl in dioxane (1 mL) at rt. Upon addition, a solid precipitated and all solvent was removed in vacuo. MeOH and heptane were added and the solid was filtered off and dried, giving the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO- d₆): δ = 3.89 (s, 3H), 7.31-7.38 (m, IH), 7.43 (ddd, J= 8.3, 7.1, 1.3 Hz, IH), 7.64 (d, J= 0.8 Hz, IH), 7.71 (dd, J= 8.2, 0.6 Hz, IH), 7.77 (dd, J= 7.8, 0.5 Hz, IH), 8.02 (d, J= 0.5 Hz, IH), 8.32 (s, IH),

8.42 (d, J= 2.0 Hz, IH), 8.64 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 291.07 (100) [MH⁺]. HPLC: t_R = 2.67 min (ZQ3, polar_5min).

3-Benzofuran-2-yl-5-(l-methyl-l//-pyrazol-4-yl)-pyridin-2-ylamine

A suspension of 3-benzofuran-2-yl-5-bromopyridin-2-ylamine (65.2 mg, 0.226 mmol, 1 eq), 1- methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (56.7 mg, 0.272 mmol, 1.2 eq), Pd(PPh₃)₄ (18.6 mg, 0.0161 mmol, 7 mol%), and potassium carbonate (101.1 mg, 0.732 mmol, 3.2 eq) in a 4: 1 mixture of DME:Η₂O (2.5 mL) was evacuated and charged with nitrogen several times, after which the sample was heated in the microwave reactor to 100 ⁰C for 45 min. EtOAc was added to dilute the reaction, which was then washed with water (2x) and brine (1 x), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo to dryness. The crude material was purified by column chromatography on silica gel [0.5"x l0" glass column, eluting with CH₂Cl₂)EtOAc 1 :0 -» 4:1 -» 1 : 1 -» 2:3 — > 3:7 — > 1 :9 — > 0: 1]. Fractions containing product were combined and concentrated in vacuo. DCM and heptane were added to the residue and the solvent was concentrated in vacuo until all CH₂Cl₂ had been removed; a solid precipitated at this point. The solid was triturated in hot heptane and filtered off, giving the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 3.86 (s, 3H), 6.28 (br s, 2H), 7.24-7.37 (m, 2H), 7.39 (d, J = 0.8 Hz, IH), 7.64-7.70 (m, 2H), 7.86 (d, J = 0.8 Hz, IH), 8.11 (d, J= 2.3 Hz, IH), 8.13 (s, IH), 8.31 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 291.09 (100) [MH⁺]. HPLC: t_R = 2.65 min (ZQ3, polar_5min).

Example 102: 3-Benzofuran-2-yl-5-(l-isopropyl-l//-pyrazol-4-yl)-pyridin-2-ylamine bis- hydrochloride

Method A was followed, except a mixture of CH₂Cl₂ and heptane was used to recrystallize the title compound. ¹H NMR (400 MHz, DMSO-^₆): δ = 1.46 (d, J= 6.8 Hz, 6H), 4.45-4.58 (m, 3H), 7.32- 7.38 (m, IH), 7.40-7.46 (m, IH), 7.64 (d, J= 0.8 Hz, IH), 7.71 (dd, J= 8.3, 0.8 Hz, IH), 7.77 (d, J = 7.1 Hz, IH), 8.03 (d, J= 0.8 Hz, IH), 8.43 (d, J= 2.0 Hz, IH), 8.45 (s, IH), 8.66 (d, J= 2.0 Hz, IH). MS (ES⁺): m/z = 319.12 (100) [MH⁺]. HPLC: t_R = 2.96 min (ZQ3, polar_5min). 3-Benzofuran-2-yl-5-(l-isopropyl-l//-pyrazol-4-yl)-pyridin-2-ylamine

Method B was followed, except the free base was recrystallized from heptane (2x) to afford the title compound. ¹H NMR (400 MHz, DMSO-^₆): δ = 1.45 (d, J= 6.8 Hz, 6H), 4.50 (spt, J= 6.7 Hz, IH), 6.27 (s, 2H), 7.31 (td, J= 14.0, 6.6 Hz, 2H), 7.39 (d, J= 0.8 Hz, IH), 7.64-7.69 (m, 2H), 7.87 (d, J = 0.5 Hz, IH), 8.14 (d, J= 2.3 Hz, IH), 8.24 (d, J= 0.5 Hz, IH), 8.33 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 319.12 (100) [MH⁺]. HPLC: t_R = 2.99 min (ZQ3, polar_5min).

Example 103 : 4- [4-(6-Amino-5-benzofuran-2-yl-pyridin-3-yl)-pyrazol-l-yl] -piperidine-1- carboxylic acid dimethylamide bis-hydrochloride Method A was followed, except a mixture of CH₂Cl₂ and heptane was used to recrystallize the title compound. ¹H NMR (400 MHz, OMSO-d₆): δ = 1.88 (qd, J= 12.0, 3.4 Hz, 2H), 2.05 (d, J= 10.9 Hz, 2H), 2.77 (s, 6H), 2.91 (t, J= 12.1 Hz, 2H), 3.66 (d, J= 13.1 Hz, 2H), 4.33-4.42 (m, IH), 7.32-7.39 (m, IH), 7.41-7.47 (m, IH), 7.63 (s, IH), 7.71 (d, J= 8.1 Hz, IH), 7.77 (d, J= 7.8 Hz, IH), 8.06 (s, IH), 8.42-8.45 (m, IH), 8.50 (s, IH), 8.66-8.69 (m, IH). MS (ES⁺): m/z = 430.98 (95) [MH⁺]. HPLC: t_R = 2.74 min (ZQ3, polar_5min).

4-[4-(6-Amino-5-benzofuran-2-yl-pyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid dimethylamide

Method B was followed, except EtOAc and MeOH mixtures were used to purify the title material. ¹H NMR (400 MHz, CDCl₃): δ = 2.00-2.14 (m, 2H), 2.18-2.25 (m, 2H), 2.88 (s, 6H), 2.91-3.00 (m, 2H), 3.83 (d, J= 13.4 Hz, 2H), 4.28^.38 (m, IH), 5.28 (br s, 2H), 7.06 (d, J= 1.0 Hz, IH), 7.26-7.31 (m, IH), 7.32-7.37 (m, IH), 7.54-7.58 (m, IH), 7.63 (dd, J = 7.6, 1.0 Hz, IH), 7.70 (d, J = 0.5 Hz, IH), 7.78 (d, J= 0.8 Hz, IH), 7.99 (d, J= 2.3 Hz, IH), 8.27 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 431.14 (100) [MH⁺]. HPLC: t_R = 2.72 min (ZQ3, polar_5min).

Example 104: 3-Benzo[6]thiophen-2-yl-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine bishydrochloride

In a microwave vial, 4-[4-(6-amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (BB2) (50 mg, 0.12 mmol), 2-benzo[Z?]thiopheneboronic acid (32 mg, 0.18 mmol), CS₂CO3 (77 mg, 0.24 mmol), and Palladium(O) tetrakis(triphenylphosphine) (7 mg, 0.006 mmol) were dissolved in 1,4-dioxane (2.0 mL) and H₂O (0.55 mL), flushed with nitrogen, sealed and heated in the microwave reactor to 100 ⁰C for 30 min. The completed reaction was diluted with EtOAc (25 mL), washed with water and brine, dried over Na₂SOz_I, filtered and concentrated. The product was purified on prep-TLC eluting with 5% 7M NH₃ in MeOH/DCM and concentrated to give the Boc compound; MS (ES+): m/z = 476.14 [MH⁺]. This compound was dissolved in DCM (3.0 mL) and charged with 1.0 M HCl in Et₂O (3.0 mL, 3.0 mmol). This mixture was stirred at rt for 2 h. The solid that had formed was filtered off and dried in vacuo, giving the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-4): δ = 2.06-2.27 (m, 4H), 3.01-3.15 (m, 2H), 3.33-3.43 (m, 2H), 4.45-4.54 (m, IH), 7.43- 7.50 (m, 2H), 7.75 (s, IH), 7.86 (br. s., IH), 7.94-7.98 (m, IH), 8.06-8.10 (m, 2H), 8.37 (d, J = 2.0 Hz, IH), 8.41 (d, J = 2.0 Hz, IH), 8.42 (s, IH), 8.91 (br. s., IH), 9.05 (br. s., IH). MS (ES+): m/z = 376.12 [MH⁺]. HPLC: t_R = 1.99 min (ZQ3, polar_5min).

Example 105: 3-(3-Methylbenzo[6]thiophen-2-yl)-5-(l-piperidin-4-yl-7//-pyrazol-4- yl)pyridin-2-ylamine bishydrochloride

To the powder of Boc protected compound was added 2 mL of 1.0M HCl in ether. The mixture was shaken at room temperature overnight. Evaporation of solvents yielded the hydrochloride salt of the title compound as yellow powder. ¹H NMR (400 MHz, CD₃OD): δ = 2.26-2.39 (m, 7H), 3.19-3.28 (m, 2H), 3.54-3.61 (m, 2H), 4.55-4.68 (m, IH), 7.43-7.53 (m, 2H), 7.88 (dd, J= 7.1, 1.5 Hz, IH), 7.93 (dd, J= 7.2, 1.4 Hz, IH), 7.98 (s, 1 H), 8.24-8.28 (m, 2H), 8.31 (d, J= 2.0 Hz, IH). MS (ES+): m/z = 390.25 (100) [MH⁺]. HPLC: t_R = 0.53 min (UPLC-ACQUITY, Analytical)

4-{4-[6-Amino-5-(3-methylbenzo[6]thiophen-2-yl)-pyridin-3-yl]-pyrazol-l-yl}-piperidine-l- carboxylic acid tert-buty\ ester

To the DME solution of 4,4,5, 5-tetramethyl-2-(3-methylbenzo[Z?]thiophen-2-yl)- [l,3,2]dioxaborolane (2.3 mL, 0.50 mmol, 2 eq.) from the previous step were added 4-[4-(6-amino-5- bromopyridin-3-yl)-pyrazol-l-yl]piperidine-l -carboxylic acid tert-butyl ester (BB3) (120 mg, 0.29 mmol, 1 eq.), potassium carbonate (104 mg, 0.75 mmol, 3 eq.), water (0.5 mL), and 1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium ^• DCM (10 mg, 0.01 mmol, 0.05 eq.). The mixture was evacuated and filled with nitrogen (3x) and heated in a microwave reactor to 100 ⁰C for 30 min. The crude was passed through Thiol-SPE to remove Pd. The clear solution was purified with the MDPS. ¹H NMR (400 MHz, CD₃OD): δ = 1.47 (s, 9 H), 1.87-2.00 (m, 2H), 2.09 (d, J = 10.4 Hz, 2H), 2.31 (s, 3H), 2.95 (br. s., 2H), 3.35 (s, 2H), 4.22 (d, J= 13.4 Hz, 2H), 4.37 (tt, J= 11.6, 4.1 Hz, IH), 7.36-7.47 (m, 2H), 7.75-7.82 (m, 3H), 7.87 (d, J= 7.6 Hz, IH), 8.05 (s, IH), 8.25 (d, J= 1.8 Hz, IH). MS (ES+): m/z = 490.37 (100) [MH⁺]. HPLC: t_R = 0.93 min (UPLC-ACQUITY, Analytical). 4,4,5,5-Tetramethyl-2-(3-methylbenzo [b] thiophen-2-yl)- [1 ,3,2] dioxaborolane A flask containing [Ir(OMe)(COD)J₂ (20 mg, 0.030 mmol), 4,4'-di-tert-butyl-[2,2']bipyridinyl (20 mg, 0.060 mmol) and 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l,3,2]dioxaborolane (250 mg, 1.0 mmol) was evacuated and refilled with argon (3x), then charged with anhydrous DME (5 mL) and 3- methylbenzothiophene (296 mg, 2.0 mmol). The resulting mixture was evacuated and refilled with argon (3x) again and kept stirring under argon at ambient temperature overnight. The resulting boronate was not isolated, but the reaction solution was used directly in the Suzuki coupling step. MS (ES+): m/z = 275.14 (100) [MH⁺]. HPLC: t_R = 1.49 min (UPLC-ACQUITY, Analytical).

Example 106: 3-Benzoxazol-2-yl-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine dihydrochloride

A solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (BB3) (0.075 g, 0.16 mmol) and 2- chlorobenzoxazole (0.029 g, 0.19 mmol) in 1,4-dioxane (1.8 mL) and H₂O (0.6 mL) was charged with potassium carbonate (0.066 g, 0.48 mmol) and (l,l'bis-(diphenylphosphino)-ferrocene) palladium dichloride (0.002 g, 0.003 mmol) under an atmosphere of nitrogen and the reaction was irradiated in the microwave reactor at 100 ⁰C for 30 minutes. The reaction mixture was partitioned between EtOAc and water and separated. The aqueous was extracted with EtOAc (3 x) and the combined organic fractions were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography on silica gel [eluting w/ 3% MeOH in DCM] to afford the Boc-protected product; MS (ES+): m/z = 460.8 [MH⁺]. This product was taken up in DCM, charged with 0.25 mL of 1.0 M HCl in ether, and stirred at rt overnight. A solid precipitated out of solution, which was filtered off and dried in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.09-2.31 (m, 4H), 3.06-3.18 (m, 2H), 3.42 (d, J= 12.8 Hz, 2H), 4.46-4.57 (m, IH), 7.42-7.50 (m, 2H), 7.80 (dd, J = 6.2, 2.2 Hz, IH), 7.86 (dd, J= 5.8, 2.2 Hz, IH), 8.02 (s, IH), 8.35 (s, IH), 8.51 (br. s., IH), 8.56 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 360.83 [MH⁺]. HPLC: t_R = 2.03 min (ZQ2, polar_5min).

Example 107: 3-Benzothiazol-2-yl-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine dihydrochloride The procedure for 3-benzoxazol-2-yl-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2-ylamine dihydrochloride except using 2-chlorobenzothiazole in place of 2-chlorobenzoxazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.10-2.22 (m, 2H), 2.27 (d, J = 13.5 Hz, 2H), 3.07-3.18 (m, 2H), 3.43 (d, J= 13.2 Hz, 2H), 4.47-4.57 (m, IH), 7.50 (t, J= 7.5 Hz, IH), 7.55-7.61 (m, IH), 8.02 (s, IH), 8.10 (d, J= 8.0 Hz, IH), 8.16 (d, J= 7.7 Hz, IH), 8.21 (br. s., IH), 8.33 (s, IH), 8.50 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 376.80 [MH⁺]. HPLC: t_R = 2.02 min (ZQ2, polar_5min).

Example 108: 3-Benzothiazol-2-yl-5-[l-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-lH-pyrazol-4- yl] -pyridin-2-ylamine trihydrochloride Method A was followed, except the title material was dissolved in minimal CH₂Cl₂ and then recrystallized from hot heptane. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.05-2.14 (m, 2H), 2.19-2.37 (m, 4H), 2.71 (d, J= 5.1 Hz, 2H), 4.02 (br s, 2H), 4.79 (tt, J= 11.5, 5.7 Hz, IH), 7.48-7.55 (m, IH), 7.57-7.63 (m, IH), 8.05 (s, IH), 8.13 (d, J= 7.6 Hz, IH), 8.19 (d, J= 7.3 Hz, IH), 8.29-8.35 (m, 2 H), 8.49 (d, J= 2.3 Hz, IH), 10.28 (br s, IH); 3H singlet for N-methyl is hidden beneath DMSO peak. MS (ES⁺): m/z = 417.16 (29) [MH⁺]. HPLC: t_R = 2.04 min (ZQ2, polar_5min).

Example 109: 3-Benzothiazol-2-yl-5-[l-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-lH-pyrazol-4- yl] -pyridin-2-ylamine

A suspension of 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-pyridin-2- ylamine (BB8) (95.6 mg, 0.271 mmol, 1.2 eq), 3-(4-iodopyrazol-l-yl)-8-methyl-8- azabicyclo[3.2.1]octane (69.1 mg, 0.218 mmol, 1.0 eq), (l,l'-bis-(diphenylphosphino)-ferrocene) palladium dichloride (16.0 mg, 0.0219 mmol, 10 mol%), and K₂CO₃ (92.0 mg, 0.666 mmol, 3 eq) in a 4: 1 ratio of DME to H₂O (2.5 mL) was evacuated and charged with nitrogen several times, after which the sample was heated in the microwave reactor to 80 ⁰C for 30 min. The reaction mixture was partitioned between EtOAc and water and the layers were separated. The aqueous layer was back extracted with EtOAc (3x) and the combined organic layers were washed with water (1 x) and brine (1 x), dried over anhydrous Na₂SOzJ, filtered, and concentrated in vacuo to dryness. The emulsion that had formed was collected separately and extracted with CH₂Cl₂ (2x), washed with brine (1 x), dried over anhydrous Na₂SOzJ, filtered, and concentrated in vacuo. All organics were combined. The crude material was adsorbed onto silica gel and purified by column chromatography on silica gel [10"x0.5" column, eluting with neat EtOAc → 7N NH₃(MeOH):EtOAc 2% → 3% → 5%]. Fractions containing product were pooled and concentrated in vacuo. The product was recrystallized from neat acetonitrile [heated until boiling, cooled to -20 ⁰C for 16 h], giving the title material as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.72-1.79 (m, 2H), 2.05 (ddd, J= 13.1, 5.8, 3.3 Hz, 2H), 2.13-2.25 (m, 4H), 2.40 (s, 3H), 3.29-3.40 (m, 2H), 4.49-4.63 (m, IH), 7.12 (br s, 2H), 7.39-7.44 (m, IH), 7.50 (AAA, J = 8.2, 7.2, 1.3 Hz, IH), 7.71 (s, IH), 7.72 (s, IH), 7.92 (dd, J = 7.9, 0.6 Hz, IH), 7.99 (d, J = 2.0 Hz, IH), 8.02 (dd, J= 8.1, 0.5 Hz, IH), 8.32 (d, J= 2.0 Hz, IH). MS (ES⁺): m/z = 417.13 (24) [MH⁺]. HPLC: t_R = 2.12 min (ZQ2, polar_5min).

3-Benzothiazol-2-yl-5-(4,4,5,5-tetramethyl- [1 ,3,2] dioxaborolan-2-yl)-pyridin-2-ylamine (BB8) The title compound was prepared as a light brown solid by following the General Procedure for the Preparation of Pinacol Boronates, using 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (15.3 g, 50 mmol), bis(pinacolato)diboron (16.5 g, 65 mmol), Pd₂(dba)₃ (3 mol %), tricyclohexylphosphine (12 mol %) and KOAc (7.85 g, 80 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 7.43-7.58 (m, 4H), 7.94 (d, J = 8.1 Hz, IH), 8.05 (d, J= 8.1 Hz, IH), 8.40 (d, J= 1.8 Hz, IH), 8.60 (d, J= 1.5 Hz). MS(ES+): m/z = 353.14/354.09/355.15 (33/100/35) [MH⁺]. HPLC: fe_. = 4.19 min (polar_5min, ZQ3). Data for the corresponding boronic acid: MS(ES+): m/z = 271.06/272.00/273.06 (60/100/45)

[MH⁺]. HPLC: t_R = 2.39 min (polar_5min, ZQ3).

3-Benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7)

The title compound was prepared from 3-benzothiazol-2-ylpyridin-2-ylamine (22.7 g, 100 mmol) and NBS (17.8 g, 100 mmol) as a brown solid following the General Procedure for the Bromination of Aminopyridines with NBS. ¹H NMR (CDCl₃, 300 MHz): δ = 7.17 (brs, 2H), 7.41 (t, J= 6.9 Hz, IH), 7.50 (t, J= 6.9 Hz, IH), 7.89 (d, J= 2.4 Hz, IH), 7.95 (d, J= 2.4 Hz, IH), 8.03 (d, J= 2.1 Hz, IH), 8.20 (d, J= 2.1 Hz, IH). MS(ES+): m/z = 305.98/307.94 (91/100) [MH⁺]. HPLC: t_R = 3.62 min (nonpolar_5min, ZQ3).

3-Benzothiazol-2-ylpyridin-2-ylamine The title compound was prepared following the procedure for 3-(5-chloro-8-fluoroisoquinolin-3- yl)-pyridin-2-ylamine, using 3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine (30.0 g, 136 mmol), 2-chlorobenzothiazole (16.5 g, 97 mmol), Pd(PPh₃)₄ (3.3 g, 3 mol%), and Cs₂CO₃ (72.6 g, 223 mmol). ¹H NMR (CDCl₃, 300 MHz): δ = 6.71 (dd, J= 6.8, 3.6 Hz, IH), 7.13 (brs, 2H), 7.38 (t, J = 8.4 Hz, IH), 7.47 (t, J= 8.4 Hz, IH), 7.87 (d, J= 6.0 Hz, IH), 7.95 (dd, J= 6.2, 1.5 Hz, IH), 7.99 (d, J= 6.0 Hz, IH), 8.18 (dd, J = 6.2, 1.2 Hz, IH).

Example 110: 5-[l-(8-Azabicyclo[3.2.1]oct-3-yl)-lH-pyrazol-4-yl]-3-benzothiazol-2-ylpyridin- 2-ylamine

To a stirring solution of 3-[4-(5-benzothiazol-2-yl-6-ethoxycarbonylaminopyridin-3-yl)-pyrazol-l- yl]-8-azabicyclo[3.2.1 ]octane-8-carboxylic acid ethyl ester (7.1 mg, 0.013 mmol, 1 eq) and potassium hydroxide (22.2 mg, 0.396 mmol, 30 eq) in 1 ,2-ethanediol (3 mL), hydrazine hydrate (7 μL, 0.1 mmol, 10 eq) was added and the solution was stirred at reflux (T = 200 ⁰C) for 9 h. The reaction mixture was poured into water and extracted with ether. The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by prep. TLC [Silicycle, 1000 μm, 20^χ20cm plate, developed twice in a 8% 7N NH₃(MeOH): CH₂Cl₂ solvent system.] The desired band was scraped from the plate, the silica gel was completely rinsed of all product, and the filtrate was concentrated in vacuo, giving the title compound as a yellow solid. MS (ES⁺): m/z = 403.17 (40) [MH⁺]. HPLC: t_R = 2.37 min (ZQ3, polar_5min).

3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-8-azabicyclo[3.2.1]octane-8- carboxylic acid ethyl ester To a solution of 3-benzothiazol-2-yl-5-[l-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-lH-pyrazol-4-yl]- pyridin-2-ylamine (50.8 mg, 0.122 mmol; 1 eq) and K₂CO₃ (1.2 mg, 0.0087 mmol, 7 mol%) in toluene (3 mL), ethyl chloroformate (67.0 mg, 0.617 mmol, 5 eq) in toluene (1 mL) was added. The solution was heated to reflux for a total of 10 h (temp = 110 ⁰C). The residue was dissolved in water. The aqueous mixture was extracted with CH₂Cl₂ (3x) and the combined organic layers were dried over anhydrous Na₂SOz_I, filtered, and concentrated in vacuo. The crude was purified by column chromatography on silica gel [0.5"x 10" column, eluting with CH₂Cl₂:Et0Ac 1 :0 → 2: 1 → 1 : 1 → 1 :2 — > 0: 1]. Fractions containing product were combined and concentrated in vacuo to give the title compound. MS (ES⁺): m/z = 475.13 (100) [MH⁺]. HPLC: t_R = 3.41 min (ZQ2, polar_5min).

3-[4-(5-Benzothiazol-2-yl-6-ethoxycarbonylaminopyridin-3-yl)-pyrazol-l-yl]-8- azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester

From above reaction, the title material was also isolated. MS (ES⁺): m/z = 547.10 (65) [MH⁺]. HPLC: t_R = 3.76 min (ZQ2, polar_5min).

Example 111: 3-Benzothiazol-2-yl-5-[l-(tetrahydropyran-4-yl)-l//-pyrazol-4-yl]-pyridin-2- ylamine

Method E was followed. Trituration gave the title compound as a yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 2.09-2.23 (m, 4H), 3.55-3.63 (m, 2H), 4.12-4.20 (m, 2H), 4.37-4.48 (m, IH), 7.13 (br s, 2H), 7.37-7.46 (m, IH), 7.51 (ddd, J= 8.2, 7.2, 1.3 Hz, IH), 7.69 (d, J = 0.8 Hz, IH), 7.78 (d, J = 0.8 Hz, IH), 7.89-7.94 (m, IH), 7.99-8.05 (m, 2H), 8.34 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 378.13 (100) [MH⁺]. HPLC: t_R = 3.20 min (ZQ3, polar_5min).

4-Iodo-l-(tetrahydropyran-4-yl)-l//-pyrazole

Method C was followed, using 4-iodotetrahydro-2H-pyran. The crude material was purified by column chromatography on silica gel [0.5"x 10" glass column, eluting with neat CH₂Cl₂ — > CH₂Cl₂:Et0Ac 1% — > 2% — > neat EtOAc]. The resulting material was contaminated with the 4- iodopyrazole starting material but was carried on to the next step without further purification. ¹H NMR (400 MHz, CDCl₃): δ = 1.97-2.17 (m, 4H), 3.54 (td, J= 11.6, 2.9 Hz, 2H), 4.06-4.15 (m, 2H), 4.30- 4.42 (m, IH), 7.49 (s, IH), 7.53 (s, IH). MS (ES⁺): m/z = 278.98 (100) [MH⁺]. HPLC: t_R = 2.89 min (ZQ3, polar_5min).

Example 112: 3-Benzothiazol-2-yl-5-(l//-pyrazol-4-yl)-pyridin-2-ylamine Method E was followed, giving the title compound as a yellow solid. ¹H NMR (400 MHz, CDCI3): δ = 7.16 (br s, 2H), 7.42 (td, J = 7.6, 1.0 Hz, IH), 7.48-7.54 (m, IH), 7.87 (s, 2H), 7.90-7.94 (m, IH), 8.01-8.04 (m, IH), 8.06 (d, J = 2.0 Hz, IH), 8.38 (d, J= 2.3 Hz, IH), 10.25 (br s, IH). MS (ES⁺): m/z = 294.08 (100) [MH⁺]. HPLC: t_R = 2.83 min (ZQ3, polar_5min).

Example 113: 3-Benzothiazol-2-yl-5-(l-cyclohexyl-l//-pyrazol-4-yl)-pyridin-2-ylamine bis- hydrochloride

Method A was followed. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 1.16-1.31 (m, IH), 1.36-1.51 (m, 2H), 1.64-1.79 (m, 3H), 1.80-1.89 (m, 2H), 2.08 (dd, J= 12.6, 2.3 Hz, 2H), 4.15 (tt, J= 11.5, 3.8 Hz, IH), 7.50-7.56 (m, IH), 7.57-7.63 (m, IH), 7.97 (s, IH), 8.13 (d, J= 7.6 Hz, IH), 8.20 (d, J= 7.33 Hz, IH), 8.37-8.43 (m, 2H), 8.48 (d, J= 2.0 Hz, IH). MS (ES+): m/z = 376.16 (100) [MH⁺]. HPLC: t_R = 4.03 min (ZQ3, polar_5min).

3-Benzothiazol-2-yl-5-(l-cyclohexyl-l//-pyrazol-4-yl)-pyridin-2-ylamine Method B was followed, except the crude reaction mixture was concentrated in vacuo first, after which a standard aqueous workup was performed using CH₂CI₂ as extraction solvent. Prep-TLC purification [Silicycle, 1000 μm, 20><20cm plate, one development in 1 : 1 EtOAc:CH₂Cl₂ solvent system] was utilized; the desired band was scraped from the plate, the silica gel was rinsed well with copious amounts of the same solvent system, and the filtrate was concentrated in vacuo. The title material was recrystallized from heptane. ¹H NMR (400 MHz, CDCl₃): δ = 1.24-1.37 (m, IH), 1.40- 1.54 (m, 2H), 1.72-1.87 (m, 3H), 1.95 (dt, J= 13.6, 3.1 Hz, 2H), 2.19-2.30 (m, 2H), 4.17 (tt, J= 11.8, 3.8 Hz, IH), 7.11 (br s, 2H), 7.38-7.45 (m, IH), 7.51 (ddd, J= 8.2, 7.1, 1.1 Hz, IH), 7.67 (d, J= 0.5 Hz, IH), 7.76 (d, J= 0.8 Hz, IH), 7.91 (dd, J= 8.0, 0.6 Hz, IH), 7.99-8.06 (m, 2H), 8.34 (d, J= 2.0 Hz, IH). MS (ES⁺): m/z = 376.15 (100) [MH⁺]. HPLC: t_R = 4.06 min (ZQ3, polar_5min). l-Cyclohexyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole Method C was followed, using bromocyclohexane equivalents (2 eq). The crude material was also purified by column chromatography on silica gel [0.5"x 10" glass column, eluting with CH₂C^EtOAc mixtures]. ¹H NMR (400 MHz, CDCl₃): δ = 1.32 (s, 12H), 1.39-1.50 (m, 2H), 1.60-1.80 (m, 4H), 1.88 (d, J= 13.4 Hz, 2H), 2.16 (d, J= 11.1 Hz, 2H), 4.04-4.20 (m, IH), 7.74 (s, IH), 7.78 (s, IH). MS (ES⁺): m/z = 277.16 (100) [MH⁺]. HPLC: t_R = 3.75 min (ZQ3, polar_5min).

Example 114: 3-Benzothiazol-2-yl-5-l-[l-(2-methoxyethyl)-piperidin-4-yl]-l//-pyrazol-4-yl- pyridin-2-ylamine

Method B was followed, except the crude material was purified by pTLC [Silicycle, 1000 μm, 20χ20cm plate, developed once in 2% 7N NH₃ (MeOH): EtOAc solvent system]; the desired band was scraped from the plate, the silica gel was rinsed well with copious amounts of the same solvent system, and the filtrate was concentrated in vacuo. The title material was recrystallized from hot heptane. ¹H NMR (400 MHz, CDCl₃): δ = 2.07-2.30 (m, 6H), 2.66 (t, J = 5.6 Hz, 2H), 3.14 (d, J = 11.6 Hz, 2H), 3.39 (s, 3H), 3.56 (t, J= 5.6 Hz, 2H), 4.16-4.27 (m, IH), 7.13 (br s, 2H), 7.42 (td, J= 7.6, 1.1 Hz, IH), 7.51 (add, J= 8.2, 7.2, 1.3 Hz, IH), 7.68 (d, J= 0.5 Hz, IH), 7.75 (d, J= 0.8 Hz, IH), 7.89-7.95 (m, IH), 7.99-8.05 (m, 2H), 8.33 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 435.16 (53) [MH⁺]. HPLC: t_R = 2.57 min (ZQ3, polar_5min).

Example 115: 3-Benzothiazol-2-yl-5-l-[l-(2,2,2-trifluoroethyl)-piperidin-4-yl]-lH-pyrazol-4- yl-pyridin-2-ylamine dihydrochloride

Method A was followed. ¹H NMR (400 MHz, DMSO-^₆) δ 2.16 (br s, 4H), 2.87 (br s, 2H), 3.24 (br s, 2H), 3.64 (br s, 2H), 4.23-4.40 (m, 2H), 7.53-7.60 (m, IH), 7.60-7.66 (m, IH), 8.09 (s, IH), 8.17 (dd, J= 7.7, 0.4 Hz, IH), 8.22-8.27 (m, IH), 8.53-8.57 (m, 2H), 8.63 (d, J= 1.8 Hz, IH), 8.91 (br s, IH). MS (AP⁺): m/z 459.11 (100) [MH⁺]. HPLC: t_R = 3.69 min (ZQ3, polar_5min).

3-Benzothiazol-2-yl-5-l-[l-(2,2,2-trifluoroethyl)-piperidin-4-yl]-l//-pyrazol-4-yl-pyridin-2- ylamine

Method B was followed, except 7N NH₃(MeOH^CH₂Cl₂ mixtures were required for column chromatography. ¹H NMR (400 MHz, CDCl₃): δ = 2.08-2.25 (m, 4H), 2.62 (td, J= 11.5, 2.8 Hz, 2H), 3.06 (q, J= 9.4 Hz, 2H), 3.14 (d, J= 11.9 Hz, 2H), 4.15-4.26 (m, IH), 7.12 (br s, 2H), 7.38-7.44 (m, IH), 7.50 (ddd, J= 8.3, 7.2, 1.1 Hz, IH), 7.67 (d, J= 0.5 Hz, IH), 7.76 (d, J= 0.5 Hz, IH), 7.91 (dd, J = 7.9, 0.6 Hz, IH), 7.98-8.04 (m, 2H), 8.33 (d, J= 2.0 Hz, IH). MS (AP⁺): m/z = 459.11 (100) [MH⁺]. HPLC: t_R = 3.69 min (ZQ3, polar_5min).

Example 116: 4-[4-(6-Amino-5-benzothiazol-2-yl-pyridin-3-yl)-pyrazol-l-yl]-piperidine-l- carboxamide bis-hydrochloride

Method A was followed, except the reaction was never concentrated in vacuo. The solid mixture was filtered off directly and rinsed with heptane. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 1.68-1.88 (m, 2H), 2.03 (dd, J= 12.1, 2.5 Hz, 2H), 2.88 (t, J= 11.8 Hz, 2H), 4.07 (d, J= 13.4 Hz, 2H), 4.39 (tt, J = 11.5, 4.1 Hz, IH), 5.99 (br s, IH), 7.52-7.59 (m, IH), 7.60-7.67 (m, IH), 8.06 (s, IH), 8.17 (d, J= 7.6 Hz, IH), 8.24 (dd, J= 7.8, 0.8 Hz, IH), 8.49-8.55 (m, 2H), 8.61 (s, IH), 8.86 (br s, IH). MS (ES⁺): m/z = 420.12 (100) [MH⁺]. HPLC: t_R = 2.66 min (ZQ3, polar_5min).

4-[4-(6-Amino-5-benzothiazol-2-yl-pyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxamide Method B was followed, except 7N NH₃(MeOH):EtOAc mixtures were required to isolate the title material. ¹H NMR (400 MHz, CDCl₃): δ = 1.99-2.17 (m, 2H), 2.26 (d, J= 12.4 Hz, 2H), 3.01-3.13 (m, 2H), 4.14 (d, J= 13.6 Hz, 2H), 4.38 (tt, J= 11.3, 4.1 Hz, IH), 4.51 (br s, 2H), 7.14 (br s, 2H), 7.39- 7.45 (m, IH), 7.51 (td, J= 7.7, 1.3 Hz, IH), 7.67 (s, IH), 7.78 (s, IH), 7.92 (d, J= 8.1 Hz, IH), 7.99- 8.05 (m, 2H), 8.33 (d, J= 2.3 Hz, IH). MS (ES⁺): m/z = 420.13 (100) [MH⁺]. HPLC: t_R = 2.66 min (ZQ3, polar_5min). Example 117: 4-[4-(6-Amino-5-benzothiazol-2-yl-pyridin-3-yl)-pyrazol-l-yl]-piperidine-l- carboxylic acid dimethylamide bis-hydrochloride

Method A was followed, except a mixture of CH₂Cl₂ and heptane was used to recrystallize the title compound. ¹H NMR (400 MHz, OMSO-d₆): δ = 1.84-1.97 (m, 2H), 2.06 (dd, J = 12.3, 2.7 Hz, 2H), 2.77 (s, 6H), 2.85-2.96 (m, 2H), 3.63-3.71 (m, 2H), 4.38 (tt, J = 11.5, 4.1 Hz, IH), 7.52-7.58 (m, IH), 7.59-7.65 (m, IH), 8.04 (s, IH), 8.15 (d, J= 7.6 Hz, IH), 8.22 (d, J= 7.3 Hz, IH), 8.50 (s, IH), 8.51- 8.54 (m, 2H), 8.67 (br s, IH). MS (ES⁺): m/z = 448.17 (100) [MH⁺]. HPLC: t_R = 3.05 min (ZQ3, polar_5min).

4-[4-(6-Amino-5-benzothiazol-2-yl-pyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid dimethylamide

Method B was followed, except, in addition to CH₂Cl₂:Et0Ac mixtures, 7N NH₃(MeOH) was required to completely elute the title compound. ¹H NMR (400 MHz, CDCl₃): δ = 2.01-2.16 (m, 2H), 2.17-2.28 (m, 2H), 2.89 (s, 6H), 2.91-3.01 (m, 2H), 3.84 (d, J= 13.4 Hz, 2H), 4.28-4.40 (m, IH), 7.13 (br s, 2H), 7.37-7.45 (m, IH), 7.51 (ddd, J= 8.2, 7.2, 1.3 Hz, IH), 7.69 (d, J= 0.5 Hz, IH), 7.77 (d, J = 0.5 Hz, IH), 7.92 (dd, J= 7.8, 0.5 Hz, IH), 7.98-8.05 (m, 2H), 8.34 (d, J= 2.0 Hz, IH). MS (ES⁺): m/z = 448.13 (100) [MH⁺]. HPLC: t_R= 3.05 min (ZQ3, polar_5min).

Example 118: 3-Benzothiazol-2-yl-5-(l-isopropyl-l//-pyrazol-4-yl)-pyridin-2-ylamine bis- hydrochloride Method A was followed, except heptane was used to recrystallize the title compound. ¹H NMR

(400 MHz, DMSO-(Z₆): δ = 1.41 (d, J= 6.8 Hz, 6H), 4.41-4.53 (m, IH), 7.45-7.53 (m, IH), 7.56 (dd, J = 8.1, 1.0 Hz, IH), 7.98 (s, IH), 8.10 (d, J= 8.1 Hz, IH), 8.18 (d, J= 7.8 Hz, IH), 8.42 (s, IH), 8.47 (d, J= 2.0 Hz, IH), 8.55 (d, J= 1.8 Hz, IH), 8.81 (br s, IH). MS (ES⁺): m/z = 336.12 (100) [MH⁺]. HPLC: t_R = 3.39 min (ZQ3, polar_5min). 3-Benzothiazol-2-yl-5-(l-isopropyl-l//-pyrazol-4-yl)-pyridin-2-ylamine

Method B was followed, except heptane and EtOAc mixtures were used to purify the title compound, which was then recrystallized from heptane. ¹H NMR (400 MHz, CDCl₃): δ = 1.59 (d, J = 6.6 Hz, 6H), 4.58 (septet, J= 6.7 Hz, IH), 7.12 (br s, 2H), 7.39-7.44 (m, IH), 7.51 (ddd, J= 8.2, 7.2, 1.3 Hz, IH), 7.67 (d, J= 0.5 Hz, IH), 7.76 (d, J= 0.5 Hz, IH), 7.91 (dd, J= 8.0, 0.6 Hz, IH), 8.00-8.04 (m, 2H), 8.35 (d, J= 2.0 Hz, IH). MS (ES⁺): m/z = 336.12 (100) [MH⁺]. HPLC: t_R = 3.39 min (ZQ3, polar_5min).

Example 119: 3-Benzothiazol-2-yl-5-(l-methyl-l//-pyrazol-4-yl)-pyridin-2-ylamine bis- hydrochloride Method A was followed, except hot heptane was used for trituration of the title compound. ¹H

NMR (400 MHz, DMSO-^₆): δ = 3.90 (s, 3H), 7.53-7.60 (m, IH), 7.60-7.67 (m, IH), 8.05 (d, J = 0.5 Hz, IH), 8.17 (d, J= 7.6 Hz, IH), 8.25 (d, J= 7.3 Hz, IH), 8.38 (s, IH), 8.54 (d, J= 2.3 Hz, IH), 8.63 (d, J= 2.0 Hz, IH), 9.03 (br s, IH). MS (ES⁺): m/z = 308.09 (100) [MH⁺]. HPLC: t_R = 3.04 min (ZQ3, polar_5min). 3-Benzothiazol-2-yl-5-(l-methyl-l//-pyrazol-4-yl)-pyridin-2-ylamine

Method B was followed. ¹H NMR (400 MHz, CDCl₃): δ = 3.99 (s, 3H), 7.13 (br s, 2H), 7.38-7.44 (m, IH), 7.51 (ddd, J= 8.2, 7.1, 1.1 Hz, IH), 7.62 (s, IH), 7.75 (d, J= 0.8 Hz, IH), 7.91 (dd, J= 7.8, 0.5 Hz, IH), 7.98-8.05 (m, 2H), 8.33 (d, J= 2.0 Hz, IH). MS (ES⁺): m/z = 308.09 (100) [MH⁺]. HPLC: t_R = 3.01 min (ZQ3, polar_5min).

Example 120: 3-Benzothiazol-2-yl-5-(2-morpholin-4-ylthiazol-5-yl)-pyridin-2-ylamine A solution of 4-(5-bromothiazol-2-yl)-morpholine (0.0600 g, 0.241 mmol), 3-benzothiazol-2-yl-5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (BB8) (0.110 g, 0.313 mmol), potassium carbonate (0.106 g, 0.771 mmol), and Pd(PPh₃)₄ (0.02 g, 0.02 mmol) in previously degassed DME/Water (4: 1) (2.7 mL) was placed in a microwave tube and evacuated and charged with N₂ (2^χ). The reaction mixture was heated in the microwave reactor at 100 ⁰C for 45 min. The reaction mixture was partitioned between CHCl₃ and H₂O and the layers were separated. The aqueous layer was re- extracted with CHCl₃ (3^χ), and the combined organic extracts were washed with brine (1 x), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was submitted for MDP for purification. The pure fractions were combined and the organic was concentrated in vacuo then diluted with CHCl₃ and neutralized with sat. NaHCO₃. The layers were separated, and the aqueous layer was re-extracted with CHCl₃ (3^χ). The combined organic extracts were dried over Na₂SO₄, filtered and concentrated in vacuo, giving the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 3.44 (d, J= 5.1 Hz, 4H), 3.73 (d, J= 5.1 Hz, 4H), 7.49 (t, J= 7.7 Hz, IH), 7.57 (t, J= 7.7 Hz, IH), 7.61 (s, IH), 8.00 (d, J= 2.2 Hz, IH), 8.03 (br. s., 2H), 8.10 (d, J= 7.7 Hz, IH), 8.15 (d, J= 7.3 Hz, IH), 8.36 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 396.07 (100) [MH⁺]. HPLC: t_R = 3.57 min (ZQ2, polar_5min).

Example 121 : 3-Benzothiazol-2-yl-5-[2-(4-methylpiperazin-l-yl)-thiazol-5-yl]-pyridin-2- ylamine dihydrochloride

A solution of l-(5-bromothiazol-2-yl)-4-methylpiperazine (0.0600 g, 0.229 mmol), 3-benzothiazol- 2-yl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (BB8) (0.105 g, 0.298 mmol), potassium carbonate (0.101 g, 0.732 mmol), and Pd(PPh₃)₄ (0.02 g, 0.02 mmol) in previously degassed DME/Water (4: 1) (2.54 mL) was placed in a microwave tube and evacuated and charged with N₂ (2^χ). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 45 min. A precipitate had formed from the reaction mixture and was filtered through a fritted funnel resulting in a brown solid. This solid was purified by chromatography on silica gel [eluting with 5% MeOH in CHCI₃] resulting in the title compound as a yellow solid. The solid was then dissolved in MeOH and charged with 3 equiv of IM HCl in ether and concentrated in vacuo resulting in the title compound as a dark yellow solid. ¹H NMR (400 MHz, DMSO-</₆): δ = 2.82 (d, J = 4.0 Hz, 3H), 3.13-3.26 (m, 2H), 3.46-3.58 (m, 4H), 4.07 (d, J = 15.4 Hz, 2H), 7.53 (t, J= 7.2 Hz, IH), 7.60 (t, J= 7.0 Hz, IH), 7.74 (s, IH), 8.13 (d, J= 7.7 Hz, IH), 8.18 (s, IH), 8.21 (d, J= 5.5 Hz, IH), 8.39 (d, J= 2.2 Hz, IH), 11.07 (br. s., IH). MS (ES+): m/z = 409.07 (100) [MH⁺]. HPLC: t_R = 2.13 min (ZQ2, polar_5min).

Example 122: 3-Benzothiazol-2-yl-5-(2-piperazin-l-ylthiazol-5-yl)-pyridin-2-ylamine dihydrochloride

A solution of 4-(5-bromothiazol-2-yl)-piperazine-l-carboxylic acid tert-butyl ester (0.079 g, 0.229 mmol), 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (BB8) (0.105 g, 0.298 mmol), potassium carbonate (0.101 g, 0.732 mmol), and Pd(PPh₃)₄ (0.018 g, 0.016 mmol) in previously degassed DME/H₂O (4: 1) (4.0 mL) was placed in a microwave tube and evacuated and charged with N₂ (2x). The reaction mixture was heated in the microwave reactor to 100 ⁰C for 30 min. The reaction mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified on prep-TLC eluting with 3% 7M NH₃ in MeOH/DCM yielding 4-[5-(6-ammo-5-benzothiazol-2-ylpyridin-3-yl)-thiazol-2-yl]-piperazme- 1-carboxylic acid tert-butyl ester, MS (ES+): m/z = 495.06 [MH⁺]. To a solution of this compound in DCM (1.0 mL) was added IM HCl in ether (2.0 mL, 2.0 mmol), and the mixture was stirred at room temperature overnight. The solid that formed was filtered off and purified on the MDP. To a solution of the material thus obtained in DCM (1.0 mL) was added IM HCl in ether (1.0 mL, 1.0 mmol). The precipitate was filtered off and dried in vacuo, yielding the title compound as yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.95-3.00 (m, 4H), 3.46-3.53 (m, 4H), 7.40 (s, IH), 7.42-7.48 (m, IH), 7.53 (dd, J= 15.3, 1.1 Hz, IH), 7.98-8.05 (m, 2H), 8.07 (d, J= 2.3 Hz, IH), 8.23 (d, J= 2.3 Hz, IH). MS (ES+): m/z = 395.06 (55) [MH⁺]. HPLC: t_R = 2.11 min (ZQ2, polar_5min). 4-(5-Bromothiazol-2-yl)-piperazine-l-carboxylic acid tert-buty\ ester

A solution of 2,5-dibromothiazole (1.00 g, 4.12 mmol) in DIPEA (3.00 mL) was charged with tert- butyl 1-piperazinecarboxylate (0.767 g, 4.12 mmol) and heated to 110 ⁰C for 3 h and then an additional 16 h at rt. The reaction mixture was partitioned between CHCl₃ and H₂O, and the layers were separated. The aqueous layer was re-extracted with CHCl₃ (3x) and the combined organic fractions were dried over Na₂SO₄, filtered and concentrated in vacuo. The crude material was purified by chromatography on silica gel [eluting with 0.5% EtOAc in CHCl₃] resulting in the title compound as a light orange solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.47 (s, 9H), 3.37-3.44 (m, 4H), 3.51-3.59 (m, 4H), 7.08 (s, IH). MS (ES+): m/z = 348.09 (51/49) [MH⁺]. HPLC: t_R = 3.73 min (ZQ2, polar_5min). Example 123: 4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-cyclohexanone

To a solution of 3-benzothiazol-2-yl-5-[l-(l,4-dioxaspiro[4.5]dec-8-yl)-lH-pyrazol-4-yl]-pyridin- 2-ylamine (0.750 g, 1.7 mmol) in dioxane (5 mL) was added 2 N HCl (1 mL), and the solution was stirred at RT for 1 h. The solvents were evaporated, and aq. satd. NaHCO₃ solution (30 mL) was added to the residue. The mixture was extracted with CH₂Cl₂ (3x40 mL), and the combined extracts were washed with water, dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude material was purified by column chromatography on silica gel using EtOAc/Hexanes (1 : 1) to give the title compound as yellow solid. ¹H NMR (400 MHz, CDCl₃): δ = 8.33 (d, J = 2.2 Hz, IH), 8.02 (dd, J = 8.4, 0.4 Hz, IH), 8.01 (d, J= 2.4 Hz, IH), 7.91 (ddd, J= 8.4, 1.2, 0.4 Hz, IH), 7.79 (d, J= 0.6 Hz, IH), 7.71 (d, J = 0.6 Hz, IH), 7.51 (ddd, J= 8.4, 7.4, 1.2 Hz, IH), 7.41 (ddd, J= 8.0, 7.4, 1.4 Hz, IH), 7.14 (brs, 2H), 4.72-4.64 (m_c, IH), 2.70-2.47 (m, 6H), 2.46-2.34 (m, 2H). MS(ES+): m/z = 390.14 (100) [MH⁺]. HPLC: t_R = 3.13 min (polar_5min, ZQ3).

Example 124 : 3-Benzothiazol-2-yl-5- [1-(1 ,4-dioxaspiro [4.5] dec-8-yl)-l//-pyrazol-4-yl] - pyridin-2-ylamine

The title compound was obtained as yellow solid following the procedure for 3-(5-chloro-8- fluoroisoquinolin-3-yl)-pyridin-2-ylamine, using l-(l,4-dioxaspiro[4.5]dec-8-yl)-4-iodo-lH-pyrazole (1.42 g, 4.2 mmol), 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-2- ylamine (BB8) (1.47 g, 4.2 mmol), Pd(PPh₃)₄ (0.08 g, 2 mol%), Cs₂CO₃ (3.28 g, 10 mmol). ¹H NMR (400 MHz, CDCl₃): δ = 8.33 (d, J= 2.2 Hz, IH), 8.02 (dd, J= 8.4, 0.4 Hz, IH), 8.01 (d, J= 2.0 Hz,

IH), 7.91 (ddd, J= 8.4, 1.2, 0.4 Hz, IH), 7.75 (d, J= 0.6 Hz, IH), 7.69 (d, J= 0.6 Hz, IH), 7.50 (ddd, J = 8.4, 7.0, 1.2 Hz, IH), 7.41 (ddd, J= 8.0, 7.4, 1.4 Hz, IH), 7.12 (brs, 2H), 4.33^.25 (m_c, IH), 4.00 (s, 4H), 2.27-2.09 (m, 4H), 1.97-1.90 (m, 2H), 1.78 (ddd, J= 4.4, 13.2, 13.2 Hz, 2H). MS(ES+): m/z = 434.14 (100) [MH⁺]. HPLC: t_R = 3.36 min (polar_5min, ZQ3). l-(l,4-Dioxaspiro[4.5]dec-8-yl)-4-iodo-l//-pyrazole

A mixture of toluene-4-sulfonic acid l,4-dioxaspiro[4.5]dec-8-yl ester (2.0 g, 6.4 mmol; prepared according to US 4360531 example LB), 4-iodopyrazole (1.36 g, 7.01 mmol), K₂CO₃ (1.06 g, 7.7 mmol), 18-crown-6 (0.2 g, 0.7 mmol) in DMF (5 mL) was heated under nitrogen at 50 ⁰C for 16 h. Water (50 mL) was added, and the reaction mixture was extracted with EtOAc (3x40 mL). The EtOAc extracts were washed with water (30 mL), dried over Na₂SO₄, filtered, and concentrated at reduced pressure. The crude material was purified by column chromatography on silica gel using EtOAc/CH₂Cl₂ (1 :9) to give the title compound. ¹H NMR (CDCl₃, 300 MHz): δ = 1.66-2.17 (m, 8H), 3.97 (s, 4H), 4.17-4.23 (m, IH), 7.27 (d, J= 3.3 Hz, IH), 7.48 (d, J= 3.3 Hz, IH). Example 125: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-carbamic acid tert- butyl ester

To a solution of 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (3.37 g, 11.0 mmol) in dioxane (50 mL) were added N-(Boc)-propargylamine (1.705 g, 11.0 mmol), Pd(PPh₃)₄ (0.250 g, 2 mol%), CuI (0.04 g), and NEt₃ (1.85 mL, 13.2 mmol). The mixture was heated under nitrogen at 80 ⁰C for 48 h. The reaction mixture was concentrated, taken up with CH₂Cl₂ (120 mL), washed with water (3x30 mL), dried over Na₂SO₄, filtered, and concentrated at reduced pressure. The crude material was purified by column chromatography on silica gel using EtOAc/Hexanes (1 :4) to give the title compound. ¹H NMR (CDCl₃, 300 MHz): δ = 1.56 (s, 9H), 4.22 (d, J = 2.4 Hz, 2H), 4.99 (bs, IH), 7.40-7.61 (m, 4H), 7.88 (d, J= 6.8 Hz, IH), 8.05-8.08 (m, 2H), 8.32 (d, J= 1.8 Hz, IH). MS (ES⁺): m/z = 381.14 (100) [MH⁺]. HPLC: t_R = 3.87 min (ZQ3, polar_5min).

Example 126: 5-(3-Aminoprop-l-ynyl)-3-benzothiazol-2-ylpyridin-2-ylamine

To a solution of [3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-carbamic acid tert- butyl ester (0.225 g, 0.6 mmol) in CH₂Cl₂ (5 mL) was added trifluoroacetic acid (0.5 mL, 6 mmol), and the mixture was stirred at RT for 2 h. Aq. satd. NaHCO₃ (20 mL) was added, and the mixture was extracted with CH₂Cl₂/Me0H (10%, 4x30 mL). The organic extracts were dried over Na₂SO₄, filtered, and concentrated at reduced pressure to give the title compound. ¹H NMR (CDCl₃, 300 MHz): δ = 3.78 (s, 2H), 7.42-7.58 (m, 2H), 7.88 (d, J = 6.8 Hz, IH), 8.05-8.07 (m, 2H), 8.32 (d, J= 1.8 Hz, IH). MS (ES⁺): m/z = 281.14 (100) [MH⁺]. HPLC: t_R = 2.01 min (ZQ2, polar_5min).

Example 127: 3-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-l,l-dimethylurea A mixture of 5-(3-aminoprop-l-ynyl)-3-benzothiazol-2-ylpyridin-2-ylamine (10.0 mg, 0.0357 mmol), N,N-dimethylcarbamoyl chloride (3.60 uL, 0.0392 mmol) , DMF (1 mL, 0.01 mol) and DIPEA (0.03 mL, 0.2 mmol) was stirred at rt for 30 min. The solution was used directly for HPLC purification. The fractions containing the pure product were concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.93 (s, 6H), 4.13^.18 (m, 2H), 7.39-7.45 (m, IH), 7.51 (td, J = 7.7, 1.3 Hz, IH), 7.96 (d, J = 7.3 Hz, IH), 8.01 (d, J = 8.1 Hz, IH), 8.09 (d, J = 2.0 Hz, lH), 8.14 (s, IH). MS (ES⁺): m/z = 352.11 (100) [MH⁺]. HPLC: t_R = 3.11 min (ZQ3, polar_5min).

Example 128: 4-Ethylpiperazine-l-carboxylic acid [3-(6-amino-5-benzothiazol-2-ylpyridin-3- yl)-prop-2-ynyl] -amide

The title compound was prepared according to the procedures described for 3-[3-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-l,l-dimethylurea. ¹H NMR (400 MHz, CD₃OD): δ = 1.13 (t, J = 7.3 Hz, 3H), 2.44-2.51 (m, 6H), 3.42-3.51 (m, 4H), 4.17 (s, 2H), 7.43-7.48 (m, IH), 7.54 (td, J = 7.7, 1.3 Hz, IH), 8.02 (dd, J = 12.6, 7.8 Hz, 2H), 8.13 (d, J = 2.0 Hz, IH), 8.17 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 422.11 (100) [MH⁺]. HPLC: t_R = 2.46 min (ZQ3, polar_5min).

Example 129 : [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl] -urea

A mixture of 5-(3-aminoprop-l-ynyl)-3-benzothiazol-2-ylpyridin-2-ylamine (10.0 mg, 0.0357 mmol), trimethylsilyl isocyanate (5.31 uL, 0.0392 mmol), DMF (1 mL, 0.01 mol) and DIPEA (0.03 mL, 0.2 mmol) was stirred at rt for 3 h. The solution was used directly for HPLC purification. The fractions containing the pure product were concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 4.14 (s, 2H), 7.39-7.45 (m, IH), 7.47-7.52 (m, IH), 7.93 (s, IH), 8.00 (d, J = 7.8 Hz, IH), 8.06 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 324.10 (100) [MH⁺]. HPLC: t_R = 2.85 min (ZQ3, polar_5min).

Example 130: Λ'-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-2- dimethylaminoacetamide

A mixture of 5-(3-aminoprop-l-ynyl)-3-benzothiazol-2-ylpyridin-2-ylamine (10.0 mg, 0.0357 mmol), dimethylaminoacetic acid (4.05 mg, 0.0392 mmol), TBTU (17.2 mg, 0.0535 mmol), DMF (1 mL, 0.01 mol) and DIPEA (0.03 mL, 0.0002 mol) was stirred at rt for 30 min. The solution was used directly for HPLC purification. The fractions containing the pure product were concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.66 (br. s., 6H), 3.54 (br. s., 2H), 4.28 (s, 2H), 7.42-7.47 (m, IH), 7.53 (td, J = 7.7, 1.3 Hz, IH), 7.99 (d, J = 7.3 Hz, IH), 8.03 (d, J = 7.6 Hz, IH), 8.09 (d, J = 2.0 Hz, IH), 8.15 (d, J = 1.8 Hz, IH). MS (ES⁺): m/z = 366.13 (100) [MH⁺]. HPLC: t_R = 2 A3 min (ZQ3, polar_5min).

Example 131 : Λ'-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-2-pyrrolidin-l- ylacetamide The title compound was prepared according to the procedures described for N-[3-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-prop-2-ynyl]-2-dimethylaminoacetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.06 (br. s., 4H), 3.27 (br. s., 4H), 3.88 (s, 2H), 4.29 (s, 2H), 7.41-7.47 (m, IH), 7.49- 7.55 (m, IH), 7.97 (d, J = 8.1 Hz, IH), 8.02 (d, J = 8.1 Hz, IH), 8.06 (d, J = 2.0 Hz, IH), 8.15 (d, J = 1.8 Hz, IH). MS (ES⁺): m/z = 392.12 [MH⁺]. HPLC: t_R = 2.49min (ZQ3, polar_5min).

Example 132: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4- ylethanone

A mixture of [4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-acetic acid (5.00 mg, 0.0142 mmol), morpholine (10.0 mg, 0.11 mmol), TBTU (9.14 mg, 0.0284 mmol), DIPEA (0.02 mL, 0.1 mmol) and DMF (2 mL, 0.03 mol) was stirred at rt for 10 min. The solution was transferred to a separatory funnel, diluted with EtOAc and washed 3 x with water. The organic layer was concentrated in vacuo and loaded onto a prep TLC plate, eluting with 5% MeOH / DCM. The band containing the pure product was filtered off using 1 : 1 MeOH / DCM, and the filtrate was concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 3.60-3.64 (m, 4H), 3.72 (dt, J = 12.8, 4.7 Hz, 4H), 5.17 (s, 2H), 7.40-7.45 (m, IH), 7.48-7.54 (m, IH), 7.85 (s, IH), 7.94-7.98 (m, 2H), 8.02 (d, J = 7.8 Hz, IH), 8.16 (d, J = 2.3 Hz, IH), 8.30 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 421.12 (100) [MH⁺]. HPLC: t_R = 2.79 min (ZQ3, polar_5min).

[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-acetic acid

A mixture of (4-iodopyrazol- 1 -yl)-acetic acid methyl ester (124 mg, 0.467 mmol), 3-benzothiazol- 2-yl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (BB8) (150.0 mg, 0.4246 mmol), Pd(PPh₃ )₄ (40 mg, 0.03 mmol), potassium fluoride (74.0 mg, 1.27 mmol) and 4: 1 dioxane:water (4: 1, l,4-dioxane:H₂O, 6 mL) was heated in the microwave reactor at 85 ⁰C for 30 min. The solution was concentrated in vacuo and dry-loaded onto silica gel for column chromatography. The material was eluted with 2% MeOH / DCM. The fractions containing the product were concentrated in vacuo. The material was redissolved in 1,4-dioxane (5 mL), and 4M HCl in 1,4-dioxane (1 mL) was added. The solution was heated to 50 ⁰C in a sealed tube for 3 h. The solvent was removed in the corrosive pump to afford the title compound as an orange solid. MS (ES⁺): m/z = 352.08 (100) [MH⁺]. HPLC: t_R = 2.78 min (ZQ3, polar_5min).

(4-Iodopyrazol-l-yl)-acetic acid methyl ester:

A mixture of 4-iodopyrazole (1.000 g, 5.155 mmol), Cs₂CO₃ (2.016 g, 6.186 mmol) and DMF (20 mL, 0.2 mol) was added chloroacetic acid methyl ester (0.5440 mL, 6.186 mol) at 0 ⁰C. The reaction was allowed to stir for 1 h at rt. The material was transferred to a separatory funnel, diluted with EtOAc, and washed with water several times to remove DMF. The organic layer was dry-loaded onto silica gel, and column chromatography was used to purify, eluting with 3 : 1 Hexanes / EtOAc, affording the title compound as a clear liquid. ¹H NMR (400 MHz, CDCl₃): δ = 3.79 (s, 3H), 4.93 (s, 2H), 7.54 (s, IH), 7.57 (s, IH). MS (ES⁺): m/z = 266.95 (100) [MH⁺]. HPLC: t_R = 2.73 min (ZQ3, polar_5min).

Example 133: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-pyrrolidin-l- ylethanone

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 1.89-1.95 (m, 2H), 2.05 (quintet, J = 6.8 Hz, 2H), 3.49 (t, J = 6.9 Hz, 2H), 3.58 (t, J = 6.8 Hz, 2H), 5.03 (s, 2H), 7.38-7.43 (m, IH), 7.49 (td, J = 7.6, 1.4 Hz, IH), 7.80 (s, IH), 7.90-7.94 (m, 2H), 7.99 (d, J = 7.6 Hz, IH), 8.12 (d, J = 2.3 Hz, IH), 8.27 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 405.15 (100) [MH⁺]. HPLC: t_R = 2.88 min (ZQ3, polar_5min). Example 134: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^r-(2- methoxyethyl)-acetamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 3.35 (s, 3H), 3.41-3.45 (m, 2H), 3.45-3.49 (m, 2H), 4.88 (s, 2H), 7.41 (t, J = 7.6 Hz, IH), 7.49 (t, J = 7.7 Hz, IH), 7.84 (s, IH), 7.93 (d, J = 8.1 Hz, IH), 7.96 (s, IH), 7.99 (d, J = 8.1 Hz, IH), 8.12 (d, J = 2.0 Hz, IH), 8.27 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 409.12 (100) [MH⁺]. HPLC: t_R = 2.75 min (ZQ3, polar_5min).

Example 135: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-(3- hydroxypyrrolidin-l-yl)-ethanone

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 1.98 (dd, J = 8.5, 4.2 Hz, IH), 2.11 (dd, J = 9.1, 4.3 Hz, IH), 3.52-3.75 (m, 4H), 4.43-4.53 (m, IH), 5.01-5.09 (m, 2H), 7.38-7.43 (m, IH), 7.49 (td, J = 7.7, 1.3 Hz, IH), 7.81 (s, IH), 7.94 (t, J = 3.7 Hz, 2H), 8.00 (d, J = 7.8 Hz, IH), 8.13 (d, J = 2.3 Hz, IH), 8.27 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 421.07 (100) [MH⁺]. HPLC: t_R = 2.29 min (ZQ2, polar_5min).

Example 136: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-iV-(2- hydroxyethyl)-acetamide The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 3.35-3.39 (m, 2H), 3.63 (td, J = 5.4, 2.0 Hz, 2H), 4.89 (d, J = 1.8 Hz, 2H), 7.40-7.45 (m, IH), 7.51 (t, J = 7.7 Hz, IH), 7.85 (d, J = 1.5 Hz, IH), 7.95 (d, J = 7.8 Hz, IH), 7.98 (d, J = 1.5 Hz, IH), 8.01 (d, J = 8.1 Hz, IH), 8.14 (t, J = 2.3 Hz, IH), 8.29 (t, J = 2.1 Hz, IH). MS (ES⁺): m/z = 395.07 (100) [MH⁺]. HPLC: t_R = 2.27 min (ZQ2, polar_5min).

Example 137: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^r- methylacetamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 2.79 (s, 3H), 4.86 (s, 2H), 7.39-7.44 (m, IH), 7.47-7.53 (m, IH), 7.84 (s, IH), 7.92-7.97 (m, 2H), 8.01 (d, J = 7.6 Hz, IH), 8.14 (d, J = 2.3 Hz, IH), 8.28 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 365.11 (100) [MH⁺]. HPLC: t_R = 2.63 min (ZQ3, polar_5min). Example 138: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ',Λ'-bis-(2- methoxyethyl)-acetamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 3.34 (s, 3H), 3.43 (s, 3H), 3.54-3.58 (m, 2H), 3.60-3.64 (m, 4H), 3.71 (t, J = 4.9 Hz, 2H), 5.28 (s, 2H), 7.40-7.46 (m, IH), 7.49-7.53 (m, IH), 7.83 (s, IH), 7.93 (s, IH), 7.97 (d, J = 7.3 Hz, IH), 8.02 (d, J = 7.6 Hz, IH), 8.16 (d, J = 2.0 Hz, IH), 8.30 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 467.16 (100) [MH⁺]. HPLC: t_R = 2.95 min (ZQ3, polar_5min).

Example 139: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-(4- hydroxypiperidin-l-yl)-ethanone

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 1.46-1.60 (m, 2H), 1.84-1.96 (m, 2H), 3.26 (ddd, J = 13.2, 9.4, 3.4 Hz, IH), 3.33-3.40 (m, IH), 3.80-3.93 (m, 2H), 4.01 (d, J = 4.3 Hz, IH), 5.16 (s, 2H), 7.41 (t, J = 7.6 Hz, IH), 7.50 (t, J = 7.7 Hz, IH), 7.82 (s, IH), 7.92 (s, IH), 7.95 (d, J = 8.1 Hz, IH), 8.00 (d, J = 8.1 Hz, IH), 8.14 (d, J = 2.3 Hz, IH), 8.28 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 435.15 (100) [MH⁺]. HPLC: t_R = 2.54 min (ZQ3, polar_5min).

Example 140: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^/,Λ^/- dimethylacetamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 3.01 (s, 3H), 3.15 (s, 3H), 5.15 (s, 2H), 7.40-7.45 (m, IH), 7.51 (td, J = 7.7, 1.3 Hz, IH), 7.83 (s, IH), 7.94 (s, IH), 7.96 (d, J = 7.3 Hz, IH), 8.01 (d, J = 7.6 Hz, IH), 8.15 (d, J = 2.3 Hz, IH), 8.29 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 379.15 (100) [MH⁺]. HPLC: t_R = 2.70 min (ZQ3, polar_5min).

Example 141 : 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-piperidin-l- ylethanone

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylethanone. ¹H NMR (400 MHz, CD₃OD): δ = 1.59 (d, J = 5.1 Hz, 2H), 1.64-1.74 (m, 4H), 3.52-3.60 (m, 4H), 5.13 (s, 2H), 7.42 (t, J = 7.6 Hz, IH), 7.50 (t, J = 7.7 Hz, IH), 7.82 (s, IH), 7.91 (s, IH), 7.95 (d, J = 7.8 Hz, IH), 8.00 (d, J = 7.8 Hz, IH), 8.14 (t, J = 2.3 Hz, IH), 8.27-8.30 (m, IH). MS (ES⁺): m/z = 419.17 (100) [MH⁺]. HPLC: t_R = 3.08 min (ZQ3, polar_5min). Example 142: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4- ylpropan-1-one

A mixture of 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-propionic acid (5.00 mg, 0.0142 mmol), morpholine (10.0 mg, 0.11 mmol), TBTU (9.14 mg, 0.0284 mmol), DIPEA (0.02 mL, 0.1 mmol) and DMF (2 mL, 0.03 mol) was stirred at rt for 10 min. The solution was transferred to a separatory funnel, diluted with EtOAc and washed 3 x with water. The organic layer was concentrated in vacuo and loaded onto a prep TLC plate, eluting with 5% MeOH / DCM. The band containing the pure product was filtered off using 1 : 1 MeOH / DCM, and the filtrate was concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 1.74 (d, J = 7.1 Hz, 3H), 3.50-3.72 (m, 8H), 5.62 (q, J = 7.1 Hz, IH), 7.42-7.47 (m, IH), 7.50-7.56 (m, IH), 7.88 (s, IH), 8.01 (dd, J = 10.7, 8.2 Hz, 2H), 8.17 (s, IH), 8.21 (d, J = 2.0 Hz, IH), 8.34 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 435.16 (100) [MH⁺]. HPLC: t_R = 2.89 min (ZQ3, polar_5min).

2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-propionic acid

The title compound was prepared according to the procedures described for [4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl] -acetic acid methyl ester. MS (ES⁺): m/z = 366.13 (100) [MH⁺]. HPLC: t_R = 2.90 min (ZQ3, polar_5min).

2-(4-Iodopyrazol-l-yl)-propionic acid methyl ester

The title compound was prepared according to the procedures described for (4-iodopyrazol- 1 -yl)- acetic acid methyl ester. ¹H NMR (400 MHz, CDCl₃): δ = 1.79 (d, J = 7.6 Hz, 3H), 3.76 (s, 3H), 5.11 (q, J = 7.3 Hz, IH), 7.55 (s, IH), 7.60 (s, IH).

Example 143: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ',Λ'-bis-(2- methoxyethyl)-propionamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.70 (d, J = 6.8 Hz, 3H), 3.30 (s, 3H), 3.38 (s, 3H), 3.48-3.67 (m, 7H), 3.88-3.98 (m,

IH), 5.72 (q, J = 6.8 Hz, IH), 7.40-7.45 (m, IH), 7.51 (td, J = 7.7, 1.3 Hz, IH), 7.84 (s, IH), 7.96-8.03 (m, 2H), 8.10 (s, IH), 8.17 (d, J = 2.0 Hz, IH), 8.31 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 481.14 (100) [MH⁺]. HPLC: t_R = 2.96 min (ZQ2, polar_5min).

Example 144: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^/- methylpropionamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.78 (d, J = 7.1 Hz, 3H), 2.76 (s, 3H), 5.02 (q, J = 7.1 Hz, IH), 7.38-7.44 (m, IH), 7.49 (td, J = 7.7, 1.3 Hz, IH), 7.83 (s, IH), 7.94 (d, J = 8.1 Hz, IH), 8.00 (d, J = 8.1 Hz, IH), 8.07 (s, IH), 8.14 (d, J = 2.3 Hz, IH), 8.29 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 379.14 (100) [MH⁺]. HPLC: f_R = 2.79 min (ZQ3, polar_5min).

Example 145: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-propionamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-l -morpholin-4-ylpropan- 1 -one. ¹H NMR (400 MHz,

CD₃OD): δ = 1.81 (d, J = 7.3 Hz, 3H), 5.07 (q, J = 7.3 Hz, IH), 7.39-7.45 (m, IH), 7.50 (td, J = 7.7, 1.3 Hz, IH), 7.86 (s, IH), 7.96 (d, J = 7.8 Hz, IH), 8.01 (d, J = 8.3 Hz, IH), 8.09 (s, IH), 8.16 (d, J = 2.3 Hz, IH), 8.30 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 365.11 (100) [MH⁺]. HPLC: t_R = 2.68 min (ZQ3, polar_5min).

Example 146: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^r-(2- methoxyethyl)-propionamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.79 (d, J = 7.1 Hz, 3H), 3.34 (s, 3H), 3.37-3.42 (m, 2H), 3.43-3.48 (m, 2H), 5.05 (q, J = 7.2 Hz, IH), 7.38-7.44 (m, IH), 7.47-7.52 (m, IH), 7.83 (s, IH), 7.94 (d, J = 7.6 Hz, IH), 8.00 (d, J = 7.8 Hz, IH), 8.04 (s, IH), 8.12 (d, J = 2.3 Hz, IH), 8.28 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 423.16 (100) [MH⁺]. HPLC: t_R = 2.87 min (ZQ3, polar_5min).

Example 147: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-iV-(2- hydroxyethyl)-propionamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.80 (d, J = 7.1 Hz, 3H), 3.33-3.37 (m, 2H), 3.62 (t, J = 5.6 Hz, 2H), 5.06 (q, J = 7.2 Hz, IH), 7.40-7.45 (m, IH), 7.48-7.53 (m, IH), 7.85 (s, IH), 7.95 (d, J = 7.3 Hz, IH), 8.01 (d, J = 7.8 Hz, IH), 8.08 (s, IH), 8.16 (d, J = 2.0 Hz, IH), 8.29 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 409.14 (100) [MH⁺]. HPLC: t_R = 2.61 min (ZQ3, polar_5min).

Example 148: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ',Λ'- dimethylpropionamide

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.72 (d, J = 7.1 Hz, 3H), 2.99 (s, 3H), 3.12-3.18 (m, 3H), 5.55 (q, J = 6.9 Hz, IH), 7.40 (t, J = 7.6 Hz, IH), 7.46-7.52 (m, IH), 7.77 (s, IH), 7.93 (d, J = 7.8 Hz, IH), 7.98-8.01 (m, 2H), 8.11 (d, J = 2.3 Hz, IH), 8.27 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 393.14 (100) [MH⁺]. HPLC: fc = 2.90 min (ZQ3, polar_5min).

Example 149: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-p yrazol-l-yl]-l-(3- hydroxypyrrolidin-l-yl)-propan-l-one The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.76 (td, J = 7.2, 3.5 Hz, 3H), 1.89-2.14 (m, 2H), 3.49-3.67 (m, 3H), 3.73-3.81 (m, IH), 4.39-4.52 (m, IH), 5.36-5.50 (m, IH), 7.44 (t, J = 7.3 Hz, IH), 7.50-7.55 (m, IH), 7.87 (s, IH), 8.01 (dd, J = 10.7, 8.0 Hz, 2H), 8.16-8.21 (m, 2H), 8.34 (br. s., IH). MS (ES⁺): m/z = 435.16 (100) [MH⁺]. HPLC: t_R = 2.65 min (ZQ3, polar_5min).

Example l50: 2- [4-(6- Amino-5-benzothiazol-2-ylpy ridin-3-yl)-py razol- 1 -yl] -1 -(4- hydroxypiperidin-l-yl)-propan-l-one

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz,

CD₃OD): δ = 1.31-1.45 (m, IH), 1.46-1.58 (m, J = 16.5, 8.3, 8.3, 3.9 Hz, IH), 1.72 (t, J = 6.9 Hz, 3H), 1.77-1.93 (m, 2H), 3.32-3.48 (m, 2H), 3.80-3.99 (m, 2H), 4.18 (d, J = 12.9 Hz, IH), 5.60-5.68 (m, IH), 7.40-7.45 (m, IH), 7.51 (td, J = 7.7, 1.3 Hz, IH), 7.86 (d, J = 5.8 Hz, IH), 7.97-8.03 (m, 2H), 8.14 (s, IH), 8.18 (d, J = 2.0 Hz, IH), 8.32 (s, IH). MS (ES⁺): m/z = 449.15 (100) [MH⁺]. HPLC: f_R = 2.69 min (ZQ3, polar_5min).

Example 151: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-pyrrolidin-l- ylpropan-1-one

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz,

CD₃OD): δ = 1.75 (d, J = 7.1 Hz, 3H), 1.87-1.95 (m, 2H), 1.97-2.05 (m, 2H), 3.47 (t, J = 7.1 Hz, 2H), 3.53-3.70 (m, 2H), 5.43 (q, J = 7.1 Hz, IH), 7.41-7.46 (m, IH), 7.50-7.55 (m, IH), 7.87 (s, IH), 8.01 (dd, J = 11.0, 7.7 Hz, 2H), 8.18 (s, IH), 8.20 (d, J = 2.3 Hz, IH), 8.34 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 419.15 (100) [MH⁺]. HPLC: t_R = 3.05 min (ZQ3, polar_5min).

Example 152: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-piperidin-l- ylpropan-1-one

The title compound was prepared according to the procedures described for 2-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4-ylpropan-l-one. ¹H NMR (400 MHz, CD₃OD): δ = 1.44 (td, J = 7.3, 3.9 Hz, IH), 1.53-1.62 (m, 3H), 1.64-1.68 (m, 2H), 1.72 (d, J = 7.1 Hz, 3H), 3.41-3.50 (m, IH), 3.52-3.59 (m, IH), 3.61-3.75 (m, 2H), 5.62 (q, J = 6.9 Hz, IH), 7.40-7.46 (m, IH), 7.52 (td, J = 7.6, 1.3 Hz, IH), 7.86 (s, IH), 8.00 (dd, J = 10.9, 7.8 Hz, 2H), 8.14 (s, IH), 8.18- 8.20 (m, IH), 8.32 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 433.18 (100) [MH⁺]. HPLC: t_R = 3.30 min (ZQ3, polar_5min).

Example 153: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-pyrrolidin-l- ylpropan-1-one

A mixture of 3-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-propionic acid (7.0 mg, 0.013 mmol), pyrrolidine (9 mg, 0.1 mmol), TBTU (8.24 mg, 0.0257 mmol), DIPEA (0.02 mL, 0.1 mmol), and DMF (2 mL, 0.02 mol) was stirred at rt for 10 min. The solution was transferred to a separatory funnel, diluted with EtOAc and washed 3 x with water. The organic layer was concentrated in vacuo and loaded onto a prep TLC plate, eluting with 5% MeOH / DCM. The band containing the pure product was filtered off using 1 : 1 MeOH / DCM, and the filtrate was concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 1.85 (q, J = 6.4 Hz, 2H), 1.88-1.96 (m, 2H), 2.92 (t, J = 6.6 Hz, 2H), 3.39 (q, J = 7.1 Hz, 4H), 4.49 (t, J = 6.6 Hz, 2H), 7.39-7.44 (m, IH), 7.47-7.52 (m, IH), 7.81 (s, IH), 7.94-7.97 (m, 2H), 8.00 (d, J = 7.8 Hz, IH), 8.12 (d, J = 2.3 Hz, IH), 8.27 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 419.13 (100) [MH⁺]. HPLC: t_R = 2.99 min (ZQ3, polar_5min).

3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-propionic acid

A mixture of 3-(4-iodopyrazol-l-yl)-propionic acid methyl ester (174 mg, 0.623 mmol), 3- benzothiazol-2-yl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-pyridin-2-ylamine (200.0 mg, 0.5662 mmol), Pd(PPh₃ )₄ (50 mg, 0.04 mmol), potassium fluoride (98.7 mg, 1.70 mmol), and 4: 1 dioxane:water (4: 1, l,4-dioxane:H₂O, 8 mL) was heated in the microwave reactor at 85 ⁰C for 30 min. The solution was concentrated in vacuo, and dry-loaded onto silica gel for column chromatography. The material was eluted with 2% MeOH / DCM. The fractions containing the product were concentrated in vacuo. The material was dissolved in cone. HCl (4 mL) and heated to 60 ⁰C for 30 min in a sealed tube. The solvent was removed using the corrosive pump to afford the title compound as an orange solid. MS (ES⁺): m/z = 366.14 (100) [MH⁺]. HPLC: t_R = 2.59 min (ZQ2, polar_5min). 3-(4-Iodopyrazol-l-yl)-propionic acid methyl ester To a mixture of 4-iodopyrazole (1.000 g, 5.155 mmol), Cs₂CO₃ (2.016 g, 6.186 mmol), and DMF (20 mL, 0.2 mol) was added methyl 3-chloropropanoate (758.1 mg, 6.186 mmol) at 0 ⁰C. The reaction was heated to 50 ⁰C for 1 h. The material was transferred to a separatory funnel, diluted with EtOAc, and washed with water several times to remove DMF. The organic layer was dry-loaded onto silica gel, and column chromatography was used for purification, eluting with 3: lHexanes / EtOAc, affording the title compound as a clear liquid. MS (ES⁺): m/z = 280.95 (100) [MH⁺]. HPLC: t_R = 2.91 min (ZQ3, polar_5min). Example 154: (25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidine-2-carboxylic acid

A mixture of 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-2- ylamine (BB8) (200 mg, 0.566 mmol), (2S,4S)-4-(4-iodopyrazol-l-yl)-pyrrolidine-l,2-dicarboxylic acid 1 -benzyl ester 2-methyl ester (309.0 mg, 0.679 mmol), Pd(PPh₃)₄ (60 mg, 0.06 mmol), potassium fluoride (98.7 mg, 1.70 mmol), and 4: 1 dioxane:water (5 mL) was heated in the microwave reactor at 85 ⁰C for 30 min. The material was concentrated in vacuo, then dry-loaded onto silica gel for column chromatography. The product was eluted with 2— >5% MeOH / DCM, and the fractions containing the product were concentrated in vacuo. The material was dissolved in cone. HCl, transferred to a sealed tube and heated at 60 ⁰C for 2 h. The solvent was removed using the corrosive pump to afford the title compound as a brown solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.73 (ddd, J = 14.0, 6.5, 4.5 Hz, IH), 3.07 (ddd, J = 14.1, 10.0, 7.5 Hz, IH), 3.81-3.93 (m, 2H), 4.68 (dd, J = 10.0, 6.7 Hz, IH), 5.36 (ddd, J = 6.8, 3.8, 3.5 Hz, IH), 7.56-7.63 (m, 2H), 8.05 (s, IH), 8.08-8.11 (m, IH), 8.16 (d, J = 7.6 Hz, IH), 8.32-8.36 (m, 2H), 8.72 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 407.13 (100) [MH⁺]. HPLC: t_R = 2.28 min (ZQ2, polar_5min).

Example 155: (25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidine-2-carboxylic acid dimethylamide

To a solution of (2S,4S)-4-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine- 2-carboxylic acid (5.00 mg, 0.00969 mmol) in DMF (2 mL) at rt were added dimethylamine hydrochloride (20 mg, 0.25 mmol) and DIPEA (0.1 mL, 0.6 mmol), and the mixture was stirred for 1 min. TBTU (6.22 mg, 0.0194 mmol) was then added, and the solution was stirred for 10 min. The material was transferred to a separatory funnel. T he organic layer was washed with water, and concentrated in vacuo. The material was loaded onto a prep TLC plate, eluting with 6% (7N NH₃ in MeOH) / DCM. The band containing the product was collected and filtered off with 1 : 1 MeOH /

DCM. The filtrate was concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.15-2.21 (m, IH), 2.82-2.91 (m, IH), 3.00 (s, 3H), 3.12 (s, 3H), 3.23 (dd, J = 12.4, 6.3 Hz, IH), 3.49 (dd, J = 12.0, 3.4 Hz, IH), 4.15 (t, J = 8.3 Hz, IH), 4.98-5.05 (m, IH), 7.42- 7.47 (m, IH), 7.53 (td, J = 7.7, 1.3 Hz, IH), 7.85 (s, IH), 8.02 (dd, J = 11.6, 7.8 Hz, 2H), 8.13 (s, IH), 8.20 (d, J = 2.3 Hz, IH), 8.32 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 434.14 (100) [MH⁺]. HPLC: t_R = 2.12 min (ZQ2, polar_5min).

Example 156: {(25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-pyrrolidin-l-ylmethanone The title compound was prepared according to the procedures described for (2S,4S)-4-[4-(6-amino-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.92 (q, J = 6.8 Hz, 2H), 1.98-2.03 (m, 2H), 2.21 (ddd, J = 13.4, 7.8, 5.3 Hz, IH), 2.85 (dt, J = 13.6, 8.2 Hz, IH), 3.23 (dd, J = 12.4, 6.6 Hz, IH), 3.43-3.53 (m, 4H), 3.64 (dt, J = 10.3, 6.6 Hz, IH), 4.01 (t, J = 8.1 Hz, IH), 4.98-5.04 (m, IH), 7.41-7.46 (m, IH), 7.49-7.54 (m, IH), 7.84 (s, IH), 8.00 (dd, J = 11.4, 7.8 Hz, 2H), 8.15 (s, IH), 8.16-8.19 (m, IH), 8.31 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 460.10 (100) [MH⁺]. HPLC: t_R = 2.12 min (ZQ2, polar_5min).

Example 157: {(25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-morpholin-4-ylmethanone The title compound was prepared according to the procedures described for (2S,4S)-4-[4-(6-amino-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): 8 = 2.17-2.27 (m, IH), 2.84 (dt, J = 13.6, 8.3 Hz, IH), 3.24 (dd, J = 12.4, 6.6 Hz, IH), 3.50 (dd, J = 12.5, 3.4 Hz, IH), 3.58-3.74 (m, 8H), 4.14 (t, J = 8.2 Hz, IH), 4.98-5.03 (m, IH), 7.43-7.47 (_m> IH), 7.53 (td, J = 7.7, 1.3 Hz, IH), 7.85 (s, IH), 8.02 (dd, J = 11.2, 7.5 Hz, 2H), 8.13 (s, IH), 8.19 (d, J = 2.3 Hz, IH), 8.32 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 476.14 (100) [MH⁺]. HPLC: ?_R = 2.10 min (ZQ2, polar_5min).

Example 158: {(25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-piperidin-l-ylmethanone The title compound was prepared according to the procedures described for (2S,4S)-4-[4-(6-amino-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.55-1.72 (m, 6H), 2.13-2.19 (m, IH), 2.84 (dt, J = 13.6, 8.2 Hz, IH), 3.22 (dd, J = 12.4, 6.6 Hz, IH), 3.47-3.61 (m, 5H), 4.13 (t, J = 8.3 Hz, IH), 4.98-5.04 (m, IH), 7.42-7.47 (m, IH), 7.53 (td, J = 7.7, 1.3 Hz, IH), 7.85 (s, IH), 8.01 (dd, J = 11.9, 7.8 Hz, 2H), 8.11 (s, IH), 8.19 (d, J = 2.0 Hz, IH), 8.32 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 474.13 (100) [MH⁺]. HPLC: t_R = 2.21 min (ZQ2, polar_5min).

Example 159: {(25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-(3-hydroxypyrrolidin-l-yl)-methanone The title compound was prepared according to the procedures described for (2S,4S)-4-[4-(6-amino-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.86-1.95 (m, IH), 1.97-2.07 (m, IH), 2.16 (s, IH), 2.78 (d, J = 8.8 Hz, IH), 3.15 (dd, J = 11.9, 5.8 Hz, IH), 3.37-3.44 (m, 2H), 3.47-3.56 (m, 2H), 3.64 (d, J = 14.7 Hz, IH), 3.91- 3.99 (m, IH), 4.30-4.42 (m, IH), 4.89-4.96 (m, IH), 7.33-7.38 (m, IH), 7.41-7.46 (m, IH), 7.75 (s, IH), 7.92 (dd, J = 11.0, 8.2 Hz, 2H), 8.05-8.08 (m, IH), 8.10 (t, J = 1.8 Hz, IH), 8.23 (s, IH). MS (ES⁺): m/z = 476.09 (100) [MH⁺]. HPLC: t_R = 2.00 min (ZQ2, polar_5min).

Example 160: {(25',45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-azetidin-l-ylmethanone The title compound was prepared according to the procedures described for (2S,4S)-4-[4-(6-ammo-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.23 (ddd, J = 13.6, 8.0, 5.4 Hz, IH), 2.32-2.41 (m, 2H), 2.70-2.79 (m, IH), 3.21-3.27 (m, IH), 3.40-3.48 (m, IH), 3.82 (t, J = 8.2 Hz, IH), 4.02-4.11 (m, 2H), 4.24-4.39 (m, 2H), 4.99 (br. s., IH), 7.43-7.47 (m, IH), 7.53 (td, J = 7.7, 1.3 Hz, IH), 7.85 (s, IH), 8.02 (dd, J = 11.2, 8.0 Hz, 2H), 8.18 (s, IH), 8.20 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 446.09 (100) [MH⁺]. HPLC: t_R = 2.05 min (ZQ2, polar_5min).

Example 161: {4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}- acetic acid A mixture of 3-benzothiazol-2-yl-5-(l -piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine (211.0 mg, 0.5604 mmol), Cs₂CO₃ (730 mg, 2.24 mmol), and DMF (10 mL, 0.1 mol) at 0 ⁰C was charged with methyl chloroacetate (0.0493 mL, 0.560 mmol) and then heated at 40 ⁰C overnight. The solvent was removed in vacuo, and the material was dry-loaded onto silica gel for column chromatography, eluting with 2— >5% MeOH / DCM. The fractions containing the pure ester were concentrated in vacuo and redissolved in cone. HCl. The material was transferred to a sealed tube, and heated overnight at 50 ⁰C. The HCl was removed using the corrosive pump to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-ώ): δ = 2.36 (br. s., 4H), 3.34 (d, J = 11.4 Hz, 2H), 3.71 (d, J = 9.1 Hz, 2H), 4.19 (br. s., 2H), 4.31-4.41 (m, IH), 4.51 (br. s., 2H), 7.54-7.60 (m, IH), 7.61-7.67 (m, IH), 8.12-8.20 (m, 2H), 8.24 (d, J = 7.1 Hz, IH), 8.52 (d, J = 1.3 Hz, IH), 8.58-8.65 (m, 2H), 10.49 (br. s., IH). MS (ES⁺): m/z = 435.09 (100) [MH⁺]. HPLC: t_R = 2.24 min (ZQ2, polar_5min).

Example 162: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-acetamide

A mixture of {4-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl} -acetic acid (10.0 mg, 0.0184 mmol), NH₄Cl (2.0 mg, 0.037 mmol), TBTU (8.86 mg, 0.0276 mmol) and DMF (1 mL) was charged with DIPEA (0.03 mL, 0.2 mmol) and allowed to stir at rt for 10 min. The solution was used directly for HPLC purification. The fractions containing the pure product were concentrated in vacuo to afford the title compound as a white solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.17-2.35 (m, 4H), 2.69 (td, J = 11.9, 2.5 Hz, 2H), 3.28 (d, J = 12.4 Hz, 2H), 3.37 (s, 2H), 4.29-4.40 (m, IH), 7.41- 7.47 (m, IH), 7.53 (td, J = 7.6, 1.3 Hz, IH), 7.89 (s, IH), 8.01 (dd, J = 12.3, 8.0 Hz, 2H), 8.11 (s, IH), 8.19 (d, J = 2.0 Hz, IH), 8.32 (d, J = 2.3 Hz, IH).

Example 163: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- ylJ-N-methylacetamide The title compound was prepared according to the procedures described for 2- {4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.10-2.32 (m, 4H), 2.52 (t, J = 9.5 Hz, 2H), 2.81 (s, 3H), 3.11 (d, J = 12.4 Hz, 2H), 3.20 (s, 2H), 4.21-4.33 (m, IH), 7.40-7.47 (m, IH), 7.49-7.56 (m, IH), 7.88 (s, IH), 8.01 (dd, J = 12.0, 8.0 Hz, 2H), 8.11 (s, IH), 8.19 (d, J = 2.0 Hz, IH), 8.33 (d, J = 2.0 Hz, IH).

Example 164: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-ΛyV-dimethylacetamide

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.28-2.50 (m, 4H), 2.98-3.04 (m, 3H), 3.04-3.13 (m, 5H), 3.56 (A, J = 12.1 Hz, 2H), 4.02 (s, 2H), 4.44-4.56 (m, IH), 7.44 (t, J = 7.6 Hz, IH), 7.50-7.57 (m, IH), 7.90 (s, IH), 8.01 (dd, J = 12.8, 8.0 Hz, 2H), 8.12 (s, IH), 8.18 (d, J = 2.0 Hz, IH), 8.32 (d, J = 2.3 Hz, IH).

Example 165: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-l-azetidin-l-ylethanone

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.14-2.31 (m, 4H), 2.36 (dt, J = 15.7, 7.8 Hz, 2H), 2.58-2.73 (m, 2H), 3.26 (br. s., 2H), 3.41 (s, 2H), 4.07 (t, J = 8.0 Hz, 2H), 4.28-4.39 (m, 3H), 7.40-7.48 (m, IH), 7.53 (td, J = 7.7, 1.3 Hz, IH), 7.88 (s, IH), 8.02 (dd, J = 12.1, 8.1 Hz, 2H), 8.13 (s, IH), 8.20 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.3 Hz, IH).

Example 166: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-l-pyrrolidin-l-ylethanone The title compound was prepared according to the procedures described for 2- {4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.86-1.97 (m, 2H), 1.98-2.07 (m, 2H), 2.27-2.47 (m, 4H), 2.97-3.08 (m, 2H), 3.44-3.61 (m, 6H), 3.89 (s, 2H), 4.42-4.53 (m, IH), 7.41-7.47 (m, IH), 7.53 (td, J = 7.6, 1.1 Hz, IH), 7.90 (s, IH), 8.01 (dd, J = 13.4, 7.8 Hz, 2H), 8.13 (s, IH), 8.19 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.0 Hz, IH). Example 167: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-l-(3-hydroxypyrrolidin-l-yl)ethanone

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.91-2.16 (m, 2H), 2.25-2.43 (m, 4H), 2.92-3.07 (m, 2H), 3.44-3.69 (m, 6H), 3.76-3.96 (m, 2H), 4.41-4.53 (m, 2H), 7.40-7.48 (m, IH), 7.48-7.56 (m, IH), 7.89 (s, IH), 8.01 (dd, J = 13.3, 7.7 Hz, 2H), 8.13 (s, IH), 8.19 (d, J = 2.0 Hz, IH), 8.32 (d, J = 2.3 Hz, IH).

Example 168: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-l-piperidin-l-ylethanone The title compound was prepared according to the procedures described for 2- {4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.51-1.76 (m, 6H), 2.25-2.45 (m, 4H), 2.94-3.08 (m, 2H), 3.42-3.48 (m, 2H), 3.48-3.61 (m, 4H), 3.98 (s, 2H), 4.47 (ddd, J = 10.2, 5.6, 5.2 Hz, IH), 7.39-7.47 (m, IH), 7.48-7.56 (m, IH), 7.89 (s, IH), 8.00 (dd, J = 13.4, 7.8 Hz, 2H), 8.11 (s, IH), 8.18 (d, J = 2.0 Hz, IH), 8.31 (d, J = 2.0 Hz, IH).

Example 169: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-l-(4-hydroxypiperidin-l-yl)ethanone

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.42-1.64 (m, 2H), 1.83-2.00 (m, 2H), 2.27-2.44 (m, 4H), 2.94-3.05 (m, 2H), 3.19-3.31 (m, 2H), 3.51 (d, J = 12.4 Hz, 2H), 3.77 (td, J = 9.2, 4.2 Hz, IH), 3.86-4.11 (m, 4H), 4.42-4.54 (m, IH), 7.41- 7.48 (m, IH), 7.50-7.57 (m, IH), 7.90 (s, IH), 8.01 (dd, J = 13.5, 8.0 Hz, 2H), 8.13 (s, IH), 8.20 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.0 Hz, IH).

Example 170: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-l-morpholin-4-ylethanone

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.26-2.43 (m, 4H), 2.85-3.02 (m, 2H), 3.48 (d, J = 12.6 Hz, 2H), 3.53-3.58 (m, 2H), 3.63 (t, J = 4.5 Hz, 2H), 3.67-3.77 (m, 4H), 4.46 (ddd, J = 10.2, 5.3, 5.2 Hz, IH), 7.42-7.49 (m, IH), 7.50-7.57

(m, IH), 7.91 (s, IH), 8.02 (dd, J = 12.9, 8.1 Hz, 2H), 8.14 (s, IH), 8.20 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.0 Hz, IH).

Example 171 : 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-Λ'-(2-hydroxyethyl)-acetamide The title compound was prepared according to the procedures described for 2- {4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.15-2.34 (m, 4H), 2.55-2.65 (m, 2H), 3.18 (d, J = 12.1 Hz, 2H), 3.29 (s, 2H), 3.39 (t, J = 5.6 Hz, 2H), 3.60-3.68 (m, 2H), 4.25-4.37 (m, IH), 7.41-7.48 (m, IH), 7.53 (td, J = 7.6, 1.3 Hz, IH), 7.88 (s, IH), 8.02 (dd, J = 12.6, 7.8 Hz, 2H), 8.12 (s, IH), 8.20 (d, J = 2.0 Hz, IH), 8.33 (d, J = 1.8 Hz, IH).

Example 172: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-Λ'-(2-methoxyethyl)-acetamide

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.12-2.30 (m, 4H), 2.52 (t, J = 10.6 Hz, 2H), 3.12 (d, J = 11.9 Hz, 2H), 3.21 (s, 2H), 3.37 (s, 3H),

3.42-3.47 (m, 2H), 3.47-3.52 (m, 2H), 4.22-4.34 (m, IH), 7.40-7.47 (m, IH), 7.49-7.55 (m, IH), 7.87

(s, IH), 8.00 (dd, J = 11.5, 8.0 Hz, 2H), 8.10 (s, IH), 8.17 (d, J = 2.3 Hz, IH), 8.31 (d, J = 2.0 Hz, IH).

Example 173: 2-{4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l- yl}-Λ',Λ'-bis-(2-methoxyethyl)-acetamide

The title compound was prepared according to the procedures described for 2-{4-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidin-l-yl}-acetamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.22-2.42 (m, 4H), 2.91 (td, J = 11.6, 2.8 Hz, 2H), 3.34 (s, 3H), 3.38 (s, 3H), 3.43 (d, J = 12.4 Hz, 2H), 3.53-3.68 (m, 8H), 3.94 (s, 2H), 4.38-4.49 (m, IH), 7.41-7.47 (m, IH), 7.53 (td, J = 7.6, 1.3 Hz, IH), 7.89 (s, IH), 8.01 (dd, J = 12.9, 7.8 Hz, 2H), 8.12 (s, IH), 8.18 (d, J = 2.3 Hz, IH), 8.32 (d, J = 2.0 Hz, IH).

Example 174 : (2Λ,45)-4- [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl] - pyrrolidine-2-carboxylic acid A mixture of 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-2- ylamine (BB8) (151 mg, 0.428 mmol), (2R,4S)-4-(4-iodopyrazol-l-yl)-pyrrolidine-l,2-dicarboxylic acid 1-benzyl ester 2-methyl ester (177 mg, 0.389 mmol), Pd(PPh₃)₄ (20 mg, 0.02 mmol), potassium fluoride (67.8 mg, 1.17 mmol), and 4: 1 dioxane:water (4 mL) was heated in the microwave reactor at 85 ⁰C for 30 min. The solution was dry-loaded onto silica gel for column chromatography, eluting with 2— >5% MeOH / DCM. The fractions containing the product were concentrated in vacuo and dissolved in cone. HCl. The material was heated to 60 ⁰C for 3 h in a sealed tube. The solvent was removed on the corrosive pump to afford the title compound as an orange solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.55-2.67 (m, IH), 2.74 (br. s., IH), 3.76-3.87 (m, 2H), 4.45 (t, J = 8.6 Hz, IH), 5.25 (dd, J = 6.1, 3.0 Hz, IH), 7.44 (t, J = 7.6 Hz, IH), 7.49-7.55 (m, IH), 7.88 (s, IH), 7.97 (d, J = 7.6 Hz, IH), 8.02 (d, J = 7.8 Hz, IH), 8.06 (s, IH), 8.16 (d, J = 2.0 Hz, IH), 8.30 (d, J = 2.0 Hz, IH). Example 175 : (2Λ,4S)-4- [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl] - pyrrolidine-2-carboxylic acid dimethylamide

A mixture of (2R,4S)-4-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol- l-yl]-pyrrolidine-2- carboxylic acid (10.00 mg, 0.019 mmol), dimethylamine (0.009 g, 0.2 mmol), TBTU (12.4 mg, 0.0388 mmol), and DMF (1 mL) was charged with DIPEA (0.03 mL, 0.2 mmol) and allowed to stir at rt for 10 min. The solution was used directly for HPLC purification. The fractions containing the pure product were concentrated in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): 8 = 2.40-2.51 (m, IH), 2.87 (d, J = 6.1 Hz, IH), 3.04 (s, 3H), 3.09 (s, 3H), 3.72 (br. s., IH), 3.85 (dd, J = 12.5, 6.4 Hz, IH), 5.02 (t, J = 8.7 Hz, IH), 5.29 (br. s., IH), 7.42-7.48 (m, IH), 7.54 (td, J = 7.7, 1.3 Hz, IH), 7.96 (s, IH), 8.02 (dd, J = 15.2, 7.6 Hz, 2H), 8.14 (s, IH), 8.21 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.3 Hz, IH).

Example 176: {(2Λ,45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-pyrrolidin-l-ylmethanone The title compound was prepared according to the procedures described for (2R,4ιS)-4-[4-(6-amino-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.89-2.07 (m, 4H), 2.41-2.55 (m, IH), 2.86 (s, IH), 3.43-3.67 (m, 5H), 3.78- 3.87 (m, IH), 4.79 (t, J = 8.6 Hz, IH), 5.27 (br. s., IH), 7.42-7.48 (m, IH), 7.51-7.57 (m, IH), 7.95 (s, IH), 8.02 (dd, J = 15.3, 8.0 Hz, 2H), 8.14 (s, IH), 8.21 (d, J = 2.0 Hz, IH), 8.34 (d, J = 2.3 Hz, IH).

Example 177: {(2Λ,45)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-(3-hydroxypyrrolidin-l-yl)methanone

The title compound was prepared according to the procedures described for (2R,4S)-4-[4-(6-amino- 5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.93-2.18 (m, 2H), 2.44-2.56 (m, IH), 2.79-2.93 (m, IH), 3.55 (d, J = 16.9 Hz, 2H), 3.61-3.79 (m, 3H), 3.85 (d, J = 14.4 Hz, IH), 4.48 (d, J = 18.4 Hz, IH), 4.72-4.84 (m, IH), 5.30 (br. s., IH), 7.42-7.49 (m, IH), 7.51-7.58 (m, IH), 7.96 (s, IH), 8.02 (dd, J = 15.0, 8.0 Hz, 2H), 8.14 (s, IH), 8.20 (d, J = 2.0 Hz, IH), 8.34 (d, J = 2.0 Hz, IH).

Example 178: {(2Λ,4S)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-piperidin-l-ylmethanone

The title compound was prepared according to the procedures described for (2R,4S)-4-[4-(6-amino- 5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 1.54-1.77 (m, 6H), 2.49 (dd, J = 9.1, 7.1 Hz, IH), 2.83-2.92 (m, IH), 3.48 (t, J = 5.4 Hz, 2H), 3.57-3.69 (m, 2H), 3.75 (br. s., IH), 3.84-3.92 (m, IH), 5.05 (t, J = 9.0 Hz, IH), 5.31 (br. s., IH), 7.43-7.50 (m, IH), 7.53-7.58 (m, IH), 7.98 (s, IH), 8.04 (dd, J = 15.5, 8.0 Hz, 2H), 8.15 (s, IH), 8.22 (d, J = 2.3 Hz, IH), 8.35 (d, J = 2.3 Hz, IH).

Example 179: {(2Λ,4S)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]- pyrrolidin-2-yl}-morpholin-4-ylmethanone The title compound was prepared according to the procedures described for (2R,4ιS)-4-[4-(6-amino-

5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2-carboxylic acid dimethylamide. ¹H NMR (400 MHz, CD₃OD): δ = 2.43-2.56 (m, IH), 2.78-2.90 (m, IH), 3.55 (br. s., 2H), 3.62-3.75 (m, 7H), 3.79-3.91 (m, IH), 4.97-5.03 (m, IH), 5.21-5.34 (m, IH), 7.42-7.49 (m, IH), 7.51-7.57 (m, IH), 7.96 (br. s., IH), 8.02 (dd, J = 15.3, 7.7 Hz, 2H), 8.11-8.16 (m, IH), 8.20 (d, J = 2.3 Hz, IH), 8.33 (d, J = 2.3 Hz, IH).

Example 180: {(5)-4-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidin-2- yl}-methanol

A solution of (2S,4S)-4-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-pyrrolidine-2- carboxylic acid (10.0 mg, 0.0155 mmol) in THF (4 mL, 0.05 mol) was cooled to -78 ⁰C. LiAlH₄ (1.0 M in THF; 0.2 mL, 0.2 mmol) was added slowly, and the mixture was allowed to warm to rt overnight. The material was concentrated in vacuo, then dissolved in DCM, transferred to a separatory funnel, and washed with sat. NaHCO₃. The organic layer was loaded onto a prep TLC plate, eluting with 8% (7N NH₃ in MeOH) / DCM. The band containing the product was filtered off using 1 : 1 MeOH / DCM. The filtrate was concentrated in vacuo to afford the title compound (mixture of diastereomers) as a yellow solid. MS (ES⁺): m/z = 393.14 [MH⁺].

Example 181 : 5-(l-Azetidin-3-yl-l//-pyrazol-4-yl)-3-benzothiazol-2-ylpyridin-2-ylamine trifhioroacetate A solution of 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)pyridin-2-ylamine

(BB8) (30 mg, 0.080 mmol), 3-(4-iodopyrazol-l-yl)-azetidine-l -carboxylic acid tert-butyl ester (59 mg, 0.17 mmol), potassium carbonate (40 mg, 0.20 mmol), and Pd(dppf)Cl₂ (3 mg, 0.01 mmol) in 1,4- dioxane (1.5 mL) and H₂O (0.5 mL) was left to stir at 100 ⁰C for 30 min in the microwave reactor. The mixture was passed through PL-Thiol MP SPE and the residue was concentrated in vacuo. The resulting oil was partitioned between EtOAc and water (3x). The combined organic extracts were treated with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by prep TLC (EtOAc:hexane (3:2)), giving 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)- pyrazol-l-yl]-azetidine-l -carboxylic acid tert-butyl ester, MS (ES+): m/z = 449 [MH⁺]. This material was left to stir at rt in a (1 :1) DCM:TFA mixture for 15 min. The solid that formed was filtered off and dried in vacuo, affording the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 4.53 (d, J = 8.1 Hz, IH), 4.58 (d, J = 7.3 Hz, 4H), 5.49 (quint, J= 7.4 Hz, IH), 7.49-7.56 (m, IH), 7.60 (dd, J= 15.4, 1.3 Hz, IH), 8.07 (d, J= 8.1 Hz, IH), 8.12 (d, J= 7.8 Hz, IH), 8.16 (s, IH), 8.21 (s, IH), 8.33 (d, J= 2.3 Hz, IH), 8.57 (d, J= 2.0 Hz, IH). MS (ES+): m/z = 349.16 (100) [MH⁺]. HPLC: f_R = 1.99 min (ZQ2, polar_5min).

3-(4-Iodopyrazol-l-yl)-l-azetidine-l-carboxylic acid tert-buty\ ester A mixture of 3-methanesulfonyloxyazetidine-l-carboxylic acid tert-butyl ester (4.0 g, 15.9 mmol),

4-iodopyrazole (3.1 g, 15.9 mmol), potassium carbonate (2.85 g, 20.6 mmol, 1.3eq), and 18-crown-6 (400 mg) in dry DMF (15mL) was heated at 85 ⁰C for 24 h. The reaction mixture was cooled to RT, poured into water and extracted with EtOAc (3x20 mL). The combined organic layers were washed with water (2x 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography using hexanes / DCM / EtOAc (8: 1 : 1) to give the title compound. ¹H NMR (300 MHz, CDCl₃): δ = 1.47 (s, 9H), 4.29(m, 2H), 4.36 (m, 2H), 5.05 (m, IH), 7.59 (s, IH), 7.60 (s, IH).

General Procedure F for libraries based on BB7

To a solution of 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (25.0 mg, 0.0529 mmol, 1 eq.), boronic acid or ester (0.118 mmol, 2 eq.), and potassium carbonate (24.5 mg, 0.178, 3 eq.) in dioxane (0.9 mL) and water (0.3 mL) was added 1 , 1 '-bis(diphenylphosphino)- ferrocene]dichloropalladium(II) ^• DCM (2 mg, 0.003 mmol, 0.05 eq.). The mixture was evacuated and filled with nitrogen 3 times and heated in the microwave reactor to 100 ⁰C for 30 min. The reaction mixture was passed through 500 mg Thiol-SPE to remove palladium. The clear solution was submitted to MDPS for purification.

The following examples were prepared using General Procedure F.

Example 182: [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(4-methylpiperazin-l- yl)methanone MS (ES+): m/z = 430.10 (100) [MH⁺]. HPLC: t_R = 2.10 min (ZQ2, polar_5min).

Example 183 : 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ',Λ'-dimethylbenzamide

MS (ES+): m/z = 375.10 (100) [MH⁺]. HPLC: t_R = 3.18 min (ZQ2, polar_5min). ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.99 (br. s., 6H), 7.45-7.54 (m, 3H), 7.54-7.60 (m, IH), 7.76-7.82 (m, 2H), 8.07-8.13 (m, 3H), 8.16 (d, J= 7.3 Hz, IH), 8.25 (d, J= 2.3 Hz, IH), 8.58 (d, J= 2.3 Hz, IH).

Example 184: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(4-methylpiperazin-l- yl)methanone

MS (ES+): m/z = 430.10 (100) [MH⁺]. HPLC: t_R = 2.11 min (ZQ2, polar_5min). Example 185: 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-(2- dimethylaminoethyl)benzamide

MS (ES+): m/z= 418.11 (100) [MH⁺]. HPLC: t_R = 2.15 min (ZQ2, polar_5 min).

Example 186: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ',Λ'-dimethylbenzamide MS (ES+): m/z = 375.10 (100) [MH⁺]. HPLC: t_R = 3.19 min (ZQ2, polar_5min). ¹H NMR (400

MHz, DMSO-(Z₆): δ = 2.97 (s, 3H), 3.02 (s, 3H), 7.34-7.39 (m, IH), 7.45-7.60 (m, 3H), 7.72 (t, J = 1.6 Hz, IH), 7.76-7.82 (m, IH), 8.05-8.18 (m, 4H), 8.24 (d, J = 2.3 Hz, IH), 8.56 (d, J= 2.5 Hz, IH).

Example 187: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-(2- dimethylaminoethyl)benzamide

MS (ES+): m/z = 418.10 (100) [MH⁺]. HPLC: t_R = 2.16 min (ZQ2, polar_5min).

Example 188: 5-Benzothiazol-2-yl-6'-(3-dimethylaminopropoxy)-[3,3']bipyridinyl-6-ylamine

MS (ES+): m/z = 406.10 (100) [MH⁺]. HPLC: t_R = 2.18 min (ZQ2, polar_5min).

Example 189 : [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl] morpholin-4-ylmethanone

MS (ES+): m/z = 417.09 (100) [MH⁺]. HPLC: t_R = 2.18 min (ZQ2, polar_5min).

Example 190 : 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)benzamide MS (ES+): m/z = 347.07 (100) [MH⁺]. HPLC: t_R = 2.86 min (ZQ2, polar_5min).

Example 191 : 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ',Λ'-diethylbenzamide

MS (ES+): m/z = 403.14 (100) [MH⁺]. HPLC: t_R = 3.58 min (ZQ2, polar_5min).

Example 192: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-furan-2-ylmethylbenzamide

MS (ES+): m/z = All .Ql (100) [MH⁺]. HPLC: t_R = 3.47 min (ZQ2, polar_5min).

Example 193 : 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-furan-2-ylmethylbenzamide

MS (ES+): m/z = 427.07 (100) [MH⁺]. HPLC: t_R = 3.44 min (ZQ2, polar_5min).

Example 194 : 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-methylbenzamide

MS (ES+): m/z = 361.08 (100) [MH⁺]. HPLC: t_R = 3.06 min (ZQ2, polar_5min).

Example 195: [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]piperidin-l-ylmethanone MS (ES+): m/z = 415.13 (100) [MH⁺]. HPLC: t_R = 3.71 min (ZQ2, polar_5min). Example 196 : 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)benzamide

MS (ES+): m/z = 347.07 (100) [MH⁺]. HPLC: t_R = 3.89 min (ZQ2, polar_5min).

Example 197: 3-Benzothiazol-2-yl-5-[l-(2-morpholin-4-ylethyl)-l//-pyrazol-4-yl]pyridin-2- ylamine

MS (ES+): m/z = 407.11 (100) [MH⁺]. HPLC: t_R = 2.08 min (ZQ2, polar_5min).

Example 198 : 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-cyclopropylbenzamide

MS (ES+): m/z = 387.10 (100) [MH⁺]. HPLC: t_R = 3.20 min (ZQ2, polar_5min).

Example 199 : 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-methylbenzamide

MS (ES+): m/z = 361.08 (100) [MH⁺]. HPLC: t_R = 3.00 min (ZQ2, polar_5min).

Example 200: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid To a solution of 3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester (0.980 g,

2.7 mmol) in dioxane/H₂O (5:1, 30 mL) was added K₂CO3 (1.5 g, 11 mmol), and the mixture was heated at 50 ⁰C for 16 h. Evaporation of the solvents and neutralization with acetic acid gave a precipitate that was filtered off and dried in vacuo to give the title compound. ¹H NMR (DMSO-dβ, 300 MHz): δ = 7.51-7.66 (m, 3H), 7.95-8.00 (m, 2H), 8.14-8.18 (m, 4H), 8.24 (d, J= 8.4 Hz, 2H), 8.29 (d, J = 1.8 Hz, IH), 8.61 (d, J = 2.1 Hz, IH). MS(ES+): m/z = 348.06 (100) [MH⁺]. HPLC: t_R = 3.42 min (polar_5min, ZQ3).

3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester A mixture of 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (1.37 g, 4.5 mmol), 3- (carbomethoxy)phenylboronic acid (0.85 g, 4.7 mmol), Pd(PPh₃)₄ (5 mol%), and Cs₂CO₃ (3.5 g, 10.8 mmol) in dioxane/H₂O (4: 1, 30 mL) were heated under nitrogen at 90 ⁰C for 5 h. Solvents were removed in vacuo, water (10 mL) was added to the residue, and the mixture was extracted with EtOAc (3x 10 mL). The combined EtOAc extracts were dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude material thus obtained was purified by column chromatography on silica gel using mixtures of EtOAc/Hexanes to give the title compound. ¹H NMR (CDCl₃, 300 MHz): δ = 7.28 (brs, 2H), 7.41 (t, J= 6.9 Hz, IH), 7.51 (t, J= 6.9 Hz, IH), 7.64 (d, J= 7.5 Hz, IH), 7.77 (d, J= 6.3 Hz, IH), 7.92 (d, J= 7.8 Hz, IH), 8.01-8.05 (m, 2H), 8.18 (d, J= 2.1 Hz, IH), 8.26 (t, J= 1.8 Hz, IH), 8.47 (d, J = 2.1 Hz, IH).

Example 201: 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid Following the procedure for 3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester, the title compound was prepared from 4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester (1.2 g, 3.3 mmol) and K₂CO₃ (1.5 g, 11 mmol) in dioxane/H₂O (5: 1, 30 mL). ¹H NMR (400 MHz, DMSO-(Z₆): δ = 13.0 (very brs, IH), 8.62 (d, J= 2.2 Hz, IH), 8.29 (d, J= 2.2 Hz, IH), 8.19- 8.13 (m, 3H), 8.12 (d, J= 7.8 Hz, IH), 8.04-8.00 & 7.88-7.84 (AA¹BB', 4H), 7.57 (ddd, J= 1.0, 7.0, 8.0 Hz, IH), 7.49 (ddd, J= 1.0, 7.4, 8.0 Hz, IH). MS(ES+): m/z = 348.08 (100) [MH⁺]. HPLC: fc = 3.29 min (polar_5min, ZQ2).

4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester Following the procedure for 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester, the title compound was prepared from 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (2.0 g, 6.5 mmol), 4-(carbomethoxyphenyl)boronic acid (0.85 g, 4.7 mmol), Pd(PPh₃ )₄ (5 mol %) and Cs₂CO₃ (3.5 g, 10.8 mmol).

Example 202: 6'-Amino-5'-benzothiazol-2-yl-[3,3']bipyridinyl-6-carboxylic acid

Following the procedures for 3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester and the benzoic acid, the title compound was prepared from 3-benzothiazol-2-yl-5-bromopyridin- 2-ylamine (BB7) (1.1 g, 3.6 mmol), 5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridine-2- carboxylic acid methyl ester (1.0 g, 3.8 mmol), Pd(PPh₃)₄ (2 mol %), and Cs₂CO₃ (2.83 g, 8.7 mmol) in DMF/H₂O (24 mL, 5: 1). ¹H NMR (400 MHz, DMSO-(Z₆): δ = 8.90 (s, IH), 8.61 (d, J= 2.0 Hz, IH), 8.31 (d, J= 2.0 Hz, IH), 8.20-8.07 (m, 5H), 7.96 (brd, J= 8.4 Hz, IH), 7.57 (dt, J= 1.0, 8.0 Hz, IH), 7.49 (dt, J= 1.0, 8.0 Hz, IH); COOH proton not visible. MS(ES+): m/z = 349.08 (100) [MH⁺], 305.09 (8) [MH⁺ - CO₂]. HPLC: t_R = 2.89 min (polar_5min, ZQ3).

Example 203: 6-Amino-5-benzothiazol-2-yl-[3,4']bipyridinyl-2'-carboxylic acid

Following the procedure for 3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester, the title compound was prepared from 6-amino-5-benzothiazol-2-yl-[3,4']bipyridinyl-2'- carboxylic acid methyl ester (1.14 g, 3.2 mmol) and NaOH (0.48 g, 12 mmol) in MeOH (10 mL). ¹H NMR (400 MHz, DMSO-(Z₆): δ = 13.0 (very brs, IH), 8.62 (d, J= 2.2 Hz, IH), 8.29 (d, J= 2.2 Hz, IH), 8.19-8.13 (m, 3H), 8.12 (d, J= 7.8 Hz, IH), 8.04-8.00 & 7.88-7.84 (AA¹BB', 4H), 7.57 (ddd, J= 1.0, 7.0, 8.0 Hz, IH), 7.49 (ddd, J= 1.0, 7.4, 8.0 Hz, IH). MS(ES+): m/z = 348.08 (100) [MH⁺]. HPLC: t_R = 3.29 min (polar_5min, ZQ2).

6-Amino-5-benzothiazol-2-yl-[3,4']bipyridinyl-2'-carboxylic acid methyl ester Following the procedure for 4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-benzoic acid methyl ester, the title compound was prepared from 3-benzothiazol-2-yl-5-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine (BB8) (1.41 g, 4.0 mmol), 4-iodopyridine-2-carboxylic acid methyl ester (0.85 g, 3.2 mmol), Pd(PPh₃)₄ (2 mol %) and Cs₂CO₃ (2.5 g, 7.7 mmol) in dioxane/water (5: 1; 18 mL). ¹H NMR (CD₃OD, 300 MHz): δ = 4.01 (s, 3H), 7.38-7.45 (m, 2H), 7.70 (dd, J = 7.2, 2.4 Hz, IH), 7.85 (d, J = 6.8 Hz, IH), 7.95 (d, J= 6.8 Hz, IH), 8.21 (d, J= 2.4 Hz, IH), 8.31 (d, J = 2.4 Hz, IH), 8.44 (d, J= 2.4 Hz, IH), 8.70 (d, J= 7.2 Hz, IH).

General Procedure G for (Het)aryl Amides To a suspension of 3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)benzoic acid (20 mg, 0.058 mmol,

1 eq.) in 1 mL DCM were added TBTU (19.4 mg, 0.060 mmol, 1.05 eq.), DIPEA (10 μL, 0.058 mmol, 1 eq.), and the amine (0.116 mmol, 2 eq.). The mixture was stirred at room temperature overnight. If the mixture was heterogeneous, the solid was filtered off and dried in vacuo. Otherwise, DCM was evaporated, and the residue was dissolved in DMSO for MDP purification. The following examples were prepared using General Procedure G.

Example 204: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]pyrrolidin-l-ylmethanone

MS (ES+): m/z = 401.11 (100) [MH⁺]. HPLC: t_R = 3.39 min (ZQ2, polar_5min).

Example 205: Λ'-(2-Acetylaminoethyl)-3-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)benzamide

MS (ES+): m/z = 432.07 (100) [MH⁺]. HPLC: t_R = 2.75 min (ZQ2, polar_5min).

Example 206: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]piperidin-l-ylmethanone

MS (ES+): m/z = 415.13 (100) [MH⁺]. HPLC: t_R = 3.68 min (ZQ2, polar_5min).

Example 207: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ^f-(2- diethylaminoethyl)benzamide

MS (ES+): m/z = 446.14 (100) [MH⁺]. HPLC: t_R = 2.26 min (ZQ2, polar_5min).

Example 208: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(c/s-3,5- dimethylpiperazin-l-yl)methanone

MS (ES+): m/z = 444.12 (100) [MH⁺]. HPLC: t_R = 2.20 min (ZQ2, polar_5min).

Example 209: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-iV-(3-pyrroIidin-l- ylpropyl)benzamide

MS (ES+): m/z = 458.15 (100) [MH⁺]. HPLC: t_R = 2.23 min (ZQ2, polar_5min).

Example 210: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ^r-methyl-Λ'-(l-methylpiperidin- 4-yl)benzamide MS (ES+): m/z = 458.15 (100) [MH⁺]. HPLC: t_R = 2.14 min (ZQ2, polar_5min). Example 211: 2-{4-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)benzoyl]piperazin-l-yl}-l- pyrrolidin-1-ylethanone

MS (ES+): m/z = 527.15 (100) [MH⁺]. HPLC: t_R = 2.26 min (ZQ2, polar_5min).

Example 212: l-{4-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)benzoyl]piperazin-l- yljethanone

MS (ES+): m/z = 458.08 (100) [MH⁺]. HPLC: t_R = 2.81 min (ZQ2, polar_5 min).

Example 213: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(3-hydroxypiperidin-l- yl)methanone

MS (ES+): m/z = 431.10 (100) [MH⁺]. HPLC: t_R = 2.90 min (ZQ2, polar_5min).

Example 214: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(c/s-2,6- dimethylmorpholin-4-yl)methanone MS (ES+): m/z = 445.13 (100) [MH⁺]. HPLC: t_R = 3 Al min (ZQ2, polar_5min).

Example 215: 2-{4-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)benzoyl]piperazin-l-yl}-Λ^/,Λ^/- dimethylacetamide

MS (ES+): m/z = 501.12 (100) [MH⁺]. HPLC: t_R = 2.19 min (ZQ2, polar_5min).

Example 216: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ',Λ'-bis-(2- methoxyethyl)benzamide

MS (ES+): m/z = 463.13 (100) [MH⁺]. HPLC: t_R = 3.31 min (ZQ2, polar_5min).

Example 217: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(4-pyrrolidin-l- ylpiperidin-l-yl)methanone

MS (ES+): m/z = 484.29 (100) [MH⁺]. HPLC: t_R = 2.16 min (ZQ2, polar_5min).

Example 218: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-iV-(l-methylpiperidin-4- yl)benzamide

MS (ES+): m/z = 444.28 (100) [MH⁺]. HPLC: t_R = 2.19 min (ZQ2, polar_5min).

Example 219: l-[3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)benzoyl]piperidine-4-carboxylic acid amide MS (ES+): m/z = 458.23 (100) [MH⁺]. HPLC: t_R = 2.68 min (ZQ2, polar_5min). Example 220 : 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ^r-(2-dimethylaminoethyl)-Λ^/- methylbenzamide

MS (ES+): m/z = 432.25 (100) [MH⁺]. HPLC: t_R = 2.15 min (ZQ2, polar_5min).

Example 221: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ^f-((15',25)-2- hydroxycyclohexyl)benzamide

MS (ES+): m/z = 445.13 (100) [MH⁺]. HPLC: t_R = 2.23 min (ZQ2, polar_5min).

Example 222: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(3-hydroxypyrrolidin-l- yl)methanone

MS (ES+): m/z = 417.19 (100) [MH⁺]. HPLC: t_R = 0.73 min (UPLC-ACQUITY, Analytical).

Example 223: 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-(3-imidazol-l- ylpropyl)benzamide MS (ES+): m/z = 455.25 (100) [MH⁺]. HPLC: t_R = 0.65 min (UPLC-ACQUITY, Analytical).

Example 224 : [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl] -(3- dimethylaminopyrrolidin-l-yl)methanone

MS (ES+): m/z = 444.24 (100) [MH⁺]. HPLC: t_R = 2.18 min (ZQ2, polar_5min).

Example 225 : 3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-Λ'-(3-morpholin-4- ylpropyl)benzamide

MS (ES+): m/z = 474.21 (100) [MH⁺]. HPLC: t_R = 3.28 min (ZQ2, polar_5min).

Example 226: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(4-methyl-[l,4]diazepan- l-yl)methanone

MS (ES+): m/z = 444.20 (100) [MH⁺]. HPLC: t_R = 0.62 min (UPLC-ACQUITY, Analytical).

Example 227: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(3,3-difluoropyrrolidin-l- yl)methanone

MS (ES+): m/z = 437.18 (100) [MH⁺]. HPLC: t_R = 0.99 min (UPLC-ACQUITY, Analytical).

Example 228: [3-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenyl]-(c/s-3,4,5- trimethylpiperazin-l-yl)methanone MS (ES+): m/z = 458.24 (100) [MH⁺]. HPLC: t_R = 0.63 min (UPLC-ACQUITY, Analytical). Example 229 : 3-(l ,3-Benzothiazol-2-yl)-5-(l/7-indol-2-yl)pyridin-2-amine

A mixture of 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (25 mg, 0.080 mmol), 1-Boc- indole-2-boronic acid (40 mg, 0.20 mmol) and potassium carbonate (34 mg, 0.24 mmol) in 1,4-dioxane (1.4 mL) and H₂O (0.5 mL) was degassed and refilled with argon (3x) prior to the addition of Pd(dppf)Cl₂ (6 mg, 0.01 mmol) . The reaction mixture was degassed and refilled with argon (2x) and left to stir at 100 ⁰C in the microwave reactor for 30 min. Then, the mixture was passed through PL- Thiol MP SPE resin and concentrated in vacuo. The residual oil was partitioned between DCM and H₂O. The combined organic layers were treated with brine, dried over anhydrous Na₂Sθ₄ and concentrated in vacuo. The resulting Boc-protected intermediate was left to stir in (1 : 1) DCM:TFA mixture (1.0 mL) at rt for 15 min. Purification via MDP afforded the title compound as a yellow solid. MS (ES+): m/z = 343.08 (100) [MH⁺]. HPLC: t_R = 4.00 min (ZQ3, polar_5min).

Example 230: 3-(l,3-Benzothiazol-2-yl)-5-(l//-pyrrol-2-yl)pyridin-2-amine

The procedure for 3-(l,3-benzothiazol-2-yl)-5-(lH-indol-2-yl)pyridin-2-amine was followed. MS (ES+): m/z = 293.09 (100) [MH⁺]. HPLC: t_R = 3.44 min (ZQ3, polar_5min).

Example 231 : iV-4- [6-Amino-5-(l ,3-benzothiazol-2-yl)pyridin-3- yl] phenylmethanesulfonamide

The procedure for 3-(l,3-benzothiazol-2-yl)-5-(lH-indol-2-yl)pyridin-2-amine was followed, except the treatment with TFA/DCM was omitted. MS (ES+): m/z = 397.10 (100) [MH⁺]. HPLC: t_R = 3.32 min (ZQ3, polar_5min).

Example 232: 5-(l,3-Benzothiazol-2-yl)-l',2',3',6'-tetrahydro-3,4'-bipyridin-6-amine

The procedure for 3-(l,3-benzothiazol-2-yl)-5-(lH-indol-2-yl)pyridin-2-amine was followed. MS (ES+): m/z = 309.11 (100) [MH⁺]. HPLC: t_R = 2.17 min (ZQ3, polar_5min).

Example 233 : 3- [6-Amino-5-(l ,3-benzothiazol-2-yl)pyridin-3-yl] phenol

A mixture of 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (100 mg, 0.330 mmol), 3- hydroxyphenylboronic acid (68 mg, 0.49 mmol) and potassium carbonate (140 mg, 0.980 mmol) in 1,4- dioxane (4.5 mL) and H₂O (1.5 mL) was degassed and refilled with argon (3 x) prior to the addition of Pd(dppf)Cl₂ (10 mg, 0.020 mmol). The reaction mixture was degassed and refilled with argon (2x) and left to stir at 100 ⁰C for 30 min in the microwave reactor. Then, the mixture was passed through a pad of Celite and to the filtrate was partitioned between EtOAc and NaHCθ3 aq. soln. (3 x). The combined organic extracts were treated with brine, dried over anhydrous Na₂SOz_I, filtered, and concentrated in vacuo. Purification via silica gel chromatography (5% MeOH in DCM) afforded the title compound as a yellow solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 6.75-6.77 (m, IH), 7.04-7.04 (m, IH), 7.10-7.12 (m, IH), 7.27 (t, J= 8.0 Hz, IH), 7.46-7.50 (m, IH), 7.55-7.58 (m, IH), 8.02 (br.s., 2H), 8.10-8.16 (m, 3H), 8.46 (d, J = 4.0 Hz, IH), 9.54 (s, IH). MS (ES+): m/z = 320.09 (100) [MH⁺]. HPLC: t_R = 3.44 min (ZQ3, polar_5min).

Example 234: Methyl 3-[6-amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenoxyacetate

A solution of 3-[6-amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenol (80 mg, 0.20 mmol), potassium carbonate (100 mg, 0.700 mmol) and chloroacetic acid methyl ester (33 mg, 0.30 mmol) in DMF was left to stir at rt overnight. To the mixture was added EtOAc (10 mL), which was left to stir at rt for 10 min. Then, the mixture was washed with NaHCθ3 aq. soln. (2x). The combined organic extracts were treated with brine, dried over anhydrous Na₂SC^ and concentrated in vacuo. Purification via silica gel chromatography (5% MeOH in DCM) afforded the title compound as a yellow solid. MS (ES+): m/z = 392.02 (100) [MH⁺]. HPLC: t_R = 3.63 min (ZQ3, polar_5min).

Example 235: [3-(6-Amino-5-benzothiazol-2-yl-pyridin-3-yl)-phenoxy]acetic acid To a suspension of methyl 3-[6-amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenoxyacetate (75 mg, 0.19 mmol) in EtOH (4.0 mL) and H₂O (4.0 mL) was added 3M aqueous NaOH (0.30 mL, 1.0 mmol). The reaction mixture was left to stir at rt overnight. Then, the mixture was acidified with IM HCl aqueous to pH = 2. Vacuum filtration afforded the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 4.80 (s, 2H), 6.93 (dd, J = 7.7, 2.1 Hz, IH), 7.25-7.29 (m, IH), 7.31 (d, J = 7.8 Hz, IH), 7.40 (t, J= 7.8 Hz, IH), 7.48-7.54 (m, IH), 7.55-7.62 (m, IH), 8.15 (dd, J= 18.4, 7.6 Hz, 2H), 8.31 (d, J= 2.0 Hz, IH), 8.55 (d, J= 2.3 Hz, IH), 13.06 (br. s., IH). MS (ES+): m/z = 378.07 (100) [MH⁺]. HPLC: t_R = 3.50 min (ZQ3, polar_5min).

Example 236: Ethyl 4-[6-amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenoxyacetate A mixture of 3-benzothiazol-2-yl-5-bromopyridin-2-ylamine (BB7) (100 mg, 0.330 mmol), 4-(2- ethoxy-2-oxoethoxy)benzeneboronic acid (100 mg, 0.600 mmol) and potassium fluoride (57 mg, 0.98 mmol) in 1,4-dioxane (9.0 mL) and H₂O (3.0 mL) was degassed and refilled with argon (3x) prior to the addition of Pd(dppf)Cl₂ (10 mg, 0.020 mmol). The reaction mixture was degassed and refilled with argon (2x) and left to stir at 100 ⁰C for 2 h. The mixture was quickly passed through a silica gel pad (5% MeOH in DCM), which afforded the title compound as a yellow solid. MS (ES+): m/z = 406.10 (100) [MH⁺]. HPLC: t_R = 3.90 min (ZQ3, polar_5min).

Example 237: 4-[6-Amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenoxyacetic acid

To a suspension of ethyl 4-[6-amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenoxyacetate (132 mg, 0.330 mmol) in EtOH (2.0 mL) was added 3M aqueous NaOH (0.50 mL, 1.5 mmol). Then, the mixture was acidified to pH = 2 with IM aq. HCl. Vacuum filtration afforded the title compound as a yellow solid. MS (ES+): m/z = 506.88 (100) [MH⁺]. HPLC: t_R = 3.14 min (ZQ3, polar_5min).

Example 238 : 2- [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy] -iV-methylacetamide

To a suspension of 4-[6-amino-5-(l,3-benzothiazol-2-yl)pyridin-3-yl]phenoxyacetic acid (20 mg, 0.050 mmol) in DMF (1.0 mL) were added methylammonium chloride (4 mg, 0.06 mmol), TBTU (19 mg, 0.060 mmol) and DIEA (0.05 mL, 0.3 mmol). The mixture was left to stir at rt for 30 min. Purification via MDP afforded the title compound as a yellow solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.67 (d, J = 4.8 Hz, 3H), 4.51 (s, 2H), 7.04-7.10 (m, 2H), 7.45-7.52 (m, IH), 7.54-7.59 (m, IH), 7.63-7.68 (m, 2H), 7.97 (s, 2H), 8.10 (d, J= 7.8 Hz, IH), 8.13-8.17 (m, 2H), 8.48 (d, J= 2.3 Hz, IH). MS (ES+): m/z = 391.10 (100) [MH⁺]. HPLC: t_R = 3.20 min (ZQ3, polar_5min).

Example 239 : 2- [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy] -N,N- dimethylacetamide

The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.86 (s, 3H), 3.02 (s, 3H), 4.86 (s, 2H), 6.99-7.05 (m, 2H), 7.45-7.51 (m, IH), 7.53-7.59 (m, IH), 7.59-7.64 (m, 2H), 7.96 (s, 2H), 8.08-8.17 (m, 3H), 8.47 (d, J = 2.3 Hz, IH). MS (ES+): m/z = 405.15 (100) [MH⁺]. HPLC: t_R = 3.23 min (ZQ3, polar_5min).

Example 240: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-Λ'-benzylacetamide

The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 467.09 (100) [MH⁺]. HPLC: t_R = 3.81 min (ZQ3, polar_5min).

Example 241: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenoxy]-l-pyrrolidin-l- ylethanone

The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 431.14 (100) [MH⁺]. HPLC: t_R = 3.41 min (ZQ3, polar_5min).

Example 242 : 2- [4-(6- Amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy] -TV- [3-(2- oxopyrrolidin-l-yl)-propyl]acetamide

The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 502.15 (100) [MH⁺]. HPLC: t_R = 3.09 min (ZQ3, polar_5min).

Example 243 : 2- [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenoxy] -iV-(2- hydroxycyclohexyljacetamide The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 475.14 (100) [MH⁺]. HPLC: t_R = 3.32 min (ZQ3, polar_5min).

Example 244: 2-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenoxy]-l-morpholin-4- ylethanone The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 447.10 (100) [MH⁺]. HPLC: t_R = 3.24 min (ZQ3, polar_5min).

Example 245 : 2- [4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)phenoxy] -N- cyclohexylmethylacetamide The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 473.16 (100) [MH⁺]. HPLC: t_R = 4.15 min (ZQ3, polar_5min).

Example 246: 2-[4-(6-Amino-5-benzothiazol-2-yl-pyridin-3-yl)phenoxy]-l-[4-(2- hydroxyethyl)piperazin-l-yl]ethanone The procedure for 2-[4-(6-amino-5-benzothiazol-2-ylpyridin-3-yl)-phenoxy]-N-methylacetamide was followed. MS (ES+): m/z = 490.15 (100) [MH⁺]. HPLC: t_R = 2.44 min (ZQ3, polar_5min).

Example 247: 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-[7-(l//-pyrazol-4-yl)benzothiazol-2- yl] pyridin-2-ylamine dihydrochloride A solution of 4-[6-amino-5-(7-bromobenzothiazol-2-yl)-pyridin-3-yl]-pyrazol-l-ylpiperidine-l- carboxylic acid tert-butyl ester (30 mg, 0.050 mmol), 4-pyrazoleboronic acid (12 mg, 0.11 mmol), potassium carbonate (20 mg, 0.20 mmol) and Pd(dppf)Cl₂ (2 mg, 0.01 mmol) in 1,4-dioxane (1.2 mL) and H₂O (0.4 mL) was left to stir at 100 ⁰C for 30 min in the microwave reactor. Then, the mixture was passed through PL-Thiol MP SPE resin and the filtrate was concentrated in vacuo. The resulting oil was partitioned between DCM and H₂O (3x). The combined organic extracts were treated with brine, dried over anhydrous Na₂Sθ₄ and concentrated in vacuo. The Boc-protected intermediate was isolated via prep TLC (5% MeOH in DCM), MS (ES+): m/z = 543 [MH⁺]. The resulting solid was taken up in DCM (1.0 mL) and IM HCl in ether (1.0 mL) was added. The mixture was left to stir at rt for Ih. The resulting precipitate was collected by vacuum filtration and washed with DCM, which afforded the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.30-2.44 (m, 4H), 3.21-3.29 (m, 2H), 3.56-3.67 (m, 2H), 4.59-4.71 (m, IH), 7.68 (t, J= 7.8 Hz, IH), 7.79 (d, J= 6.8 Hz, IH), 8.07-8.12 (m, 2H), 8.27 (s, 2H), 8.37 (d, J = 2.0 Hz, IH), 8.42 (s, IH), 8.85 (d, J= 1.8 Hz, IH). MS (ES+): m/z = 443.14 (100) [MH⁺]. HPLC: t_R = 1.77 min (ZQ3, nonpolar_5min). Example 248: 3-[7-(l-Methyl-l/7-pyrazol-4-yl)benzothiazol-2-yl]-5-(l-piperidin-4-yl-l/7- pyrazol-4-yl)pyridin-2-ylamine dihydrochloride

The procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-[7-(lH-pyrazol-4-yl)benzothiazol-2- yl]pyridin-2-ylamine dihydrochloride was followed. ¹H NMR (400 MHz, DMSO-<i₆): δ = 2.06-2.34 (m, 4H), 3.05-3.20 (m, 2H), 3.35-3.45 (m, 2H), 3.98 (s, 3H), 4.44-4.60 (m, IH), 7.62 (t, J = 7.8 Hz, IH), 7.72 (dd, J = 7.6, 1.01 Hz, IH), 8.02 (dd, J= 8.0, 1.0 Hz, IH), 8.08 (d, J= 3.5 Hz, 2H), 8.36 (s, 1 H) 8.42 (s, IH) 8.47 (br. s., IH) 8.53 (d, J= 2.0 Hz, IH). MS (ES+): m/z = 457.13 (100) [MH⁺]. HPLC: t_R = 1.89 min (ZQ3, nonpolar_5min).

Example 249: 5-(l-Piperidin-4-yl-l/7-pyrazol-4-yl)-3-[7-(7/7-pyrrol-2-yl)benzothiazol-2- yl]pyridin-2-ylamine dihydrochloride

The procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-[7-(lH-pyrazol-4-yl)benzothiazol-2- yl]pyridin-2-ylamine dihydrochloride was followed. ¹H NMR (400 MHz, DMSO-iie): δ = 1.93-2.07 (m, 2H), 2.08-2.17 (m, 2H), 2.80-2.91 (m, 2H), 3.20-3.28 (m, 2H), 4.30-4.41 (m, IH), 6.25-6.33 (m, IH), 6.77-6.84 (m, IH), 7.00-7.06 (m, IH), 7.60 (t, J= 7.8 Hz, IH), 7.74 (d, J= 7.1 Hz, IH), 7.91 (br. s., 2H), 7.94 (d, J= 8.1 Hz, IH), 8.00 (s, IH), 8.27 (d, J= 2.3 Hz, IH), 8.30-8.39 (m, 2H), 8.50 (d, J = 2.3 Hz, IH), 11.64 (br. s., IH). MS (ES+): m/z = 442.19 (100) [MH⁺]. HPLC: t_R = 2.34 min (ZQ3, polar_5min).

Example 250: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(7-pyridin-3-ylbenzothiazol-2- yl)pyridin-2-ylamine dihydrochloride

The procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-[7-(lH-pyrazol-4-yl)benzothiazol-2- yl]pyridin-2-ylamine dihydrochloride was followed. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.02-2.32 (m, 4H), 3.04-3.16 (m, 2H), 3.45-3.48 [m, 2H], 4.44-4.53 (m, IH), 7.65-7.70 (m, 2H), 7.71-7.79 (m, IH), 8.05 (s, IH), 8.20 (dd, J= 8.1, 1.0 Hz, IH), 8.26 (dt, J= 7.8, 1.9 Hz, IH), 8.33 (br. s., IH), 8.38 (s, IH), 8.53 (d, J= 2.0 Hz, IH), 8.59 (br. s., IH), 8.75 (dd, J= 4.8, 1.5 Hz, IH), 8.82 (br. s., IH), 9.02 (d, J= 1.5 Hz, IH). MS (ES+): m/z = 454.13 (100) [MH⁺]. HPLC: t_R = 1.86 min (ZQ3, nonpolar_5min).

Example 251 : 5-(l-Piperidin-4-yl-l/7-pyrazol-4-yl)-3-[7-(l/7-pyrrol-3-yl)benzothiazol-2- yl] pyridin-2-ylamine trifhioroacetate The procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-[7-(lH-pyrazol-4-yl)benzothiazol-2- yl]pyridin-2-ylamine dihydrochloride was followed, except that TFA in DCM was used for removing the Boc group. ¹H NMR (400 MHz, CD₃OD): δ = 2.24-2.43 (m, 4H), 3.19-3.29 (m, 2H), 3.60 (d, J = 13.1 Hz, 2H), 4.60 (ddd, J= 10.2, 5.3, 5.2 Hz, IH), 6.66 (q, J= 2.5 Hz, IH), 6.92 (q, J= 2.7 Hz, IH), 7.28-7.36 (m, IH), 7.55 (t, J= 7.8 Hz, IH), 7.59-7.65 (m, IH), 7.86-7.93 (m, IH), 8.00 (s, IH), 8.19- 8.31 (m, 2H), 8.57 (d, J= 2.0 Hz, IH), 10.76 (br. s., IH). MS (ES+): m/z = 442.19 (100) [MH⁺]. HPLC: t_R = 2.38 min (ZQ3, polar_5min).

Example 252: 3-(6-Fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine A solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid fert-butyl ester (BB8) (0.075 g, 0.16 mmol) and 2-chloro-6- fluorobenzothiazole (0.090 g, 0.48 mmol) in 1,4-dioxane (1.7 mL) and H₂O (0.6 mL) was charged with potassium carbonate (0.066 g, 0.48 mmol) and (l,l'bis-(diphenylphosphino)-ferrocene) palladium dichloride (0.002 g, 0.003 mmol) under an atmosphere of nitrogen. The mixture was irradiated in the microwave at 100 ⁰C, for 30 min. The reaction mixture was partitioned between EtOAc and water and separated. The aqueous layer was extracted with EtOAc (3x) and the combined organic fractions were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by chromatography on silica gel [eluting 80% EtOAc in hexanes] to afford the Boc-protected product, MS (ES+): m/z = 495 [MH⁺]. This compound was taken up in DCM, charged with 0.25 mL of 1.0 M HCl in ether, and stirred at rt overnight. A solid precipitated out of solution that was filtered off and dried in vacuo to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^): δ = 2.11-2.31 (m, 4H), 3.05-3.18 (m, 2H), 3.41 (d, J= 12.8 Hz, 2H), 4.47-4.57 (m, IH), 7.47 (td, J= 9.0, 2.7 Hz, IH), 8.06 (s, IH), 8.12-8.19 (m, 2H), 8.36 (br. s., IH), 8.4 (s, IH), 8.53 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 395.12 [MH⁺]. HPLC: t_R = 2.03 min (ZQ2, polar_5min).

Example 253 : 3-(6-Chlorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2,6-dichloro-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.10-2.30 (m, 4H), 3.06-3.18 (m, 2H), 3.41 (d, J= 13.2 Hz, 2H), 4.52 (ddd, J= 14.8, 10.6, 4.2 Hz, IH), 7.62 (dd, J= 8.8, 1.8 Hz, IH), 8.05 (s, IH), 8.12 (d, J= 8.8 Hz, IH), 8.31 (br. s., IH), 8.37 (br. s., 2H), 8.53 (s, IH). MS (ES+): m/z = 411.08 [MH⁺]. HPLC: t_R = 2.30 min (ZQ2, polar_5min).

Example 254: 3-(6-Methylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-6-methyl-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 2.10-2.31 (m, 4H), 3.12 (q, J= 10.6 Hz, 2H), 3.42 (d, J= 12.4 Hz, 2H), 4.47-4.57 (m, IH), 7.41 (d, J= 6.9 Hz, IH), 7.96- 8.02 (m, 2H), 8.05 (s, IH), 8.31 (br. s., IH), 8.38 (s, IH), 8.49 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 391.15 [MH⁺]. HPLC: t_R = 2.22 min (ZQ2, polar_5min).

Example 255: 3-(6-Methoxybenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin- 2-ylamine Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-6-methoxy-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-iie): δ = 2.10-2.30 (m, 4H), 3.04-3.17 (m, 2H), 3.41 (d, J= 12.8 Hz, 2H), 3.89 (s, 3H), 4.48-4.59 (m, IH), 7.20 (dd, J= 9.1, 2.5 Hz, IH), 7.78 (d, J = 2.5 Hz, IH), 8.03 (d, J= 9.1 Hz, IH), 8.08 (s, IH), 8.38-8.45 (m, 2H), 8.50 (d, J= 2.0 Hz, IH). MS (ES+): m/z = 407.12 [MH⁺]. HPLC: t_R = 2.13 min (ZQ2, polar_5min).

Example 256: 3-(4-Fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-4-fluoro-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.11-2.22 (m, 2H), 2.23-2.31 (m, 2H), 3.06-3.18 (m, 2H), 3.42 (d, J= 12.1 Hz, 2H), 4.48-4.57 (m, IH), 7.42-7.49 (m, IH), 7.50-7.57 (m, IH), 8.00-8.07 (m, 2H), 8.30 (br. s., IH), 8.37 (br. s., IH), 8.54 (s, IH). MS (ES+): m/z = 395.12 [MH⁺]. HPLC: t_R = 2.05 min (ZQ2, polar_5min).

Example 257: 3-(4-Methylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-iodo-4-methyl-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.10-2.31 (m, 4H), 2.74 (s, 3H), 3.05-3.18 (m, 2H), 3.41 (d, J= 13.2 Hz, 2H), 4.49-4.57 (m, IH), 7.41-7.48 (m, 2H), 8.02 (dd, J= 6.4, 2.7 Hz, IH), 8.09 (s, IH), 8.45 (s, IH), 8.49 (br. s., IH), 8.56 (d, J= 1.8 Hz, IH). MS (ES+): m/z = 391.14 [MH⁺]. HPLC: t_R = 2.11 min (ZQ2, polar_5 min).

Example 258: 3-(5-Chlorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2,5-dichloro-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-iie): δ = 2.10-2.22 (m, 2H), 2.22-2.30 (m, 2H), 3.12 (q, J= 11.1 Hz, 2H), 3.42 (d, J= 12.4 Hz, 2H), 4.47-4.55 (m, IH), 7.56 (d, J = 8.4 Hz, IH), 8.03 (s, IH), 8.19-8.24 (m, 2H), 8.26 (br. s., IH), 8.35 (s, IH), 8.52 (s, IH). MS (ES+): m/z = 411.09/413.10 (3:1) [MH⁺]. HPLC: t_R = 2.18 min (ZQ2, polar_5min). 2,5-Dichloro-l,3-benzothiazole

To 5-chloro-2-mercaptobenzothiazole (1.5 g, 7.4 mmol) was added sulfuryl chloride (5 mL, excess) with stirring below 5 ⁰C under nitrogen. The resulting suspension was stirred for 3 h at rt, carefully poured onto ice (100 g), and stirred for another 2 h. The white solid that separated out was filtered off, washed repeatedly with cold water, and dried in vacuo to afford the title compound. ¹H-NMR (CDCl₃, 300 MHz): δ = 7.95 (s, IH), 7.70 (d, J = 8.4 Hz, IH), 7.37 (d, J = 8.7 Hz, IH). S-Chloro^-mercaptobenzothiazole

A solution of 5-chloro-2-fluoroaniline (2.0 g, 13.7 mmol, 1 eq.) and potassium O-ethyl dithiocarbonate (4.8 g, 30.3 mmol, 2.2 eq) in anhydrous DMF (20 mL) was heated at 100 ⁰C under nitrogen for 4 h. The reaction mixture was cooled to room temp., diluted with water (50 mL), and acidified with 2N HCl with constant stirring at low temperature. Yellowish solid was collected by filtration, and washed with cold water. The wet filter cake was dissolved in ethyl acetate (50 mL), and the solution was dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound as yellowish solid. ¹H-NMR (CDCl₃, 300 MHz): δ = 7.71 (d, J= 8.1 Hz, IH), 7.34 (d, J= 8.1Hz, IH), 7.27 (s, IH).

Example 259: 3-(7-Chlorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2,7-dichloro-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.10-2.22 (m, 2H), 2.23-2.31 (m, 2H), 3.12 (q, J= 11.1 Hz, 2H), 3.42 (d, J= 12.4 Hz, 2H), 4.46-4.56 (m, IH), 7.60-7.66 (m, 2H), 8.09 (s, IH), 8.12 (dd, J= 6.2, 2.9 Hz, IH), 8.44 (s, 2H), 8.56 (d, J= 1.8 Hz, IH). MS (ES+): m/z = 411.09/413.06 (3:1) [MH⁺]. HPLC: t_R = 2.16 min (ZQ2, polar_5min). 2,7-Dichloro-l,3-benzothiazole

The title compound was prepared from 2,3-dichloroaniline via 7-chloro-2-mercaptobenzothiazole as described for 2,5-dichloro-l,3-benzothiazole.

Example 260: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(7-trifluoromethylbenzothiazol-2-yl)- pyridin-2-ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-7-trifluoromethyl-l,3-benzothiazole in place of 2-chloro-6-fluoro-l,3- benzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.12-2.31 (m, 4H), 3.05-3.18 (m, 2H), 3.41 (d, J= 12.8 Hz, 2H), 4.47-4.57 (m, IH), 7.83 (t, J= 8.0 Hz, IH), 7.97 (d, J= 7.3 Hz, IH), 8.12 (s, IH), 8.47 (d, J= 8.0 Hz, IH), 8.49 (s, IH), 8.57 (s, IH), 8.60 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 445.08 [MH⁺]. HPLC: t_R = 2.38 min (ZQ2, polar_5min). 2-Chloro-7-trifluoromethyl-l,3-benzothiazole

The title compound was prepared from 2-fluoro-3-trifluoromethylaniline via 2-mercapto-7- trifluoromethyl-l,3-benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 90 ⁰C for 4 h.

Example 261 : 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(5-trifluoromethylbenzothiazol-2-yl)- pyridin-2-ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-5-trifluoromethyl-l,3-benzothiazole in place of 2-chloro-6- fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^): δ = 2.12-2.30 (m, 4H), 3.04-3.17 (m, 2H), 3.36-3.45 (m, 2H), 4.48^.58 (m, IH), 7.84 (dd, J= 8.6, 1.2 Hz, IH), 8.07 (s, IH), 8.40-8.44 (m, 2H), 8.46 (d, J= 8.4 Hz, IH), 8.54 (s, IH), 8.57 (d, J= 2.2 Hz, IH). MS (ES+): m/z = 445.09 [MH⁺]. HPLC: t_R = 2.39 min (ZQ2, polar_5min). 2-Chloro-5-trifluoromethyl-l,3-benzothiazole

The title compound was prepared from 2-fluoro-5-trifluoromethylaniline via 2-mercapto-5- trifluoromethyl-l,3-benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 95 ⁰C for 4 h.

Example 262: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(4-trifluoromethylbenzothiazol-2-yl)- pyridin-2-ylamine

A mixture of 4- {4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (BB8) (75 mg, 0.16 mmol), 2-chloro-4- trifluoromethyl-l,3-benzothiazole (46 mg, 0.19 mmol), potassium carbonate (66 mg, 0.48 mmol), Pd(PPh₃)₄ (18 mg, 0.016 mmol) in DME (3 mL) and H₂O (1 mL) was evacuated and refilled with N₂ (3x), then it was heated at 100 ⁰C for 30 min in the microwave reactor. The mixture was diluted with EtOAc (30 mL), washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (Hex.:EtOAc = 30:70 → 15:85) to give a yellow solid. This material was dissolved in DCM (2 mL) and treated with IM HCl in diethyl ether (3 mL). The resulting mixture was stirred at room temperature overnight. The title compound was collected by filtration as a yellow solid and washed with DCM. MS (ES+): m/z = 445.10 [MH⁺]. 2-Chloro-4-trifluoromethyl-l,3-benzothiazole

The title compound was prepared from 2-fluoro-5-trifluoromethylaniline via 2-mercapto-4- trifluoromethyl-l,3-benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 100 ⁰C for 6 h. Example 263 : 3-(7-Methylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-7-methyl-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): 8 = 2.11-2.31 (m, 4H), 2.61 (s, 3H), 3.12 (q, J= 11.8 Hz, 2H), 3.42 (d, J= 12.8 Hz, 2H), 4.46-4.56 (m, IH), 7.36 (d, J= 7.3 Hz, IH), 7.52 (t, J = 7.7 Hz, IH), 7.97 (d, J= 8.0 Hz, IH), 8.07 (s, IH), 8.43 (br. s., 2H), 8.52 (s, IH). MS (ES+): m/z = 391.16 [MH⁺]. HPLC: t_R = 2.24 min (ZQ2, polar_5min). 2-Chloro-7-methyl-l,3-benzothiazole The title compound was prepared from 2-fluoro-3-methylaniline via 2-mercapto-7-methyl-l,3- benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 180 ⁰C for 24 h in a sealed tube.

Example 264: 3-(7-Methoxybenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin- 2-ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-7-methoxy-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.80 (d, J= 2.0 Hz, IH), 8.38 (s, IH), 8.35 (d, J= 2.0 Hz, IH), 8.07 (s, IH), 7.79 (d, J= 8.0 Hz, IH), 7.59 (m, IH), 7.13 (d, J= 7.6 Hz, IH), 4.66 (m, 1 H), 4.06 (s, 3H), 3.59-3.62 (m, 2H), 2.33-2.39 (m, 4H). MS(ES+): m/z = 407.13 [MH⁺]. HPLC: t_R = 1.78 min (polar_5min, ZQ3).

2-Chloro-7-methoxy-l,3-benzothiazole

The title compound was prepared from 2-bromo-3-methoxyaniline via 2-mercapto-7-methoxy-l,3- benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 120 ⁰C for 10 h.

Example 265: 3-(4-Bromobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 4-bromo-2-chloro-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.81 (s, IH), 8.44 (s, IH), 8.41 (s, IH), 8.11 (d, J= 8.0 Hz, IH), 8.08 (s, IH), 7.84 (d, J= 8.0 Hz, IH), 7.47 (t, J= 8.0 Hz, IH), 4.68 (m, IH), 3.59-3.63 (m, 2H), 2.38-2.41 (m, 4H). MS(ES+): m/z = 455.01/456.92 [MH⁺]. HPLC: t_R = 1.59 min (polar_5min, ZQ3). 4-Bromo-2-chloro-l,3-benzothiazole The title compound was prepared from 2,6-dibromoaniline via 4-bromo-2-mercapto-l,3- benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 150 ⁰C for 16 h.

Example 266: 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-(6-trifluoromethoxybenzothiazol-2-yl)- pyridin-2-ylamine

Following the procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-(4- trifluoromethylbenzothiazol-2-yl)-pyridin-2-ylamine, but using 2-chloro-6-trifluoromethoxy-l,3- benzothiazole, the title compound was obtained as yellow solid. MS (ES+): m/z = 461.08 [MH⁺].

2-Chloro-6-trifluoromethoxy-l,3-benzothiazole The title compound was prepared from 2-bromo-4-trifluoromethoxyaniline via 2-mercapto-6- trifluoromethoxy-l,3-benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 150 ⁰C for 16 h.

Example 267: 2-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-benzothiazole-5- carbonitrile

Following the procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-(4- trifluoromethylbenzothiazol-2-yl)-pyridin-2-ylamine, but using 2-chloro-l,3-benzothiazole-5- carbonitrile, the title compound was obtained as yellow solid. MS (ES+): m/z = 402.13 [MH⁺].

2-Chloro-l,3-benzothiazole-5-carbonitrile The title compound was prepared from 3-amino-4-chlorobenzonitrile via 2-mercapto- 1 ,3- benzothiazole-5-carbonitrile as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 95 ⁰C for 1O h.

Example 268: 2-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-benzothiazole-6- carbonitrile

Following the procedure for 5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-3-(4- trifluoromethylbenzothiazol-2-yl)-pyridin-2-ylamine, but using 2-chloro-l,3-benzothiazole-6- carbonitrile, the title compound was obtained as yellow solid. MS (ES+): m/z = 402.13 [MH⁺].

2-Chloro-l,3-benzothiazole-6-carbonitrile The title compound was prepared from 4-amino-3-chlorobenzonitrile via 2-mercapto- 1 ,3- benzothiazole-6-carbonitrile as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 120 ⁰C for 12 h.

Example 269: 3-(7-Fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine To a solution of 4-{4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (BB8) (60 mg, 0.127 mmol, 1 eq), 2-chloro- 7-fluoro-4-trifluoromethyl-l,3-benzothiazole (42 mg, 0.153 mmol, 1.2eq), and potassium carbonate (43 mg, 0.317 mmol, 2.5 eq) in 20% aq. dioxane (15 mL) was bubbled N₂ gas for 15 min. Catalyst PdCl₂dppf (5 mol%) was added to the stirred solution and N₂ gas bubbling continued for another 10 min. The reaction mixture was then heated at 80 ⁰C for 2 h. Cooling of the reaction mixture and evaporation of dioxane under reduced pressure yielded a brown residue. It was diluted with water (50 mL) and extracted with ethyl acetate (3x20 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield a yellowish-green solid. It was purified by column chromatography (50% ethyl acetate in hexane) to afford the BOC-protected title compound as yellowish-green solid; MS(ES+): m/z = 563 [MH⁺]. To a solution of this Boc derivative (40 mg, 0.07 mmol) at 0-5 ⁰C in dry DCM (10 ml) was added 4M HCl in dioxane (0.2 ml) dropwise and stirred the reaction mixture overnight at rt. Removed solvent under reduced pressure to afford the title compound as yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 9.06-8.96 (brm, IH), 8.85-8.73 (brm, IH), 8.61 (d, J = 2.0 Hz, IH), 8.42 (s, IH), 8.41 (d, J = 2.0 Hz, IH), 8.17 (very brs, IH), 8.09 (s, IH), 8.03 (dd, J= 5.2, 8.4 Hz, IH), 7.59 (t, J= 8.4 Hz, IH), 4.56-4.46 (m_c, IH), 3.41 (brd, J= 12.4 Hz, 2H), 3.12 (brq, J= 11.4 Hz, 2H), 2.31-2.11 (m, 4H). MS(ES+): m/z = 463.05 (100) [MH⁺], 380.02 (80) [MH⁺ - piperidine]. HPLC: t_R = 2.29 min (polar_5min, ZQ2).

2-Chloro-7-fluoro-4-trifluoromethyl-l,3-benzothiazole The title compound was prepared from 2,3-difluoro-6-trifluoromethylaniline via 2-mercapto-7- fluoro-4-trifluoromethyl-l,3-benzothiazole as described for 2,5-dichloro-l,3-benzothiazole except that in the first step the reaction mixture was heated to 90 ⁰C for 4 h.

Example 270: 3-(7-Fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 7-fluoro-2-iodo-l,3-benzothiazole and conducting the Suzuki coupling at 50 ⁰C for 1.5 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.84 (d, J= 2.0 Hz, IH), 8.41 (m, IH), 8.40 (s, IH), 8.09 (s, IH), 8.04 (dd, J= 0.8, 8.0 Hz, IH), 7.66 (m, IH), 7.38 (m, IH), 4.66 (m, 1 H), 3.62 (dt, J= 3.2, 13.2, 2H), 3.24-3.28 (m, 2H), 2.36-2.40 (m, 4H). MS(ES+): m/z = 395.12 [MH⁺]. HPLC: t_R = 1.62 min (polar_5min, ZQ3).

7-Fluoro-2-iodo-l,3-benzothiazole

To a solution of p-TsOHΗ₂O (570 mg, 3.0 mmol, 3 eq) in acetonitrile (10 mL) was added 2- amino-7-fluoro-l,3-benzothiazole (168 mg,1.0 mmol). The resulting suspension was cooled to 10 ⁰C, a solution OfNaNO₂ (138 mg, 2.0 mmol, 2 eq) and KI (412 mg, 2.5 mmol, 2.5 eq) in 3 mL of water was added, and the reaction mixture was stirred for 4 h. The pH of the reaction mixture was adjusted to 9- 10 by addition of saturated aq. NaHCθ3 solution, and the reaction mixture was extracted with ethyl acetate (3x20 mL). The combined extracts were, washed with aqueous sodium thiosulfate solution (30 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The brownish residue was purified by column chromatography (eluted by 1% methanol in DCM) to give the title compound. ¹H- NMR (CDCl₃, 300 MHz): δ = 7.71 (dd, J= 8.4 & 0.9, IH), 7.42-7.39 (m, IH), 7.12 (dt, J= 8.1 &1.2, IH).

2-Amino-7-fluoro-l,3-benzothiazole

A mixture of 7-fluoro-2-methylsulfonyl-l,3-benzothiazole (500 mg, 2.16 mmol) in 10 mL ethanol and 20% ethanolic ammonia (20 mL) was heated at 160 ⁰C in a sealed tube for 12 h. It was cooled to RT, ethanol was removed under reduced pressure, and the brownish residue was purified by column chromatography (5% to 10% methanol in methylene chloride) to afford the title compound. ¹H-NMR (CDCl₃, 300 MHz): δ = 7.35 (d, J = 7.5 Hz, IH), 7.33-7.37 (m, IH), 6.93-6.84 (m, IH), 5.30 (brs, 2H). 7-Fluoro-2-methanesulfonyl-l,3-benzothiazole

To a well-stirred solution of 7-fluoro-2-methylsulfanyl-l,3-benzothiazole (1.1 g, 5.5 mmol) in acetic acid (15 mL) was added a solution Of KMnO₄ (1.74 g, 11 mmol, 2 eq, dissolved in 15 mL water) dropwise, and the reaction mixture was stirred at rt for 30 min. The reaction mixture was extracted with EtOAc (5x25 mL), and the combined organic layers were washed with water (2x20 mL) and brine (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound. ¹H-NMR (CDCl₃, 300 MHz): δ = 8.12 (d, J= 8.1 Hz, IH), 7.83-7.28 (m, IH), 7.04-6.97 (m, IH), 3.41 (s, 3H).

7-Fluoro-2-methylsulfanyl-l,3-benzothiazole

To a well-stirred solution of 7-fluoro-2-mercaptobenzothiazole (1.0 g, 5.4 mmol) in 10 % aq. NaOH (10 mL) was added methyl iodide (2.14 g, 2.8 eq) dropwise, and the reaction mixture was stirred at rt for 30 min. A yellowish solid was collected by filtration, washed with cold water, and dissolved in ethyl acetate (50 mL). The EtOAc solution was dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the title compound. ¹H-NMR (CDCl₃, 300 MHz): δ = 7.66 (d, J= 8.1 Hz, IH), 7.40-7.33 (m, IH), 7.04-6.97 (m, IH), 2.80 (s, 3H). 7-Fluoro-2-mercaptobenzothiazole

The title compound was prepared from 2,3-difluoroaniline as described for 5-chloro-2- mercaptobenzothiazole except that in the first step the reaction mixture was heated to 90 ⁰C for 4 h.

Example 271 : 3-(5-Methoxybenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin- 2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-5-methoxy-l,3-benzothiazole and conducting the Suzuki coupling at 55 ⁰C for 4 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.75 (s, IH), 8.40 (s, IH), 8.34 (s, IH), 8.06 (s, IH), 7.95 (d, J = 8.8 Hz, IH), 7.69 (d, J = 2.4 Hz, IH), 7.21 (dd, J= 2.4, 8.8 Hz, IH), 4.67 (m, IH), 3.94 (s, 3 H), 3.59-3.62 (m, 2H), 3.25-3.27 (m, 2H), 2.34-2.39 (m, 4H). MS(ES+): m/z = 407.13 [MH⁺]. HPLC: t_R = 1.12 min (polar_5min, ZQ3). 2-Iodo-5-methoxy-l ,3-benzothiazole

The title compound was prepared following the route for 7-fluoro-2-iodo-l,3-benzothiazole from 2,3-difluoroaniline, starting from 2-chloro-5-methoxyaniline and conducting the first step at 150 ⁰C for 16 h.

Example 272: 3-(5-Methylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-5-methyl-l,3-benzothiazole and conducting the Suzuki coupling at 80 ⁰C for 3 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 8.96-8.87 (brm, IH), 8.75-8.65 (brm, IH), 8.51 (d, J= 2.0 Hz, IH), 8.40 (s, IH), 8.37 (brs, IH), 8.35 (very brs, IH), 8.06 (d, J= 8.0 Hz, IH), 8.06 (s, IH), 7.36 (dd, J= 8.0, 1.0 Hz, IH), 4.56-4.48 (m_c, IH), 3.11 (brq, J= 11.0 Hz, 2H), 2.30-2.10 (m, 4H); CH₃ and additional 2H hidden under water peak. MS(ES+): m/z = 391.14 (72) [MH⁺], 308.09 (100) [MH⁺ - piperidine]. HPLC: t_R = 2.10 min (polar_5min, ZQ2). 2-Iodo-5-methyl-l ,3-benzothiazole

The title compound was prepared following the route for 7-fluoro-2-iodo-l,3-benzothiazole from 2,3-difluoroaniline, starting from 2-fluoro-5-methylaniline and conducting the first step at 180 ⁰C for 48 h in a sealed tube.

Example 273: 3-(7-Bromobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 7-bromo-2-iodo-l,3-benzothiazole and conducting the Suzuki coupling at 60 ⁰C for 4 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 9.20-9.09 (brm, IH), 9.02-8.90 (brm, IH), 8.61 (very brs, IH), 8.60 (s, 2H), 8.52 (s, IH), 8.18 (d, J= 8.0 Hz, IH), 8.13 (s, IH), 7.78 (d, J= 8.0 Hz, IH), 7.58 (t, J= 8.0 Hz, IH), 4.57- 4.47 (m_c, IH), 3.40 (brd, J= 12.8 Hz, 2H), 3.11 (brq, J= 11.2 Hz, 2H), 2.31-2.12 (m, 4H). MS(ES+): m/z = 454.98/457.00 (79/83) [MH⁺], 371.94/373.95 (95/100) [MH⁺ - piperidine]. HPLC: t_R = 2.22 min (polar_5min, ZQ2). 7-Bromo-2-iodo-l,3-benzothiazole The title compound was prepared following the route for 7-fluoro-2-iodo- 1 ,3-benzothiazole from

2,3-difluoroaniline, starting from 2,3-dibromoaniline (prepared according to J. Org. Chem. 1990, 55(9), 2739) and conducting the first step at 95 ⁰C for 4 h.

Example 274: 3-(4,5-Difluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin- 2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-chloro-4,5-difluoro-l,3-benzothiazole and conducting the Suzuki coupling at 80 ⁰C for 3 h, the title compound was obtained as a yellow solid. MS (ES⁺): m/z = 413.13 [MH⁺]. HPLC: t_R = 2.46 min (ZQ3, polar_5min). 2-Chloro-4,5-difluoro-l,3-benzothiazole

To a mixture of 2-amino-4,5-difluoro-l,3-benzothiazole (130 mg, 0.70 mmol) and CUSO₄ (20 mg) in cone. HCl (20 mL) was added NaNU₂ (96 mg, 1.4 mmol, 2 eq, dissolved in 5 mL of water) dropwise at -10 ⁰C over about 15 min. The reaction mixture was stirred for 1 h, poured into a solution of CuCl (67 mg, 0.7 mmol, 1 eq.) in cone. HCl (20 mL), and stirring was continued at ambient temp, for 30 min. The reaction mixture was extracted with diethyl ether (3><30 mL). The combined organic layers were washed with water (10 mL), dilute ammonium hydroxide (10 mL), brine (20 ml), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluted by 2% methanol in methylene chloride) to afford the title compound. ¹H-NMR (CDCl₃, 300 MHz): δ = 7.20-7.15 (m, IH), 7.13-7.04 (m, IH). 2-Amino-4,5-difluoro-l,3-benzothiazole

The title compound was prepared following the route for 2-amino-7-fluoro-l,3-benzothiazole from 2,3-difluoroaniline, starting from 2,3,6-trifluoroaniline and conducting the first step at 100 ⁰C for 4 h.

Example 275: 2-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-benzothiazole-7- carbonitrile

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-l,3-benzothiazole-7-carbonitrile and conducting the Suzuki coupling at 55 ⁰C for 3 h, the title compound was obtained as a brown solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.10-2.31 (m, 4H), 3.05-3.18 (m, 2H), 3.37-3.44 (m, 2H), 3.77 (brs, 2H), 4.45- 4.54 (m, IH), 7.51 (brs, IH), 7.75-7.78 (m, IH), 8.07 (d, J= 7.2 Hz, IH), 8.10 (s, IH), 8.44-8.48 (m, 3H), 8.58 (brs, IH), 8.88 (brs, IH), 9.10 (brs, IH). MS(ES+): m/z = 402.13 (100) [MH⁺]. HPLC: f_R = 2.06 min (ZQ3, polar_5min).

2-Iodo-l,3-benzothiazole-7-carbonitrile

The title compound was prepared from 2-methylsulfanyl-l,3-benzothiazole-7-carbonitrile as described for 7-fluoro-2-iodo- 1 ,3-benzothiazole. 2-Methylsulfanyl-l ,3-benzothiazole-7-carbonitrile

The title compound was prepared from 7-bromo-2-methylsulfanyl-l,3-benzothiazole by heating with CuCN (1.0 eq.) in DMF at 160 ⁰C for 12 h.

Example 276 : 3-(5-Bromobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 5-bromo-2-iodo-l,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.11-2.30 (m, 4H), 3.11 (q, J = 11.0 Hz, 2H), 3.41 (d, J= 12.8 Hz, 2H), 4.47-4.56 (m, IH), 7.74 (dd, J= 8.6, 2.0 Hz, IH), 8.03-8.08 (m, 2H), 8.34 (br. s., IH), 8.39 (s, IH), 8.51 (d, J= 1.4 Hz, IH), 8.54 (d, J = 2.2 Hz, IH). MS (ES+): m/z = 455.02/457.00 [MH⁺]. HPLC: t_R = 2.19 min (ZQ2, polar_5min).

5-Bromo-2-iodo-l,3-benzothiazole

The title compound was obtained following the procedure for 7-fluoro-2-iodo-l,3-benzothiazole, using 2-amino-5-bromo- 1,3-benzothiazole.

Example 277: 3-(4-Methoxybenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin- 2-ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-4-methoxy- 1,3-benzothiazole in place of 2-chloro-6-fluorobenzothiazole of the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.09-2.30 (m, 4H), 3.05- 3.19 (m, 2H), 3.42 (d, J= 13.2 Hz, 2H), 4.01 (s, 3H), 4.46-4.56 (m, IH), 7.14 (d, J= 8.0 Hz, IH), 7.46 (t, J= 8.07 Hz, IH), 7.70 (d, J= 8.0 Hz, IH), 8.03 (s, IH), 8.25 (br. s., IH), 8.36 (s, IH), 8.49 (d, J = 2.2 Hz, IH). MS (ES+): m/z = 407.14 [MH⁺]. HPLC: t_R = 1.93 min (ZQ2, polar_5min).

2-Chloro-4-methoxy-l,3-benzothiazole The title compound was obtained following the procedure for 2-chloro-4,5-difluoro- 1,3- benzothiazole, using 2-amino-4-methoxy- 1,3-benzothiazole.

Example 278: 3-(4-Chlorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2,4-dichlorobenzothiazole in place of 2-chloro-6-fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-iie): δ = 2.10-2.31 (m, 4H), 3.05-3.19 (m, 2H), 3.33-3.48 (m, 2H), 4.46-4.59 (m, IH), 7.53 (t, J= 7.8 Hz, IH), 7.71 (d, J= 7.3 Hz, IH), 8.07 (s, IH), 8.19 (d, J= 8.0 Hz, IH), 8.41 (br. s., 2H), 8.56 (s, IH). MS (ES+): m/z = 411.09/413.08 (3:1) [MH⁺]. HPLC: t_R = 2.16 min (ZQ2, polar_5min). 2,4-Dichloro-l,3-benzothiazole

The title compound was obtained following the procedure for 2-chloro-4,5-difluoro-l,3- benzothiazole, using 2-amino-4-chloro-l,3-benzothiazole.

Example 279: 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-(6-trifluoromethylbenzothiazol-2-yl)- pyridin-2-ylamine

Same procedure as 3-(6-fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)-pyridin-2- ylamine except using 2-chloro-6-trifluoromethyl-l,3-benzothiazole in place of 2-chloro-6- fluorobenzothiazole to afford the title compound as a yellow solid. ¹H NMR (400 MHz, DMSO-^₆): δ = 2.11-2.30 (m, 4H), 3.11 (q, J = 10.8 Hz, 2H), 3.41 (d, J = 12.4 Hz, 2H), 4.47-4.58 (m, IH), 7.92 (d, J = 8.4 Hz, IH), 8.08 (s, IH), 8.32 (d, J= 8.4 Hz, IH), 8.43 (br. s., 2H), 8.58 (br. s., IH), 8.76 (br. s., IH). MS (ES+): m/z = 445.08 [MH⁺]. HPLC: t_R = 2.25 min (ZQ2, polar_5min).

2-Chloro-6-trifluoromethyl-l,3-benzothiazole

The title compound was obtained following the procedure for 2-chloro-4,5-difluoro-l,3- benzothiazole, using 2-amino-6-trifluoromethyl- 1 ,3-benzothiazole.

Example 280 : 3-(7-Methyl-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-l/7- pyrazol-4-yl)-pyridin-2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-7-methyl-4-trifluoromethyl-l,3-benzothiazole and conducting the Suzuki coupling at 55 ⁰C for 3 h, the title compound was obtained as a yellow-green solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 2.10-2.31 (m, 4H), 2.70 (s, 3H), 3.07-3.18 (m, 2H), 3.37- 3.44 (m, 2H), 3.54 (brs, 2H), 4.47-4.56 (m, IH), 7.53 (d, J= 9.2 Hz, IH), 7.88 (d, J= 7.6 Hz, IH), 8.08 (d, J= 0.8 Hz, IH), 8.41-8.46 (m, 2H), 8.57 (d, J= 2.4 Hz, IH), 8.76 (brs, IH), 8.96 (brs, IH). MS(ES+): m/z = 459.09 (100) [MH⁺]. HPLC: t_R = 2.32 min (ZQ3, polar_5min). 2-Iodo-7-methyl-4-trifluoromethyl-l ,3-benzothiazole

The title compound was obtained following the procedure for 7-fluoro-2-iodo-l,3-benzothiazole, using 2-amino-7-methyl-4-trifluoromethyl- 1 ,3-benzothiazole.

2-Amino-7-methyl-4-trifluoromethyl-l,3-benzothiazole

A solution of bromine in dichloromethane (3.4 mL, 1.0M in DCM, 1.0 eq) was added dropwise to a solution of (5-methyl-2-trifluoromethylphenyl)-thiourea (800 mg, 3.4 mmol, 1.0 eq) in dry DCM (100 mL) below 30 ⁰C. The reaction mixture was heated at reflux for 3 h and cooled to room temp. A precipitate was collected by filtration, then suspended in water (20 mL), and the pH was adjusted to 11 with NH₄OH. The mixture was then extracted with ethyl acetate (3 x20 mL), and the combined organic layers were washed with water (30 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The brown residue was purified by column chromatography on silica gel (eluted by 1% methanol in DCM) to afford 2-amino-7-methyl-4-trifluoromethyl-l,3-benzothiozole as white solid. ¹H-NMR (CDCl₃, 300 MHz): δ = 7.53 (d, J= 8.4, IH), 7.15 (d, J= 8.4, IH), 5.76 (brs, 2H), 2.59 (s, 3H).

(5-Methyl-2-trifluoromethylphenyl)-thiourea

Benzoyl chloride (880 mg, 6.2 mmol, 1.1 eq) was added dropwise to a solution of ammonium thiocyanate (471 mg, 6.2 mmol, 1.1 eq) in acetone (20 mL). The suspension was heated at reflux, and 2-trifluoromethyl-5-methylaniline (1.0 g, 5.7 mmol, 1.0 eq) was added. The reaction was diluted with acetone (10 mL) and continued to heat under reflux for 1 h. To this mixture, a solution of NaOH (706 mg, 17.6 mmol, 3.1 eq) in water (10 mL) was added and heated at reflux for 1.5 h. The reaction mixture was cooled, and solvents were removed under reduced pressure. The pH was adjusted to 5 with cone. HCl and then to 11 with aqueous NH₄OH to give a precipitate. It was filtered off, washed with water, and dried under vacuum to yield the title compound as white solid. ¹H-NMR (CDCI3, 300 MHz): δ = 7.74 (brs, IH), 7.67 (d, J= 8.1 Hz, IH), 7.42 (d, J= 8.1 Hz, IH), 6.16 (brs, 2H), 2.75 (s, 3H).

Example 281: 5-(l-Piperidin-4-yl-l//-pyrazol-4-yl)-3-(5-trifluoromethoxybenzothiazol-2-yl)- pyridin-2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-5-trifluoromethoxy-l,3-benzothiazole and conducting the Suzuki coupling at 50 ⁰C for 2 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, CD₃OD): δ = 8.84 (d, J= 1.6 Hz, IH), 8.43 (s, IH), 8.42 (d, J= 2.0 Hz, IH), 8.24 (d, J= 8.4 Hz, IH), 8.15 (m, IH), 8.09 (s, IH), 7.55 (m, IH), 4.68 (m, IH), 3.61-3.68 (m, 2H), 3.28-3.30 (m, 2H), 2.35-2.42 (m, 4H). MS(ES+): m/z = 461.15 [MH⁺]. HPLC: t_R = 1.84 min (polar_5min, ZQ3).

2-Iodo-5-trifhioromethoxy-l,3-benzothiazole

The title compound was obtained following the procedures for the synthesis of 2-iodo-7-methyl-4- trifluoromethyl-l,3-benzothiazole from 2-trifluoromethyl-5-methylaniline, using 3- trifluoromethoxyaniline.

Example 282: 3-(7-Chloro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 7-chloro-2-iodo-4-trifluoromethyl-l,3-benzothiazole and conducting the Suzuki coupling at 70 ⁰C for 3 h, the title compound was obtained as a yellow-green solid. ¹H NMR (400 MHz, DMSO-<i₆): δ = 2.14-2.36 (m, 4H), 3.05-3.18 (m, 2H), 3.37-3.44 (m, 2H), 4.01 (brs, 2H), 4.45-4.56 (m, IH), 7.82 (d, J= 8.4 Hz, IH), 7.99 (d, J= 8.4 Hz, IH), 8.11 (s, IH), 8.25 (brs, IH), 8.46 (s, IH), 8.47 (d, J = 2.0 Hz, IH), 8.62 (d, J = 2.4 Hz, IH), 8.86 (brs, IH), 9.06 (brs, IH). MS(ES+): m/z = 478.98/481.00 (100/76) [MH⁺]. HPLC: t_R = 2.37 min (ZQ3, polar_5min). 7-Chloro-2-iodo-4-trifluoromethyl-l,3-benzothiazole

The title compound was obtained following the procedures for the synthesis of 2-iodo-7-methyl-4- trifluoromethyl-l,3-benzothiazole from 2-trifluoromethyl-5-methylaniline, using 5-chloro-2- trifluoromethylaniline.

Example 283 : 3-(5-Fluorobenzothiazol-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2- ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 5-fluoro-2-iodo- 1 ,3-benzothiazole and conducting the Suzuki coupling at 55 ⁰C for 3 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 9.20-9.09 (brm, IH), 9.04-8.92 (brm, IH), 8.71 (very brs, IH), 8.58 (d, J= 2.0 Hz, IH), 8.55 (brs, IH), 8.47 (s, IH), 8.28 (dd, J= 5.2, 9.0 Hz, IH), 8.10 (s, IH), 8.01 (dd, J= 2.6, 9.4 Hz, IH), 7.47 (dt, J= 2.4, 9.0 Hz, IH), 4.58-4.48 (m_c, IH), 3.40 (brd, J= 12.5 Hz, 2H), 3.11 (brq, J = 12.0 Hz, 2H), 2.30-2.12 (m, 4H). MS(ES+): m/z = 395.09 (73) [MH⁺], 312.05 (100) [MH⁺ - piperidine]. HPLC: t_R = 2.06 min (polar_5min, ZQ2). 5-Fluoro-2-iodo-l,3-benzothiazole

The title compound was obtained following the procedures for the synthesis of 2-iodo-7-methyl-4- trifluoromethyl-l,3-benzothiazole from 2-trifluoromethyl-5-methylaniline, using 3-fluoroaniline.

Example 284: 2-[2-Amino-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-3-yl]-benzothiazole-4- carbonitrile

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-chloro-l,3-benzothiazole-4-carbonitrile and conducting the Suzuki coupling at 80 ⁰C for 2 h, the title compound was obtained as a yellow solid. ¹H NMR

(OMSO-d₆, 400 MHz): δ = 2.04-2.23 (m, 4H), 3.04 (m, 2H), 3.30 (m, 2H), 4.44 (m_c, IH), 7.59 (t, J= 7.8 Hz, IH), 7.99 (s, IH), 8.03 (dd, J= 7.6, 1.0 Hz, IH), 8.34 (s, IH), 8.49 (dd, J= 8.1, 1.0 Hz, IH), 8.51 (d, J= 2.3 Hz, IH), 8.86 (broad s, IH), 9.03 (broad s, IH). MS (ES⁺): m/z = 402.15 [MH⁺]. HPLC: t_R = 2.28 min (ZQ3, polar_5min). 2-Chloro-l ,3-benzothiazole-4-carbonitrile

The title compound was prepared from 2-amino-l,3-benzothiazole-4-carbonitrile as described for 2-chloro-4,5-difluoro- 1 ,3-benzothiazole.

2-Amino-l,3-benzothiazole-4-carbonitrile

The title compound was prepared from 2-amino-4-bromo-l,3-benzothiazole by heating with CuCN (1.0 eq.) in DMF at 160 ⁰C for 12 h. 2-Amino-4-bromo-l ,3-benzothiazole

The title compound was obtained following the procedures for the synthesis of 2-amino-7-methyl- 4-trifluoromethyl-l,3-benzothiazole from 2-trifluoromethyl-5-methylaniline, using 2-bromoaniline.

Example 285: 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-(4-trifluoromethoxybenzothiazol-2-yl)- pyridin-2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-4-trifluoromethoxy-l,3-benzothiazole and conducting the Suzuki coupling at 50 ⁰C for 12 h, the title compound was obtained as a yellow solid.

¹H NMR (400 MHz, DMSO-^₆): δ = 9.12-9.03 (brm, IH), 8.94-8.82 (brm, IH), 8.57 (d, J = 2.0 Hz, IH), 8.41 (brs, 2H), 8.34 (very brs, 2H), 8.26 (dd, J = 2.2, 6.6 Hz, IH), 8.07 (s, IH), 7.66-7.60 (m, 2H),

4.57-4.48 (m_c, IH), 3.41 (brd, J= 12.8 Hz, 2H), 3.11 (brq, J= 11.2 Hz, 2H), 2.30-2.12 (m, 4H).

MS(ES+): m/z = 461.06 (74) [MH⁺], 378.06 (100) [MH⁺ - piperidine]. HPLC: t_R = 2.27 min

(polar_5min, ZQ2).

2-Iodo-4-trifhioromethoxy-l,3-benzothiazole The title compound was obtained following the procedures for the synthesis of 2-iodo-7-methyl-4- trifluoromethyl-l,3-benzothiazole from 2-trifluoromethyl-5-methylaniline, using 2- trifluoromethoxyaniline.

Example 286: 3-(5-Fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 5-fluoro-2-iodo-4-trifluoromethyl-l,3-benzothiazole and conducting the Suzuki coupling at 80 ⁰C for 2 h, the title compound was obtained as a yellow solid. ¹H NMR (400 MHz, OMSO-d₆): δ = 9.02-8.92 (brm, IH), 8.80-8.70 (brm, IH), 8.58 (dd, J= 4.8, 9.2 Hz, IH), 8.57 (d, J= 2.0 Hz, IH), 8.37 (s, IH), 8.31 (d, J= 2.0 Hz, IH), 8.17 (brs, IH), 8.05 (s, IH), 7.64 (dd, J= 9.2, 11.2 Hz, IH), 4.56-4.47 (m_c, IH), 3.40 (brd, J= 12.8 Hz, 2H), 3.11 (brq, J= 11.4 Hz, 2H), 2.30-2.11 (m, 4H). MS(ES+): m/z = 463.07 (95) [MH⁺], 380.02 (100) [MH ⁺ - piperidine]. HPLC: t_R = 2.28 min (polar_5min, ZQ2).

5-Fluoro-2-iodo-4-trifluoromethyl-l,3-benzothiazole The title compound was obtained following the procedure for the synthesis of 2-iodo-7-methyl-4- trifluoromethyl-l,3-benzothiazole from 2-amino-7-methyl-4-trifluoromethyl-l,3-benzothiazole, using 2-amino-5-fluoro-4-trifluoromethyl- 1 ,3-benzothiazole.

Example 287: 3-(4-Bromo-6-trifluoromethoxybenzothiazol-2-yl)-5-(l-piperidin-4-yl-lH- pyrazol-4-yl)-pyridin-2-ylamine A mixture of 4- {4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (BB8) (75 mg, 0.16 mmol), 4-bromo-2-iodo- 6-trifluoromethoxy-l,3-benzothiazole (81 mg, 0.19 mmol), potassium carbonate (66 mg, 0.48 mmol), Pd(PPh₃)₄ (18 mg, 0.016 mmol) in DME (3 mL) and H₂O (1 mL) was evacuated and refilled with N₂ (3x), then it was heated at 80 ⁰C for 2 h. The mixture was diluted with EtOAc (30 mL), washed with brine (10 mL), and dried over anhydrous sodium sulfate. The residue was purified by silica gel chromatography (Hex.:EtOAc = 30:70 → 15:85) to give the Boc-protected title compound as a yellow solid, MS (ES+): m/z = 639/641 (1/1) [MH⁺]. This material was dissolved in DCM (1 mL) and treated with IM HCl in diethyl ether (3 mL, 3 mmol). The resulting mixture was stirred at room temperature overnight. The solid that formed was filtered off, washed with DCM, and dried in vacuo to give the title compound as yellow solid. MS (ES+): m/z = 538.98/540.96 (1/1) [MH⁺]. 4-Bromo-2-iodo-6-trifluoromethoxy-l,3-benzothiazole

The title compound was obtained following the procedures for the synthesis of 2-iodo-7-methyl-4- trifluoromethyl-l,3-benzothiazole from 2-trifluoromethyl-5-methylaniline, using 2-bromo-4- trifluoromethoxyaniline.

Example 288: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-piperidin-l- ylpropan-1-one

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 1.48-1.56 (m, 4H), 1.60-1.66 (m, 2H), 2.98 (t, J = 6.6 Hz, 2H), 3.39-3.45 (m, 2H), 3.50- 3.56 (m, 2H), 4.49 (t, J = 6.6 Hz, 2H), 7.40-7.44 (m, IH), 7.48-7.53 (m, IH), 7.80 (s, IH), 7.95 (t, J = 4.0 Hz, 2H), 8.00 (d, J = 7.6 Hz, IH), 8.11 (d, J = 2.0 Hz, IH), 8.27 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 433.16 (100) [MH⁺]. HPLC: t_R = 3.22 min (ZQ2, polar_5min).

Example 289: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-(3- hydroxypyrrolidin-l-yl)-propan-l-one

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 1.88-2.07 (m, 2H), 2.89-3.01 (m, 2H), 3.34-3.41 (m, IH), 3.41-3.49 (m, IH), 3.51-3.58 (m, 2H), 4.34-4.43 (m, J = 17.0, 4.3, 4.3, 2.5, 2.2 Hz, IH), 4.49 (td, J = 6.6, 1.6 Hz, 2H), 7.40-7.45 (m, IH), 7.49-7.53 (m, IH), 7.84 (s, IH), 7.96-8.03 (m, 3H), 8.14 (d, J = 2.3 Hz, IH), 8.29 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 435.11 (100) [MH⁺]. HPLC: t_R = 2.58 min (ZQ3, polar_5min).

Example 290: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-(4- hydroxypiperidin-l-yl)-propan-l-one The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 1.36-1.46 (m, 2H), 1.75-1.85 (m, 2H), 3.01 (td, J = 6.6, 3.4 Hz, 2H), 3.10-3.26 (m, 2H), 3.71-3.84 (m, 2H), 3.99-4.07 (m, IH), 4.48 (t, J = 6.7 Hz, 2H), 7.40-7.45 (m, IH), 7.49-7.53 (m, IH), 7.84 (s, IH), 7.96-8.02 (m, 3H), 8.14 (d, J = 2.3 Hz, IH), 8.29 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 449.15 (100) [MH⁺]. HPLC: t_R = 2.62 min (ZQ3, polar_5min).

Example 291: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-l-morpholin-4- ylpropan-1-one

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz,

CD₃OD): δ = 2.97 (t, J = 6.4 Hz, 2H), 3.43-3.48 (m, 2H), 3.54-3.64 (m, 6H), 4.50 (t, J = 6.4 Hz, 2H), 7.38-7.43 (m, IH), 7.47-7.51 (m, IH), 7.78 (s, IH), 7.91-7.94 (m, 2H), 7.99 (d, J = 7.6 Hz, IH), 8.08 (d, J = 2.3 Hz, IH), 8.25 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 435.15 (100) [MH⁺]. HPLC: t_R = 2.81 min (ZQ3, polar_5min).

Example 292: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^r-(2- methoxyethyl)-propionamide

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 2.77 (t, J = 6.6 Hz, 2H), 3.27 (s, 3H), 3.32-3.35 (m, 2H), 3.36-3.39 (m, 2H), 4.46 (t, J = 6.6 Hz, 2H), 7.38-7.43 (m, IH), 7.46-7.51 (m, IH), 7.76 (s, IH), 7.85 (s, IH), 7.93 (d, J = 7.3 Hz, IH), 7.99 (d, J = 7.6 Hz, IH), 8.07 (d, J = 2.3 Hz, IH), 8.24 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 423.16 (100) [MH⁺]. HPLC: t_R = 2.72 min (ZQ3, polar_5min).

Example 293: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^f-(2- hydroxyethyl)-propionamide

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 2.79 (t, J = 6.7 Hz, 2H), 3.25-3.29 (m, 2H), 3.56 (t, J = 5.6 Hz, 2H), 4.48 (t, J = 6.6 Hz, 2H), 7.39-7.44 (m, IH), 7.47-7.53 (m, IH), 7.78 (s, IH), 7.89 (s, IH), 7.95 (d, J = 8.1 Hz, IH), 8.00 (d, J = 7.6 Hz, IH), 8.10 (d, J = 2.3 Hz, IH), 8.26 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 409.13 (100) [MH⁺]. HPLC: t_R = 2.52 min (ZQ3, polar_5min).

Example 294: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ',Λ'-bis-(2- methoxyethyl)-propionamide The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 3.07 (t, J = 6.4 Hz, 2H), 3.29 (s, 3H), 3.32 (s, 3H), 3.49 (q, J = 4.8 Hz, 4H), 3.53-3.59 (m, 4H), 4.51 (t, J = 6.4 Hz, 2H), 7.41-7.46 (m, IH), 7.52 (td, J = 7.6, 1.3 Hz, IH), 7.81 (s, IH), 7.92 (s, IH), 7.96 (d, J = 7.3 Hz, IH), 8.02 (d, J = 7.6 Hz, IH), 8.12 (d, J = 2.0 Hz, IH), 8.28 (d, J = 2.3 Hz, IH). MS (ES⁺): m/z = 481.14 (100) [MH⁺]. HPLC: t_R = 3.01 min (ZQ3, polar_5min).

Example 295: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^/,Λ^/- dimethylpropionamide

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz,

CD₃OD): δ = 2.93 (s, 3H), 2.97 (t, J = 6.7 Hz, 2H), 2.99 (d, J = 1.0 Hz, 3H), 4.48 (t, J = 6.4 Hz, 2H), 7.41 (t, J = 7.6 Hz, IH), 7.49 (t, J = 7.6 Hz, IH), 7.77 (s, IH), 7.91-7.95 (m, 2H), 7.99 (d, J = 8.3 Hz, IH), 8.09 (dd, J = 2.1, 1.1 Hz, IH), 8.25 (d, J = 1.0 Hz, IH). MS (ES⁺): m/z = 393.14 (100) [MH⁺]. HPLC: t_R = 2.83 min (ZQ3, polar_5min).

Example 296: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-Λ^r- methylpropionamide

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 2.69 (d, J = 1.0 Hz, 3H), 2.76 (t, J = 6.4 Hz, 2H), 4.43-4.49 (m, 2H), 7.41 (t, J = 7.7 Hz, IH), 7.47-7.53 (m, IH), 7.79 (s, IH), 7.90 (s, IH), 7.95 (d, J = 7.8 Hz, IH), 8.00 (d, J = 8.1 Hz, IH), 8.09-8.12 (m, IH), 8.24-8.27 (m, IH). MS (ES⁺): m/z = 379.15 (100) [MH⁺]. HPLC: t_R = 2.65 min (ZQ3, polar_5min).

Example 297: 3-[4-(6-Amino-5-benzothiazol-2-ylpyridin-3-yl)-pyrazol-l-yl]-propionamide

The title compound was prepared according to the procedures described for 3-[4-(6-amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]- 1 -pyrrolidin- 1 -ylpropan- 1 -one. ¹H NMR (400 MHz, CD₃OD): δ = 2.80 (t, J = 6.6 Hz, 2H), 4.46 (t, J = 6.6 Hz, 2H), 7.39-7.44 (m, IH), 7.47-7.52 (m, IH), 7.77 (s, IH), 7.89 (s, IH), 7.94 (d, J = 8.1 Hz, IH), 8.00 (d, J = 8.1 Hz, IH), 8.09 (d, J = 2.3 Hz, IH), 8.25 (d, J = 2.0 Hz, IH). MS (ES⁺): m/z = 365.11 (100) [MH⁺]. HPLC: t_R = 2.57 min (ZQ3, polar_5min).

Example 298: 5-(l-Piperidin-4-yl-lH-pyrazol-4-yl)-3-(4,5,6,7-tetrahydro-benzothiazol-2-yl)- pyridin-2-ylamine A mixture of 4- {4-[6-amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester (BB8) (30 mg, 0.064 mmol), 2-iodo-4,5,6,7- tetrahydrobenzothiazole (20 mg, 0.077 mmol), potassium carbonate (26 mg, 0.19 mmol), and Pd(PPh₃ )₄ (7.4 mg, 0.0064 mmol) in DME (1.5 mL) and H₂O (0.5 mL) was evacuated and refilled with N₂ (3x). It was then heated at 100 ⁰C for 30 min in the microwave reactor. The mixture was diluted with EtOAc (30 mL), washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (Hex.:EtOAc = 30:70 → 15:85) to give a yellow solid. This material was dissolved in DCM (2 mL) and treated with IM HCl in diethyl ether (3 mL). The resulting mixture was stirred at room temperature for 3 h. The title compound was collected by filtration as a yellow solid, washed with DCM, and dried in vacuo. ¹H NMR (DMSO-(Z₆, 400 MHz): δ = 1.82-1.88 (m, 4H), 2.14-2.23 (m, 4H), 2.81-2.87 (m, 4H), 3.35-3.40 (m, 2H), 4.55 (m_c, IH), 8.09 (s, IH), 8.44 (d, J = 2.0 Hz, IH), 8.47 (s, IH), 8.50 (d, J = 2.0 Hz, IH). MS (ES+): m/z = 381.17 [MH⁺].

2-Iodo-4,5,6,7-tetrahydrobenzothiazole

The title compound was obtained following the procedure for 7-fluoro-2-iodo-l,3-benzothiazole, using 4,5,6,7-tetrahydrobenzothiazol-2-ylamine.

Example 299: 5-(l-Piperidin-4-yl-l/7-pyrazol-4-yl)-3-(5,6,7,8-tetrahydro-4/7- cycloheptathiazol-2-yl)-pyridin-2-ylamine

Following the procedure for 3-(7-fluoro-4-trifluoromethylbenzothiazol-2-yl)-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine, using 2-iodo-5,6,7,8-tetrahydro-4H-cycloheptathiazole and conducting the Suzuki coupling at 55 ⁰C for 3 h, the title compound was obtained as a yellow solid. MS (ES⁺): m/z = 395.19 [MH⁺]. HPLC: t_R = 2.21 min (ZQ3, polar_5min). 2-Iodo-5,6,7,8-tetrahydro-4//-cycloheptathiazole

The title compound was obtained following the procedure for 7-fluoro-2-iodo-l,3-benzothiazole, using 5,6,7,8-tetrahydro-4H-cycloheptathiazol-2-ylamine.

Example 300: 3-(3,4-Dihydro-lH-isoquinolin-2-yl)-5-(l-piperidin-4-yl-lH-pyrazol-4-yl)- pyridin-2-ylamine

A mixture of 4- {4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-ylj-piperidine-l-carboxylic acid tert-butyl ester (BB4) (93.9 mg, 0.200 mmol), 1,2,3,4- tetrahydroisoquinoline (53.3 mg, 0.400 mmol), cupric acetate (36.3 mg, 0.200 mmol), pyridine (32 μL, 0.40 mmol) and DCM (5 mL, 80 mmol) was stirred at rt under an atmosphere of air (Reaction A). Another reaction was set up with the same amount of above reagents, and 4 A molecular sieves (53 mg, 264 mg/mmol SM) was added (Reaction B). After stirring overnight at rt, the same amount of molecular sieve as in reaction B was added to reaction A. After stirring at rt for 7 h, both reaction mixtures were combined, washed with EDTA solution (2%, 3><30 ml), water (30 ml) and brine (30 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give a dark-blue solid. Purification by prep. TLC eluting with 5% MeOH/DCM gave 4-{4-[6-amino-5-(3,4-dihydro-lH-isoqumolm-2-yl)-pyridin-3- yl]-pyrazol-l-yl}-piperidine-l-carboxylic acid tert-butyl ester as brown oil; MS(ES+): m/z = 475.12 [MH⁺]. This brown oil was dissolved in MeOH (10 mL), 1.0 M of HCl in Et₂O (10 mL) was added, and the solution was stirred at rt for 3 d. The solvent was removed; the residue was dissolved in DMSO and purified by Gilson HPLC to give the title compound as light-brown oil. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 1.99-2.11 (m, 2H), 2.12-2.19 (m, 2H), 2.89-2.99 (m, 2H), 3.00-3.05 (m, 2H), 3.12- 3.18 (m, 2H), 3.26-3.33 (m, 2H), 4.10 (s, 2H), 4.33^.43 (m, IH), 5.51 (brs, 2H), 7.13-7.19 (m, 4H), 7.47 (d, J = 2.0 Hz, IH), 7.82 (s, IH), 7.99 (d, J = 2.0 Hz, IH), 8.13 (s, IH), 8.30 (brs, 2H). MS(ES+): m/z = 375.17 (42) [MH⁺]. HPLC: t_R = 1.73 min (ZQ2, polar_5min).

Example 301 : 3-(5-Fluoro-3,4-dihydro-l//-isoquinolin-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol-4- yl)-pyridin-2-ylamine

4- {4-[6-Amino-5-(5-fluoro-3,4-dihydro- lH-isoquinolin-2-yl)-pyridin-3-yl]-pyrazol- 1 -yl} - piperidine- 1 -carboxylic acid tert-buiyl ester (34 mg) was dissolved in MeOH (20 mL), 1.0 M of HCl in Et₂O (20 mL) was added, and the mixture was stirred at rt overnight. The solvent was removed in vacuo to give a brown oil. It was purified by Gilson ΗPLC eluting with H₂O / CH₃CN / 0.1% formic acid mixtures to give the title compound contaminated with the corresponding formamide. This material was dissolved in MeOH (2 ml), aqueous NaOH (10 N, 2 ml) was added, and the solution was stirred at rt overnight. It was then treated with water (5 ml) and extracted with DCM (3x20 ml). The extracts were washed with water (2x20 ml), brine (20 ml), dried over MgSO₄, filtered, and concentrated in vacuo, to give the title compound as a beige solid. ¹H NMR (400 MHz, CD₃OD): δ = 1.79-1.92 (m, 2H), 1.98-2.06 (m, 2H), 2.63-2.70 (m, 2H), 2.90 (t, J= 6.0 Hz, 2H), 3.06-3.14 (m, 2H), 3.18-3.24 (m, 2H), 4.06 (s, 2H), 4.15-4.23 (m, IH), 6.82 (d, J= 8.8 Hz, IH), 6.85-6.88 (m, IH), 7.05-7.12 (m, IH), 7.44 (d, J= 2.4 Hz, IH), 7.66 (d, J= 0.8 Hz, IH), 7.83 (d, J= 2.0 Hz, IH), 7.91 (d, J= 0.4 Hz, IH). MS(ES+): m/z = 394.14 (45) [MH⁺]. HPLC: t_R = 2.21 min (ZQ2, polar_5min).

4-{4-[6-Amino-5-(5-fluoro-3,4-dihydro-lH-isoquinolin-2-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine-1-carboxylic acid tert-buty\ ester

A mixture of 4- {4-[6-Ammo-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-1-yl} -piperidine- 1 -carboxylic acid tert-butyl ester (BB4) (170 mg, 0.358 mmol), 5-fluoro-

1,2,3,4-tetrahydroisoquinoline (114 mg, 0.716 mmol), cupric acetate (65.7 mg, 0.358 mmol), pyridine (59 μL, 0.72 mmol), 4 A molecular sieves (95 mg, 264 mg/mmol SM), and DCM (9 mL, 100 mmol) was stirred at rt under an atmosphere of air for 5 d. The mixture was diluted with DCM (50 ml), washed with EDTA solution (2%, 3x50 ml), water (3x50 ml) and brine (50 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give a dark black oil that was purified by MDPS to give the title compound as a brown oil. ¹H NMR (400 MHz, CDCl₃): δ = 1.48 (s, 9H), 1.87-1.99 (m, 2H), 2.12-2.19 (m, 2H), 2.84-2.98 (m, 2H), 3.00 (t, J = 5.6 Hz, 2H), 3.34 (t, J= 6.0 Hz, 2H), 4.17 (s, 2H), 4.22-4.36 (m, 3H), 6.90 (d, J= 7.2 Hz, IH), 6.98 (t, J= 8.4 Hz, IH), 7.18-7.24 (m, IH), 7.50 (d, J= 2.0 Hz, IH), 7.59 (s, IH), 7.65 (s, IH), 7.67 (d, J= 1.6 Hz, IH). MS(ES+): m/z = 494.38 (100) [MH⁺]. HPLC: t_R = 2.84 min (ZQ2, polar_5min).

Example 302: 3-(5-Chloro-3,4-dihydro-lH-isoquinolin-2-yl)-5-(l-piperidin-4-yl-l//-pyrazol- 4-yl)-pyridin-2-ylamine

4- {4- [6-Amino-5-(5-chloro-3,4-dihydro- lH-isoquinolin-2-yl)-pyridin-3-yl]-pyrazol- 1-yl}- piperidine- 1 -carboxylic acid tert-butyl ester (26 mg, 0.051 mmol) was dissolved in MeOH (20 mL), 1.0 M of HCl in Et₂O (20 mL) was added, and the mixture was stirred at rt overnight. The solvent was removed in vacuo to give the title compound as a brown solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.32- 2.39 (m, 4H), 3.11 (t, J= 6.0 Hz, 2H), 3.22-3.32 (m, 2H), 3.42 (t, J= 6.0 Hz, 2H), 3.59 (d, J= 13.2 Hz, 2H), 4.27 (s, 2H), 4.58-4.68 (m, IH), 7.16 (d, J= 7.6 Hz, IH), 7.22 (t, J= 8.0 Hz, IH), 7.32 (d, J= 8.0 Hz, IH), 7.97 (s, IH), 7.98 (s, IH), 8.33 (s, IH). MS(ES+): m/z = 409.10/411.08 (46/18) [MH⁺]. HPLC: t_R = 2.25 min (ZQ2, polar_5min).

4-{4-[6-Amino-5-(5-chloro-3,4-dihydro-l//-isoquinolin-2-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine-1-carboxylic acid tert-butyl ester

A mixture of 4- {4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-l-yl}-piperidine-l -carboxylic acid tert-butyl ester (BB4) (245 mg, 0.517 mmol), 5-chloro- 1,2,3,4-tetrahydroisoquinoline (175 mg, 1.03 mmol), cupric acetate (94.8 mg, 0.517 mmol), pyridine (84 μL, 1.0 mmol), 4 A molecular sieves (139 mg, 264 mg/mmol SM), and DCM (9 mL, 100 mmol) was stirred at rt under an atmosphere of air for 3 d. The mixture was diluted with DCM (50 ml), washed with EDTA solution (2%, 3x50 ml), water (3x50 ml) and brine (50 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give a dark black oil that was purified by MDPS to give the title compound as a brown solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.48 (s, 9H), 1.88-1.99 (m, 2H), 2.12- 2.19 (m, 2H), 2.84-2.98 (m, 2H), 3.04 (t, J= 6.0 Hz, 2H), 3.36 (t, J= 6.0 Hz, 2H), 4.16 (s, 2H), 4.22- 4.36 (m, 3H), 7.02 (d, J= 7.6 Hz, IH), 7.19 (t, J= 8.0 Hz, IH), 7.33 (d, J= 7.6 Hz, IH), 7.50 (s, IH), 7.62 (s, IH), 7.66 (s, IH), 7.69 (s, IH). MS(ES+): m/z = 508.77/511.16 (52/20) [MH⁺]. HPLC: t_R = 3.00 min (ZQ2, polar_5min).

Example 303: 3-(5,8-Difluoro-3,4-dihydro-lH-isoquinolin-2-yl)-5-(l-piperidin-4-yl-l/7- pyrazol-4-yl)-pyridin-2-ylamine

4- {4-[6-Amino-5-(5,8-difluoro-3,4-dihydro- lH-isoquinolin-2-yl)-pyridin-3-yl]-pyrazol- 1 -yl} - piperidine- 1 -carboxylic acid tert-butyl ester (26 mg, 0.051 mmol) was dissolved in MeOH (20 mL), 1.0 M of HCl in Et₂O (20 mL) was added, and the mixture was stirred at rt overnight. The solvent was removed in vacuo to give the title compound as a brown solid. ¹H NMR (400 MHz, CD₃OD): δ = 2.33- 2.42 (m, 4H), 3.08 (t, J = 5.2 Hz, 2H), 3.23-3.36 (m, 2H), 3.39 (t, J = 5.6 Hz, 2H), 3.59 (d, J= 12.8 Hz, 2H), 4.24 (s, 2H), 4.62-4.72 (m, IH), 6.99-7.04 (m, 2H), 7.97 (s, IH), 8.01 (s, IH), 8.07 (s, IH), 8.39 (s, IH). MS(ES+): m/z = 411.08 (42) [MH⁺]. HPLC: t_R = 2.10 min (ZQ2, polar_5min).

4-{4-[6-Amino-5-(5,8-difluoro-3,4-dihydro-l//-isoquinolin-2-yl)-pyridin-3-yl]-pyrazol-l-yl}- piperidine-1-carboxylic acid tert-butyl ester

A mixture of 4- {4-[6-Amino-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridin-3-yl]- pyrazol-1-yl} -piperidine-1-carboxylic acid tert-butyl ester (BB4) (245 mg, 0.517 mmol), 5,8-difluoro- 1,2,3,4-tetrahydroisoquinoline (175 mg, 1.03 mmol), cupric acetate (94.8 mg, 0.517 mmol), pyridine (84 μL, 1.0 mmol), 4 A molecular sieves (139 mg, 264 mg/mmol SM), and DCM (9 mL, 100 mmol) was stirred at rt under an atmosphere of air for 3 d. The mixture was diluted with DCM (50 ml), washed with EDTA solution (2%, 3x50 ml), water (3x50 ml) and brine (50 ml), dried over MgSO₄, filtered, and concentrated in vacuo to give a dark black oil that was purified by MDPS to give the title compound as a brown solid. ¹H NMR (400 MHz, CDCl₃): δ = 1.48 (s, 9H), 1.88-1.99 (m, 2H), 2.12- 2.19 (m, 2H), 2.84-2.98 (m, 2H), 3.00 (t, J= 5.6 Hz, 2H), 3.31 (t, J= 6.0 Hz, 2H), 4.17 (s, 2H), 4.22- 4.36 (m, 3H), 6.92-6.97 (m, IH), 7.55 (d, J= 1.6 Hz, IH), 7.63 (s, IH), 7.67 (s, IH), 7.72 (d, J= 1.2 Hz, IH). MS(ES+): m/z = 511.16 (100) [MH⁺]. HPLC: t_R = 2.93 min (ZQ2, polar_5min).

Example 304: 3-Naphthalen-2-yl-5-(l-piperidin-4-yl-l//-pyrazol-4-yl)-pyridin-2-ylamine trihydrochloride To a solution of 4-[4-(6-amino-5-naphthalen-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidine-l- carboxylic acid tert-butyl ester (15.2 mg, 0.0324 mmol) in 1,4-dioxane (1.0 mL, 13 mmol) was added HCl (4.0 M solution in 1,4-dioxane; 1.0 mL, 4.0 mmol), and the mixture was stirred at ambient temperature for 2 h. Almost immediately a white solid precipitated. The solid was filtered off, washed with MTBE, and dried in vacuo overnight to give the title compound as off-white solid. ¹H NMR (400 MHz, DMSO-(Z₆): δ = 14.7 (very brs, IH), 9.32-9.17 (brm, IH), 9.17-9.02 (brm, IH), 8.43 (s, IH), 8.42 (d, J= 2.0 Hz, IH), 8.31 (d, J= 2.0 Hz, IH), 8.12 (s, IH), 8.11 (d, J= 4.8 Hz, IH), 8.08 (s, IH), 8.06- 8.00 (m_c, 2H), 7.75 (brs, 2H), 7.66-7.59 (m, 3H), 4.53-4.45 (m_c, IH), 3.36 (brd, J= 13.0 Hz, 2H), 3.08 (brq, J= 11.2 Hz, 2H), 2.27-2.08 (m, 4H). MS(ES+): m/z = 370.19 (37) [MH⁺], 287.12 (100) [MH⁺ - piperidine]. HPLC: t_R = 1.88 min (polar_5min, ZQ3). 4-[4-(6-Amino-5-naphthalen-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert- butyl ester

A solution of 2-naphthylboronic acid (43 mg, 0.25 mmol), Pd(PPh₃)₄ (23 mg, 0.020 mmol), and a mixture of 4-[4-(6-amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-butyl ester and 4-[4-(2-amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-butyl ester (together 92.2 mg, 0.138 mmol) in 1,4-dioxane (3.5 mL, 45 mmol) in a sealable microwave tube was charged with a solution of CS₂CO3 (140 mg, 0.44 mmol) in H₂O (0.90 mL, 50 mmol), flushed with nitrogen, sealed and irradiated in the microwave reactor at 105 ⁰C for 60 min. More 2-naphthylboronic acid (11 mg, 0.064 mmol) and Pd(PPh₃ )₄ (5.6 mg, 0.0048 mmol) were added, and the solution was heated in the microwave reactor at 105 ⁰C for 30 min. Further 2-naphthylboronic acid (12 mg, 0.070 mmol) and Pd(PPh₃ )₄ (4.5 mg, 0.0039 mmol) were added to the solution, which was then heated in the microwave reactor to 105 ⁰C for 30 min. The reaction mixture was diluted with EtOAc, washed with aq. NaHCO₃ solution, water, and brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was chromatographed on silica gel [10 g / 70 mL prepacked cartridge, eluting with DCM → 1% MeOH in DCM → 2% MeOH in DCM → 3% MeOH in DCM]. One obtained a mixture of the title compound and its regioisomer, 4-[4-(2-amino-5-naphthalen-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidine- 1-carboxylic acid tert-butyl ester, as yellow-brown solid. This mixture of regioisomers was separated using the MDPS. ¹H NMR (400 MHz, CDCl₃): δ = 8.26 (d, J = 2.4 Hz, IH), 7.99-7.45 (m, 10H), 4.60 (s, 2H), 4.39^.21 (m, 3H), 2.98-2.85 (brm, 2H), 2.19 (brt, J= 13.0 Hz, 2H), 2.05-1.89 (m_c, 2H), 1.48 (s, 9H). MS(ES+): m/z = 470.19 (100) [MH⁺]. HPLC: t_R = 2.85 min (polar_5min, ZQ3).

4-[4-(2-Amino-5-naphthalen-2-ylpyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert- butyl ester

¹H NMR (400 MHz, CDCl₃): δ = 8.40 (d, J= 2.4 Hz, IH), 7.99-7.45 (m, 10H), 4.69 (s, 2H), 4.39- 4.21 (m, 3H), 2.98-2.85 (brm, 2H), 2.19 (bit, J= 13.0 Hz, 2H), 2.05-1.89 (m_c, 2H), 1.49 (s, 9H). MS(ES+): m/z = 470.19 (100) [MH⁺]. HPLC: t_R = 3.00 min (polar_5min, ZQ3).

4-[4-(6-Amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert-buty\ ester and 4-[4-(2-Amino-5-bromopyridin-3-yl)-pyrazol-l-yl]-piperidine-l-carboxylic acid tert- butyl ester

A solution of 2-amino-3,5-dibromopyridine (96.8 mg, 0.384 mmol), 4-[4-(4,4,5,5-tetramethyl- 1, 3, 2-dioxaborolan-2-yl)-pyrazol-l-yl]-piperidine- 1-carboxylic acid tert-butyl ester (BBl) (146 mg, 0.388 mmol), and Pd(PPh₃)₄ (35 mg, 0.030 mmol) in 1,4-dioxane (3.2 mL, 41 mmol) was flushed with nitrogen. A solution Of Cs₂CO₃ (277 mg, 0.850 mmol) in H₂O (0.80 mL, 44 mmol) was added, and the resulting mixture was flushed again with nitrogen and irradiated in the microwave reactor at 100 ⁰C for 30 min. The reaction was worked up by diluting with EtOAc (~ 70 mL), washing with water and brine, and drying over MgSO₄. The extract was filtered and dried in vacuo, giving a brown oil. It was chromatographed on silica gel [10 g / 70 mL prepacked cartridge, eluting with DCM → 1% MeOH in DCM → 2% MeOH in DCM → 4% MeOH in DCM]. One obtained a mixture of the regioisomeric title compounds as brown solid. This mixture was used in the next step without separation. 6-Amino isomer: ¹H NMR (400 MHz, CDCl₃): δ = 8.14 (d, J= 2.0 Hz, IH), 7.78 (d, J= 2.0 Hz, IH), 7.67 (s, IH), 7.57 (s, IH), 4.98 (brs, 2H), 4.36-4.21 (brm, 3H), 2.91 (bit, J= 11.2 Hz, 2H), 2.20-2.11 (brm, 2H), 2.01-1.88 (m_c, 2H), 1.48 (s, 9H). MS(ES+): m/z = 422.03/423.99 (90/100) [MH⁺]. HPLC: t_R = 4.18 min (polar_15min, ZQ3). 2-Amino isomer: ¹H NMR (400 MHz, CDC13): δ = 8.03 (d, J= 2.4 Hz, IH), 7.71 (d, J = 0.5 Hz, IH), 7.64 (d, J = 0.5 Hz, IH), 7.52 (d, J= 2.0 Hz, IH), 4.76 (brs, 2H), 4.36- 4.21 (brm, 3H), 2.91 (bit, J= 11.2 Hz, 2H), 2.20-2.11 (brm, 2H), 2.01-1.88 (m_c, 2H), 1.48 (s, 9H). MS(ES+): m/z = 422.03/424.00 (99/100) [MH⁺]. HPLC: t_R = 4.58 min (polar_15min, ZQ3).

Claims

1. A compound of Formula I, or a pharmaceutically acceptable salt thereof,

I wherein: Rl is isoquinolin-3-yl, benzothiazol-2-yl, l,2,3,4-tetrahydroisoquinolin-3-yl, 4,5,6,7- tetrahydrobenzothiazol-2-yl, benzofuran-2-yl, benzoxazol-2-yl, benzothiophen-2-yl, 5,6,7,8-tetrahydro- 4H-cycloheptathiazol-2-yl, 3,3-disubstituted 3H-indol-2-yl, imidazo[l,2-α]pyridine-2-yl, thiazolo[4,5- c]pyridin-2-yl, oxazolo[4,5-c]pyridin-2-yl, imidazo[l,2-α]pyrazin-2-yl, furo[2,3-c]pyridin-2-yl, thieno[2,3-c]pyridin-2-yl, or 2-naphthyl, any of which is optionally further substituted with one to four independent R3 groups;

X is pyrazol, phenyl, pyridyl, thiazolyl, imidazolyl, furyl, thienyl, pyrrolyl, indolyl, indazolyl, or tetrahydropyridyl;

R2 is Η, halogen, CN, alkyl, cycloalkyl, bicycloalkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, amino, aminoalkyl, alkylamino, alkylsulfonyl, C(=O)R4, C(=O)OR4, C(=O)NR5R6, NR7C(=O)R4, NR7C(=O)OR4, NR7C(=O)NR5R6, NR7S(=O)₂R4, NR7S(=O)R4, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, heteroaryl, -alkyl-C(=O)R4, -alkyl-C(=O)OR4, -alkyl- C(=O)NR5R6, -alkyl-NR7C(=O)R4, -alkyl-NR7C(=O)OR4, -alkyl-NR7C(=O)NR5R6, -alkyl- NR7SO₂R4, -alkyl-NR7SOR4, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally substituted by one or more independent R3 groups; R3 is Η, halogen, CN, alkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, amino, aminoalkyl, alkylamino, alkylsulfonyl, C(=O), C(=S), C(=O)R4, C(=O)OR4, C(=O)NR5R6, NR7C(=O)R4, NR7C(=O)OR4, NR7C(=O)NR5R6, NR7SO₂R4, NR7SOR4, aryl, heterocyclyl, heteroaryl, -alkyl-C(=O)R4, -alkyl-C(=O)OR4, -alkyl-C(=O)NR5R6, -alkyl- NR7C(=O)R4, -alkyl-NR7C(=O)OR4, -alkyl-NR7C(=O)NR5R6, -alkyl-NR7SO₂R4, -alkyl-NR7SOR4, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally further substituted by one or more independent R7 groups;

R4 is alkyl, cycloalkyl, alkenyl, alkynyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, amino, aminoalkyl, alkylamino, dialkylamino, alkylsulfonyl, aryl, heterocyclyl, heteroaryl, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally further substituted by one or more independent R7 groups;

R5 and R6 are each independently Η, alkyl, cycloalkyl, or alkoxyalkyl, any of which is optionally substituted by one or more independent R7 groups; or R5 and R6 taken together with the atom that they are attached to form a 4-7 membered saturated or unsaturated heterocycle; wherein said heterocycle is optionally further substituted by one or more independent R7 groups;

R7 is H, halogen, alkyl, trifluoroalkyl, alkoxy, CN, cycloalkyl, alkoxyalkyl, aryl, hetaryl, or heterocyclyl; n is 0, 1 or 2. 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Rl is isoquinolin-3-yl, benzothiazol-2-yl, l,2,3,4-tetrahydroisoquinolin-3-yl, 4,5,6,7-tetrahydrobenzothiazol- 2-yl, benzofuran-2-yl, benzoxazol-2-yl, benzothiophen-2-yl, 3,3-disubstituted 3H-indol-2-yl, imidazo[l,2-α]pyridine-2-yl, thiazolo[4,5-c]pyridin-2-yl, oxazolo[4,5-c]pyridin-2-yl, imidazo[l,

2- α]pyrazin-2-yl, furo[2,3-c]pyridin-2-yl, or thieno[2,3-c]pyridin-2-yl, any of which is optionally further substituted by one to four independent R3 groups.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Rl is isoquinolin-3-yl, benzothiazol-2-yl, l,2,3,4-tetrahydroisoquinolin-3-yl, 4,5,6,7-tetrahydrobenzothiazol- 2-yl, benzoxazol-2-yl, 3,3-disubstituted 3H-indol-2-yl, or imidazo[l,2-α]pyridine-2-yl, any of which is optionally further substituted by one to four independent R3 groups.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Rl is isoquinolin-3-yl, benzothiazol-2-yl, benzoxazol-2-yl, or imidazo[l,2-α]pyridine-2-yl, any of which is optionally further substituted by one to four independent R3 groups.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Rl is isoquinolin-3-yl or benzothiazol-2-yl, any of which is optionally further substituted by one to four independent R3 groups.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Rl is thiazolo[4,5-c]pyridin-2-yl, oxazolo[4,5-c]pyridin-2-yl, imidazo[l,2-α]pyrazin-2-yl, furo[2,3-c]pyridin- 2-yl, or thieno[2,3-c]pyridin-2-yl, any of which is optionally further substituted by one to four independent R3 groups.

7. The compound of any of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I has the Formula Ia

Ia

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iaa

laa wherein

Raa is H, alkoxy, or alkyl wherein alkoxy or alkyl is optionally further substituted with halogen; and Rab is H or F.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula lab.

lab

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of has the Formula lac

wherein

Rc is H or alkyl wherein alkyl is optionally further substituted with halogen.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula lad:

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iae

Iae wherein Y is O or S.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iaf.

Iaf

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula lag

wherein

Rga and Rgb are independently alkyl, alkoxy or alkylthio wherein said alkyl group is optionally further substituted with halogen; or Rga and Rgb, together with the carbon atom that both are attached to, form a 3-7-membered saturated or unsaturated ring containing zero to two O, N, or S atoms.

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iah:

Iah

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iai:

Iai wherein W is CR3 or N.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iaj

Iaj wherein W is CR3 or N.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula Iak:

wherein W is CR3 or N.

19. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula IaI:

wherein Y is O or S, and W is CR3 or N.

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula lam:

21. The compound of any of claims 1 -20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, cycloalkyl, bicycloalkyl, alkylsulfonyl, C(=O)NR5R6, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, heteroaryl, -alkyl-C(=O)R4, -alkyl-C(=O)OR4, -alkyl- C(=O)NR5R6, -alkyl-NR7C(=O)R4, -alkyl-NR7C(=O)OR4, -alkyl-NR7C(=O)NR5R6, -alkyl- NR7SO₂R4, -alkyl-NR7SOR4, aryl-alkyl, heterocyclyl-alkyl, or heteroaryl-alkyl, any of which is optionally further substituted by one or more independent R3 groups.

22. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

23. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is heterocyclyl or heterobicycloalkyl, any of which is optionally further substituted by one or more independent R3 groups.

24. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

25. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

26. The compound of any of claims 1 -20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

27. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

28. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

29. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

30. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

31. The compound of any of claims 1 -20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

32. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

33. The compound any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

34. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

35. The compound of any of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

36. The compound of any of claims 1 -20, or a pharmaceutically acceptable salt thereof, wherein R2 is H, alkyl, aryl, heterocyclyl, heterobicycloalkyl, heterospiroalkyl, or heteroaryl, any of which is optionally further substituted by one or more independent R3 groups.

37. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of Structure Name

3-(8-Chloroisoquinolin-3-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(5-Bromo-8-fluoroisoquinolin-3-yl)- 5-(l -piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(5-Chloro-8-fluoroisoquinorm-3-yl)- 5-(l -piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(5-Chloro-6,8-difluoroisoquinolin-3- yl)-5-(l -piperidin-4-yl- lH-pyrazol-4- yl)-pyridin-2-ylamine

3-(8-Chloro-7-fluoroisoquinolin-3-yl)- 5-(l -piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(8-Fluoroisoquinolin-3-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-[8-Fluoro-5-(lH-pyrazol-4-yl)- isoquinolin-3-yl]-5-(l-piperidin-4-yl- lH-pyrazol-4-yl)-pyridin-2-ylamine

3-[8-Fluoro-5-(l -methyl- lH-pyrazol- 4-yl)-isoquinolin-3-yl]-5-(l -piperidin- 4-yl- lH-pyrazol-4-yl)-pyridin-2- ylamine

(2S,4S)-4-[4-(6-Amino-5-benzothiazol- 2-ylpyridin-3-yl)-pyrazol- 1-yl]- pyrrolidine-2-carboxylic acid

{(2S,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidin-2-yl} -morpholin-4- ylmethanone

{(2S,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidin-2-yl} -piperidin- 1 - ylmethanone

{(2S,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidin-2-yl} -(3- hydroxypyrrolidin- 1 -yl)-methanone

{(2S,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidin-2-yl} -azetidin- 1 - ylmethanone

{4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3 -yl)-pyrazol- 1 -yl] -piperidin- 1-yl} -acetic acid

2-{4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]-piperidin- l-yl}-acetamide

2-{4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]-piperidin- 1 -yl} - 1 -pyrrolidin- 1 -ylethanone

2-{4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]-piperidin- 1 -yl} - 1 -(3-hydroxypyrrolidin- 1 - yl)ethanone

2-{4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]-piperidin- 1 -yl} - 1 -(4-hydroxypiperidin- 1 - yl)ethanone 2- {4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]-piperidin- 1 -yl} - 1 -morpholin-4-ylethanone

2- {4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]-piperidin- 1 -yl} -N-(2-hydroxyethyl)-acetamide

(2R,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidine-2-carboxylic acid

{(2R,4S>4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidin-2-yl} -pyrrolidin- 1 - ylmethanone

{(2R,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol- 1 -yl]-pyrrolidin-2-yl} -(3- hydroxypyrrolidin- 1 -yl)methanone {(2R,4S)-4-[4-(6-Amino-5- benzothiazol-2-ylpyridin-3-yl)-pyrazol-

1 -yl]-pyrrolidin-2-yl} -morpholin-4-

{(£)-4-[4-(6-Amino-5-benzothiazol-2- ylpyridin-3-yl)-pyrazol- 1 -yl]- pyrrolidin-2-yl} -methanol

5-(l-Azetidin-3-yl- lH-pyrazol-4-yl)-3- benzothiazol-2-ylpyridin-2-ylamine

5-(l -Piperidin-4-yl- lH-pyrazol-4-yl)- 3-[7-(lH-pyrazol-4-yl)benzothiazol-2- yl]pyridin-2-ylamine

5-(l -Piperidin-4-yl- lH-pyrazol-4-yl)- 3-[7-(7H-pyrrol-2-yl)benzothiazol-2- yl]pyridin-2-ylamine

5-(l -Piperidin-4-yl- lH-pyrazol-4-yl)- 3-(7-pyridin-3-ylbenzothiazol-2- yl)pyridin-2-ylamine

3-(4-Fluorobenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(5-Chlorobenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(7-Chlorobenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(7-Methylbenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(7-Methoxybenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(4-Bromobenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

2-[2-Amino-5-(l -piperidin-4-yl- IH- pyrazol-4-yl)-pyridin-3-yl]- benzothiazole-5-carbonitrile

3-(7-Bromobenzothiazol-2-yl)-5-(l- piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

3-(4,5-Difluorobenzothiazol-2-yl)-5- (1 -piperidin-4-yl- lH-pyrazol-4-yl)- pyridin-2-ylamine

38. A method of treating a patient having a condition which is mediated by protein kinase activity, said method comprising administering to the patient a therapeutically effective amount of a compound of any of claims 1-37, or a pharmaceutically acceptable salt thereof.

39. The method of claim 38 wherein said protein kinase is KDR, Tie-2, Flt3, FGFR3, AbI, Aurora A, c-Src, IGF-IR, ALK, c-MET, RON, PAKl, PAK2, or TAKl.

40. The method of claim 38 wherein the condition mediated by protein kinase activity is cancer.

41. The method of claim 40 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, or malignant ascites.

42. The method of claim 40 wherein the cancer is lung cancer, bladder cancer, pancreatic cancer, kidney cancer, gastric cancer, breast cancer, colon cancer, prostate cancer (including bone metastases), hepatocellular carcinoma, ovarian cancer, esophageal squamous cell carcinoma, melanoma, an anaplastic large cell lymphoma, an inflammatory myofibroblastic tumor, or a glioblastoma.

43. A pharmaceutical composition comprising a compound of any of claims 1-37, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.